Health Evidence Review Commission

August 11, 2022

1:30 PM - 4:30 PM

Online meeting

Join online meeting here

+16692545252,,1612432743#,,,,*206873#

Section 1.0

Call to Order

AGENDA

Yes I am HEALTH EVIDENCE REVIEW COMMISSION

Online Meeting

August 11, 2022

1:30-4:30 pm

(All agenda items are subject to change and times listed are approximate)

#	Time	Item	Presenter	Action Item
1	1:30 PM	Call to order	Kevin Olson	
2	1:35 PM	Approval of minutes (5/19/2022)	Kevin Olson	X
3	1:40 PM	Director's report	Jason Gingerich	
4	1:45 PM	Value-based Benefits Subcommittee report	Ariel Smits	X
5	2:35 PM	Reproductive Health Equity Act preventive services report	Amy Cantor	X
6	2:45 PM	Continuous Glucose Monitoring scope statement	Amy Cantor	X
7	3:20 PM	High Frequency Chest Wall Oscillation Devices • Coverage guidance • Prioritized List changes	Ariel Smits	X
8	4:20 PM	Next steps • Schedule next meeting – 10/6/2022, online meeting	Kevin Olson	
9	4:25 PM	Other public comment	Daphne Peck	
10	4:30 PM	Adjournment	Kevin Olson	

Note: Public comment will be taken on each topic per HERC policy at the time at which that topic is discussed.

MINUTES

HEALTH EVIDENCE REVIEW COMMISSION
Online Meeting
May 19, 2022

Members Present: Kevin Olson, MD, Chair; Holly Jo Hodges, MD, MBA, Vice-Chair; Devan Kansagara, MD; Lynnea Lindsey, PhD; Leslie Sutton; Adriane Irwin, PharmD, Kathryn Schabel, MD; Max Kaiser, DO; Cris Pinzon, MPH, BSN, BS, RN; Stacy Geisler, DDS, PhD; Ben Hoffman, MD; Mike Collins (departed prior to the votes on PANDAS and PANS).

Members Absent: Deborah Espesete, LAc, MAcOM, MPH.

Staff present: Ariel Smits, MD, MPH; Amy Cantor, MD, MPH; Jason Gingerich; Liz Walker, PhD, MPH; Daphne Peck.

Also Attending: Bethany Godlewski, Shauna Durbin, Val King, MD, (OHSU Center for Evidence-based Policy); Andrea Stroud; Antoinette Awuakye; Ben Botkin (The Lund Report); Bob Cuyler; Cathy Daraee; Christian Moller-Andersen; Christin Gallo; Christina Cronin-Vejar; Cynthia Witcraft; Dan Twibell (PACE Foundation); David Zimmerman; Dr. Rogalsky; Elisa Bledsoe; Erin Thompson, MD; Gabriella True (ASPIRE); Greg Showell; Ivan Vejar; Jaymey Sweeney; Jen; Joe Perekupka; Kimberly; Kym McCornack Laura McKeane; Leia Hughey, Ph.D; Leif Bruce; Marija Micic; Mary Clogston; Maureen McGee; Mike Cusnir MD; Mike Daines, MD; Miya; Monica Frederick; Nate Myszka; Paul Lewis, MD; Rachael Wiggins Emory; Renee Doan; Sarah Lemley; Stephanie; Tyler Miguel-Harrison; Val Halpin; Wendy Nawara.

Call to Order

Kevin Olson, Chair of the Health Evidence Review Commission (HERC), called the meeting to order; roll was called. A quorum of members was present at the meeting.

Each member and staff person introduced themselves.

Minutes Approval

MOTION: To approve the minutes of the 3/10/2022 meeting as presented. CARRIES 12-0.

Director's Report

Staff changes
Gingerich said Daphne Peck has a new role, as Program and Outreach Coordinator. She will continue to support the Commission and take on the additional role. He then said Dr. Amy Cantor, a new Medical Director recently started. Cantor introduced herself.

EPSDT waiver discussions
No update to report; hopefully by the August meeting there will be more to discuss.

Equity project update/outreach plan
Gingerich discussed Peck's work with plain language and community outreach plans. He said this is a part of a larger equity initiative, which will include the discussions referenced at the last meeting regarding making decisions when there is insufficient evidence. As a part of this, Peck will be polling for dates for a potential day-long retreat, in winter or spring of 2023.

Naturopath applications status update
Gingerich said there are four applicants thus far and the recruitment is open until May 31, 2022.

Value-based Benefits Subcommittee (VbBS) Report on Prioritized List Changes
Meeting materials pages 36-90

Ariel Smits reported the VbBS met earlier in the day, 5/19/2022. She summarized the subcommittee's recommendations.

RECOMMENDED CODE MOVEMENT (changes to the 10/1/2022 Prioritized List unless otherwise noted)

- Add the procedure codes for visual field testing to the list of covered diagnostic tests
- Add the code for temporary urethral stents to a non-funded line
- Add the code for fecal lactoferrin quantitative testing to the list of covered diagnostic tests
- Add the codes for placements of gastric neurostimulators to a funded line with a new guideline
- Add the procedure codes for coronary CT angiography to the list of covered diagnostic tests
- Delete the procedure code for rhinophyma shaving from a currently-funded line and add to an unfunded line
- Add the procedure code for shoulder arthroplasty with subacromial spacers to an unfunded line
- Add the diagnosis codes for benign carcinoid tumors to several funded lines
- Make various straightforward guideline and coding changes

RECOMMENDED GUIDELINE CHANGES (changes to the 10/1/2022 Prioritized List unless otherwise noted)

- Edit the adenoidectomy guideline to allow adenoidectomy with the placement of the first set of tympanostomy tubes in certain situations
- Edit the guideline regarding bone anchored hearing aids (BAHAs) so that bilateral BAHAs are included on the relevant lines. Specify that maintenance and replacement of BAHAs in adulthood is also included
- Delete the guideline restricting the use of MRIs in multiple sclerosis
- Add the guideline for erythropoietin to a line with non-end stage chronic renal disease and add a requirement that the patient have sufficient iron stores in order to receive this treatment
- Edit the new orthodontia guideline to remove separate mention of qualifying criteria which are already encompassed in another tool, and add a requirement for a dental visit to ensure good oral health before beginning orthodontia treatment

Testimony:

Equine Therapy
Leia Hughey, PhD, who testified at VbBS earlier in the day, said she had her concerns addressed at that meeting and had nothing further to add.

Freespira:
Monica Frederick, an employee of Freespira. Ms. Frederick clarified that Freespira is not a smartphone app but is an FDA cleared class to medical device that is supported by health coaching and data analytics. Also, it treats panic disorders and post-traumatic stress disorder (PTSD), rather than substance use disorder. She said that as of April 1, CMS established a HCPCS code for this application.

Robert Cuyler, PhD, an employee of Freespira and a clinical psychologist. Dr. Cuyler gave a very brief walkthrough of the intervention and the components.

Joe Perekupka, CEO of Freespira highlighted a 35% overall reduction of medical costs within the Medicaid marketplace with this device.

Olson said the MED Project is currently doing a review of these types of services and we will wait for that report before we take up a review.

Y90 liver directed therapy:
Mike Cusnir MD, of Mount Sinai in Miami, testified about treatment for metastatic colon cancer and liver disease.

MOTION: To accept the VbBS recommendations on *Prioritized List changes* not related to coverage guidances, as stated. See the VbBS minutes of 5/19/2022 for a full description. Carries: 12-0.

Coverage Guidance Topic: Bariatric procedures scope statement
Meeting materials, page 91

Testimony

Derek Rogalsky MD said he is an Oregon Southern coast bariatric surgeon whose patients are mainly on the Oregon Health Plan. He said he thought it would be useful to look at the long-term comparative studies and not just randomized control trials (RTCs).

Dr. Valerie King from OHSU's Center for Evidence-based Policy, HERC's contractor, said the work they do for HERC usually uses RTCs unless there is a compelling reason to look at other comparative studies. Discussion centered around what would be helpful to look for in the literature.

MOTION: To approve the proposed scope statement as presented. Carries 12-0.

Coverage Guidance Topic: PANDAS/PANS
Meeting materials, pages 96-224

Gingerich read the appointed experts' biographies. Godlewski and Smits presented an overview of the evidence, the GRADE Table and the proposed coverage guidance from EbGS.

Testimony

Sarah Lemley, Executive Director of Northwest PANDAS/PANS Network offered testimony. She said there are 20 years of published data about the efficacy of IVIG. She then read through a list of names of persons and organizations endorsing coverage.

Christina Cronin-Vejar gave testimony of her personal experience as a parent of a child with this condition. She urged the Commission to approve coverage.

Dan Twibell, PACE Foundation spoke, sharing he is the father of a PANDAS child. He said the PACE Foundation has been instrumental in helping to set up clinical trails for IVIG treatment. He urged the Commission to adopt the guidance adopted by the Value-based Benefits Subcommittee.

Discussion

Sutton said she has appreciated the conversation between the public comment and the experts during discussions on this complicated issue.

Pinzon asked about the disease occurrence. Smits said it is difficult to know as there are not rigorous standardized diagnostic criteria. Lemley offered the PANDAS network conservatively estimates that one in 200 children are affected. Daines said not all patients will require IVIG; only a very small percentage progress to that stage.

It was mentioned that certain infectious disease doctors sent in public comment asking that their specialty be removed from the list of specialties to be consultant regarding PANDAS and PANS in the coverage guidance recommendation.

MOTION: To approve the proposed coverage guidance as presented. Carries 7-3. *(Absent: Collins; Voted no: Hodges, Kaiser, Geisler)*

MOTION: To approve the proposed guideline for the Prioritized List as proposed. Carries 7-3. *(Absent: Collins; Voted no: Hodges, Kaiser, Geisler)*

Approved Coverage Guidance:

HERC Coverage Guidance

Tonsillectomy, adenoidectomy, adenotonsillectomy, plasma exchange, and prophylactic antibiotic therapy are not recommended for coverage to treat pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS) (*weak recommendation*).

Up to 3 monthly immunomodulatory courses of intravenous immunoglobulin (IVIG) therapy are recommended for coverage to treat PANDAS and PANS (*weak recommendation*) when both of the following are met:

A) A clinically appropriate trial of two or more less-intensive treatments (for example, appropriate limited course of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, selective serotonin reuptake inhibitors (SSRIs), behavioral therapy, short-course antibiotic therapy) was either not effective, not tolerated, or did not result in sustained improvement in symptoms (as measured by a lack of clinically meaningful improvement on a validated instrument directed at the patient's primary symptom complex). These trials may be done concurrently, AND

B) A consultation with and recommendation from a pediatric subspecialist (for example, pediatric neurologist, pediatric psychiatrist, neurodevelopmental pediatrician, pediatric rheumatologist, pediatric allergist/immunologist) as well as the recommendation of the patient's primary care provider (for example, family physician, pediatrician, pediatric nurse practitioner, naturopath). The subspecialist consultation may be a teleconsultation. For adolescents, an adult subspecialist consult may replace a pediatric subspecialist consult.

A reevaluation at 3 months by both the primary care provider and pediatric expert is required for continued therapy of IVIG. This evaluation must include clinical testing with a validated instrument, which must be performed pretreatment and posttreatment to demonstrate clinically meaningful improvement.

Note: Other treatments (corticosteroids, SSRIs, NSAIDs, short-course antibiotics, and behavioral therapies) were included in an initial version of this report. These therapies were determined to be beyond the scope of a HERC coverage guidance, as these therapies are commonly used for many indications and are not typically subject to utilization control. Only treatments subject to coverage criteria were retained for the final version of this report.

Changes for the Prioritized List of Health Services:

1) Add ICD-10-CM D89.9 to Line 313

Add ICD-10-CM D89.9 (Disorder involving the immune mechanism, unspecified) to Line 313 DISORDERS INVOLVING THE IMMUNE SYSTEM.

2) Adopt a new guideline based on the Coverage Guidance Box Language

Guideline Note 227: PANDAS and PANS
Line 313

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is included on this line when coded with ICD-10-CM D89.89 (Other specified disorders involving the immune mechanism, not elsewhere classified). Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) is included on this line when coded with ICD-10-CM D89.9 (Disorder involving the immune mechanism, unspecified).

Up to 3 monthly immunomodulatory courses of intravenous immunoglobulin (IVIG) therapy are included on this line to treat PANDAS and PANS when both of the following are met:

a) A clinically appropriate trial of two or more less-intensive treatments (for example, appropriate limited course of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, selective serotonin reuptake inhibitors (SSRIs), behavioral therapy, short-course antibiotic therapy) was either not effective, not tolerated, or did not result in sustained improvement in symptoms (as measured by a lack of clinically meaningful improvement on a validated instrument directed at the patient's primary symptom complex). These trials may be done concurrently, AND
b) A consultation with and recommendation from a pediatric subspecialist (for example, pediatric neurologist, pediatric psychiatrist, neurodevelopmental pediatrician, pediatric rheumatologist, pediatric allergist/immunologist) as well as the recommendation of the patient's primary care provider (for example, family physician, pediatrician, pediatric nurse practitioner, naturopath). The subspecialist consultation may be a teleconsultation. For adolescents, an adult subspecialist consult may replace a pediatric subspecialist consult.

A reevaluation at 3 months by both the primary care provider and pediatric expert is required for continued therapy of IVIG. This evaluation must include clinical testing with a validated instrument, which must be performed pretreatment and posttreatment to demonstrate clinically meaningful improvement. Long term antibiotic therapy is not included on this line for treatment of PANDAS/PANS. Therapeutic plasma exchange (CPT 36514) does not pair with PANDAS or PANS (ICD-10-CM D89.89 or D89.9).

Next Steps

Next meeting is August 11, 2022, online. Several Commissioners may be unable to attend. Peck will poll the membership to find a suitable date for an August meeting.

Public Comment

There was no additional public comment at this time.

Adjournment

Meeting adjourned at 4:15 pm. Next meeting will be from 1:30-4:30 pm in August, online.

Value-based Benefits Subcommittee Recommendations Summary
For Presentation to:
Health Evidence Review Commission on May 19, 2022

For specific coding recommendations and guideline wording, please see the text of the 5/19/2022 VbBS minutes.

RECOMMENDED CODE MOVEMENT (changes to the 10/1/2022 Prioritized List unless otherwise noted)

- Add the procedure codes for visual field testing to the list of covered diagnostic tests
- Add the code for temporary urethral stents to a non-funded line
- Add the code for fecal lactoferrin quantitative testing to the list of covered diagnostic tests
- Add the codes for placements of gastric neurostimulators to a funded line with a new guideline
- Add the procedure codes for coronary CT angiography to the list of covered diagnostic tests
- Delete the procedure code for rhinophyma shaving from a currently-funded line and add to an unfunded line
- Add the procedure code for shoulder arthroplasty with subacromial spacers to an unfunded line
- Add the diagnosis codes for benign carcinoid tumors to several funded lines
- Make various straightforward guideline and coding changes

ITEMS CONSIDERED BUT NO RECOMMENDATIONS FOR CHANGES MADE

- Coverage for spinal cord stimulation for diabetic peripheral neuropathy was considered but not added

RECOMMENDED GUIDELINE CHANGES (changes to the 10/1/2022 Prioritized List unless otherwise noted)

- Edit the adenoidectomy guideline to allow adenoidectomy with the placement of the first set of tympanostomy tubes in certain situations
- Edit the guideline regarding bone anchored hearing aids (BAHAs) so that bilateral BAHAs are included on the relevant lines. Specify that maintenance and replacement of BAHAs in adulthood is also included
- Delete the guideline restricting the use of MRIs in multiple sclerosis
- Add the guideline for erythropoietin to a line with non-end stage chronic renal disease and add a requirement that the patient have sufficient iron stores in order to receive this treatment
- Edit the new orthodontia guideline to remove separate mention of qualifying criteria which are already encompassed in another tool, and add a requirement for a dental visit to ensure good oral health before beginning orthodontia treatment *(effective January 1, 2023)*

VALUE-BASED BENEFITS SUBCOMMITTEE
Online meeting
May 19, 2022
8:00 AM – 1:00 PM

Members Present: Kevin Olson, MD, Chair; Holly Jo Hodges, MD, MBA, Vice-chair; Cris Pinzon, MPH, BSN, BS, RN; Kathryn Schabel, MD (arrived 8:45); Brian Duty, MD (arrived 8:30); Mike Collins; Adriane Irwin, PharmD; David Saenger, MD.

Members Absent:

Staff Present: Ariel Smits, MD, MPH; Amy Cantor, MD, MPH; Jason Gingerich; Liz Walker, PhD, MPH; Daphne Peck.

Also Attending: Dawn Mautner, MD, Kaz Rafia DMD, and Kristty Zamora-Polanco (Oregon Health Authority); Michael Yu (OHA Ombuds); Bethany Godlewski, Shauna Durbin, and Valerie King, MD, MPH (Center for Evidence Based Policy); Alison Christy, MD, PhD; Paria Zarrinnegar, MD; Michael Daines, MD; Julie Falardeau, MD; Peggy Kelley, MD; Leia Hughey, PhD; Monica Frederick, Robert Cuyler, PhD, and Joe Perekupka (Freespira); Sarah Lemley and Kym McCornack, Northwest PANDAS/PANS Network; Cristin Cronin-Vejar; Ivan Vejar; Deborah Miller; Dan Twibell (PACE Foundation); Laura McKeane; Kimberly Goddard (Rep Prusak's office); Cynthis Witcraft, Christian Moller-Andersen; Bob Cuyler; bhoveke_gobhi

- **Roll Call/Minutes Approval/Staff Report**

  The meeting was called to order at 8:00 am and roll was called. A quorum of members was present at the meeting. Minutes from the March 10, 2022 VbBS meeting were reviewed and approved.

  Gingerich introduced Amy Cantor as a new Medical Director for HERC. He also announced Daphne Peck's expanded role as Program and Outreach Coordinator for HERC, to sustain the efforts related to plain language summaries as well as other initiatives to improve public engagement and gather community input.

  Gingerich mentioned that a new law (HB 2992) will allow a per diem reimbursement to members in certain situations, and more information is forthcoming. Smits announced that the congenital foot diagnosis review has been delayed until August to allow further expert input. She also reviewed the errata document and presented the summary of the HERC staff's below the funding line diagnosis review. Members of the subcommittee as well as the public were encouraged to suggest additional topics or research related to these decisions.

- **Topic: Straightforward/Consent Agenda**

Discussion: There was no discussion about the consent agenda items other than the "items discussed with leadership with no changes recommended" [see below].

The following members gave public testimony about topics which staff reviewed and discussed with leadership, but recommended no changes:

1) Freespira: Monica Frederick, an employee of Freespira, testified that Freespira is a digital therapeutic device with FDA approval. Freespira is for the treatment of panic disorder and post-traumatic stress disorder (PTSD), not opioid use. It is not a smartphone app. She said that HCPCS A9291 was published in April 2022: "Prescription digital behavioral therapy, FDA cleared, per course of treatment", and this code would be appropriate to use with Freespira. Bob Cuyler, PhD, Clinical Psychologist and Chief Clinical Officer of Freespira testified about how the device addresses respiratory dysfunction related to panic and PTSD. The device is used at home and monitored by a health coach at the company. The typical treatment protocol is twice daily use for 28 days. He noted that there is an extensive public literature on this intervention and multiple peer-reviewed studies find clinically significant symptom reduction in >70% of patients. Other studies have found a savings of 35% in medical spending in the one year period after treatment, mainly due to reduced medical visits. He noted the device has a high response rate in Medicaid populations. Joe Perekupka, CEO of Freespira, testified about how the device can help symptoms, address social determinants of health, and help patients gain access to care.
    a. HERC staff noted that devices like Freespira are likely to be included in an upcoming MED report on digital therapeutics. If it is not included in the published MED report, staff will research this device for a future HERC meeting.
2) Equine therapy: Leia Hughey, a licensed clinical psychologist who owns an equine facility where she treats families/children with mental health issues, testified about one CCO discontinuing coverage for equine therapy, which she said is evidence-based practice. Children with better insurance can access this treatment, so it is discriminatory for OHP patients.
    a. Subcommittee members encouraged Dr. Hughey to contact OHA's Health Systems Division regarding contracting. This is not an evidence question as psychotherapy is covered whether or not it is conducted in an equine setting.

Recommended Actions:

1) Remove 11960 (Insertion of tissue expander(s) for other than breast, including subsequent expansion) and 11971 (Removal of tissue expander without insertion of implant) from all current Prioritized List lines.
    a. Advise HSD to add 11960 and 11971 to the Ancillary Procedures File
2) Advise HSD to add B4100 (Food thickener, administered orally, per ounce) to the Ancillary Procedure File
3) Remove 58559-58563 (Hysteroscopy with various surgical procedures) from line 1 PREGNANCY
4) Add 61538 and 61539 (Craniotomy with elevation of bone flap), and 61781 (Stereotactic computer-assisted (navigational) procedure; cranial, intradural) to line 174 GENERALIZED CONVULSIVE OR PARTIAL EPILEPSY WITHOUT MENTION OF IMPAIRMENT OF CONSCIOUSNESS
5) Change the name of line 572 to ~~OTHER~~ MINOR COMPLICATIONS OF A PROCEDURE
6) Delete I86.1 (Scrotal varices) from line 548 SUBLINGUAL, SCROTAL, AND PELVIC VARICES
    a. Rename line 548 SUBLINGUAL~~, SCROTAL,~~ AND PELVIC VARICES
7) Add 90759 (Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule) to line 3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS

a. Advise HSD to remove 90759 from the Excluded File

8) Add 47562 and 47563 (Laparoscopy, surgical; cholecystectomy) to line 641 GALLSTONES WITHOUT CHOLECYSTITIS
9) Advise HSD to place the new COVID-related ICD-10-CM codes as shown below:

ICD-10 Code	Code Description	Recommended Placement
Z28.310	Unvaccinated for COVID-19	Informational File
Z28.311	Partially vaccinated for COVID-19	Informational File
Z28.39	Other under-immunization status [non-COVID vaccines]	Informational File

10) Add the following HCPCS codes to the line/file as shown below:

HCPCS Code	Code Description	Recommended Placement
D1708	Pfizer-BioNTech Covid-19 vaccine administration – third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS or line 399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS
D1709	Pfizer-BioNTech Covid-19 vaccine administration – booster dose	3
D1710	Moderna Covid-19 vaccine administration – third dose	3
D1711	Moderna Covid-19 vaccine administration – booster dose	3
D1712	Janssen Covid-19 vaccine administration - booster dose	3
D1713	Pfizer-BioNTech Covid-19 vaccine administration tris-sucrose pediatric – first dose	3
D1714	Pfizer-BioNTech Covid-19 vaccine administration tris-sucrose pediatric – second dose	3
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	3
M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not	3

HCPCS Code	Code Description	Recommended Placement
	recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg.	ANCILLARY PROCEDURES FILE
Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg.	ANCILLARY PROCEDURES FILE
Q0222	Injection, bebtelovimab, 175 mg	ANCILLARY PROCEDURES FILE
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	399
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	399
Q0239	Injection, bamlanivimab, 700 mg	ANCILLARY PROCEDURES FILE
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	399

11) Add the following CPT codes to line 3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS

CPT Code	Code Description	Recommended Placement
91310	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS

CPT Code	Code Description	Recommended Placement
		Pending FDA approval/EUA
0104A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose	3 *Pending FDA approval/EUA*
0074A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS

MOTION: To approve the recommendations stated in the consent agenda. CARRIES 6-0. *(Absent: Duty, Schabel)*

- **Topic: Visual field testing**

Discussion: Smits presented the summary document. There was minimal discussion.

Public testimony
Julie Falardeau, ophthalmologist, OHSU: Dr. Falardeau testified that visual field testing is a diagnostic tool for a variety of conditions, such as tumor progression or localizing residual field deficits. The ability to objectively quantify visual deficits is very important and she relies very heavily on this tool to answer diagnostic questions.

Recommended Actions:
1) Remove visual field testing (CPT 92081-92083, 92133) from all current lines on the Prioritized List
    a. Advise HSD to add CPT 92081-92083, 92133 to the Diagnostic Procedure File

MOTION: To recommend the code changes as presented. CARRIES 6-0.
(Absent: Duty, Schabel)

- **Topic: Adenoidectomy update**

Discussion: Smits presented the summary document. Hodges requested clarification of the wording around when symptoms were directly related to the adenoids. Dr. Kelley suggested "ear infections associated with rhinorrhea." Further subcommittee discussion also added "and/or upper respiratory infection."

Dr. Kelley also requested a review of the current guideline for tonsillectomy, specifically on the number of required strep infections needed for qualifying for surgery. HERC staff will review her materials and bring this topic in August for further discussion.

Recommended Actions:
1) Modify GN51 as shown in Appendix A

MOTION: To recommend the guideline note changes as amended. CARRIES 6-0.
(Absent: Duty, Schabel)

- **Topic: Bilateral bone anchored hearing aids**

Discussion: Smits reviewed the summary document. Dr. Kelley recommended removing the proposed guideline criteria that a "patient is clinically unsuitable for other medical or surgical treatments" as a patient might be suitable for a surgery but is getting adequate hearing with a BAHA. Dr. Kelley also noted that some children older than age 5 use the headband-mounted BAHA devices and that if these work well, then the child should not be forced to undergo surgical implantation. The guideline was modified to allow headband use after age 5.

The subcommittee discussed coverage after age 20. The intent is that persons who had a BAHA inserted or a BAHA headband used prior to age 21 to continue to have these devices maintained after that age. Two sentences which reflect that intent were added to the guideline.

Recommended Actions:
1) Modify GN103 as shown in Appendix A

MOTION: To recommend the guideline note changes as amended. CARRIES 8-0.

- **Topic: Temporary urethral stents 2022**

Discussion: There was minimal discussion for this topic.

Recommended Actions:
1) Add HCPCS C9769 (Cystourethroscopy, with insertion of temporary prostatic implant/stent with fixation/anchor and incisional struts) to line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS
2) Modify GN173 as shown in Appendix A

MOTION: To recommend the code and guideline note changes as presented. CARRIES 8-0.

- **Topic: Fecal lactoferrin**

Discussion: There was minimal discussion for this topic.

Recommended Actions:
1) Remove 83631 Lactoferrin, fecal; quantitative from Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS

a. Advise HSD to place CPT 83631 on the Diagnostic Procedures File

2) Delete the GN173 entry for CPT 83631

MOTION: To recommend the code and guideline note changes as presented. CARRIES 8-0.

- **Topic: Gastric neurostimulators**

Discussion: There was minimal discussion for this topic.

Recommended Actions:

1) Add the following codes to lines 8 TYPE 1 DIABETES MELLITUS, 27 TYPE 2 DIABETES MELLITUS and 529 DISORDERS OF FUNCTION OF STOMACH AND OTHER FUNCTIONAL DIGESTIVE DISORDERS
    a. CPT 43647 Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum
    b. CPT 43648 Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum
    c. CPT 43881 Implantation or replacement of gastric neurostimulator electrodes, antrum, open
    d. CPT 43882 Revision or removal of gastric neurostimulator electrodes, antrum, open
    e. HCPCS E0765 FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea
2) Advise HSD to remove the above codes from the Excluded File
3) Adopt a new guideline for lines 8, 27, and 529 as shown in Appendix B

MOTION: To recommend the code and guideline note changes as presented. CARRIES 8-0.

- **Topic: Routine monitoring MRIs in multiple sclerosis**

Discussion: There was minimal discussion for this topic. Hodges requested that the minutes reflect the intent is that MRI of both the brain and spine are covered for multiple sclerosis.

Recommended Actions:

1) Delete Diagnostic Guideline D10

MOTION: To recommend the guideline note changes as presented. CARRIES 8-0.

- **Topic: Coronary CT angiography**

Discussion: There was minimal discussion for this topic.

Recommended Actions:

1) Remove CPT 75572 and 75574 (CT heart) from line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS
    a. Advise HSD to add CPT 75572 and 75574 to the Diagnostic Procedures File
    b. Remove the entries for CPT 75572 and 75574 from GN173
2) Advise HSD to add CPT 0501T-0504T (Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease) to the Diagnostic Procedures File

MOTION: To recommend the code and guideline note changes as presented. CARRIES 8-0.

- **Topic: Rhinophyma shaving**

Discussion: There was minimal discussion for this topic.

Recommended Actions:

1) Remove CPT 30120 (Excision or surgical planing of skin of nose for rhinophyma) from the following lines
    a. 466 CHRONIC SINUSITIS
    b. 506 NASAL POLYPS, OTHER DISORDERS OF NASAL CAVITY AND SINUSES
    c. 525 BENIGN NEOPLASM OF NASAL CAVITIES, MIDDLE EAR AND ACCESSORY SINUSES
2) Add CPT 30120 to line 522 ROSACEA; MILD/MODERATE ACNE

MOTION: To recommend the code changes as presented. CARRIES 8-0.

- **Topic: Spinal cord stimulators for diabetic peripheral neuropathy**

Discussion: Smits presented the issue summary. There was concern regarding the small sample sizes in the studies presented. Olson noted that the best evidence regarding rates of adverse events was 6%, there was a signal for effectiveness of this therapy, but the lack of large sample sizes makes the effectiveness of the therapy in a larger population unknown. He noted that it was an invasive therapy. Pinzon noted that diabetics are at high risk of infection with any surgery. Hodges noted the high cost of the procedure, as well as the cost of treating complications. The decision was to make no change in the non-pairing of spinal cord stimulators with diabetic peripheral neuropathy.

- **Topic: Shoulder arthroplasty with subacromial spacers**

Discussion: There was minimal discussion for this topic

Recommended Actions:

1) Place HCPCS C9781 (Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression,

acromioplasty, and biceps tenodesis when performed) on line 662/GN173 as shown in Appendix A

MOTION: To recommend the code and guideline note changes as presented. CARRIES 8-0.

- **Topic: Erythropoietin in chronic renal disease**

Discussion: Smits reviewed the issue summary. Olson requested that wording be added to the guideline to require that there be no iron deficiency prior to erythropoietin therapy.

Recommended Actions:
1) Modify GN7 as shown in Appendix A

MOTION: To recommend the guideline note changes as presented. CARRIES 8-0.

- **Topic: Orthodontia guideline update**

Discussion: There was minimal discussion for this topic.

Recommended Actions:
1) Modify Guideline Note 196 as shown in Appendix A

MOTION: To recommend the guideline note changes as presented. CARRIES 8-0.

- **Topic: Benign gastrointestinal carcinoid tumors**

Discussion: There was minimal discussion for this topic.

Recommended Actions:
1) Add the ICD-10-CM D3A.0 family (benign GI carcinoid tumors) to line 157 CANCER OF COLON, RECTUM, SMALL INTESTINE AND ANUS and remove from line 638 BENIGN NEOPLASMS OF DIGESTIVE SYSTEM
2) Add ICD-10CM D3A.093 (Benign carcinoid tumor of the kidney) to line 214 CANCER OF KIDNEY AND OTHER URINARY ORGANS and remove from line 638 BENIGN NEOPLASMS OF DIGESTIVE SYSTEM

MOTION: To recommend the code changes as presented. CARRIES 8-0.

- **Topic: Coverage Guidance— PANDAS/PANS**

Discussion: The Center for Evidence Based Policy (CEBP) and HERC staff presented the evidence review on PANDAS/PANS from EbGS. Smits reviewed the recommended changes to the Prioritized List that would correspond with the EbGS recommendations.

Staff noted that the Oregon pediatric infectious disease specialists requested that they not be included in this guideline. A friendly amendment was made to remove mention of this group from the proposed Prioritized List guideline.

Public testimony

1) Sarah Lemley, Executive Director of the NW PANDAS/PANS Network and mother of a child with PANDAS: Ms. Lemley testified that there is a lack of expertise in these conditions in Oregon. She said the Commission needs to rely on the expertise of national experts. She listed Oregon and national experts who agreed with current recommendations, including psychiatrists and neurologists. Per Ms. Lemley, IVIG is approved for PANDAS by several commercial insurers. Bethany Godlewski, CEBP staff, clarified that that research reflected in the coverage guidance failed to find payer policies supporting coverage by commercial insurers.

2) Cristina Cronin-Vejar, mother of a patient with PANDAS/PANS: Ms. Cronin-Vejar testified of her daughter's symptoms, which were relieved partially by antibiotics, NSAIDs, tonsillectomy, SSRIs, and other treatments. However, she noted that her daughter has never returned to her baseline self after these therapies. Her daughter has difficultly with school. Not having access to IVIG is very distressing to her family.

3) Deborah Miller, the mother of patient with PANDAS: Ms. Miller urged adoption of proposed coverage, stating that her child needs IVIG therapy.

4) Dan Twibell, PACE foundation and father of a PANDAS child: Mr. Twibell testified that PACE is a non-profit organization dedicated to increasing awareness and treatment for PANDAS/PANS. PACE recommends that the EbGS recommendation be adopted by VbBS and HERC.

The subcommittee discussed their concerned with the lack of efficacy for these invasive and possibly harmful treatments. The experts were asked what percentage of PANDAS/PANS patients require IVIG. Daines replied that 10-15% of patients receive IVIG in his specialty clinic and that less-invasive treatments are always tried first. Olson asked how the effectiveness of IVIG or other therapies are determined. Daines replied that his center uses neuropsychiatric testing, but he has many specialists in his clinic. OCD-related scores can be used. Olson asked what the timeframe is for when clinicians see a response to IVIG treatment. Daines replied that response is generally seen in the first 3 months of IVIG. He only continues IVIG past 3 months if there is a significant but partial response. Pinzon asked how long children require IVIG treatment. Daines replied that most children only require a few months of treatment, but about 5% require long-term IVIG treatment. Some children need repeat IVIG for recurrent symptoms after a subsequent infection. Multidisciplinary clinics that are readily available are the ideal setting for treatment; in the absence of such a center, a skilled provider can be sufficient for IVIG decisions. Hodges asked if this therapy is available in Oregon, as OHP rules require treatment in-state when available. Drs. Zarrinnegar and Christy both indicated that their health systems provide IVIG treatment. It was also noted that IVIG can be infused in the home.

Pinzon reflected that the testimony indicated that Oregon does not have the expertise for treatment of PANDAS/PANS. Zarrinnegar noted that she learned about PANDAS treatment through individual training/education and through reaching out to specialty centers in other states.

Olson reflected on the lack of evidence but the need to balance the vulnerability of the population. Pinzon also noted that the severity of the symptoms affects the decision around coverage. There was general concern with including coverage for plasmapheresis. The subcommittee recommended removing plasmapheresis from the proposed Prioritized List guideline as well as recommend that HERC strike coverage of plasmapheresis from the blue box of the coverage guidance report and amend the plasmapheresis evidence table.

Saenger expressed concern for how the end point of treatment is determined. He also expressed concern for the very small trial as the only evidence for this decision. He noted concern that assessment of effectiveness could be biased in these trials. Olson responded that the evidence base is very small, but the population is vulnerable and there is national expert consensus regarding treatment. Godlewski noted that Daines' IVIG trial data should be available in the next year or two. The subcommittee had concerns with waiting to provide coverage for sick, vulnerable children in the interim until the data from that study is available. Olson noted that if coverage of IVIG is adopted, it can be revisited once trial data from the study is available.

Saenger noted concern with publication bias, as negative trials tend to not get published. Hodges expressed concern about paying for an experimental treatment.

The final decision was to recommend the proposed guideline with the striking of plasmapheresis as a coverage therapy.

Recommended Actions:

1) Add ICD-10-CM D89.9 (Disorder involving the immune mechanism, unspecified) to line 313
2) Add a new guideline to line 313 DISORDERS INVOLVING THE IMMUNE SYSTEM as shown in Appendix B

A motion was made to approve the amended changes to the Prioritized List based on the draft coverage guidance scheduled for review by HERC at its May 19, 2022 meeting. **Motion approved 6-2** *(Opposed: Hodges, Saenger).*

- **Public Comment:**

  No additional public comment was received.

- **Issues for next meeting:**
  Review of the tonsillectomy guideline

- **Next meeting:**

  August 11, 2022, virtual meeting.

- **Adjournment:**

  The meeting adjourned at 12:30 PM.

Appendix A

Revised Guideline Notes

~~**DIAGNOSTIC GUIDELINE D10, MRI IN MULTIPLE SCLEROSIS**~~

~~MRI is a diagnostic test for multiple sclerosis and should not be used for routine monitoring of disease.~~

~~MRI may be considered in the following circumstances:~~

- ~~A) Suspected drug failure in the setting of clinical relapse in patients with objective changes in neurological status or documented new clinical symptoms such as urinary urgency or cognitive changes~~
- ~~B) Evaluation of a clear objective progression in clinical symptoms in patients with previously relapsing disease to rule out ongoing inflammatory disease when conversion to secondary progressive MS is suspected~~
- ~~C) Patients who require enhanced pharmacovigilance, including~~
  - ~~1) Yearly monitoring for patients treated with natalizumab who are JCV seropositive~~
  - ~~2) One MRI for patients who switch from natalizumab to other therapeutics (including fingolimod, alemtuzumab and dimethyl fumarate) one year after the switch from natalizumab~~

GUIDELINE NOTE 7, ERYTHROPOIESIS-STIMULATING AGENT (ESA) GUIDELINE

Lines 12,59,92,94,111-115,125,133,135,157,158,161,163,179,191,199,200,208,210,214,215,217, 229,234,237,238,258-262,271,276,286-288,294,295,314-316,329,339,396,397,401,419,435,559,593

- A) Indicated for anemia (Hgb < 10gm/dl or Hct < 30%) induced by cancer chemotherapy given within the previous 8 weeks or in the setting of myelodysplasia.
  - 1) Reassessment should be made after 8 weeks of treatment. If no response, treatment should be discontinued. If response is demonstrated, ESAs should be discontinued once the hemoglobin level reaches 10, unless a lower hemoglobin level is sufficient to avoid the need for red blood cell (RBC) transfusion.
- B) Indicated for anemia (Hgb < 10gm/dl or HCT < 30%) associated with HIV/AIDS.
  - 1) An endogenous erythropoietin level < 500 IU/L is required for treatment, and patient may not be receiving zidovudine (AZT) > 4200 mg/week.
  - 2) Reassessment should be made after 8 weeks. If no response, treatment should be discontinued. If response is demonstrated, the lowest ESA dose sufficient to reduce the need for RBC transfusions should be used, and the Hgb should not exceed 11gm/dl.
- C) Indicated for anemia (Hgb < 10 gm/dl or HCT <30%) associated with chronic renal disease ~~failure~~, with or without dialysis, in the absence of iron deficiency.
  - 1) Reassessment should be made after 12 weeks. If no response, treatment should be discontinued. If response is demonstrated, the lowest ESA dose sufficient to reduce the need for RBC transfusions should be used, and the Hgb should not exceed 11gm/dl. In those not on dialysis, the Hgb level should not exceed 10gm/dl.

Appendix A

GUIDELINE NOTE 51, CHRONIC OTITIS MEDIA WITH EFFUSION

Lines 311,424,446,476

Antibiotic and other medication therapy (including antihistamines, decongestants, and nasal steroids) are not indicated for children with chronic otitis media with effusion (OME) (without another appropriate diagnosis).

Patients with specific higher risk conditions (including craniofacial anomalies, Down's syndrome, and cleft palate, or documented speech and language delay) along with hearing loss and chronic otitis media with effusion are intended to be included on Line 311 or Line 446 for children up to and including age 7. Otherwise hearing loss associated with chronic otitis media with effusion (without those specific higher risk conditions) is only included on Line 476.

For coverage to be considered on Line 311, Line 446 or Line 476, there should be a 3 to 6 month watchful waiting period after diagnosis of otitis media with effusion, and if documented hearing loss is greater than or equal to 25dB in the better hearing ear, tympanostomy surgery may be indicated, given short- but not long- term improvement in hearing. Formal audiometry is indicated for children with chronic OME present for 3 months or longer. Children with language delay, learning problems, or significant hearing loss should have hearing testing upon diagnosis. Children with chronic OME who are not at risk for language delay (such as those with hearing loss <25dB in the better hearing ear) or developmental delay should be reexamined at 3- to 6-month intervals until the effusion is no longer present, significant hearing loss is identified, or structural abnormalities of the eardrum or middle ear are suspected.

Adenoidectomy is ~~not indicated at the time of first pressure equalization tube insertion. It may be indicated in children aged 4 and older who are having their second set of tubes.~~ included on these lines at the time of tympanostomy tube insertion for children under age 4 with symptoms directly related to the adenoids (for example, ear infection associated with rhinorrhea and/or upper respiratory infection) OR in children aged 4 years or older.

Removal of retained tympanostomy tubes requiring anesthesia (CPT code 69424) or as an office visit, is included on Line 424 as a complication, pairing with ICD-10-CM H74.8.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx

GUIDELINE NOTE 103, BONE ANCHORED HEARING AIDS

Lines 311,446

Bone anchored hearing aids (BAHA, CPT 69714, 69715; HCPCS L8690-L8694) are included on these lines when the following criteria are met:

A) The patient is aged 5-20 years for initial implanted bone anchored hearing aids or headband mounted BAHA devices; headband mounted BAHA devices may be used for children under age 5; AND

B) ~~Treatment is for unilateral severe to profound hearing loss when the contralateral ear has normal hearing with or without a hearing aid~~

C) ~~Traditional air amplification hearing aids and contralateral routing of signal (CROS) hearing aid systems are not indicated or have been tried and are found to be not effective~~
D) ~~Implantation is unilateral.~~
E) The patient has one of the following:
   1) Permanent bilateral conductive or mixed hearing loss (for example, congenital malformation of the middle/external ear, microtia, or ossicular disease) unable to be aided by conventional air conducting devices; OR
   2) Unilateral conductive hearing loss with ear canal stenosis or ear canal atresia that is unlikely to benefit from surgery; OR
   3) Profound unilateral sensorineural hearing loss when the contralateral ear has normal hearing with or without a hearing aid; OR
   4) Temporary bilateral conductive hearing loss in patients with cleft palate and middle ear effusions until their palate is repaired and tympanostomy tubes can be placed (for BAHA headband only).

Continuation and maintenance of these devices is included on these lines. This includes patients over the age of 20 who received these devices in childhood or adolescence.

Use of BAHA for treatment of tinnitus is not covered.

[see further wording changes made at the 5/19/22 HERC meeting]

GUIDELINE NOTE 169, ORTHODONTICS FOR CRANIOFACIAL ANOMALIES AND HANDICAPPING MALOCCLUSION

Line 256

Orthodontic treatment is included on this line for persons under the age of 21 with

1) Cleft lip and palate, cleft palate or cleft lip with alveolar process involvement, OR
2) Other craniofacial anomalies resulting in significant malocclusion expected to result in difficulty with mastication, speech, or other oral function, OR
3) ~~Deep impinging overbite when lower incisors are destroying the soft tissue of the palate, tissue laceration and/or clinical attachment must be present, OR~~
4) ~~Crossbite of individual anterior teeth when clinical attachment loss and recession of the gingival margin are present, OR~~
5) ~~Severe traumatic deviation, OR~~
6) ~~Overjet greater than 9mm with incompetent lips or mandibular protrusion (reverse overjet) greater than 3.5mm with masticatory and speech difficulties; OR~~
7) Severe malocclusions with a Handicapping Labiolingual Deviation Index California Modification score of 26 or higher; AND
8) Free and clear of active decay and periodontal disease, verified by a dental exam in past 6 months

Advanced dental imaging is included on this line only when required for surgical planning for repair of craniofacial anomalies

Appendix A

GUIDELINE NOTE 173, INTERVENTIONS THAT ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS FOR CERTAIN CONDITIONS

Line 662

The following Interventions are prioritized on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

Procedure Code	Intervention Description	Rationale	Last Review
C9781	Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon)	Insufficient evidence of effectiveness	May 2022
53855 C9769	Temporary prostatic stents	Insufficient evidence of effectiveness	~~October, 2015~~ May 2022
~~75572~~	~~Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology~~	~~Insufficient evidence of effectiveness~~	~~December, 2009~~
~~75574~~	~~Computed tomography, heart~~	~~Insufficient evidence of benefit, unclear harms of radiation exposure~~	~~August, 2013 Coverage guidance~~
~~83631~~	~~Lactoferrin, fecal; quantitative~~	~~Insufficient evidence of effectiveness~~	~~January 2006~~

Appendix B

New Guideline Notes

GUIDELINE NOTE XXX GASTRIC ELECTRICAL STIMULATION

Line 8, 27,529

Gastric electrical stimulation (CPT 43657, 43648, 43881, 43882) is included on these lines only for pairing with diabetic gastroparesis (ICD-10-CM E10.43, E11.43) or idiopathic gastroparesis (ICD-10-CM K31.84) and only when ALL of the following criteria are met:

1) The patient has intractable nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology; AND
2) The patient is refractory or intolerant of prokinetic medications and antiemetic medications; AND
3) The patient is not on opioid medications; AND
4) The patient does not have abdominal pain as the predominant symptom.

GUIDELINE NOTE XXX PANDAS AND PANS

Line 313

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is included on this line when coded with ICD-10-CM D89.89 (Other specified disorders involving the immune mechanism, not elsewhere classified). Pediatric Acute-Onset Neuropsychiatric Syndrome *(*PANS) is included on this line when coded with ICD-10-CM D89.9 (Disorder involving the immune mechanism, unspecified).

Up to 3 monthly immunomodulatory courses of intravenous immunoglobulin (IVIG) therapy is included on this line to treat PANDAS and PANS when both of the following are met:

a) A clinically appropriate trial of two or more less-intensive treatments (for example, appropriate limited course of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, selective serotonin reuptake inhibitors (SSRIs), behavioral therapy, short-course antibiotic therapy) was either not effective, not tolerated, or did not result in sustained improvement in symptoms (as measured by a lack of clinically meaningful improvement on a validated instrument directed at the patient's primary symptom complex). These trials may be done concurrently, AND
b) A consultation with and recommendation from a pediatric subspecialist (for example, pediatric neurologist, pediatric psychiatrist, neurodevelopmental pediatrician, pediatric rheumatologist, pediatric allergist/immunologist) as well as the recommendation of the patient's primary care provider (for example, family physician, pediatrician, pediatric nurse practitioner, naturopath). The subspecialist consultation may be a teleconsultation. For adolescents, an adult subspecialist consult may replace a pediatric subspecialist consult.

A reevaluation at 3 months by both the primary care provider and pediatric expert is required for continued therapy of IVIG. This evaluation must include clinical testing with a validated instrument, which must be performed pretreatment and posttreatment to demonstrate clinically meaningful improvement.

Appendix B

Long term antibiotic therapy is not included on this line for treatment of PANDAS/PANS. Therapeutic plasma exchange (CPT 36514) does not pair with PANDAS or PANS (ICD-10-CM D89.89 or D89.9) on this line.

MINUTES

Evidence-based Guidelines Subcommittee

Online meeting
April 7, 2022
2:00-5:10pm

Members Present: Devan Kansagara, MD, Chair; Alison Little, MD, MPH; Lynnea Lindsey, PhD; Leslie Sutton (departed at 3:15); Max Kaiser, DO; Leda Garside, RN, MBA; Lisa Kouzes, DC; Abigail Khan, MD; Ben Hoffman, MD; Mimi McDonnell, MD.

Staff Present: Ariel Smits, MD, MPH; Jason Gingerich; Daphne Peck.

Also Attending: Val King MD, MPH, Shauna Durbin & Bethany Godlewski (OHSU Center for Evidence-based Policy); Aaron Trimble, MD; Ben Botkin (Lund Report); Bobbie Clark; Carrie Woodman; Cathy Daraee; Christina Cronin-Vejar; Christine Fallabel; Derek Rogalsky, MD; Erin Scow; Gary Hansen; Greg Showell; Jaymey Sweeney; Jennifer Gore; Joey Razzano; Kimberly Goddard (Representative Prusak Office); Kym McCornack; Melanie Ewald; Meryam; Paria Zarrinnegar; Paul Ryan; Dr. Alison Christy (Providence Pediatric Neurology); Sarah Lemley; Tim Kelly; Val Halpin; Wendy Nawara; Yarisel.

---

1. Call to Order

Devan Kansagara called the meeting of the Evidence-based Guidelines Subcommittee (EbGS) to order at 2:00 pm. A quorum of members was present at the meeting.

---

2. Minutes Review

Minutes from the 12/2/2021 meeting were reviewed and approved 10-0.

---

3. Staff Report

Gingerich read aloud the orientation statement.
Kansagara welcomed two new members to the subcommittee (McDonnell and Hoffman). The rest of the subcommittee members gave brief introductions.

Kansagara nominated Alison Little to be Vice-Chair of the subcommittee. Little gave a brief introduction, including that she is anticipating to retire at the end of 2022. A motion was made to elect Alison Little as Vice-Chair of the subcommittee. **Motion was approved 10-0**. Gingerich noted that given Little's upcoming retirement, he asked members to indicate their interest for the position in 2023.

---

4. Review Public Comment: PANDAS/PANS

Kansagara asked the staff to walk through the public comment disposition. Smits summarized the key feedback received from the public during the comment period; similar concerns were grouped together and addressed at the beginning of the public disposition document. There were many comments submitted and Smits reviewed proposed responses to each one. Changes proposed included requiring one pediatric subspecialist for referral for IVIG instead of requiring two subspecialists; expanding access to specialists to include adult providers for adolescents; expanding access to providers to include more provider types; clarifying the length of an appropriate trial of lesser-invasive therapy; allowing use of telemedicine and teleconsultations.

Kansagara outlined the major difference between this proposed recommendation and the recommendation from the last meeting is lowering the requirement from two pediatric subspecialists down to requiring one subspecialist.

Gingerich introduced the three appointed experts for this topic by reading their biographical statements:

Dr. Alison Christy is the Clinical Director for Providence Pediatric Neurology at Providence St. Vincent Medical Center. She is a pediatric neuroimmunologist and her areas of expertise include neuroimmunological disorders, pediatric neurology and movement disorders. She has given multiple talks on the topic of PANDAS/PANS at professional conferences in Portland. She is director of the Doernbecher Immune Brain Disorders Clinic. Christy has no relevant conflicts of interest to disclose.

Dr. Michael Daines is Associate Professor and Division Chief of Pediatric Allergy, Immunology and Rheumatology at University of Arizona. He is also the Co-Director for the Children's Post Infectious Autoimmune Encephalitis Center of Excellence in Tucson, AZ. His specialties are pediatric allergy and immunology. Daines is the lead investigator of an FDA-approved phase 3 clinical trial for IVIG in the treatment of PANS. His division also oversees several active research projects related to PANDAS/PANS and has a registry for patients and family members. Dr. Daines has received industry funding from Octapharma for the design of the Phase 3 IVIG trial (paid to the university). He has also received travel reimbursements from the PACE Foundation, a PANDAS/PANS advocacy organization.

Dr. Paria Zarrinnegar is Assistant Professor of Psychiatry at OHSU, joining in 2018. She is a board-certified psychiatrist who specializes in biopsychosocial assessment among children and adolescents. Zarrinnegar has no relevant conflicts of interest to disclose.

Kansagara invited public testimony, and limited the testimony to three minutes per person.

Public testimony

Sarah Lemley, Director of the Northwest PANDAS PANS Network: Ms. Lemley said she has no conflicts. She thanked the subcommittee for their deliberations on this topic. She urged the committee to adopt Option 2 and said that Option 1 imposes cumbersome barriers for families who are already stretched thin. Requiring one pediatric subspecialist would align Oregon with most other states in allowing a treatment pathway for IVIG.

Paul Ryan, PACE Foundation (PANDAS/PANS advocacy group): Mr. Ryan said he has no conflicts. He urged the subcommittee to vote for Option 2 and to expand the provider type eligible to treat this population to include rheumatologists and infectious disease specialists. He thanked the committee for their time.

Christina Cronin-Vejar, parent: Ms. Cronin-Vejar said she has no conflicts. She described her child's disease and treatment history, including tonsillectomy. She said her family considered IVIG but could not afford the treatment. She said there is a significant lack of providers who know about PANDAS/PANS and even fewer who are comfortable treating this population. She urged the subcommittee to vote for Option 2 and said these children deserve appropriate medical treatment.

Kym McCornack, parent: Ms. McCornack thanked the subcommittee. She described her daughter's disease and treatment history, including accessing IVIG and subsequent symptom remission. She urged the subcommittee to listen to the family experiences and vote for Option 2.

Sutton asked what other states' coverage of PANDAS/PANS treatments look like and the use of telehealth and/or teleconsultations/provider-to-provider consultations. Mr. Ryan said there is a lot of variety across the eight states but that telehealth has grown in its uptake since the COVID public health emergency. Ryan stated that depends on the subspecialist and whether they decide to see the child in-person or consult with the referring provider. Hoffman said that a physical exam can be a very important component of evaluation, especially for PANDAS/PANS and how complicated these diseases are, and being sure that use of plasmapheresis is only ever prescribed appropriately. Kansagara mentioned the testimony of another testifier from the December meeting and how one child was ultimately diagnosed with Wilson's disease. Kansagara said that e-consults typically consist of a brief review of chart notes and labs and do not allow for the type of in-depth evaluation that a video visit would afford. Lindsey agreed with Kansagara saying that an e-consult does not include an interaction with the child and that the intent of the proposed recommendation is that a subspecialist evaluate the child experiencing PANDAS/PANS.

Gingerich presented the two options that staff had prepared. Kansagara highlighted the differences between the two options. Little asked the appointed experts what their feedback was. Christy described a recent patient story and her consultations with three other pediatric subspecialists within a short period of time, emphasizing that once access to one pediatric subspecialist is achieved, subsequent interactions with subspecialists can be accomplished within a short time frame. Christy noted Daines' testimony from the last meeting was that he only treats about 5% of his patients with IVIG, and that her concern with Option 2 is that it would lead to overtreatment and misdiagnoses. Smits asked if modifying the recommendation to requiring one pediatric subspecialist as well as one e-consult with a second subspecialist would alleviate her concern and Christy responded that that modification seemed reasonable. Kansagara said that is what Option 1(b) currently accomplishes and that the concern from the members of the public, as well as the dearth of available providers, from the past few meetings indicates that requiring multiple subspecialists is too onerous to accomplish.

Khan stated that her concern with allowing use of e-consults at all makes her uncomfortable, stating that e-consultations are typically done with conditions that can be diagnosed in a relatively straightforward manner with a high degree of confidence using objective data, and that is not the case with these conditions. She stated that if the issue is limited resources and a limited provider pool, then e-consults could pose a higher risk to patients and families. Kansagara clarified that Option 1 (b) would require one subspecialist visit with the child and that the second subspecialist encounter could be done

through an e-consult. Khan said that she would expect an e-consult to maintain the same standards of practice, regardless of if it is the first opinion or the second. Kansagara agreed and questioned if the second e-consult becomes superfluous because it wouldn't offer a detailed examination to provide any added benefit.

Kouzes stated a reasonable family physician would seek out opinions from other specialists and that enforcing that process is not necessary. She stated that if the assumption is that the providers are reasonable, then having one primary care physician and the single subspecialist consult is adequate. Hoffman said that part of the risk is, from his own experience in Portland, is that there is potential of abuse and as long as there is oversight, competent primary care physicians and subspecialists should be enough. Kouzes responded that she understands the risk of abuse but that the policy should assume that licensing boards will be the appropriate venue to address abuse. Hoffman agreed. Kansagara said the requirement for one subspecialist to weigh has less to do with the concerns about malpractice than a nuaced decision that requires expertise and there is a real medical value in having at least one subspecialist perform a detailed examination given that some of these treatments have potential harms.

Kaiser said he prefers Option 1 because the diagnostic criteria are evolving for this subset of diseases, the understanding of the disease is evolving, and the understanding of the efficacy of treatments is evolving. These diseases differ than most well-defined conditions that the subcommittee discusses, and given the vulnerability of this population, Option 1 is a good balance. Hoffman said if he is concerned about a child having PANDAS/PANS, he will utilize treatment options within his scope, which does not include plasmapheresis or IVIG. He said if he calls Dr. Christy and she agrees with IVIG, he would feel comfortable proceeding with that treatment plan. Given that, he prefers Option 2. Godlewski said the medical polcieis for Aetna, Moda and Regence Blue Cross Blue Shield all say that IVIG is considered investigational for PANDAS/PANS. McDonnell said she agrees with Khan that adding a provider-to-provider or e-consult would not be a useful requirement. Kansagara agreed and said it would be difficult to meaningfully use e-consults for these conditions. Kouzes and Kaiser discussed whether patients would find subspecialists first or if their primary care provider would be willing to reach out to experts. Hoffman said that the second consultation is a barrier. Lindsey said she does not feel the group does not have a good grasp of how e-consults are defined, and she is worried that the coverage guidance might be unclear as a result. Kansagara said the use of e-consults will differ based on the practice setting, and informally polled the subcommittee members where they stand between the two options. Most members preferred advancing Option 2 to the Commission for consideration. Kouzes made recommendations to adjust the wording of Option 2(b) to include allergists and infectious disease specialists as well as some other edits.

A motion was made to refer the draft coverage guidance with Option 2 as modified to the Health Evidence Review Commission for review. **Motion approved 7-1 (Nay: Kaiser, Abstained: Little, Absent: Sutton).**

DRAFT HERC Coverage Guidance

Tonsillectomy, adenoidectomy, adenotonsillectomy, and prophylactic antibiotic therapy are not recommended for coverage to treat pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS) (*weak recommendation*).

Up to 3 monthly immunomodulatory courses of intravenous immunoglobulin (IVIG) therapy or therapeutic plasma exchange are recommended for coverage to treat PANDAS and PANS (*weak recommendation*) when both of the following are met:

A) A clinically appropriate trial of two or more less-intensive treatments (for example, appropriate limited course of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, selective serotonin reuptake inhibitors (SSRIs), behavioral therapy, short-course antibiotic therapy) was either not effective, not tolerated, or did not result in sustained improvement in symptoms (as measured by a lack of clinically meaningful improvement on a validated instrument directed at the patient's primary symptom complex). These trials may be done concurrently, AND

B) A consultation with and recommendation from a pediatric subspecialist (for example, pediatric neurologist, pediatric psychiatrist, neurodevelopmental pediatrician, pediatric rheumatologist, pediatric allergist/immunologist, pediatric infectious disease specialist) as well as the recommendation of the patient's primary care provider (for example, family physician, pediatrician, pediatric nurse practitioner, naturopath). The subspecialist consultation may be a teleconsultation. For adolescents, an adult subspecialist consult may replace a pediatric subspecialist consult.

A reevaluation at 3 months by both the primary care provider and pediatric expert is required for continued therapy of IVIG or plasma exchange. This evaluation must include clinical testing with a validated instrument, which must be performed pretreatment and posttreatment to demonstrate clinically meaningful improvement.

Note: Other treatments (corticosteroids, SSRIs, NSAIDs, short-course antibiotics, and behavioral therapies) were included in an initial version of this report. These therapies were determined to be beyond the scope of a HERC coverage guidance, as these therapies are commonly used for many indications and are not typically subject to utilization control. Only treatments subject to coverage criteria were retained for the final version of this report.

---

5. Review Coverage Guidance: High-Frequency Chest Wall Oscillation Devices

Gingerich introduced Dr. Aaron Trimble, the appointed expert for this topic, by reading aloud his biographical statement:

Dr. Aaron Trimble is Assistant Professor in Pulmonary and Critical Care Medicine at Oregon Health and Science University. He has expertise in pulmonology and conducts research in cystic fibrosis and mucociliary clearance. He prescribes high-frequency chest wall oscillation devices for patients with cystic fibrosis and bronchiectasis and is also part of the adult CF clinic at OHSU. He has received grant funding from the Cystic Fibrosis Foundation to study high-frequency chest wall oscillation devices. He has also received research funding and food/travel/beverages for his work on CF medications.

Kansagara outlined the process for reviewing the draft coverage guidance for the new members. Gingerich presented the GRADE table as King summarized the evidence overview for the draft coverage guidance, including revisions made to the hospitalizations and pulmonary exacerbations outcomes for the cystic fibrosis GRADE table. This resulted in rating the hospitalization outcome from having a 'low' confidence of evidence to a 'very low' confidence of evidence. Smits summarized the changes made to the rationale and balance of benefits and harms tables as a result of the downgraded confidence of evidence.

Smits summarized the non-cystic fibrosis bronchiectasis GRADE table, stating that staff relied on expert testimony as well as extrapolated evidence for cystic fibrosis to make a recommendation for coverage for this population. Smits presented the option of recommending against coverage for non-cystic fibrosis bronchiectasis. There were no changes in recommendations made for the other two conditions included in the draft coverage guidance.

Kansagara summarized the reasons that the subcommittee initially voted to recommend coverage for cystic fibrosis, including that children need treatment options when manual chest physiotherapy is not available. McDonnell asked why chest wall oscillation devices would be offered to patients with cystic fibrosis if chest physiotherapy failed (criterion A). Trimble responded by saying that the heterogeneity of patients with cystic fibrosis undergoing different treatments will result in differential outcomes for individual patients. Therefore, failing chest physiotherapy does not mean the vest option will fail, as some patients respond to the vest better than others. Hoffman agreed and added that even if a caregiver is capable of performing chest physiotherapy, it is onerous to children and their families. Trimble responded that there are more adults than children with cystic fibrosis now that life expectancy has increased and that adults with cystic fibrosis do not have parents who are capable of performing manual therapy and might other treatment options.

Smits reviewed the recommendations for each of the four conditions. Smits asked if the group wanted to change the recommendation for the cystic fibrosis condition. Lindsey said the testimony heard in prior meetings was compelling enough that the weaker evidence does not change her decision to vote to recommend coverage. Little stated that she previously voted not to recommend coverage and will continue to do so. Smits then surveyed the group if they wanted to change their recommendation for non-cystic fibrosis bronchiectasis. McDonnell noted the paucity of evidence for this condition. Smits reviewed the recommendations for chronic obstructive pulmonary disease and neuromuscular diseases. Kansagara stated that the neuromuscular diseases group contains a heterogenous array of individuals with various disorders and given the small size of each subpopulation, it is very hard to study and highly unlikely that future evidence would emerge, necessitating the reliance on expert testimony. Trimble said that chest wall oscillation is designed to clear the airway and that people with neuromuscular diseases often have issues with aspiration.

Gingerich presented the HERC Guidance Development Framework and Kansagara discussed the flowchart to help organize the various factors the group needs to consider when making coverage decisions. The group discussed costs associated with vest purchases and claims data that can provide context for the decision. Kansagara asked the group what they felt about keeping the COPD recommendation unchanged; there was no discussion. He then surveyed the group about the neuromuscular diseases condition; there was no discussion. Kansagara asked the group about the cystic fibrosis recommendation; there was no discussion. Kansagara asked the group about the non-cystic fibrosis bronchiectasis recommendation; Lindsey stated she would vote for non-coverage for this

coniditon. Hoffman agreed with Lindsey. Kouzes said that posting the non-coverage recommendation for comment might generate more public comment and provide more insight for the next meeting.

Smits revised the rationale table for non-cystic fibrosis bronchiectasis, stating that the larger population makes it more feasible to expect that a trial could be conducted to generate future research.

Trimble stated that he has concerns of equity if the subcommittee relies on a no-vote to generate public comment to refine the decision-making for the next meeting. He does not have any confidence that the patients he sees will or are able to engage in this process, citing language and socioeconomic barriers. Garside said she agrees with Trimble's health equity concerns. Gingerich asked if Trimble could submit formal comment during the public comment period that summarizes his sentiment to ensure that important factor is considered at the next meeting. Smits asked Trimble to encourage his colleagues to also engage in the coverage guidance process. There was no public comment.

A motion was made to refer the draft coverage guidance as modified for a formal 21-day public comment period. **Motion approved 8-1 (Nay: Little, Absent: Sutton).**

DRAFT HERC Coverage Guidance

High-frequency chest wall oscillation devices are recommended for coverage for patients with cystic fibrosis (*weak recommendation*) when there is documentation of frequent exacerbations requiring antibiotics, frequent hospitalization, or rapidly declining lung function measured by spirometry, despite either:

A) having received chest physiotherapy and positive expiratory pressure therapy, OR
B) documentation that chest physiotherapy and positive expiratory pressure devices are not tolerated or not available (e.g., inability of a caregiver to perform chest physiotherapy).

High-frequency chest wall oscillation devices are not recommended for coverage for patients with non-cystic fibrosis bronchiectasis (*weak recommendation*).

High-frequency chest wall oscillation devices are recommended for coverage for patients with neuromuscular disease resulting in chronic lung disease (*weak recommendation*) when there is evidence of chronic lung infection, despite either:

A) having received chest physiotherapy and positive expiratory pressure therapy, OR
B) documentation that chest physiotherapy and positive expiratory pressure devices are not tolerated, contraindicated, or not available (e.g., inability of a caregiver to perform chest physiotherapy).

High-frequency chest wall oscillation devices are not recommended for coverage for patients with chronic obstructive pulmonary disease *(weak recommendation)*.

---

6. Review Scope Statement: Bariatric Procedures

Gingerich presented the scope statement. Smits summarized the document. Kansagara invited public testimony.

Public Testimony

Greg Showell: Mr. Showell said he is a registered nurse and a bariatric program coordinator in Corvallis. He said these bariatric interventions are needed and lowering the BMI to 30 expands access to care. He said the bariatric surgery candidates undergo a rigorous screening process to ensure that patients are good candidates for these procedures.

Derek Rogalsky: Dr. Rolgalsky is a bariatric surgery in Coos Bay and states he has no conflicts. He said he performs his procedures at an MBSAQIP-accredited center. He agrees that bariatric surgery should be expanded to adolescents. He had minor comments regarding the scope statement. He encouraged the study designs to be expanded beyond RCTs to include prospective cohort studies. He briefly summarized the evidence profiles of various bariatric procedures.

McDonnell asked about including a question regarding revisional bariatric procedures; King said that could be added as a subgroup for Key Question 3. The group discussed eligible study designs that could be included.

A motion was made to refer the scope statement as modified to the Health Evidence Review Commission for review. **Motion approved 9-0 (Nay: 0, Absent: Sutton).**

---

7. Review scope statement: Continuous glucose monitors

Continuous glucose monitors scope statement was tabled until the next meeting due to time constraints.

---

8. Adjournment

The meeting was adjourned at 5:10 pm. The next meeting is scheduled for June 2 from 2:00-5:00 pm online.

Highlights

Behavioral Health Advisory Panel
Virtual Meeting
July 25, 2022
3:00 pm--5:00 pm

Members Present: Lynnea Lindsey, PhD Chair; Gary Cobb; Eric Davis, MSW, CADC III, PSS; MSCP; Sheldon Levy, PhD; John Bischof, MD.

Members Absent: Sondra Marshal MD; Kathy Savicki, LCSW

Staff Present: Jason Gingerich; Ariel Smits, MD, MPH; Liz Walker, PhD, MPH; Daphne Peck

Also Attending: Trevor Douglass, Andrew Gibler, and Libbie Rascon (OHA); Michael Yu (OHA Ombuds office); Lisa Kouzes, Ben Slabaugh, Jennifer Henderson, Amanda Parish, Adrienne Auxier, Henry Kaiser, Yvonne Hubbard, Mark Newey, Nancy W, Ann Ford, Ryan, Mike, Wenonoa Spivac, Amelia Harju, Lindsey Phillips, Evyan Daugherty, Tami Stump, Jamie Reed, Allison, Sandi Kock, Jennifer Keating, Maddie Vucovich, crystal, Molly

---

1. CALL TO ORDER

The meeting was called to order at 3:05 PM. The highlights of the BHAP 2021 meeting were reviewed and no changes recommended.

Gingerich reviewed the purpose of the behavioral health advisory panel, which is to inform the HERC Medical Director in making recommendations for VbBS and HERC consideration.

---

2. PRIORITIZED LIST ISSUES

1) 2023 ICD-10-CM code placement
    a. The panel agreed with all staff recommendations for code placements, with recommendation to add the dysfunction line placement for all the dementia diagnoses.
    b. Structure of dementia line
        a. Smits asked the group if there should be any changes made to the current structure of the dementia line (line 201). Currently, there are psychotherapy codes on this line. The group felt that mood disorders or coping skill training may need to be addressed with psychotherapy codes and therefore they are appropriate on that line. Patients with dementia may need a G-tube or urinary catheter or PT or other services which are on the dysfunction lines; therefore, it is appropriate to also have these diagnoses on the dysfunction lines. Based on this discussion, no changes will be recommended

for the current placement of dementia diagnoses on both a unique line and on the dysfunction lines.

2) Straightforward coding issues
   A. Straightforward coding changes
      a. The members agreed with staff recommendations with the following exceptions:
         i. Do not remove HCPCS G2214 from current lines. This code is meant to be used in variety of settings
         ii. Do not remove domiciliary visit from behavioral health lines. Many times a behaviorist is needed for a multi-disciplinary approach to patients in these settings.
         iii. Leave perpetrator of abuse codes as Informational. These persons receive another diagnosis before treatment, such as explosive disorder, pedophilia, etc. Members have not seen these diagnoses being used for provision of mental health services.
      b. The members then when on to discuss moving the diagnoses on line 575 PERSONALITY DISORDERS EXCLUDING BORDERLINE AND SCHIZOTYPAL to a covered line. Historically, these diagnoses were considered untreatable, but current thought is that these are treatable conditions. Staff will prepare a biennial review proposal to merge these diagnoses into the upper, covered personality disorder line such as line 96 BORDERLINE PERSONALITY DISORDER or line 412 SCHIZOTYPAL PERSONALITY DISORDERS, and bring back for further discuss at an upcoming BHAP meeting
   B. Drug induced movement disorders
      a. There was no discussion among members. They agreed with staff recommendations on this topic.
3) Conduct disorder/impulse disorder prioritization
   a. BHAP members strongly felt that this condition should be funded and agreed with staff recommendations. There was minimal discussion. There was acknowledgement that these diagnoses disporportionately affect black and Hispanic children; however, the panel felt that the importance to cover treatment of these diagnoses overrode any concern for disproportionate use in certain populations.
4) Insomnia
   a. BHAP members felt that the staff recommendation was appropriate. Bishof wanted to distinguish primary from secondary insomnia, but other members felt this would be difficult. HERC staff will consult with a pediatric psychiatrist whether the behavioral insomnia of childhood disagnoses should be included in the final recommendation brought to HERC.
5) Childhood disorders of social functioning
   a. Lindsey felt that this was a issue where the line between school-based services and medical services and disability services. Levy noted that children with these diagnoses tend to have a history of abuse and neglect. Other diagnoses could be used to obtain psychiatric evaluation and testing.

---

3. Public comment

Yvonne Hubbard had a question regarding T1016 (Case management, each 15 minutes) and why it did not appear on the Prioritized List. HERC staff replied that this code as Ancilllary.

---

4. ADJOURNMENT

The meeting was adjourned at 4:26 pm.

Appendix A
Recommended Guideline Revisions

Section 2.0

Staff Report

Below the Line Review Summary

Color Key	
	Topics under development
	Upcoming discussion topics
	Reviewed but no changes planned
	Already approved changes

Request source	Topic Description	Meeting Date	Planned Imp. Date	Summary of change (or recommended change, decision not to change)
Staff review	Deformities of upper body and all limbs	tbd		Review with orthopedics expert
Staff review	Congenital anomalies of knee (Knee problems since birth)	tbd		Review with orthopedics expert
Staff review	Genitourinary with minimal or no treatment required (genital and urinary organs)	tbd		Review with urology expert
Dr. Hoffman	Congenital ear anomalies without hearing impairment	tbd		Only microtia (ICD10 17.2) might be considered to move to funded line and most treatment recommendations are only to repair for cosmetic reasons. Severe microtia (grade 3 and 4) would have hearing impairment and the hearing issues are addressed on line 311
Dr. Hoffman	Conduct disorder/impulse disorders (A type of behavior disorder)	8/11/2022		BHAP recommended adding to funded region
Staff review	Behavioral health coding	8/11/2022		Based on review of social emotional learning codes.
Staff review	Sleep disorders other than sleep apnea (including insomnia)	8/11/2022		Consider adding insomnia above the funding line for cognitive behavioral therapy for insomnia (CBTi). Consider role of medication.
Staff (Val King)	Temporomandibular Joint Syndrome (TMJ) (Pain and dysfunction in the jaw joint and muscles controlling jaw movement)	8/11/2022		Review evidence; no change recommended at this time
HSD nurse reviewer	Median and radial nerve lesions	8/11/2022		Proposal to add to covered nerve lesion line with ulnar nerve lesions

Request source	Topic Description	Meeting Date	Planned Imp. Date	Summary of change (or recommended change, decision not to change)
Staff review	Deformities of foot	October, 2022		Under review with ortho and podiatry, likely October 2022 review
Staff review	Somatic symptoms line (Extreme feelings and anxiety about physical symptoms)	October or November (BHAP)		Review with BHAP for any need for reprioritization of one or more diagnoses or of entire line
Staff review	Broader Orthopedic review	October or November		Look through denied claims for candidates for review
Staff review	Benign neoplasm of the digestive system (Surgery for an abnormal growth found in the stomach or intestines)	5/19/2022		Added benign carcinoid tumors to funded region
HSD	Bilateral bone anchored hearing aids (BAHA) (A specific type of hearing aid for children)	5/19/2022	10/1/2022	Proposal to expand coverage from unilateral to bilateral
Staff review	Scrotal varices (An enlargement of the veins within the skin that holds the testicles (scrotum))	5/19/2022	10/1/2022	Already on line 327 as well as line 548 with no guideline. Propose to remove from line 548 and change name of line
Staff review	Other complications of a procedure	5/19/2022	10/1/2022	Propose to rename line "Minor" as diagnoses are minor
Staff review	Anemias due to kidney diseases (erythropoietin) (A drug to treat low blood count caused by kidney disease)	5/19/2022		Recommend clarifying coverage of erythropoietin for non-end stage kidney disease
Staff review	Esophageal ulcer	3/10/2022	10/1/2022	Added to funded region
Dr. Hoffman	Foreign body in digestive tract	3/10/2022	1/1/2022	Had already been addressed prior to the concern raised, but implementation was pending
Staff review	Generalized muscle weakness	3/10/2022	10/1/2022	Added to funded region
HSD Staff	Handicapping malocclusion	11/18/2021	1/1/2023	Working on implementation issues; addition to funded region planned for 1/1/2023
CCO	Dorsal rhizotomy	3/10/2022	10/1/2022	Added to funded region
Staff review	Corneal abcess	3/10/2022	10/1/2022	Added to funded region

Request source	Topic Description	Meeting Date	Planned Imp. Date	Summary of change (or recommended change, decision not to change)
Staff review	Lichen planus	3/12/2020	10/1/2022	Change name of line to reflect mild/moderate; severe forms on funded line as defined by Guideline Note 21
Staff review	Mastoiditis	3/12/2020	10/1/2022	Added to funded region
Dr. Hoffman	Nightmare disorder	11/18/2021	1/1/2022	Added to funded region
Dr. Hoffman	Oral candidiasis (thrush)	8/12/2021	10/1/2021	Added to funded region for feeding problems in newborns line
Dr. Hoffman	Phimosis (acquired penile complications, circumcision etc)	10/7/2021	1/1/2022	Clarified coverage criteria for acquired vs congenital anomalies of the penis. Added to funded region for acquired anomalies.
Staff review	Polydactyly	3/12/2020	10/1/2022	Clarified earlier decision to confirm in funded region
Public	Rhinoplasty/septoplasty/ deviated septum	8/12/2021	10/1/2022	Created new criteria for septoplasty, clarified conditions for coverage. Some new coverage and new limitations for services that would be cosmetic.
Advocates	Selective mutism	11/18/2021	1/1/2022	Moved to funded anxiety line
Staff review	Sjogren syndrome	3/10/2022	10/1/2022	Added to funded region
Staff review	Tendon and ligament injuries	3/10/2022	10/1/2022	Added to funded region for full tears
Staff review	Viral endocarditis, myocarditis, pericarditis, cardiomyopathy	3/10/2022	10/1/2022	Added to funded region
Staff review	Vitiligo	10/7/2021	1/1/2022	Added vitiligo as a funded condition. Affects children's social function
Staff review	Acquired torsion of penis	3/10/2022	10/1/2022	Added to funded region
Staff review	Agenesis of lung	3/10/2022	10/1/2022	Added to funded region for supportive care
EPSDT	Child growth and development	11/18/2021	1/1/2022	Added path to coverage for treatments supporting growth, development and participation in school for children
Staff review	Chronic pancreatitis		1/1/2022	Already merged for 2022 before this review
Staff review	Vitiligo of eyelid	3/10/2022	10/1/2022	Added to funded region

Request source	Topic Description	Meeting Date	Planned Imp. Date	Summary of change (or recommended change, decision not to change)
Staff review	Physical therapy for minor musculoskeletal conditions (Injuries and disorders that affect the human body's movement or muscles, tendons, ligaments, nerves, discs, blood vessels, etc.)			Limited benefit; would be very difficult to implement
Dr. Hoffman	Allergic rhinitis (Nasal allergies/Hay fever)			No change; little impact on health except when comorbidity or growth/development/school exceptions apply
Dr. Hoffman	Angiodema (Swelling (edema) of the lower layer of skin and tissue just under the skin)	11/18/2021	1/1/2022	Removed unfunded duplicate line (no substantive change, was already covered)
Dr. Hoffman	Benign bone neoplasm			No change made; serious benign neoplasms are on line 401; Guideline 137 clarifies which are covered.
Dr. Hoffman	Congenital anomalies of female genital tract excluding vagina			No change: Diagnoses on this line have no treatment. Other anomalies that require repair are on funded line(s)
Dr. Hoffman	Dermatophytoses (ringworm, etc.)			No change; primary care and preferred medications should be sufficient for these conditions
Dr. Hoffman	Diaper rash			No change: Primary care and preferred medications (nystatin) should be sufficient
Dr. Hoffman	Dysmenorrhea			No change; primary care and preferred medications (NSAIDS, birth control) should be sufficient for these conditions
Dr. Hoffman	Hodeolum/chalazeon			No change; primary care and preferred meds should be sufficient for these conditions. Rare exceptions can be considered through existing processes
Dr. Hoffman	Mild eczema			No change; primary care and preferred medications should be sufficient for these conditions
Dr. Hoffman	Mild psoriasis			No change; primary care and preferred medications should be sufficient for these conditions

Request source	Topic Description	Meeting Date	Planned Imp. Date	Summary of change (or recommended change, decision not to change)
Dr. Hoffman	Minor burns			No change: Primary care and preferred medications should be sufficient
Advocates	Pica (Persistent eating of non-food items (for example clay, wool, lead, wood) at an age when it is considered to be developmentally inappropriate)	3/10/2022	10/1/2022	No change: Removed ambiguity of coverage for pica in children (should have already been in funded region), renamed line to clarify that the unfunded line is "Pica in adults"
Dr. Hoffman	Symptomatic urticaria			No change; primary care and preferred medications should be sufficient for these conditions
Staff review	Angiosarcoma of liver; intrahepatic bile duct carcinoma			Liver angiosarcoma has a very poor prognosis with any treatment (6 months even with surgery). Per NIH, the only treatment of bile duct carcinoma is palliative care
Staff review	Central retinal artery occlusion			Reviewed; no effective treatment is available
Dr. Hoffman	Conversion disorders F44.4-7, include non-epilectic seizures			Cognitive behavioral therapy would be available with another underlying disorder such as depression. No other treatment for actual disorder indicated
Staff review	Cysts of Bartholin's gland and vulva			N75.1 (Abscess of Bartholin's gland) is included on line 205. Cysts typically have no symptoms and do not need treatment
Staff review	Enophthalmos			Treatment is directed at underlying diseases, which appear in funded region
Dr. Hoffman	Infectious mononucleosis			Primary care should be sufficient; there is no treatment for this condition
Staff review	Miscellaneous rare congenital anomalies			Individual consideration will be required
Staff review	Nasal polyps			and saline. Surgery indicated if causing chronic sinusitis due to blockage of sinus ostia (would be covered on chronic sinusitis line)
Staff review	Personality disorders			No effective treatment

Request source	Topic Description	Meeting Date	Planned Imp. Date	Summary of change (or recommended change, decision not to change)
Staff review	Secondary and ill-defined neoplasms			Treatment should be targeted to primary cancer, which would be covered.
Staff review	Thrombosed and complicated hemorrhoids			Generally treated with fiber and observation. Could be addressed based on individual review
Staff review	Tension headaches			Primary care and NSAIDs are effective treatments.

Section 3.0

VbBS Report

Errata
August 2022

1) On August 2, 2022, the following corrections were made to the January 1, 2022 Prioritized List:

    a. An incorrect ICD-10-CM code (Z91.020) was removed from Guideline Note 203 PEANUT ALLERGY TREATMENT and replaced with ICD-10-CM Z91.010, which is the correct code for allergy to peanuts.
    b. Line 433 was removed from Guideline Note 73, PENILE ANOMALIES, and corrected to reference Line 434, HYPOSPADIAS AND EPISPADIAS.

Tympanostomy Guideline Updates

Plain Language Summary:
Background: The proposed changes would update the ear tubes guideline for recurrent ear infections to align with new national guidelines which 1) allows adenoidectomy at the time of ear tube placement, and 2) expands the definition of an at-risk child to include intellectual disability, learning disorders, autism spectrum disorder and other conditions.

Should OHP cover this treatment? Staff recommends covering this treatment for additional conditions because the national guidelines have changed.

Questions:

1) Should the tympanostomy guideline be updated based on the AAO-HNS 2022 guideline change?
2) Should adenoidectomy be added to the acute otitis media line with a guideline update allowing use with tympanostomy tube placement based on the AAO-HNS 2022 guideline change?

Question sources:

1) Dr. Peggy Kelley, pediatric ENT
2) Dr. Max Kaiser, CCO medical director

Issue: American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) has updated their tympanostomy guideline. One major change is in the definition of an "at risk" child. Currently, GN29 states "Patients with craniofacial anomalies, Down's syndrome, cleft palate, permanent hearing loss of 25dB or greater independent of otitis media with effusion, and patients with speech and language delay may be considered for tympanostomy if unresponsive to appropriate medical treatment or having recurring infections (without needing to meet the strict "recurrent" definition above)."

Dr. Kelley recommends that GN29 be modified to read: "Patient with suspected or confirmed speech and language delay, autism spectrum disorder, syndromes or craniofacial disorders that include cognitive, speech, or language delays, blindness or uncorrectable visual impairment, cleft palate, developmental delay, intellectual disability, learning disorder or attention-deficit/hyperactivity disorder may be considered for tympanostomy tube placement." Dr. Kelley also recommends the addition of atelectasis (collapsed eardrum) to the list of complications qualifying for ear tubes.

Of note, children over the age of 7 (post-language acquisition) are included in GN51 if they have chronic otitis media.

At the May 2022 meeting, the guideline for chronic otitis media was modified to allow adenoidectomy at the time of tympanostomy tube placement for children under age 4 with symptoms directly related to the adenoids. On staff review, the new AAO guideline for adenoidectomy with tympanostomy tubes appears to relate to tubes placed for either recurrent acute or chronic otitis media.

Current Prioritized List status

GUIDELINE NOTE 29, TYMPANOSTOMY TUBES IN ACUTE OTITIS MEDIA

Line 389

Tympanostomy tubes (CPT 69433, 69436) are only included on this line as treatment for:

A) recurrent acute otitis media (three or more well-documented and separate episodes in six months or four or more well-documented and separate episodes in the past 12 months with at

least one episode in the past six months) in patients who have unilateral or bilateral middle ear effusion at the time of assessment for tube candidacy, or

B) patients with complicating conditions (immunocompromised host, meningitis by lumbar puncture, acute mastoiditis, sigmoid sinus/jugular vein thrombosis by CT/MRI/MRA, cranial nerve paralysis, sudden onset dizziness/vertigo, need for middle ear culture, labyrinthitis, or brain abscess).

Patients with craniofacial anomalies, Down's syndrome, cleft palate, permanent hearing loss of 25dB or greater independent of otitis media with effusion, and patients with speech and language delay may be considered for tympanostomy if unresponsive to appropriate medical treatment or having recurring infections (without needing to meet the strict "recurrent" definition above).

Removal of retained tympanostomy tubes requiring anesthesia (CPT code 69424) or as an office visit, is included on Line 424 as a complication, pairing with ICD-10-CM H74.8.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx

GUIDELINE NOTE 51, CHRONIC OTITIS MEDIA WITH EFFUSION

Lines 311,424,446,476

Antibiotic and other medication therapy (including antihistamines, decongestants, and nasal steroids) are not indicated for children with chronic otitis media with effusion (OME) (without another appropriate diagnosis).

Patients with specific higher risk conditions (including craniofacial anomalies, Down's syndrome, and cleft palate, or documented speech and language delay) along with hearing loss and chronic otitis media with effusion are intended to be included on Line 311 or Line 446 for children up to and including age 7. Otherwise hearing loss associated with chronic otitis media with effusion (without those specific higher risk conditions) is only included on Line 476.

For coverage to be considered on Line 311, Line 446 or Line 476, there should be a 3 to 6 month watchful waiting period after diagnosis of otitis media with effusion, and if documented hearing loss is greater than or equal to 25dB in the better hearing ear, tympanostomy surgery may be indicated, given short- but not long- term improvement in hearing. Formal audiometry is indicated for children with chronic OME present for 3 months or longer. Children with language delay, learning problems, or significant hearing loss should have hearing testing upon diagnosis. Children with chronic OME who are not at risk for language delay (such as those with hearing loss <25dB in the better hearing ear) or developmental delay should be reexamined at 3- to 6-month intervals until the effusion is no longer present, significant hearing loss is identified, or structural abnormalities of the eardrum or middle ear are suspected.

Adenoidectomy is included on these lines at the time of tympanostomy tube insertion for children under age 4 with symptoms directly related to the adenoids (for example, ear infection associated with rhinorrhea and/or upper respiratory infection) OR in children aged 4 years or older.

Removal of retained tympanostomy tubes requiring anesthesia (CPT code 69424) or as an office visit, is included on Line 424 as a complication, pairing with ICD-10-CM H74.8.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx

Expert guideline

1) **Rosenfeld 2022**, Clinical Practice Guideline: Tympanostomy Tubes in Children (Update)
    a. New evidence from 6 clinical practice guidelines, 18 systematic reviews, and 27 randomized controlled trials (RCTs)
    b. Addition of intellectual disability, learning disorder, or attention-deficit/hyperactivity disorder to the list of risk factors that place children who have otitis media with effusion (OME) at increased risk for developmental difficulties (at-risk child)
        i. Aggregate evidence quality: Grade C, based on observational studies
        ii. Level of confidence in evidence: High for children with Down syndrome, cleft palate, and/or permanent hearing loss; medium for other at-risk groups
    c. Updates list of children at risk for developmental difficulties:
        i. Permanent hearing loss independent of otitis media with effusion
        ii. Suspected or confirmed speech and language delay or disorder
        iii. Autism spectrum disorder
        iv. Syndromes (eg, Down) or craniofacial disorders that include cognitive, speech, or language delays
        v. Blindness or uncorrectable visual impairment
        vi. Cleft palate, with or without associated syndrome
        vii. Developmental delay
        viii. Intellectual disability, learning disorder, or attention-deficit/ hyperactivity disorder [these are the only new conditions added in this update]
    d. Adjuvant adenoidectomy:
        i. Clinicians may perform adenoidectomy as an adjunct to tympanostomy tube insertion for children with symptoms directly related to the adenoids (adenoid infection or nasal obstruction) OR in children aged 4 years or older to potentially reduce future incidence of recurrent otitis media or the need for repeat tube insertion
        ii. Strength of recommendation: option based on randomized controlled trials, meta-analyses, and population-level studies, with a balance of benefits and harms.
        iii. Aggregate evidence quality: Grade B, based on RCTs for persistence of OME post-surgically, rate of repeat tube insertion, and hearing outcomes; observational studies regarding the rate of tube reinsertion and hearing outcomes; and meta-analyses on the benefit of adenoidectomy in patients greater than 4 years of age as compared with those younger than 4 years of age
        iv. Level of confidence in evidence: High for symptoms related to adenoids and children over the age of 4 years; medium for role as primary treatment in select populations and role in second tube insertion procedures in patients younger than 4 years
        v. Benefits: Optimize management of adenoid-related disease (nasal obstruction, bacterial infection, chronic rhinitis); reduce need for further surgery and anesthesia; optimize hearing outcomes; decreased persistence of MEE after surgery.
        vi. Risks, harms, costs: Surgical risks of adenoidectomy, additional anesthetic risk related to need for intubation during procedure, bleeding, hypernasality, velopharyngeal insufficiency, nasopharyngeal scarring/stenosis, Grisel's syndrome, longer recovery
        vii. Benefit-harm assessment: Equilibrium (balance) of benefits vs harms

HERC staff recommendation:

1) Add adenoidectomy codes to line 389 ACUTE OTITIS MEDIA
    a. CPT 42830-42836 (Adenoidectomy primary or secondary)
2) Modify GN29 as shown below
    a. Modify the list of conditions that make a child high risk
        i. Note: AAO and Dr. Kelley recommend including "autism spectrum" as a condition for consideration for earlier tubes. HERC staff believe that one of the other conditions such as hearing loss or language delay should be met rather than just autism given the wide range of clinical presentations of that condition
    b. Add wording about adenoidectomy mirroring language adopted for GN51

GUIDELINE NOTE 29, TYMPANOSTOMY TUBES IN ACUTE OTITIS MEDIA

Line 389

Tympanostomy tubes (CPT 69433, 69436) are only included on this line as treatment for:

A) recurrent acute otitis media (three or more well-documented and separate episodes in six months or four or more well-documented and separate episodes in the past 12 months with at least one episode in the past six months) in patients who have unilateral or bilateral middle ear effusion at the time of assessment for tube candidacy, or
B) patients with complicating conditions (atelectasis [collapsed eardrum], immunocompromised host, meningitis by lumbar puncture, acute mastoiditis, sigmoid sinus/jugular vein thrombosis by CT/MRI/MRA, cranial nerve paralysis, sudden onset dizziness/vertigo, need for middle ear culture, labyrinthitis, or brain abscess).

Patients with craniofacial anomalies; syndromes~~,~~ ~~Down's syndrome~~ that include cognitive, speech, or language delays; cleft palate~~,~~; permanent hearing loss of 25dB or greater independent of otitis media with effusion~~,~~; developmental delay; intellectual disability~~,~~; learning disorder~~,~~; attention-deficit/hyperactivity disorder~~,~~; blindness or uncorrectable visual impairment~~,~~; and patients with speech and language delay may be considered for tympanostomy if unresponsive to appropriate medical treatment or having recurring infections (without needing to meet the strict "recurrent" definition above).

Adenoidectomy is included on these lines at the time of tympanostomy tube insertion for children under age 4 with symptoms directly related to the adenoids (for example, ear infection associated with rhinorrhea and/or upper respiratory infection) OR in children aged 4 years or older.

Removal of retained tympanostomy tubes requiring anesthesia (CPT code 69424) or as an office visit, is included on Line 424 as a complication, pairing with ICD-10-CM H74.8.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx

Consent Agenda Issues—August 2022

Code	Code Description	Line(s) Involved	Issue	Recommendation(s)
46615	Anoscopy; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique	157 CANCER OF COLON, RECTUM, SMALL INTESTINE AND ANUS	CPT 46615 is currently on lines 166,475,621. A CCO requested that it be added to line 157 to pair with ICD-10-CM D37.5 (Neoplasm of uncertain behavior of rectum)	Add 46615 to line 157
M50.121 M50.122 M50.123 M50.13	Cervical disc disorder at C4-C5 level with radiculopathy Cervical disc disorder at C5-C6 level with radiculopathy Cervical disc disorder at C6-C7 level with radiculopathy Cervical disc disorder with radiculopathy, cervicothoracic region	346 CONDITIONS OF THE BACK AND SPINE WITH URGENT SURGICAL INDICATIONS	General cervical radiculopathy codes such as ICD-10-CM M54.12 (Radiculopathy, cervical region) are on line 346. The codes shown are only on the medical back line (line 402) and the uncovered back surgical line (line 530).	Add M50.121, M50.122, M50.123, and M50.13 to line 346
43266	Esophagogastroduodenoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)	41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION	MMC case review found that CPT 43266 should pair with ICD-10-CM K56.6X (Intestinal obstruction), which is on line 41. CPT 43266 is currently on lines 215,314,378,593,638	Add 43266 to line 41
G96.198	Other disorders of meninges, not elsewhere classified	424 COMPLICATIONS OF A PROCEDURE USUALLY REQUIRING TREATMENT	MMC case review found that CPT 63709 (Repair of dural/ cerebrospinal fluid leak or pseudomeningocele, with laminectomy) should pair with ICD-10 G96.198. One subdiagnosis of G96.198 is “acquired pseudomeningocele”. 63709 is currently on lines 33,285,424	Add G96.198 to line 424

Consent Agenda Issues—August 2022

Code	Code Description	Line(s) Involved	Issue	Recommendation(s)
K80.20 K80.50 K80.70	Calculus of gallbladder without cholecystitis without obstruction Calculus of bile duct without cholangitis or cholecystitis without obstruction Calculus of gallbladder and bile duct without cholecystitis without obstruction	55 COMPLICATED STONES OF THE GALLBLADDER AND BILE DUCTS; CHOLECYSTITIS	Coverage was added for uncomplicated gallstones when there are certain conditions met in GN167. However, the 3 ICD-10-CM codes for these conditions remain only on line 641 GALLSTONES WITHOUT CHOLECYSTITIS. These codes should be added to line 55 and stay on line 641, with GN167 determining when they are covered	Add K80.20, K80.50, K80.70 to line 55
G56.1X family G56.3X family	Other lesions of median nerve Lesion of radial nerve	416 PERIPHERAL NERVE ENTRAPMENT 509 and 537 PERIPHERAL NERVE DISORDERS	HSD nurse reviewer question. Ulnar nerve lesions (ICD-10-CM G56.2X) are on line 416. However, median nerve lesions other than carpal tunnel syndrome and radial nerve lesions are only on lines 509 and 537. (Medical and Surgical treatment respectively). Compressions of the median and radial nerves can cause issues with use of the hand and/or arm. Similar nerve lesions for the nerves innervating the foot are on line 416.	Add G56.1X family and G56.3X family to 416 PERIPHERAL NERVE ENTRAPMENT Remove G56.1X family and G56.3X family from lines 509 and 537
96450	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture	292 NEUROLOGICAL DYSFUNCTION IN POSTURE AND MOVEMENT CAUSED BY CHRONIC CONDITIONS	Spinal muscular atrophy (ICD-10-CM G12.9) is on lines 71,292,345, 377. This condition can be treated with the drug nusinersen (Spinraza) which is administered with CPT code 96450. CPT 62323 can also be used, which is on line 292.	Add CPT 96450 to line 292

Consent Agenda Issues—August 2022

Code	Code Description	Line(s) Involved	Issue	Recommendation(s)
K76.7	Hepatorenal syndrome	307 CIRRHOSIS OF LIVER OR BILIARY TRACT; BUDD-CHIARI SYNDROME; HEPATIC VEIN THROMBOSIS; INTRAHEPATIC VASCULAR MALFORMATIONS; CAROLI'S DISEASE Treatment: LIVER TRANSPLANT, LIVER-KIDNEY TRANSPLANT 493 HEPATORENAL SYNDROME Treatment: MEDICAL THERAPY	There is no treatment for hepatorenal syndrome other than a liver transplant, which corrects both the liver disease and associated impaired renal function. Even after successful liver transplantation, patients who had hepatorenal syndrome beforehand may not fully recover their kidney function. A small percentage may go on to permanent damage requiring dialysis. This diagnosis was found on denied inpatient claims review	Add K76.7 to line 307 and keep on line 493
G61 family G62 family	Inflammatory polyneuropathy Other and unspecified polyneuropathies	165 PREVENTIVE FOOT CARE IN HIGH-RISK PATIENTS	Line 165 PREVENTIVE FOOT CARE IN HIGH-RISK PATIENTS is intended to include diagnoses that place a patient at higher risk of foot ulcers and other complications. Such diagnoses include lower extremity neuropathies. HERC staff have found multiple peripheral neuropathy diagnosis codes that are missing from this line.	Add the G61 and G62 ICD-10-CM families to line 165
90584	Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use	Excluded File	The AMA released a new vaccine code for Dengue vaccine effective July 1, 2022. This is a travel vaccine.	Add 90584 to the Excluded File

Straightforward Guideline Note Changes

Issue 1: GN9 is currently attached to two lines, line 29 REGIONAL ENTERITIS, IDIOPATHIC PROCTOCOLITIS, ULCERATION OF INTESTINE and line 56 ULCERS, GASTRITIS, DUODENITIS, AND GI HEMORRHAGE. However, capsule endoscopy is used for diagnosis of conditions such as iron deficiency anemia, GI bleeding, or abdominal pain. These diagnoses are on the Diagnostic File. The two lines attached to GN9 have established diagnoses. GN9 needs to be converted to a Diagnostic Guideline and the CPT code for capsule endoscopy (CPT 91110) be placed on the Diagnostic Procedures File.

HERC staff recommendation:

1) Remove CPT 91110 (Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus through ileum, with interpretation and report) from lines 29 REGIONAL ENTERITIS, IDIOPATHIC PROCTOCOLITIS, ULCERATION OF INTESTINE and line 56 ULCERS, GASTRITIS, DUODENITIS, AND GI HEMORRHAGE.
    a. Advise HSD to add CPT 91110 to the Diagnostic Procedures File
2) Modify GN9 as shown below

~~**GUIDELINE NOTE 9**~~ **DIAGNOSTIC GUIDELINE DX, WIRELESS CAPSULE ENDOSCOPY**

~~*Lines 29,56*~~

A) Wireless capsule endoscopy is included on these lines for diagnosis of:
    1) Obscure GI bleeding suspected to be of small bowel origin with iron deficiency anemia or documented GI blood loss
    2) Suspected Crohn's disease with prior negative work up
B) Wireless capsule endoscopy is not included on these lines for:
    1) Colorectal cancer screening
    2) Confirmation of lesions of pathology normally within the reach of upper or lower endoscopes (lesions proximal to the ligament of Treitz or distal to the ileum)
C) Wireless capsule endoscopy is only included on these lines when the following conditions have been met:
    1) Prior studies must have been performed and been non-diagnostic
        a) GI bleeding: upper and lower endoscopy
        b) Suspected Crohn's disease: upper and lower endoscopy, small bowel follow through
    2) Radiological evidence of lack of stricture
    3) Only covered once during any episode of illness
    4) FDA approved devices must be used
    5) Patency capsule should not be used prior to procedure

Issue 2: The genetic testing guidelines were updated recently. A reference to the non-prenatal genetic testing guideline in the high risk breast cancer guideline was not updated to reflect this. The older version of Diagnostic Guideline D1 discussed genetic testing in section A2. The updated guideline discusses genetic testing in section B:

B) Pretest and posttest genetic counseling is required for presymptomatic and predisposition genetic testing. Pretest and posttest genetic evaluation (which includes genetic counseling) is covered when provided by a suitable trained health professional with expertise and experience in genetics.
   1) "Suitably trained" is defined as board certified or active candidate status from the American Board of Medical Genetics, American Board of Genetic Counseling, or Genetic Nursing Credentialing Commission

HERC staff recommendation:

1) Modify GN3 as shown below

GUIDELINE NOTE 3, PROPHYLACTIC TREATMENT FOR PREVENTION OF BREAST CANCER IN HIGH-RISK WOMEN

Line 191

Bilateral prophylactic breast removal and/or salpingo-oophorectomy are included on Line 191 for women without a personal history of invasive breast cancer who meet the criteria in the NCCN Clinical Practice Guidelines in Oncology (Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic V1.2022 (8/11/21) www.nccn.org). Prior to surgery, women without a personal history of breast cancer must have a genetics consultation as defined in section ~~A2~~ B of the DIAGNOSTIC GUIDELINE D1, NON-PRENATAL GENETIC TESTING GUIDELINE.

Contralateral prophylactic mastectomy is included on Line 191 for women with a personal history of breast cancer.

Hysterectomy is only included on Line 191 for women with a BRCA1 pathogenic/likely pathogenic variant who undergo the procedure at the time of risk reducing salpingo-oophrectomy

COVID-19 Related Codes
August 2022

Issues:

1) New COVID vaccine codes were released for pediatric Moderna vaccination
2) A new COVID vaccine administration code was added for the 3rd dose of the tris-sucrose vaccine formulation

HERC staff recommendations:

1) Add the following CPT codes to line 3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS

CPT Code	Code Description	Recommended Placement
0091A	Moderna Covid-19 vaccine administration – children ages 6-11 – first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS
0092A	Moderna Covid-19 vaccine administration – – children ages 6-11 – second dose	3
0093A	Moderna Covid-19 vaccine administration – – children ages 6-11 – third dose	3
91311	Moderna Covid-19 vaccine administration – children ages 6 months to 5 years	3
0111A	Moderna Covid-19 vaccine administration – children ages 6 months to 5 years – first dose	3
0112A	Moderna Covid-19 vaccine administration – – children ages 6 months to 5 years – second dose	3
0113A	Moderna Covid-19 vaccine administration – – children ages 6 months to 5 years – third dose	3
0083A	IMM ADMN SARSCOV2 3MCG/0.2ML TRIS-SUCROSE 3RD dose	3

Monkeypox Vaccination

Issue: New CPT codes were released in late July for the two vaccines with FDA authorization or EUA for prevention and pre-exposure prophylaxis for monkeypox. Monkeypox is a rare disease caused by infection with the monkeypox virus. Monkeypox virus is part of the same family of viruses as variola virus, the virus that causes smallpox.

There is currently an outbreak of monkeypox in the US, with multiple cases in Oregon. CDC recommends vaccination for people who have been exposed to monkeypox and people who are at higher risk of being exposed to monkeypox. There are two vaccines available for monkeypox: Jynneos is specific for monkeypox and ACAM2000 was initially developed for smallpox, but has activity against monkeypox.

A new CPT code was also released for the testing for monkeypox and related orthopoxviruses

HERC staff recommendations:

1) Add the following CPT codes for monkeypox vaccines to line 3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS
    a. CPT 90611 Jynneos vaccine (Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection)
    b. CPT 90622 ACAM2000 vaccine (Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use)
2) Advise HSD to add CPT 87593 (Infectious agent detection by nucleic acid (DNA or RNA); orthopoxvirus (eg, monkeypox virus, cowpox virus, vaccinia virus), amplified probe technique, each) to the DIAGNOSTIC PROCEDURES FILE

Preventive Services Guideline References Update

Issue: The preventive services guideline needs several updates:

1) The current link to the USPSTF recommendations is incorrect
2) Bright Futures was updated in July 2022 and the link needs to be updated
3) The dates of USPSTF and HRSA covered services need to be updated

HERC staff recommendations:

1) Update GN106 as shown below
    a. Update the link for the USPSTF A and B recommendations

GUIDELINE NOTE 106, PREVENTIVE SERVICES

Lines 3,622

Included on Line 3 are the following preventive services:

A) US Preventive Services Task Force (USPSTF) "A" and "B" Recommendations in effect and issued prior to January 1, ~~2021~~ 2022.
    1) ~~http://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-a-and-b-recommendations/~~ https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendation
        a) Treatment of falls prevention with exercise interventions is included on Line 292.
    2) USPSTF "D" recommendations are not included on this line or any other line of the Prioritized List.

B) American Academy of Pediatrics (AAP) Bright Futures Guidelines:
    1) http://brightfutures.aap.org. Periodicity schedule available at ~~http://www.aap.org/en-us/professional-resources/practice-support/Periodicity/Periodicity Schedule_FINAL.pdf.~~ https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf
        a) Bright Futures is the periodicity schedule for screening for EPSDT for the Oregon Health Plan.
    2) Screening for lead levels is defined as blood lead level testing and is indicated for Medicaid populations at 12 and 24 months. In addition, blood lead level screening of any child between ages 24 and 72 months with no record of a previous blood lead screening test is indicated.

C) Health Resources and Services Administration (HRSA) Women's Preventive Services-Required Health Plan Coverage Guidelines (revised January, 2022)~~as updated by HRSA in December 2019~~. Available at https://www.hrsa.gov/womens-guidelines~~-2019~~ retrieved ~~as of~~on ~~September 4, 2020~~July 28, 2022.

D) Immunizations as recommended by the Advisory Committee on Immunization Practices (ACIP): http://www.cdc.gov/vaccines/schedules/hcp/index.html or approved for the Oregon Immunization Program: https://public.health.oregon.gov/PreventionWellness/VaccinesImmunization/ImmunizationProviderResources/Documents/DMAPvactable.pdf
    1) COVID-19 vaccines are intended to be included on this line even if the specific administration code(s) do not yet appear on the line when the vaccine has both 1) FDA approval or FDA emergency use authorization (EUA) and 2) ACIP recommendation.

Colorectal cancer screening is included on Line 3 for average-risk adults aged 45 to 75, using one of the following screening programs:

A) Colonoscopy every 10 years
B) Flexible sigmoidoscopy every 5 years
C) Fecal immunochemical test (FIT) every year
D) Guaiac-based fecal occult blood test (gFOBT) every year

CT colonography (CPT 74263), FIT-DNA (CPT 81528) and mSEPT9 (HCPCS G0327) are included on Line 502 CONDITIONS FOR WHICH INTERVENTIONS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS.

Colorectal cancer screening for average-risk adults aged 76 to 85 is covered after informed decision making between patients and clinicians which includes consideration of the patient's overall health, prior screening history, and preferences.

Supervised evidence-based exercise programs for fall prevention for persons aged 65 or older OR younger patients who are at increased risk of falls are included on Line 3 using CPT 98961 or 98962 or HCPCS S9451. HCPCS S9451 is only included on Line 3 for the provision of supervised exercise therapy for fall prevention. Programs should be culturally tailored/culturally appropriate when feasible.

Note: CPT 96110 (Developmental screening (e.g., developmental milestone survey, speech and language delay screen), with scoring and documentation, per standardized instrument) can be billed in addition to other CPT codes, such as evaluation and management (E&M) codes or preventive visit codes.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx

Burst Fractures of the Spine

Plain Language Summary:
Background: Serious injury to the bones of the spine requiring immediate medical attention to prevent or minimize injury to the spinal cord.

Should OHP cover this treatment? Staff recommends cover this treatment because similar diagnosis codes are already placed in the funded region of the Prioritized List.

Question: Should burst fractures of the spine be moved to covered lines?

Question source: Denied inpatient claims review

Issue: There are multiple ICD-10-CM codes for stable and unstable burst fractures of vertebra. Some of these codes are on covered lines and some are on uncovered lines.

In general, a burst fracture is serious injury resulting from the vertebral body shattering with enough force to separate the bone fragments and compromise the vertebra's ability to support the spine. Bone fragments can also be displaced into the spinal canal or foramen, leading to pressure on the nerves and compromised function. Potential for a spinal cord injury is high. Burst fractures require immediate attention and treatment to prevent or minimize injury to the spinal cord and typically requires immediate hospitalization and treatment. If the burst fracture is not severe, i.e., has not led to neurological and/or structural compromise, a nonoperative approach can be considered. However, surgery is required if the burst fracture has significantly impaired the mechanical strength of the spine or causes compression of the spinal cord or nerves, leading to neurological deficits.

Multiple denied hospital claims for patients with spinal burst fractures were found on claims review.

ICD-10 Code	Code Description	Current Line(s)
S12.[1-6]	Fractures of cervical vertebrae, all types, open or closed	150 CERVICAL VERTEBRAL DISLOCATIONS/FRACTURES, OPEN OR CLOSED; OTHER VERTEBRAL DISLOCATIONS/FRACTURES, OPEN OR UNSTABLE; SPINAL CORD INJURIES WITH OR WITHOUT EVIDENCE OF VERTEBRAL INJURY
S12.[xxx]K	Fractures of cervical vertebrae, all types, subsequent encounter for fracture with nonunion	443 MALUNION AND NONUNION OF FRACTURE
S22.0[x][1-2]	Stable or unstable burst fracture of thoracic vertebrae, closed	478 CLOSED DISLOCATIONS/FRACTURES OF NON-CERVICAL VERTEBRAL COLUMN WITHOUT NEUROLOGIC INJURY OR STRUCTURAL INSTABILITY
S22.0[x][1-2]	Stable or unstable burst fracture of thoracic vertebrae, open	150
S32.0[x][1-2]	Stable or unstable burst fracture of lumbar vertebrae, closed	478 CLOSED DISLOCATIONS/FRACTURES OF NON-CERVICAL VERTEBRAL COLUMN WITHOUT NEUROLOGIC INJURY OR STRUCTURAL INSTABILITY

S32.0[x][1-2]	Stable or unstable burst fracture of lumbar vertebrae, open	150

HERC staff recommendation:

1) Move the S22.0[x][1-2] family and the S32.0[x][1-2] family (stable or unstable burst fractures of thoracic or lumbar spine) to line 150 CERVICAL VERTEBRAL DISLOCATIONS/FRACTURES, OPEN OR CLOSED; OTHER VERTEBRAL DISLOCATIONS/FRACTURES, OPEN OR UNSTABLE; SPINAL CORD INJURIES WITH OR WITHOUT EVIDENCE OF VERTEBRAL INJURY

Z Diagnosis Code Review

Issue: HERC staff have reviewed the current ICD-10-CM "Z" codes that are currently listed as being on the Informational Diagnosis file. "Z" codes include a variety of types of codes, and currently appear on lines, on the INFORMATIONAL DIAGNOSES file, or on the DIAGNOSTIC WORKUP FILE. Several of these codes appear to be appropriate for a clinical encounter. HERC staff proposes moving these codes as shown below.

HERC staff recommendation

1) Advise HSD to move the codes below to the Diagnostic Work Up File and remove from the Informational Diagnosis File

ICD-10 Code	Code Description	Current Placement	Recommended Placement	Comment
Z71.2	Person consulting for explanation of examination or test findings	INFORMATIONAL DIAGNOSES	DIAGNOSTIC WORKUP FILE	
Z72.51	High risk heterosexual behavior	INFORMATIONAL DIAGNOSES	DIAGNOSTIC WORKUP FILE	Appropriate for STI screening or for PrEP
Z72.52	High risk homosexual behavior	INFORMATIONAL DIAGNOSES	DIAGNOSTIC WORKUP FILE	See above
Z72.53	High risk bisexual behavior	INFORMATIONAL DIAGNOSES	DIAGNOSTIC WORKUP FILE	See above

Bronchial Thermoplasty

Plain Language Summary:
Background: Treatment for severe asthma by using heat to widen the bronchial tubes in the lungs.

Should OHP cover this treatment? Staff recommends that OHP not cover this treatment because the evidence shows little benefit and the procedure may increase short-term asthma flareups.

Question: Should bronchial thermoplasty be moved to a covered line?

Question source: Dr. Mark Buchholz, medical director, PacificSource

Issue: Bronchial thermoplasty was last reviewed in 2012 as a new 2013 CPT code. It was found to be investigational and placed on the Excluded List, and then later to line 662/GN173. Dr. Buchholtz is requesting an updated review. Bronchial thermoplasty is an interventional treatment option for severe asthma that involves the delivery of controlled radiofrequency thermal energy to the walls of accessible proximal airways with the intent of reducing excess airway smooth muscle tissue in the airways and reducing the frequency of severe asthma exacerbations on a long-term basis. It was approved by the FDA in 2010.

Updated evidence review

1) **D'Anci 2017**, AHRQ evidence review on the effectiveness and safety of bronchial thermoplasty is management of asthma
    a. N=15 studies (3 RCTs with 432 patients)
        i. Impact of bronchial thermoplasty (BT)in addition to standard care in patients with asthma
    b. BT and standard care improved asthma control (defined by the Asthma Control Questionnaire [ACQ] change from baseline to 12 months) and Asthma Quality of Life Questionnaire (AQLQ) scores more than standard care alone to a degree that was statistically significant but not clinically important (low strength of evidence [SOE]).
    c. However, BT and standard care, compared with a sham bronchoscopic procedure and standard care, did not improve asthma control (defined as ACQ change from baseline to 12 months), hospitalizations for respiratory symptoms, use of rescue medications, pulmonary physiology measures, or AQLQ scores (in the intention-to-treat analysis) (low SOE)
    d. In the RCTs comparing BT and standard care to standard care alone, evidence was insufficient to assess if BT reduced rates of severe exacerbations
    e. Common adverse events following BT during the 12-week treatment period in the RCTs included bronchial irritation, chest discomfort, cough, discolored sputum, dyspnea, night awakenings, and wheezing. Hospitalizations were more common in patients undergoing BT than with either standard care alone or sham bronchoscopy during the 12-week treatment period, as were upper respiratory tract infections, wheezing, dyspnea, lower respiratory tract infections, anxiety, and segmental atelectasis, but the events were too infrequent to achieve statistical significance. Severe adverse events (including post-procedure segmental atelectasis due to mucus plugging, hemoptysis, chest infections requiring hospitalization, and bronchial artery pseudoaneurysm) were also reported in six case reports and two small case series

f. Conclusions. While asthma control and quality of life measures modestly improved in patients undergoing BT compared to medical management alone in two controlled but nonblinded studies, these measures did not improve in the sham-controlled study. The sham-controlled, blinded study found modest improvements in severe exacerbations and significantly fewer emergency department visits following BT compared to the sham bronchoscopic procedure, but serious adverse events and post-procedure hospitalizations were more common during the 12- week treatment period in patients undergoing BT than in patients undergoing sham treatment. The available body of literature on BT is small and uncertainty remains about appropriate patient selection criteria and the effects of the treatment beyond 5 years.

2) **NICE 2018**, bronchial thermoplasty for severe asthma https://www.nice.org.uk/guidance/ipg635/evidence/overview-final-pdf-6651284509
   a. N=14 studies (2 SRs with meta-analysis, 1 RCT, 3 case series, 1 non-randomized comparative study, 1 registry and 5 case reports
   b. Quality of life: In a systematic review (SR) of 3 randomized control trials (RCTs, n=429), quality of life assessed by the Asthma Quality of Life Questionnaire (AQLQ) was statistically significantly better in patients who had bronchial thermoplasty (BT) compared with standard medical care (SMC) or sham (mean difference [MD] 0.28, 95% confidence interval [CI] 0.07 to 0.5, p=0.0099; I2=0%), at 12-month follow-up. Mean AQLQ score was 0.28 (0.07 to 0.5) higher in the BT group compared with controls (5.1 to 5.7)
   c. In the SR of 3 RCTs (n=429) asthma control measured using the Asthma Control Questionnaire (ACQ) was not statistically significantly different between patients who had BT and SMC or sham controls (MD -0.15, 95% CI -0.40 to 0.10, p=0.23; I 2=32%) at 12-month follow-up
   d. In 1 RCT (n=112) reported in the SR of 3 RCTs, the mean reduction in mild asthma exacerbations was statistically significantly higher from baseline in patients who had BT (-0.16 ± 0.37 per week) compared with SMC (0.04 ± 0.29 per week, p0.05). In another RCT (n=288) reported in the same SR, the number of severe exacerbations was statistically significantly lower in patients who had BT (0.48 ± 0.067) than sham (0.70 ± 0.122, p<0.05) at 12-month follow-up
   e. In an RCT (n=34) in the SR of 3 RCTs, complete wean from regular corticosteroids was not statistically significantly different in patients who had BT (50% [4/8]) compared with SMC (14% [1/7], p>0.05). In the same RCT, mean reduction in regular oral corticosteroid (OCS) doses was also not statistically significantly different between patients who had BT (63.5 ± 45.4%) and controls (26.21 ± 40.70%, p>0.05) at 12-month follow-up. The SR of 3 RCTs reported that the mean use of rescue medication was not statistically significantly different between patients who had BT compared with SMC or sham (MD -0.68, 95% CI - 3.63 to 2.28), p=0.65; I2=0%) at 12-month follow-up
   f. In the SR of 3 RCTs (n=429) admissions to hospital in the post-treatment period were not statistically significantly different between patients who had BT compared with sham or SMC (risk ratio [RR] 1.12, 95% CI 0.44 to 2.85, p=0.82; I 2=0%) at 12-month follow-up. This resulted in 6% (6/100) of patients who had BT needing hospitalization because of a respiratory adverse event (95% CI 1 to 21) compared with 5% (5/100) in the control group. In the SR of 6 studies, the frequency of hospital admissions for respiratory events was not statistically significantly different between 1-year and 5-year follow-up (RR 1.47, 95% CI 0.69 to 3.12, p=0.32; I2=36%) in patients who had BT

g. In the SR of 6 studies, the frequency of visits to the emergency department (ED) because of respiratory events was not statistically significantly different between 1-year and 5-year follow-up (RR 1.06, 95% CI 0.77 to 1.46, p=0.71; I2=0%) in patients who had BT
h. Admission to hospital during the treatment period was statistically significantly higher in patients who had BT compared with SMC or sham (RR 3.5, 95% CI 1.26 to 9.68, p=0.016; I2=0%, n=429) in a pooled analysis reported in the SR of 3 RCTs
i. Respiratory adverse events during the treatment period were more frequent in patients who had BT (407 events) compared with SMC or sham (106 events) in the RCT of 112 patients reported in the SR of 3 RCTs. This was similar in the RCT of 32 patients (136 events in the BT group, 57 events in controls) and in the RCT of 288 patients (85% patients BT group, 76% patients in control group) included in the same SR. Most adverse events happened within 1 day after bronchoscopy and were resolved within 7 days. The frequency of respiratory adverse events was not statistically significantly different at 1-year and 5-year follow-up (RR 3.41, 95%CI 2.96 to 3.93, p<0.00001; I2=70%) in the pooled analysis of patients who had BT, reported in the SR of 6 studies
j. Conclusions
    i. There is uncertainty about which patients may benefit from the procedure
    ii. The procedure should only be used for severe asthma that is not controlled despite optimal drug treatment
k. Recommendations:
    i. Current evidence on the safety and efficacy of bronchial thermoplasty for severe asthma is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.
    ii. The procedure should only be done by a multidisciplinary team in specialist centers with on-site access to intensive care. It should only be done by clinicians with training in the procedure and experience in managing severe asthma.
    iii. Clinicians should enter details of all patients who have the procedure onto the UK Severe Asthma Registry.
    iv. Further research should report details of patient selection and long-term safety and efficacy outcomes

HERC staff summary

Since the 2012 HERC review on this topic, AHRQ and NICE have both conducted evidence reviews. Both evidence-based organizations found that bronchial thermoplasty provides little benefit in addition to optimal medical management, and may cause increases in short term exacerbations. Both reviews found asthma control and quality of life measures to be modestly improved in patients undergoing bronchial thermoplasty, and possible modest improvements in asthma exacerbations. NICE reported no difference in hospital admission or use of steroid inhalers with bronchial thermoplasty. AHRQ concludes that "The available body of literature on BT is small and uncertainty remains about appropriate patient selection criteria and the effects of the treatment beyond 5 years." NICE concludes that bronchial thermoplasty may be considered for use in specialized settings as part of research studies.

HERC staff recommendation:

1) Update the date of last review in GN173 as shown below

GUIDELINE NOTE 173, INTERVENTIONS THAT ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS FOR CERTAIN CONDITIONS

Line 662

The following Interventions are prioritized on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

Procedure Code	Intervention Description	Rationale	Last Review
31660-31661	Bronchial thermoplasty	Insufficient evidence of effectiveness	~~January, 2014~~ August 2022

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
B37.31	Acute candidiasis of vulva and vagina	Parent code B37.3 (Candidiasis of vulva and vagina) was on line 428	428 VAGINITIS AND CERVICITIS	
B37.32	Chronic candidiasis of vulva and vagina	See above	428 VAGINITIS AND CERVICITIS	
D59.30	Hemolytic-uremic syndrome, unspecified	Parent code D59.3 (Hemolytic-uremic syndrome) was on line 99,148	99 END STAGE RENAL DISEASE 148 ACQUIRED HEMOLYTIC ANEMIAS	
D59.31	Infection-associated hemolytic-uremic syndrome	See above	99 END STAGE RENAL DISEASE 148 ACQUIRED HEMOLYTIC ANEMIAS	
D59.32	Hereditary hemolytic-uremic syndrome	See above	99 END STAGE RENAL DISEASE 148 ACQUIRED HEMOLYTIC ANEMIAS	
D59.39	Other hemolytic-uremic syndrome	See above	99 END STAGE RENAL DISEASE 148 ACQUIRED HEMOLYTIC ANEMIAS	
D68.00	Von Willebrand disease, unspecified	Parent code D68.0 (Von Willebrand's disease) was on line 109	109 COAGULATION DEFECTS	
D68.01	Von Willebrand disease, type 1	See above	109 COAGULATION DEFECTS	
D68.020	Von Willebrand disease, type 2A	See above	109 COAGULATION DEFECTS	
D68.021	Von Willebrand disease, type 2B	See above	109 COAGULATION DEFECTS	
D68.022	Von Willebrand disease, type 2M	See above	109 COAGULATION DEFECTS	
D68.023	Von Willebrand disease, type 2N	See above	109 COAGULATION DEFECTS	
D68.029	Von Willebrand disease, type 2, unspecified	See above	109 COAGULATION DEFECTS	
D68.03	Von Willebrand disease, type 3	See above	109 COAGULATION DEFECTS	
D68.04	Acquired von Willebrand disease	See above	109 COAGULATION DEFECTS	
D68.09	Other von Willebrand disease	See above	109 COAGULATION DEFECTS	
D75.821	Non-immune heparin-induced thrombocytopenia	Parent code D75.82 (Heparin induced thrombocytopenia (HIT)) was on line 303	303 THROMBOCYTOPENIA	
D75.822	Immune-mediated heparin-induced thrombocytopenia	See above	303 THROMBOCYTOPENIA	
D75.828	Other heparin-induced thrombocytopenia syndrome	See above	303 THROMBOCYTOPENIA	
D75.829	Heparin-induced thrombocytopenia, unspecified	See above	303 THROMBOCYTOPENIA	
D75.84	Other platelet-activating anti-PF4 disorders		303 THROMBOCYTOPENIA	Causes thrombocytopenia

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
D81.82	Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]		313 DISORDERS INVOLVING THE IMMUNE SYSTEM	APDS is a primary immunodeficiency disease caused by activating gain of function mutations in the PIK3CD gene. APDS and APDS-2 affected individuals present with similar symptoms, which include increased susceptibility to airway infections, bronchiectasis and lymphoproliferation
E34.30	Short stature due to endocrine disorder, unspecified	Parent code E34.3 (Short stature due to endocrine disorder) was on line 652	652 ENDOCRINE AND METABOLIC CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY	
E34.31	Constitutional short stature	Parent code E34.3 (Short stature due to endocrine disorder) was on line 652	652 ENDOCRINE AND METABOLIC CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY	
E34.321	Primary insulin-like growth factor-1 (IGF-1) deficiency	Parent code E34.3 (Short stature due to endocrine disorder) was on line 652	652 ENDOCRINE AND METABOLIC CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY	Genetic condition which results in inability to respond to human growth hormone
E34.322	Insulin-like growth factor-1 (IGF-1) resistance	Parent code E34.3 (Short stature due to endocrine disorder) was on line 652	652 ENDOCRINE AND METABOLIC CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY	Genetic condition which results in inability to respond to human growth hormone
E34.328	Other genetic causes of short stature	Parent code E34.3 (Short stature due to endocrine disorder) was on line 652	652 ENDOCRINE AND METABOLIC CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY	
E34.329	Unspecified genetic causes of short stature	Parent code E34.3 (Short stature due to endocrine disorder) was on line 652	652 ENDOCRINE AND METABOLIC CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
E34.39	Other short stature due to endocrine disorder	Parent code E34.3 (Short stature due to endocrine disorder) was on line 652	652 ENDOCRINE AND METABOLIC CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY	
E87.20	Acidosis, unspecified	Parent code E87.2 (Acidosis) was on line 221	221 DISORDERS OF FLUID, ELECTROLYTE, AND ACID-BASE BALANCE	
E87.21	Acute metabolic acidosis	Parent code E87.2 (Acidosis) was on line 221	221 DISORDERS OF FLUID, ELECTROLYTE, AND ACID-BASE BALANCE	
E87.22	Chronic metabolic acidosis	Parent code E87.2 (Acidosis) was on line 221	221 DISORDERS OF FLUID, ELECTROLYTE, AND ACID-BASE BALANCE	
E87.29	Other acidosis	Parent code E87.2 (Acidosis) was on line 221	221 DISORDERS OF FLUID, ELECTROLYTE, AND ACID-BASE BALANCE	
F01.511	Vascular dementia, unspecified severity, with agitation	Parent code F01.51 (Vascular dementia with behavioral disturbance) was on lines 71,201,292,345,377	71 NEUROLOGICAL DYSFUNCTION IN BREATHING, EATING, SWALLOWING, BOWEL, OR BLADDER CONTROL CAUSED BY CHRONIC CONDITIONS; ATTENTION TO OSTOMIES 201 CHRONIC ORGANIC MENTAL DISORDERS INCLUDING DEMENTIAS 292 NEUROLOGICAL DYSFUNCTION IN POSTURE AND MOVEMENT CAUSED BY CHRONIC CONDITIONS 345 NEUROLOGICAL DYSFUNCTION IN COMMUNICATION CAUSED BY CHRONIC CONDITIONS 377 DYSFUNCTION RESULTING IN LOSS OF ABILITY TO MAXIMIZE LEVEL OF INDEPENDENCE IN SELF-DIRECTED CARE CAUSED BY CHRONIC CONDITIONS THAT CAUSE NEUROLOGICAL DYSFUNCTION	Discussed and approved by BHAP
F01.518	Vascular dementia, unspecified severity, with other behavioral disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
F01.52	Vascular dementia, unspecified severity, with psychotic disturbance	Previously coded with F03.91 (Unspecified dementia with behavioral disturbance) was is on lines 71,201,292,345,377	71,201,292,345,377	Discussed and approved by BHAP
F01.53	Vascular dementia, unspecified severity, with mood disturbance	See F01.511	71,201,292,345,377	Discussed and approved by BHAP
F01.54	Vascular dementia, unspecified severity, with anxiety	See F01.511	71,201,292,345,377	Discussed and approved by BHAP
F01.A0	Vascular dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	New code family. Other dementia codes on lines 71,201,292,345,377	71,201,292,345,377	Discussed and approved by BHAP
F01.A11	Vascular dementia, mild, with agitation	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.A18	Vascular dementia, mild, with other behavioral disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.A2	Vascular dementia, mild, with psychotic disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.A3	Vascular dementia, mild, with mood disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.A4	Vascular dementia, mild, with anxiety	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.B0	Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.B11	Vascular dementia, moderate, with agitation	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.B18	Vascular dementia, moderate, with other behavioral disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.B2	Vascular dementia, moderate, with psychotic disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.B3	Vascular dementia, moderate, with mood disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.B4	Vascular dementia, moderate, with anxiety	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.C0	Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	See above	71,201,292,345,377	Discussed and approved by BHAP

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
F01.C11	Vascular dementia, severe, with agitation	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.C18	Vascular dementia, severe, with other behavioral disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.C2	Vascular dementia, severe, with psychotic disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.C3	Vascular dementia, severe, with mood disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F01.C4	Vascular dementia, severe, with anxiety	See above	71,201,292,345,377	Discussed and approved by BHAP
F02.811	Dementia in other diseases classified elsewhere, unspecified severity, with agitation	Parent code F02.81 (Dementia in other diseases classified elsewhere with behavioral disturbance) was on line 201 only	71,201,292,345,377	Discussed and approved by BHAP
F02.818	Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance	Parent code F02.81 (Dementia in other diseases classified elsewhere with behavioral disturbance) was on line 201 only	71,201,292,345,377	Discussed and approved by BHAP
F02.82	Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance	Parent code F02.81 (Dementia in other diseases classified elsewhere with behavioral disturbance) was on line 201 only	71,201,292,345,377	Discussed and approved by BHAP
F02.83	Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance	Parent code F02.81 (Dementia in other diseases classified elsewhere with behavioral disturbance) was on line 201 only	71,201,292,345,377	Discussed and approved by BHAP
F02.84	Dementia in other diseases classified elsewhere, unspecified severity, with anxiety	Parent code F02.81 (Dementia in other diseases classified elsewhere with behavioral disturbance) was on line 201 only	71,201,292,345,377	Discussed and approved by BHAP
F02.A0	Dementia in other diseases classified elsewhere, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.A11	Dementia in other diseases classified elsewhere, mild, with agitation	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.A18	Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
F02.A2	Dementia in other diseases classified elsewhere, mild, with psychotic disturbance	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.A3	Dementia in other diseases classified elsewhere, mild, with mood disturbance	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.A4	Dementia in other diseases classified elsewhere, mild, with anxiety	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.B0	Dementia in other diseases classified elsewhere, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.B11	Dementia in other diseases classified elsewhere, moderate, with agitation	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.B18	Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.B2	Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.B3	Dementia in other diseases classified elsewhere, moderate, with mood disturbance	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.B4	Dementia in other diseases classified elsewhere, moderate, with anxiety	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.C0	Dementia in other diseases classified elsewhere, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.C11	Dementia in other diseases classified elsewhere, severe, with agitation	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.C18	Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.C2	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F02.C3	Dementia in other diseases classified elsewhere, severe, with mood disturbance	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
F02.C4	Dementia in other diseases classified elsewhere, severe, with anxiety	Similar to F02.811	71,201,292,345,377	Discussed and approved by BHAP
F03.911	Unspecified dementia, unspecified severity, with agitation	Parent code F03.91 (Unspecified dementia with behavioral disturbance) was on lines 71,201,292,345,377	71,201,292,345,377	Discussed and approved by BHAP
F03.918	Unspecified dementia, unspecified severity, with other behavioral disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F03.93	Unspecified dementia, unspecified severity, with mood disturbance	See above	71,201,292,345,377	Discussed and approved by BHAP
F03.94	Unspecified dementia, unspecified severity, with anxiety	See above	71,201,292,345,377	Discussed and approved by BHAP
F03.A0	Unspecified dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.A11	Unspecified dementia, mild, with agitation	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.A18	Unspecified dementia, mild, with other behavioral disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.A2	Unspecified dementia, mild, with psychotic disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.A3	Unspecified dementia, mild, with mood disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.A4	Unspecified dementia, mild, with anxiety	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.B0	Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.B11	Unspecified dementia, moderate, with agitation	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.B18	Unspecified dementia, moderate, with other behavioral disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.B2	Unspecified dementia, moderate, with psychotic disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
F03.B3	Unspecified dementia, moderate, with mood disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.B4	Unspecified dementia, moderate, with anxiety	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.C0	Unspecified dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.C11	Unspecified dementia, severe, with agitation	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.C18	Unspecified dementia, severe, with other behavioral disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.C2	Unspecified dementia, severe, with psychotic disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.C3	Unspecified dementia, severe, with mood disturbance	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F03.C4	Unspecified dementia, severe, with anxiety	Similar to F03.911	71,201,292,345,377	Discussed and approved by BHAP
F06.70	Mild neurocognitive disorder due to known physiological condition without behavioral disturbance	Previously coded with F06.8 (Other specified mental disorders due to known physiological condition) which is on lines 71,201,292,345,377	71,201,292,345,377	Discussed and approved by BHAP
F06.71	Mild neurocognitive disorder due to known physiological condition with behavioral disturbance	See F06.70	71,201,292,345,377	Discussed and approved by BHAP
F10.90	Alcohol use, unspecified, uncomplicated	F11.90 (Opioid use, unspecified, uncomplicated) is on line 649	649 MENTAL DISORDERS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY	Discussed and approved by BHAP
F10.91	Alcohol use, unspecified, in remission	Other "in remission codes" are on line 4	4 SUBSTANCE USE DISORDER	Discussed and approved by BHAP
F11.91	Opioid use, unspecified, in remission	See above	4 SUBSTANCE USE DISORDER	Discussed and approved by BHAP
F12.91	Cannabis use, unspecified, in remission	See above	4 SUBSTANCE USE DISORDER	Discussed and approved by BHAP
F13.91	Sedative, hypnotic or anxiolytic use, unspecified, in remission	See above	4 SUBSTANCE USE DISORDER	Discussed and approved by BHAP
F14.91	Cocaine use, unspecified, in remission	See above	4 SUBSTANCE USE DISORDER	Discussed and approved by BHAP

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
F15.91	Other stimulant use, unspecified, in remission	See above	4 SUBSTANCE USE DISORDER	Discussed and approved by BHAP
F16.91	Hallucinogen use, unspecified, in remission	See above	4 SUBSTANCE USE DISORDER	Discussed and approved by BHAP
F18.91	Inhalant use, unspecified, in remission	See above	4 SUBSTANCE USE DISORDER	Discussed and approved by BHAP
F19.91	Other psychoactive substance use, unspecified, in remission	See above	4 SUBSTANCE USE DISORDER	Discussed and approved by BHAP
F43.81	Prolonged grief disorder	Parent code F43.8 (Other reactions to severe stress) was on line 445	445 ADJUSTMENT DISORDERS	Discussed and approved by BHAP
F43.89	Other reactions to severe stress	Parent code F43.8 (Other reactions to severe stress) was on line 445	445 ADJUSTMENT DISORDERS	Discussed and approved by BHAP
G71.031	Autosomal dominant limb girdle muscular dystrophy	Other muscular dystrophy codes are on the dysfunction lines	71 NEUROLOGICAL DYSFUNCTION IN BREATHING, EATING, SWALLOWING, BOWEL, OR BLADDER CONTROL CAUSED BY CHRONIC CONDITIONS; ATTENTION TO OSTOMIES 292 NEUROLOGICAL DYSFUNCTION IN POSTURE AND MOVEMENT CAUSED BY CHRONIC CONDITIONS 345 NEUROLOGICAL DYSFUNCTION IN COMMUNICATION CAUSED BY CHRONIC CONDITIONS 377 DYSFUNCTION RESULTING IN LOSS OF ABILITY TO MAXIMIZE LEVEL OF INDEPENDENCE IN SELF-DIRECTED CARE CAUSED BY CHRONIC CONDITIONS THAT CAUSE NEUROLOGICAL DYSFUNCTION	
G71.032	Autosomal recessive limb girdle muscular dystrophy due to calpain-3 dysfunction	See above	71,292,345,377	
G71.033	Limb girdle muscular dystrophy due to dysferlin dysfunction	See above	71,292,345,377	
G71.0340	Limb girdle muscular dystrophy due to sarcoglycan dysfunction, unspecified	See above	71,292,345,377	
G71.0341	Limb girdle muscular dystrophy due to alpha sarcoglycan dysfunction	See above	71,292,345,377	
G71.0342	Limb girdle muscular dystrophy due to beta sarcoglycan dysfunction	See above	71,292,345,377	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
G71.0349	Limb girdle muscular dystrophy due to other sarcoglycan dysfunction	See above	71,292,345,377	
G71.035	Limb girdle muscular dystrophy due to anoctamin-5 dysfunction	See above	71,292,345,377	
G71.038	Other limb girdle muscular dystrophy	See above	71,292,345,377	
G71.039	Limb girdle muscular dystrophy, unspecified	See above	71,292,345,377	
G90.A	Postural orthostatic tachycardia syndrome [POTS]		71 NEUROLOGICAL DYSFUNCTION IN BREATHING, EATING, SWALLOWING, BOWEL, OR BLADDER CONTROL CAUSED BY CHRONIC CONDITIONS; ATTENTION TO OSTOMIES 292 NEUROLOGICAL DYSFUNCTION IN POSTURE AND MOVEMENT CAUSED BY CHRONIC CONDITIONS 345 NEUROLOGICAL DYSFUNCTION IN COMMUNICATION CAUSED BY CHRONIC CONDITIONS 377 DYSFUNCTION RESULTING IN LOSS OF ABILITY TO MAXIMIZE LEVEL OF INDEPENDENCE IN SELF-DIRECTED CARE CAUSED BY CHRONIC CONDITIONS THAT CAUSE NEUROLOGICAL DYSFUNCTION 535 HYPOTENSION	See Issues
G93.31	Postviral fatigue syndrome		531 FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, AND RELATED DISORDERS	See issues
G93.32	Myalgic encephalomyelitis/chronic fatigue syndrome		531 FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, AND RELATED DISORDERS	See issues
G93.39	Other post infection and related fatigue syndromes		531 FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, AND RELATED DISORDERS	See issues
I20.2	Refractory angina pectoris		189 CHRONIC ISCHEMIC HEART DISEASE	See issues
I25.112	Atherosclerosic heart disease of native coronary artery with refractory angina pectoris		189 CHRONIC ISCHEMIC HEART DISEASE	See issues

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
I25.702	Atherosclerosis of coronary artery bypass graft(s), unspecified, with refractory angina pectoris		189 CHRONIC ISCHEMIC HEART DISEASE	See issues
I25.712	Atherosclerosis of autologous vein coronary artery bypass graft(s) with refractory angina pectoris		189 CHRONIC ISCHEMIC HEART DISEASE	See issues
I25.722	Atherosclerosis of autologous artery coronary artery bypass graft(s) with refractory angina pectoris		189 CHRONIC ISCHEMIC HEART DISEASE	See issues
I25.732	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with refractory angina pectoris		189 CHRONIC ISCHEMIC HEART DISEASE	See issues
I25.752	Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris		189 CHRONIC ISCHEMIC HEART DISEASE	See issues
I25.762	Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris		189 CHRONIC ISCHEMIC HEART DISEASE	See issues
I25.792	Atherosclerosis of other coronary artery bypass graft(s) with refractory angina pectoris		189 CHRONIC ISCHEMIC HEART DISEASE	See issues
I31.31	Malignant pericardial effusion in diseases classified elsewhere	Parent code I31.3 (Pericardial effusion (noninflammatory)) was on line 81	81 MYOCARDITIS, PERICARDITIS, AND ENDOCARDITIS	
I31.39	Other pericardial effusion (noninflammatory)	Parent code I31.3 (Pericardial effusion (noninflammatory)) was on line 81	81 MYOCARDITIS, PERICARDITIS, AND ENDOCARDITIS	
I34.81	Nonrheumatic mitral (valve) annulus calcification	Parent code I34.8 (Other nonrheumatic mitral valve disorders) was on line 257	257 DISEASES OF MITRAL, TRICUSPID, AND PULMONARY VALVES	
I34.89	Other nonrheumatic mitral valve disorders	Parent code I34.8 (Other nonrheumatic mitral valve disorders) was on line 257	257 DISEASES OF MITRAL, TRICUSPID, AND PULMONARY VALVES	
I47.20	Ventricular tachycardia, unspecified	Parent code I47.2 () was on lines 264 and 281	264 CONGESTIVE HEART FAILURE, CARDIOMYOPATHY, MALIGNANT ARRHYTHMIAS, AND COMPLEX CONGENITAL HEART DISEASE 281 LIFE-THREATENING CARDIAC ARRHYTHMIAS	
I47.21	Torsades de pointes	See above	264,281	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
I47.29	Other ventricular tachycardia	See above	264,281	
I71.010	Dissection of ascending aorta	I71.0 family (dissection of aorta) is on line 284	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.011	Dissection of aortic arch	I71.0 family (dissection of aorta) is on line 284	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.012	Dissection of descending thoracic aorta	I71.0 family (dissection of aorta) is on line 284	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.019	Dissection of thoracic aorta, unspecified	I71.0 family (dissection of aorta) is on line 284	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.10	Thoracic aortic aneurysm, ruptured, unspecified	See I71.20	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.11	Aneurysm of the ascending aorta, ruptured	See I71.10	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.12	Aneurysm of the aortic arch, ruptured	See I71.10	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.13	Aneurysm of the descending thoracic aorta, ruptured	See I71.10	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.20	Thoracic aortic aneurysm, without rupture, unspecified	Parent code I71.1 (Thoracic aortic aneurysm, without rupture) was on line 325	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I71.21	Aneurysm of the ascending aorta, without rupture	See I71.20	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I71.22	Aneurysm of the aortic arch, without rupture	See I71.20	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I71.23	Aneurysm of the descending thoracic aorta, without rupture	See I71.20	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I71.30	Abdominal aortic aneurysm, ruptured, unspecified	Parent code I71.3 (Abdominal aortic aneurysm, ruptured) was on line 284	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.31	Pararenal abdominal aortic aneurysm, ruptured	See I71.30	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.32	Juxtarenal abdominal aortic aneurysm, ruptured	See I71.30	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.33	Infrarenal abdominal aortic aneurysm, ruptured	See I71.30	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.40	Abdominal aortic aneurysm, without rupture, unspecified	Parent code I71.4 (Abdominal aortic aneurysm, without rupture) was on line 325	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I71.41	Pararenal abdominal aortic aneurysm, without rupture	See I71.40	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I71.42	Juxtarenal abdominal aortic aneurysm, without rupture	See I71.40	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
I71.43	Infrarenal abdominal aortic aneurysm, without rupture	See I71.40	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I71.50	Thoracoabdominal aortic aneurysm, ruptured, unspecified	Parent code I71.5 (Thoracoabdominal aortic aneurysm, ruptured) was on line 284	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.51	Supraceliac aneurysm of the abdominal aorta, ruptured	See I71.50	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.52	Paravisceral aneurysm of the abdominal aorta, ruptured	See I71.50	284 DISSECTING OR RUPTURED AORTIC ANEURYSM	
I71.60	Thoracoabdominal aortic aneurysm, without rupture, unspecified	Parent code I71.6 (Thoracoabdominal aortic aneurysm, without rupture) was on line 325	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I71.61	Supraceliac aneurysm of the abdominal aorta, without rupture	See I71.60	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I71.62	Paravisceral aneurysm of the abdominal aorta, without rupture	See I71.60	325 NON-DISSECTING ANEURYSM WITHOUT RUPTURE	
I77.82	Antineutrophilic cytoplasmic antibody [ANCA] vasculitis		99 END STAGE RENAL DISEASE 129 GRANULOMATOSIS WITH POLYANGIITIS 219 PULMONARY FIBROSIS	See Issues
J95.87	Transfusion-associated dyspnea (TAD)		285 COMPLICATIONS OF A PROCEDURE ALWAYS REQUIRING TREATMENT	See Issues
K76.82	Hepatic encephalopathy	Previously coded with K72.9X (Hepatic failure) which is on line 334	334 ALCOHOLIC FATTY LIVER OR ALCOHOLIC HEPATITIS, CIRRHOSIS OF LIVER	
M51.A0	Intervertebral annulus fibrosus defect, lumbar region, unspecified size	Previously coded with M51.86 (Other intervertebral disc disorders, lumbar region) which is on lines 402 and 530	402 CONDITIONS OF THE BACK AND SPINE 530 CONDITIONS OF THE BACK AND SPINE WITHOUT URGENT SURGICAL INDICATIONS	
M51.A1	Intervertebral annulus fibrosus defect, small, lumbar region	See M51.A0	402,530	
M51.A2	Intervertebral annulus fibrosus defect, large, lumbar region	See M51.A0	402,530	
M51.A3	Intervertebral annulus fibrosus defect, lumbosacral region, unspecified size	Previously coded with M51.87 (Other intervertebral disc disorders, lumbosacral region) which is on lines 402 and 530	402 CONDITIONS OF THE BACK AND SPINE 530 CONDITIONS OF THE BACK AND SPINE WITHOUT URGENT SURGICAL INDICATIONS	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
M51.A4	Intervertebral annulus fibrosus defect, small, lumbosacral region	See M51.A3	402,530	
M51.A5	Intervertebral annulus fibrosus defect, large, lumbosacral region	See M51.A3	402,530	
M62.5A0	Muscle wasting and atrophy, not elsewhere classified, back, cervical	Other muscle wasting and atrophy diagnosis codes are on lines 292 and 377	292 NEUROLOGICAL DYSFUNCTION IN POSTURE AND MOVEMENT CAUSED BY CHRONIC CONDITIONS 377 DYSFUNCTION RESULTING IN LOSS OF ABILITY TO MAXIMIZE LEVEL OF INDEPENDENCE IN SELF-DIRECTED CARE CAUSED BY CHRONIC CONDITIONS THAT CAUSE NEUROLOGICAL DYSFUNCTION	
M62.5A1	Muscle wasting and atrophy, not elsewhere classified, back, thoracic	See M62.5A0	292,377	
M62.5A2	Muscle wasting and atrophy, not elsewhere classified, back, lumbosacral	See M62.5A0	292,377	
M62.5A9	Muscle wasting and atrophy, not elsewhere classified, back, unspecified level	See M62.5A0	292,377	
M93.004	Unspecified slipped upper femoral epiphysis (nontraumatic), bilateral hips	Similar slipped upper femoral epiphysis codes are on line 355	355 CLOSED FRACTURE OF EXTREMITIES (EXCEPT MINOR TOES)	
M93.014	Acute slipped upper femoral epiphysis, stable (nontraumatic), bilateral hips	See M93.004	355	
M93.024	Chronic slipped upper femoral epiphysis, stable (nontraumatic), bilateral hips	See M93.004	355	
M93.034	Acute on chronic slipped upper femoral epiphysis, stable (nontraumatic), bilateral hips	See M93.004	355	
M93.041	Acute slipped upper femoral epiphysis, unstable (nontraumatic), right hip	See M93.004	355	
M93.042	Acute slipped upper femoral epiphysis, unstable (nontraumatic), left hip	See M93.004	355	
M93.043	Acute slipped upper femoral epiphysis, unstable (nontraumatic), unspecified hip	See M93.004	355	
M93.044	Acute slipped upper femoral epiphysis, unstable (nontraumatic), bilateral hips	See M93.004	355	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
M93.051	Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), right hip	See M93.004	355	
M93.052	Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), left hip	See M93.004	355	
M93.053	Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), unspecified hip	See M93.004	355	
M93.054	Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), bilateral hips	See M93.004	355	
M93.061	Acute slipped upper femoral epiphysis, unspecified stability (nontraumatic), right hip	See M93.004	355	
M93.062	Acute slipped upper femoral epiphysis, unspecified stability (nontraumatic), left hip	See M93.004	355	
M93.063	Acute slipped upper femoral epiphysis, unspecified stability (nontraumatic), unspecified hip	See M93.004	355	
M93.064	Acute slipped upper femoral epiphysis, unspecified stability (nontraumatic), bilateral hips	See M93.004	355	
M93.071	Acute on chronic slipped upper femoral epiphysis, unspecified stability (nontraumatic), right hip	See M93.004	355	
M93.072	Acute on chronic slipped upper femoral epiphysis, unspecified stability (nontraumatic), left hip	See M93.004	355	
M93.073	Acute on chronic slipped upper femoral epiphysis, unspecified stability (nontraumatic), unspecified hip	See M93.004	355	
M93.074	Acute on chronic slipped upper femoral epiphysis, unspecified stability (nontraumatic), bilateral hips	See M93.004	355	
M96.A1	Fracture of sternum associated with chest compression and cardiopulmonary resuscitation	S22.20XA (Unspecified fracture of sternum, initial encounter for closed fracture) is on line 490	490 CLOSED FRACTURES OF RIBS, STERNUM AND COCCYX	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
M96.A2	Fracture of one rib associated with chest compression and cardiopulmonary resuscitation	Rib fractures are on line 490	490	
M96.A3	Multiple fractures of ribs associated with chest compression and cardiopulmonary resuscitation	Rib fractures are on line 490	490	
M96.A4	Flail chest associated with chest compression and cardiopulmonary resuscitation	S22.5 (Flail chest) is on line 490	490	
M96.A9	Other fracture associated with chest compression and cardiopulmonary resuscitation	see series above	490	
N14.11	Contrast-induced nephropathy	Parent code N14.1 (Nephropathy induced by other drugs, medicaments and biological substances) was on lines 99 and 339	99 END STAGE RENAL DISEASE 339 CHRONIC KIDNEY DISEASE	
N14.19	Nephropathy induced by other drugs, medicaments and biological substances	See above	99,339	
N76.82	Fournier disease of vagina and vulva	Other Fournier's gangrene diagnoses (N49.3) are on line 47	47 DEEP ABSCESSES, INCLUDING APPENDICITIS AND	
N80.00	Endometriosis of the uterus, unspecified	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.01	Superficial endometriosis of the uterus	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.02	Deep endometriosis of the uterus	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.03	Adenomyosis of the uterus	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.101	Endometriosis of right ovary, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.102	Endometriosis of left ovary, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.103	Endometriosis of bilateral ovaries, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.109	Endometriosis of ovary, unspecified side, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.111	Superficial endometriosis of right ovary	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.112	Superficial endometriosis of left ovary	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
N80.113	Superficial endometriosis of bilateral ovaries	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.119	Superficial endometriosis of ovary, unspecified ovary	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.121	Deep endometriosis of right ovary	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.122	Deep endometriosis of left ovary	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.123	Deep endometriosis of bilateral ovaries	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.129	Deep endometriosis of ovary, unspecified ovary	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.201	Endometriosis of right fallopian tube, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.202	Endometriosis of left fallopian tube, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.203	Endometriosis of bilateral fallopian tubes, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.209	Endometriosis of unspecified fallopian tube, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.211	Superficial endometriosis of right fallopian tube	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.212	Superficial endometriosis of left fallopian tube	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.213	Superficial endometriosis of bilateral fallopian tubes	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.219	Superficial endometriosis of unspecified fallopian tube	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.221	Deep endometriosis of right fallopian tube	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.222	Deep endometriosis of left fallopian tube	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.223	Deep endometriosis of bilateral fallopian tubes	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.229	Deep endometriosis of unspecified fallopian tube	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.30	Endometriosis of pelvic peritoneum, unspecified	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
N80.311	Superficial endometriosis of the anterior cul-de-sac	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.312	Deep endometriosis of the anterior cul-de-sac	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.319	Endometriosis of the anterior cul-de-sac, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.321	Superficial endometriosis of the posterior cul-de-sac	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.322	Deep endometriosis of the posterior cul-de-sac	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.329	Endometriosis of the posterior cul-de-sac, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.331	Superficial endometriosis of the right pelvic sidewall	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.332	Superficial endometriosis of the left pelvic sidewall	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.333	Superficial endometriosis of bilateral pelvic sidewall	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.339	Superficial endometriosis of pelvic sidewall, unspecified side	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.341	Deep endometriosis of the right pelvic sidewall	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.342	Deep endometriosis of the left pelvic sidewall	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.343	Deep endometriosis of the bilateral pelvic sidewall	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.349	Deep endometriosis of the pelvic sidewall, unspecified side	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.351	Endometriosis of the right pelvic sidewall, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.352	Endometriosis of the left pelvic sidewall, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.353	Endometriosis of bilateral pelvic sidewall, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.359	Endometriosis of pelvic sidewall, unspecified side, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.361	Superficial endometriosis of the right pelvic brim	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
N80.362	Superficial endometriosis of the left pelvic brim	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.363	Superficial endometriosis of bilateral pelvic brim	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.369	Superficial endometriosis of the pelvic brim, unspecified side	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.371	Deep endometriosis of the right pelvic brim	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.372	Deep endometriosis of the left pelvic brim	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.373	Deep endometriosis of bilateral pelvic brim	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.379	Deep endometriosis of the pelvic brim, unspecified side	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.381	Endometriosis of the right pelvic brim, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.382	Endometriosis of the left pelvic brim, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.383	Endometriosis of bilateral pelvic brim, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.389	Endometriosis of the pelvic brim, unspecified side, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.391	Superficial endometriosis of the pelvic peritoneum, other specified sites	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.392	Deep endometriosis of the pelvic peritoneum, other specified sites	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.399	Endometriosis of the pelvic peritoneum, other specified sites, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3A1	Superficial endometriosis of the right uterosacral ligament	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3A2	Superficial endometriosis of the left uterosacral ligament	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3A3	Superficial endometriosis of the bilateral uterosacral ligament(s)	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3A9	Superficial endometriosis of the uterosacral ligament(s), unspecified side	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3B1	Deep endometriosis of the right uterosacral ligament	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
N80.3B2	Deep endometriosis of the left uterosacral ligament	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3B3	Deep endometriosis of bilateral uterosacral ligament(s)	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3B9	Deep endometriosis of the uterosacral ligament(s), unspecified side	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3C1	Endometriosis of the right uterosacral ligament, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3C2	Endometriosis of the left uterosacral ligament, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3C3	Endometriosis of bilateral uterosacral ligament(s), unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.3C9	Endometriosis of the uterosacral ligament(s), unspecified side, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.40	Endometriosis of rectovaginal septum, unspecified involvement of vagina	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.41	Endometriosis of rectovaginal septum without involvement of vagina	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.42	Endometriosis of rectovaginal septum with involvement of vagina	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.50	Endometriosis of intestine, unspecified		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.511	Superficial endometriosis of the rectum		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.512	Deep endometriosis of the rectum		41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.519	Endometriosis of the rectum, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.521	Superficial endometriosis of the sigmoid colon		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
N80.522	Deep endometriosis of the sigmoid colon		41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.529	Endometriosis of the sigmoid colon, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.531	Superficial endometriosis of the cecum		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.532	Deep endometriosis of the cecum		41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.539	Endometriosis of the cecum, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.541	Superficial endometriosis of the appendix		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.542	Deep endometriosis of the appendix		41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.549	Endometriosis of the appendix, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.551	Superficial endometriosis of other parts of the colon		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
N80.552	Deep endometriosis of other parts of the colon		41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.559	Endometriosis of other parts of the colon, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.561	Superficial endometriosis of the small intestine		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.562	Deep endometriosis of the small intestine		41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.569	Endometriosis of the small intestine, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A0	Endometriosis of bladder, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A1	Superficial endometriosis of bladder		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A2	Deep endometriosis of bladder		327 FUNCTIONAL AND MECHANICAL DISORDERS OF THE GENITOURINARY SYSTEM INCLUDING BLADDER OUTLET OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A41	Superficial endometriosis of right ureter		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A42	Superficial endometriosis of left ureter		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A43	Superficial endometriosis of bilateral ureters		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A49	Superficial endometriosis of unspecified ureter		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
N80.A51	Deep endometriosis of right ureter		327 FUNCTIONAL AND MECHANICAL DISORDERS OF THE GENITOURINARY SYSTEM INCLUDING BLADDER OUTLET OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A52	Deep endometriosis of left ureter		327 FUNCTIONAL AND MECHANICAL DISORDERS OF THE GENITOURINARY SYSTEM INCLUDING BLADDER OUTLET OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A53	Deep endometriosis of bilateral ureters		327 FUNCTIONAL AND MECHANICAL DISORDERS OF THE GENITOURINARY SYSTEM INCLUDING BLADDER OUTLET OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A59	Deep endometriosis of unspecified ureter		327 FUNCTIONAL AND MECHANICAL DISORDERS OF THE GENITOURINARY SYSTEM INCLUDING BLADDER OUTLET OBSTRUCTION 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A61	Endometriosis of right ureter, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A62	Endometriosis of left ureter, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A63	Endometriosis of bilateral ureters, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.A69	Endometriosis of unspecified ureter, unspecified depth		395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.B1	Endometriosis of pleura		372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
N80.B2	Endometriosis of lung		372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.B31	Superficial endometriosis of diaphragm		372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.B32	Deep endometriosis of diaphragm		372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.B39	Endometriosis of diaphragm, unspecified depth		372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.B4	Endometriosis of the pericardial space		372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.B5	Endometriosis of the mediastinal space		372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.B6	Endometriosis of cardiothoracic space		372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS 395 ENDOMETRIOSIS AND ADENOMYOSIS	See issues
N80.C0	Endometriosis of the abdomen, unspecified	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.C10	Endometriosis of the anterior abdominal wall, subcutaneous tissue	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
N80.C11	Endometriosis of the anterior abdominal wall, fascia and muscular layers	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.C19	Endometriosis of the anterior abdominal wall, unspecified depth	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.C2	Endometriosis of the umbilicus	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.C3	Endometriosis of the inguinal canal	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.C4	Endometriosis of extra-pelvic abdominal peritoneum	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.C9	Endometriosis of other site of abdomen	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.D0	Endometriosis of the pelvic nerves, unspecified	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.D1	Endometriosis of the sacral splanchnic nerves	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.D2	Endometriosis of the sacral nerve roots	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.D3	Endometriosis of the obturator nerve	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.D4	Endometriosis of the sciatic nerve	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.D5	Endometriosis of the pudendal nerve	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.D6	Endometriosis of the femoral nerve	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N80.D9	Endometriosis of other pelvic nerve	Endometrosis in the abdominal cavity is on line 395	395 ENDOMETRIOSIS AND ADENOMYOSIS	
N85.A	Isthmocele		423 MENSTRUAL BLEEDING DISORDERS	See issues document
O35.00X0	Maternal care for (suspected) central nervous system malformation or damage in fetus, unspecified, not applicable or unspecified	All pregnancy related codes are on line 1	1 PREGNANCY	
O35.00X1	Maternal care for (suspected) central nervous system malformation or damage in fetus, unspecified, fetus 1		1 PREGNANCY	
O35.00X2	Maternal care for (suspected) central nervous system malformation or damage in fetus, unspecified, fetus 2		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.00X3	Maternal care for (suspected) central nervous system malformation or damage in fetus, unspecified, fetus 3		1 PREGNANCY	
O35.00X4	Maternal care for (suspected) central nervous system malformation or damage in fetus, unspecified, fetus 4		1 PREGNANCY	
O35.00X5	Maternal care for (suspected) central nervous system malformation or damage in fetus, unspecified, fetus 5		1 PREGNANCY	
O35.00X9	Maternal care for (suspected) central nervous system malformation or damage in fetus, unspecified, other fetus		1 PREGNANCY	
O35.01X0	Maternal care for (suspected) central nervous system malformation or damage in fetus, agenesis of the corpus callosum, not applicable or unspecified		1 PREGNANCY	
O35.01X1	Maternal care for (suspected) central nervous system malformation or damage in fetus, agenesis of the corpus callosum, fetus 1		1 PREGNANCY	
O35.01X2	Maternal care for (suspected) central nervous system malformation or damage in fetus, agenesis of the corpus callosum, fetus 2		1 PREGNANCY	
O35.01X3	Maternal care for (suspected) central nervous system malformation or damage in fetus, agenesis of the corpus callosum, fetus 3		1 PREGNANCY	
O35.01X4	Maternal care for (suspected) central nervous system malformation or damage in fetus, agenesis of the corpus callosum, fetus 4		1 PREGNANCY	
O35.01X5	Maternal care for (suspected) central nervous system malformation or damage in fetus, agenesis of the corpus callosum, fetus 5		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.01X9	Maternal care for (suspected) central nervous system malformation or damage in fetus, agenesis of the corpus callosum, other fetus		1 PREGNANCY	
O35.02X0	Maternal care for (suspected) central nervous system malformation or damage in fetus, anencephaly, not applicable or unspecified		1 PREGNANCY	
O35.02X1	Maternal care for (suspected) central nervous system malformation or damage in fetus, anencephaly, fetus 1		1 PREGNANCY	
O35.02X2	Maternal care for (suspected) central nervous system malformation or damage in fetus, anencephaly, fetus 2		1 PREGNANCY	
O35.02X3	Maternal care for (suspected) central nervous system malformation or damage in fetus, anencephaly, fetus 3		1 PREGNANCY	
O35.02X4	Maternal care for (suspected) central nervous system malformation or damage in fetus, anencephaly, fetus 4		1 PREGNANCY	
O35.02X5	Maternal care for (suspected) central nervous system malformation or damage in fetus, anencephaly, fetus 5		1 PREGNANCY	
O35.02X9	Maternal care for (suspected) central nervous system malformation or damage in fetus, anencephaly, other fetus		1 PREGNANCY	
O35.03X0	Maternal care for (suspected) central nervous system malformation or damage in fetus, choroid plexus cysts, not applicable or unspecified		1 PREGNANCY	
O35.03X1	Maternal care for (suspected) central nervous system malformation or damage in fetus, choroid plexus cysts, fetus 1		1 PREGNANCY	
O35.03X2	Maternal care for (suspected) central nervous system malformation or damage in fetus, choroid plexus cysts, fetus 2		1 PREGNANCY	
O35.03X3	Maternal care for (suspected) central nervous system malformation or damage in fetus, choroid plexus cysts, fetus 3		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.03X4	Maternal care for (suspected) central nervous system malformation or damage in fetus, choroid plexus cysts, fetus 4		1 PREGNANCY	
O35.03X5	Maternal care for (suspected) central nervous system malformation or damage in fetus, choroid plexus cysts, fetus 5		1 PREGNANCY	
O35.03X9	Maternal care for (suspected) central nervous system malformation or damage in fetus, choroid plexus cysts, other fetus		1 PREGNANCY	
O35.04X0	Maternal care for (suspected) central nervous system malformation or damage in fetus, encephalocele, not applicable or unspecified		1 PREGNANCY	
O35.04X1	Maternal care for (suspected) central nervous system malformation or damage in fetus, encephalocele, fetus 1		1 PREGNANCY	
O35.04X2	Maternal care for (suspected) central nervous system malformation or damage in fetus, encephalocele, fetus 2		1 PREGNANCY	
O35.04X3	Maternal care for (suspected) central nervous system malformation or damage in fetus, encephalocele, fetus 3		1 PREGNANCY	
O35.04X4	Maternal care for (suspected) central nervous system malformation or damage in fetus, encephalocele, fetus 4		1 PREGNANCY	
O35.04X5	Maternal care for (suspected) central nervous system malformation or damage in fetus, encephalocele, fetus 5		1 PREGNANCY	
O35.04X9	Maternal care for (suspected) central nervous system malformation or damage in fetus, encephalocele, other fetus		1 PREGNANCY	
O35.05X0	Maternal care for (suspected) central nervous system malformation or damage in fetus, holoprosencephaly, not applicable or unspecified		1 PREGNANCY	
O35.05X1	Maternal care for (suspected) central nervous system malformation or damage in fetus, holoprosencephaly, fetus 1		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.05X2	Maternal care for (suspected) central nervous system malformation or damage in fetus, holoprosencephaly, fetus 2		1 PREGNANCY	
O35.05X3	Maternal care for (suspected) central nervous system malformation or damage in fetus, holoprosencephaly, fetus 3		1 PREGNANCY	
O35.05X4	Maternal care for (suspected) central nervous system malformation or damage in fetus, holoprosencephaly, fetus 4		1 PREGNANCY	
O35.05X5	Maternal care for (suspected) central nervous system malformation or damage in fetus, holoprosencephaly, fetus 5		1 PREGNANCY	
O35.05X9	Maternal care for (suspected) central nervous system malformation or damage in fetus, holoprosencephaly, other fetus		1 PREGNANCY	
O35.06X0	Maternal care for (suspected) central nervous system malformation or damage in fetus, hydrocephaly, not applicable or unspecified		1 PREGNANCY	
O35.06X1	Maternal care for (suspected) central nervous system malformation or damage in fetus, hydrocephaly, fetus 1		1 PREGNANCY	
O35.06X2	Maternal care for (suspected) central nervous system malformation or damage in fetus, hydrocephaly, fetus 2		1 PREGNANCY	
O35.06X3	Maternal care for (suspected) central nervous system malformation or damage in fetus, hydrocephaly, fetus 3		1 PREGNANCY	
O35.06X4	Maternal care for (suspected) central nervous system malformation or damage in fetus, hydrocephaly, fetus 4		1 PREGNANCY	
O35.06X5	Maternal care for (suspected) central nervous system malformation or damage in fetus, hydrocephaly, fetus 5		1 PREGNANCY	
O35.06X9	Maternal care for (suspected) central nervous system malformation or damage in fetus, hydrocephaly, other fetus		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.07X0	Maternal care for (suspected) central nervous system malformation or damage in fetus, microcephaly, not applicable or unspecified		1 PREGNANCY	
O35.07X1	Maternal care for (suspected) central nervous system malformation or damage in fetus, microcephaly, fetus 1		1 PREGNANCY	
O35.07X2	Maternal care for (suspected) central nervous system malformation or damage in fetus, microcephaly, fetus 2		1 PREGNANCY	
O35.07X3	Maternal care for (suspected) central nervous system malformation or damage in fetus, microcephaly, fetus 3		1 PREGNANCY	
O35.07X4	Maternal care for (suspected) central nervous system malformation or damage in fetus, microcephaly, fetus 4		1 PREGNANCY	
O35.07X5	Maternal care for (suspected) central nervous system malformation or damage in fetus, microcephaly, fetus 5		1 PREGNANCY	
O35.07X9	Maternal care for (suspected) central nervous system malformation or damage in fetus, microcephaly, other fetus		1 PREGNANCY	
O35.08X0	Maternal care for (suspected) central nervous system malformation or damage in fetus, spina bifida, not applicable or unspecified		1 PREGNANCY	
O35.08X1	Maternal care for (suspected) central nervous system malformation or damage in fetus, spina bifida, fetus 1		1 PREGNANCY	
O35.08X2	Maternal care for (suspected) central nervous system malformation or damage in fetus, spina bifida, fetus 2		1 PREGNANCY	
O35.08X3	Maternal care for (suspected) central nervous system malformation or damage in fetus, spina bifida, fetus 3		1 PREGNANCY	
O35.08X4	Maternal care for (suspected) central nervous system malformation or damage in fetus, spina bifida, fetus 4		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.08X5	Maternal care for (suspected) central nervous system malformation or damage in fetus, spina bifida, fetus 5		1 PREGNANCY	
O35.08X9	Maternal care for (suspected) central nervous system malformation or damage in fetus, spina bifida, other fetus		1 PREGNANCY	
O35.09X0	Maternal care for (suspected) other central nervous system malformation or damage in fetus, not applicable or unspecified		1 PREGNANCY	
O35.09X1	Maternal care for (suspected) other central nervous system malformation or damage in fetus, fetus 1		1 PREGNANCY	
O35.09X2	Maternal care for (suspected) other central nervous system malformation or damage in fetus, fetus 2		1 PREGNANCY	
O35.09X3	Maternal care for (suspected) other central nervous system malformation or damage in fetus, fetus 3		1 PREGNANCY	
O35.09X4	Maternal care for (suspected) other central nervous system malformation or damage in fetus, fetus 4		1 PREGNANCY	
O35.09X5	Maternal care for (suspected) other central nervous system malformation or damage in fetus, fetus 5		1 PREGNANCY	
O35.09X9	Maternal care for (suspected) other central nervous system malformation or damage in fetus, other fetus		1 PREGNANCY	
O35.10X0	Maternal care for (suspected) chromosomal abnormality in fetus, unspecified, not applicable or unspecified		1 PREGNANCY	
O35.10X1	Maternal care for (suspected) chromosomal abnormality in fetus, unspecified, fetus 1		1 PREGNANCY	
O35.10X2	Maternal care for (suspected) chromosomal abnormality in fetus, unspecified, fetus 2		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.10X3	Maternal care for (suspected) chromosomal abnormality in fetus, unspecified, fetus 3		1 PREGNANCY	
O35.10X4	Maternal care for (suspected) chromosomal abnormality in fetus, unspecified, fetus 4		1 PREGNANCY	
O35.10X5	Maternal care for (suspected) chromosomal abnormality in fetus, unspecified, fetus 5		1 PREGNANCY	
O35.10X9	Maternal care for (suspected) chromosomal abnormality in fetus, unspecified, other fetus		1 PREGNANCY	
O35.11X0	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 13, not applicable or unspecified		1 PREGNANCY	
O35.11X1	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 13, fetus 1		1 PREGNANCY	
O35.11X2	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 13, fetus 2		1 PREGNANCY	
O35.11X3	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 13, fetus 3		1 PREGNANCY	
O35.11X4	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 13, fetus 4		1 PREGNANCY	
O35.11X5	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 13, fetus 5		1 PREGNANCY	
O35.11X9	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 13, other fetus		1 PREGNANCY	
O35.12X0	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 18, not applicable or unspecified		1 PREGNANCY	
O35.12X1	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 18, fetus 1		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.12X2	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 18, fetus 2		1 PREGNANCY	
O35.12X3	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 18, fetus 3		1 PREGNANCY	
O35.12X4	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 18, fetus 4		1 PREGNANCY	
O35.12X5	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 18, fetus 5		1 PREGNANCY	
O35.12X9	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 18, other fetus		1 PREGNANCY	
O35.13X0	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 21, not applicable or unspecified		1 PREGNANCY	
O35.13X1	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 21, fetus 1		1 PREGNANCY	
O35.13X2	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 21, fetus 2		1 PREGNANCY	
O35.13X3	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 21, fetus 3		1 PREGNANCY	
O35.13X4	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 21, fetus 4		1 PREGNANCY	
O35.13X5	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 21, fetus 5		1 PREGNANCY	
O35.13X9	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 21, other fetus		1 PREGNANCY	
O35.14X0	Maternal care for (suspected) chromosomal abnormality in fetus, Turner Syndrome, not applicable or unspecified		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.14X1	Maternal care for (suspected) chromosomal abnormality in fetus, Turner Syndrome, fetus 1		1 PREGNANCY	
O35.14X2	Maternal care for (suspected) chromosomal abnormality in fetus, Turner Syndrome, fetus 2		1 PREGNANCY	
O35.14X3	Maternal care for (suspected) chromosomal abnormality in fetus, Turner Syndrome, fetus 3		1 PREGNANCY	
O35.14X4	Maternal care for (suspected) chromosomal abnormality in fetus, Turner Syndrome, fetus 4		1 PREGNANCY	
O35.14X5	Maternal care for (suspected) chromosomal abnormality in fetus, Turner Syndrome, fetus 5		1 PREGNANCY	
O35.14X9	Maternal care for (suspected) chromosomal abnormality in fetus, Turner Syndrome, other fetus		1 PREGNANCY	
O35.15X0	Maternal care for (suspected) chromosomal abnormality in fetus, sex chromosome abnormality, not applicable or unspecified		1 PREGNANCY	
O35.15X1	Maternal care for (suspected) chromosomal abnormality in fetus, sex chromosome abnormality, fetus 1		1 PREGNANCY	
O35.15X2	Maternal care for (suspected) chromosomal abnormality in fetus, sex chromosome abnormality, fetus 2		1 PREGNANCY	
O35.15X3	Maternal care for (suspected) chromosomal abnormality in fetus, sex chromosome abnormality, fetus 3		1 PREGNANCY	
O35.15X4	Maternal care for (suspected) chromosomal abnormality in fetus, sex chromosome abnormality, fetus 4		1 PREGNANCY	
O35.15X5	Maternal care for (suspected) chromosomal abnormality in fetus, sex chromosome abnormality, fetus 5		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.15X9	Maternal care for (suspected) chromosomal abnormality in fetus, sex chromosome abnormality, other fetus		1 PREGNANCY	
O35.19X0	Maternal care for (suspected) chromosomal abnormality in fetus, other chromosomal abnormality, not applicable or unspecified		1 PREGNANCY	
O35.19X1	Maternal care for (suspected) chromosomal abnormality in fetus, other chromosomal abnormality, fetus 1		1 PREGNANCY	
O35.19X2	Maternal care for (suspected) chromosomal abnormality in fetus, other chromosomal abnormality, fetus 2		1 PREGNANCY	
O35.19X3	Maternal care for (suspected) chromosomal abnormality in fetus, other chromosomal abnormality, fetus 3		1 PREGNANCY	
O35.19X4	Maternal care for (suspected) chromosomal abnormality in fetus, other chromosomal abnormality, fetus 4		1 PREGNANCY	
O35.19X5	Maternal care for (suspected) chromosomal abnormality in fetus, other chromosomal abnormality, fetus 5		1 PREGNANCY	
O35.19X9	Maternal care for (suspected) chromosomal abnormality in fetus, other chromosomal abnormality, other fetus		1 PREGNANCY	
O35.AXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal facial anomalies, not applicable or unspecified		1 PREGNANCY	
O35.AXX1	Maternal care for other (suspected) fetal abnormality and damage, fetal facial anomalies, fetus 1		1 PREGNANCY	
O35.AXX2	Maternal care for other (suspected) fetal abnormality and damage, fetal facial anomalies, fetus 2		1 PREGNANCY	
O35.AXX3	Maternal care for other (suspected) fetal abnormality and damage, fetal facial anomalies, fetus 3		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.AXX4	Maternal care for other (suspected) fetal abnormality and damage, fetal facial anomalies, fetus 4		1 PREGNANCY	
O35.AXX5	Maternal care for other (suspected) fetal abnormality and damage, fetal facial anomalies, fetus 5		1 PREGNANCY	
O35.AXX9	Maternal care for other (suspected) fetal abnormality and damage, fetal facial anomalies, other fetus		1 PREGNANCY	
O35.BXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal cardiac anomalies, not applicable or unspecified		1 PREGNANCY	
O35.BXX1	Maternal care for other (suspected) fetal abnormality and damage, fetal cardiac anomalies, fetus 1		1 PREGNANCY	
O35.BXX2	Maternal care for other (suspected) fetal abnormality and damage, fetal cardiac anomalies, fetus 2		1 PREGNANCY	
O35.BXX3	Maternal care for other (suspected) fetal abnormality and damage, fetal cardiac anomalies, fetus 3		1 PREGNANCY	
O35.BXX4	Maternal care for other (suspected) fetal abnormality and damage, fetal cardiac anomalies, fetus 4		1 PREGNANCY	
O35.BXX5	Maternal care for other (suspected) fetal abnormality and damage, fetal cardiac anomalies, fetus 5		1 PREGNANCY	
O35.BXX9	Maternal care for other (suspected) fetal abnormality and damage, fetal cardiac anomalies, other fetus		1 PREGNANCY	
O35.CXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal pulmonary anomalies, not applicable or unspecified		1 PREGNANCY	
O35.CXX1	Maternal care for other (suspected) fetal abnormality and damage, fetal pulmonary anomalies, fetus 1		1 PREGNANCY	
O35.CXX2	Maternal care for other (suspected) fetal abnormality and damage, fetal pulmonary anomalies, fetus 2		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.CXX3	Maternal care for other (suspected) fetal abnormality and damage, fetal pulmonary anomalies, fetus 3		1 PREGNANCY	
O35.CXX4	Maternal care for other (suspected) fetal abnormality and damage, fetal pulmonary anomalies, fetus 4		1 PREGNANCY	
O35.CXX5	Maternal care for other (suspected) fetal abnormality and damage, fetal pulmonary anomalies, fetus 5		1 PREGNANCY	
O35.CXX9	Maternal care for other (suspected) fetal abnormality and damage, fetal pulmonary anomalies, other fetus		1 PREGNANCY	
O35.DXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal gastrointestinal anomalies, not applicable or unspecified		1 PREGNANCY	
O35.DXX1	Maternal care for other (suspected) fetal abnormality and damage, fetal gastrointestinal anomalies, fetus 1		1 PREGNANCY	
O35.DXX2	Maternal care for other (suspected) fetal abnormality and damage, fetal gastrointestinal anomalies, fetus 2		1 PREGNANCY	
O35.DXX3	Maternal care for other (suspected) fetal abnormality and damage, fetal gastrointestinal anomalies, fetus 3		1 PREGNANCY	
O35.DXX4	Maternal care for other (suspected) fetal abnormality and damage, fetal gastrointestinal anomalies, fetus 4		1 PREGNANCY	
O35.DXX5	Maternal care for other (suspected) fetal abnormality and damage, fetal gastrointestinal anomalies, fetus 5		1 PREGNANCY	
O35.DXX9	Maternal care for other (suspected) fetal abnormality and damage, fetal gastrointestinal anomalies, other fetus		1 PREGNANCY	
O35.EXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal genitourinary anomalies, not applicable or unspecified		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.EXX1	Maternal care for other (suspected) fetal abnormality and damage, fetal genitourinary anomalies, fetus 1		1 PREGNANCY	
O35.EXX2	Maternal care for other (suspected) fetal abnormality and damage, fetal genitourinary anomalies, fetus 2		1 PREGNANCY	
O35.EXX3	Maternal care for other (suspected) fetal abnormality and damage, fetal genitourinary anomalies, fetus 3		1 PREGNANCY	
O35.EXX4	Maternal care for other (suspected) fetal abnormality and damage, fetal genitourinary anomalies, fetus 4		1 PREGNANCY	
O35.EXX5	Maternal care for other (suspected) fetal abnormality and damage, fetal genitourinary anomalies, fetus 5		1 PREGNANCY	
O35.EXX9	Maternal care for other (suspected) fetal abnormality and damage, fetal genitourinary anomalies, other fetus		1 PREGNANCY	
O35.FXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal musculoskeletal anomalies of trunk, not applicable or unspecified		1 PREGNANCY	
O35.FXX1	Maternal care for other (suspected) fetal abnormality and damage, fetal musculoskeletal anomalies of trunk, fetus 1		1 PREGNANCY	
O35.FXX2	Maternal care for other (suspected) fetal abnormality and damage, fetal musculoskeletal anomalies of trunk, fetus 2		1 PREGNANCY	
O35.FXX3	Maternal care for other (suspected) fetal abnormality and damage, fetal musculoskeletal anomalies of trunk, fetus 3		1 PREGNANCY	
O35.FXX4	Maternal care for other (suspected) fetal abnormality and damage, fetal musculoskeletal anomalies of trunk, fetus 4		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.FXX5	Maternal care for other (suspected) fetal abnormality and damage, fetal musculoskeletal anomalies of trunk, fetus 5		1 PREGNANCY	
O35.FXX9	Maternal care for other (suspected) fetal abnormality and damage, fetal musculoskeletal anomalies of trunk, other fetus		1 PREGNANCY	
O35.GXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal upper extremities anomalies, not applicable or unspecified		1 PREGNANCY	
O35.GXX1	Maternal care for other (suspected) fetal abnormality and damage, fetal upper extremities anomalies, fetus 1		1 PREGNANCY	
O35.GXX2	Maternal care for other (suspected) fetal abnormality and damage, fetal upper extremities anomalies, fetus 2		1 PREGNANCY	
O35.GXX3	Maternal care for other (suspected) fetal abnormality and damage, fetal upper extremities anomalies, fetus 3		1 PREGNANCY	
O35.GXX4	Maternal care for other (suspected) fetal abnormality and damage, fetal upper extremities anomalies, fetus 4		1 PREGNANCY	
O35.GXX5	Maternal care for other (suspected) fetal abnormality and damage, fetal upper extremities anomalies, fetus 5		1 PREGNANCY	
O35.GXX9	Maternal care for other (suspected) fetal abnormality and damage, fetal upper extremities anomalies, other fetus		1 PREGNANCY	
O35.HXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal lower extremities anomalies, not applicable or unspecified		1 PREGNANCY	
O35.HXX1	Maternal care for other (suspected) fetal abnormality and damage, fetal lower extremities anomalies, fetus 1		1 PREGNANCY	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
O35.HXX2	Maternal care for other (suspected) fetal abnormality and damage, fetal lower extremities anomalies, fetus 2		1 PREGNANCY	
O35.HXX3	Maternal care for other (suspected) fetal abnormality and damage, fetal lower extremities anomalies, fetus 3		1 PREGNANCY	
O35.HXX4	Maternal care for other (suspected) fetal abnormality and damage, fetal lower extremities anomalies, fetus 4		1 PREGNANCY	
O35.HXX5	Maternal care for other (suspected) fetal abnormality and damage, fetal lower extremities anomalies, fetus 5		1 PREGNANCY	
O35.HXX9	Maternal care for other (suspected) fetal abnormality and damage, fetal lower extremities anomalies, other fetus		1 PREGNANCY	
P28.30	Primary sleep apnea of newborn, unspecified	Parent code P28.3 (Primary sleep apnea of newborn) was on line 11	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
P28.31	Primary central sleep apnea of newborn	See P28.30	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
P28.32	Primary obstructive sleep apnea of newborn	See P28.30	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
P28.33	Primary mixed sleep apnea of newborn	See P28.30	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
P28.39	Other primary sleep apnea of newborn	See P28.30	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
P28.40	Unspecified apnea of newborn	Parent code P28.4 (Other apnea of newborn) was on line 11	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
P28.41	Central neonatal apnea of newborn	See P28.40	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
P28.42	Obstructive apnea of newborn	See P28.40	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
P28.43	Mixed neonatal apnea of newborn	See P28.40	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
P28.49	Other apnea of newborn	See P28.40	11 RESPIRATORY CONDITIONS OF FETUS AND NEWBORN	
Q21.10	Atrial septal defect, unspecified	Parent code Q21.1 (Atrial septal defect) was on line 118	118 ATRIAL SEPTAL DEFECT, SECUNDUM	
Q21.11	Secundum atrial septal defect	See Q21.10	118 ATRIAL SEPTAL DEFECT, SECUNDUM	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
Q21.12	Patent foramen ovale	See Q21.10	118 ATRIAL SEPTAL DEFECT, SECUNDUM	
Q21.13	Coronary sinus atrial septal defect	See Q21.10	118 ATRIAL SEPTAL DEFECT, SECUNDUM	
Q21.14	Superior sinus venosus atrial septal defect	See Q21.10	118 ATRIAL SEPTAL DEFECT, SECUNDUM	
Q21.15	Inferior sinus venosus atrial septal defect	See Q21.10	118 ATRIAL SEPTAL DEFECT, SECUNDUM	
Q21.16	Sinus venosus atrial septal defect, unspecified	See Q21.10	118 ATRIAL SEPTAL DEFECT, SECUNDUM	
Q21.19	Other specified atrial septal defect	See Q21.10	118 ATRIAL SEPTAL DEFECT, SECUNDUM	
Q21.20	Atrioventricular septal defect, unspecified as to partial or complete	Parent code Q21.2 (Atrioventricular septal defect) was on line 84	84 ENDOCARDIAL CUSHION DEFECTS	
Q21.21	Partial atrioventricular septal defect	See Q21.20	84 ENDOCARDIAL CUSHION DEFECTS	
Q21.22	Transitional atrioventricular septal defect	See Q21.20	84 ENDOCARDIAL CUSHION DEFECTS	
Q21.23	Complete atrioventricular septal defect	See Q21.20	84 ENDOCARDIAL CUSHION DEFECTS	
Q85.81	PTEN tumor syndrome		191 CANCER OF BREAST; AT HIGH RISK OF BREAST CANCER	See issues document
Q85.82	Other Cowden syndrome		191 CANCER OF BREAST; AT HIGH RISK OF BREAST CANCER	See issues document
Q85.83	Von Hippel-Lindau syndrome		125 BENIGN NEOPLASM OF THE BRAIN AND SPINAL CORD	See issues document
Q85.89	Other phakomatoses, not elsewhere classified		125 BENIGN NEOPLASM OF THE BRAIN AND SPINAL CORD	See issues document
S06.0XAA	Concussion with loss of consciousness status unknown, initial encounter	Similar code S06.0X1A (Concussion with loss of consciousness of 30 minutes or less, initial encounter) is on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.0XAD	Concussion with loss of consciousness status unknown, subsequent encounter	See above	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.0XAS	Concussion with loss of consciousness status unknown, sequela	See above	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.1XAA	Traumatic cerebral edema with loss of consciousness status unknown, initial encounter	Similar codes for traumatic cerebral edema with loss of conciousness (i.e. S06.1X1A) are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.1XAD	Traumatic cerebral edema with loss of consciousness status unknown, subsequent encounter	See above	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.1XAS	Traumatic cerebral edema with loss of consciousness status unknown, sequela	See above	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.2XAA	Diffuse traumatic brain injury with loss of consciousness status unknown, initial encounter	Similar code S06.2X1A (Diffuse traumatic brain injury with loss of consciousness of 30 minutes or less, initial encounter) is on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.2XAD	Diffuse traumatic brain injury with loss of consciousness status unknown, subsequent encounter	See above	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.2XAS	Diffuse traumatic brain injury with loss of consciousness status unknown, sequela	See above	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.30AA	Unspecified focal traumatic brain injury with loss of consciousness status unknown, initial encounter	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.30AD	Unspecified focal traumatic brain injury with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.30AS	Unspecified focal traumatic brain injury with loss of consciousness status unknown, sequela	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.31AA	Contusion and laceration of right cerebrum with loss of consciousness status unknown, initial encounter	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.31AD	Contusion and laceration of right cerebrum with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.31AS	Contusion and laceration of right cerebrum with loss of consciousness status unknown, sequela	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.32AA	Contusion and laceration of left cerebrum with loss of consciousness status unknown, initial encounter	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.32AD	Contusion and laceration of left cerebrum with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.32AS	Contusion and laceration of left cerebrum with loss of consciousness status unknown, sequela	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.33AA	Contusion and laceration of cerebrum, unspecified, with loss of consciousness status unknown, initial encounter	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.33AD	Contusion and laceration of cerebrum, unspecified, with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.33AS	Contusion and laceration of cerebrum, unspecified, with loss of consciousness status unknown, sequela	Similar codes are on line 91	91 SEVERE/MODERATE HEAD INJURY: HEMATOMA/EDEMA WITH PERSISTENT SYMPTOMS	
S06.34AA	Traumatic hemorrhage of right cerebrum with loss of consciousness status unknown, initial encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.34AD	Traumatic hemorrhage of right cerebrum with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.34AS	Traumatic hemorrhage of right cerebrum with loss of consciousness status unknown, sequela	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.35AA	Traumatic hemorrhage of left cerebrum with loss of consciousness status unknown, initial encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.35AD	Traumatic hemorrhage of left cerebrum with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.35AS	Traumatic hemorrhage of left cerebrum with loss of consciousness status unknown, sequela	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.36AA	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness status unknown, initial encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.36AD	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.36AS	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness status unknown, sequela	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.37AA	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness status unknown, initial encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.37AD	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.37AS	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness status unknown, sequela	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.38AA	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness status unknown, initial encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.38AD	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.38AS	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness status unknown, sequela	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.4XAA	Epidural hemorrhage with loss of consciousness status unknown, initial encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.4XAD	Epidural hemorrhage with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.4XAS	Epidural hemorrhage with loss of consciousness status unknown, sequela	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.5XAA	Traumatic subdural hemorrhage with loss of consciousness status unknown, initial encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.5XAD	Traumatic subdural hemorrhage with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.5XAS	Traumatic subdural hemorrhage with loss of consciousness status unknown, sequela	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.6XAA	Traumatic subarachnoid hemorrhage with loss of consciousness status unknown, initial encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.6XAD	Traumatic subarachnoid hemorrhage with loss of consciousness status unknown, subsequent encounter	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.6XAS	Traumatic subarachnoid hemorrhage with loss of consciousness status unknown, sequela	Similar codes are on line 196	196 SUBARACHNOID AND INTRACEREBRAL HEMORRHAGE/HEMATOMA; CEREBRAL ANEURYSM; COMPRESSION OF BRAIN	
S06.81AA	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, initial encounter	Similar codes such as S06.811A (Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 30 minutes or less, initial encounter) are on the dysfunction lines	71,292,345,377	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.81AD	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, subsequent encounter	See above	71,292,345,377	
S06.81AS	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, sequela	See above	71,292,345,377	
S06.82AA	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, initial encounter	See above	71,292,345,377	
S06.82AD	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, subsequent encounter	See above	71,292,345,377	
S06.82AS	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, sequela	See above	71,292,345,377	
S06.89AA	Other specified intracranial injury with loss of consciousness status unknown, initial encounter	Similar codes such as S06.891A (Other specified intracranial injury with loss of consciousness of 30 minutes or less, initial encounter) are on the dysfunction lines	71,292,345,377	
S06.89AD	Other specified intracranial injury with loss of consciousness status unknown, subsequent encounter	See above	71,292,345,377	
S06.89AS	Other specified intracranial injury with loss of consciousness status unknown, sequela	See above	71,292,345,377	
S06.8A0A	Primary blast injury of brain, not elsewhere classified without loss of consciousness, initial encounter	Similar brain injury codes are on the dysfunction lines	71,292,345,377	
S06.8A0D	Primary blast injury of brain, not elsewhere classified without loss of consciousness, subsequent encounter	See above	71,292,345,377	
S06.8A0S	Primary blast injury of brain, not elsewhere classified without loss of consciousness, sequela	See above	71,292,345,377	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.8A1A	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 30 minutes or less, initial encounter	See above	71,292,345,377	
S06.8A1D	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 30 minutes or less, subsequent encounter	See above	71,292,345,377	
S06.8A1S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 30 minutes or less, sequela	See above	71,292,345,377	
S06.8A2A	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 31 minutes to 59 minutes, initial encounter	See above	71,292,345,377	
S06.8A2D	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter	See above	71,292,345,377	
S06.8A2S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 31 minutes to 59 minutes, sequela	See above	71,292,345,377	
S06.8A3A	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter	See above	71,292,345,377	
S06.8A3D	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter	See above	71,292,345,377	
S06.8A3S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	See above	71,292,345,377	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.8A4A	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 6 hours to 24 hours, initial encounter	See above	71,292,345,377	
S06.8A4D	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 6 hours to 24 hours, subsequent encounter	See above	71,292,345,377	
S06.8A4S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 6 hours to 24 hours, sequela	See above	71,292,345,377	
S06.8A5A	Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter	See above	71,292,345,377	
S06.8A5D	Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter	See above	71,292,345,377	
S06.8A5S	Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	See above	71,292,345,377	
S06.8A6A	Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter	See above	71,292,345,377	
S06.8A6D	Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter	See above	71,292,345,377	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.8A6S	Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	See above	71,292,345,377	
S06.8A7A	Primary blast injury of brain, not elsewhere classified with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, initial encounter	See above	71,292,345,377	
S06.8A8A	Primary blast injury of brain, not elsewhere classified with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, initial encounter	See above	71,292,345,377	
S06.8A9A	Primary blast injury of brain, not elsewhere classified with loss of consciousness of unspecified duration, initial encounter	See above	71,292,345,377	
S06.8A9D	Primary blast injury of brain, not elsewhere classified with loss of consciousness of unspecified duration, subsequent encounter	See above	71,292,345,377	
S06.8A9S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of unspecified duration, sequela	See above	71,292,345,377	
S06.8AAA	Primary blast injury of brain, not elsewhere classified with loss of consciousness status unknown, initial encounter	See above	71,292,345,377	
S06.8AAD	Primary blast injury of brain, not elsewhere classified with loss of consciousness status unknown, subsequent encounter	See above	71,292,345,377	
S06.8AAS	Primary blast injury of brain, not elsewhere classified with loss of consciousness status unknown, sequela	See above	71,292,345,377	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
S06.9XAA	Unspecified intracranial injury with loss of consciousness status unknown, initial encounter	See above	71,292,345,377	
S06.9XAD	Unspecified intracranial injury with loss of consciousness status unknown, subsequent encounter	See above	71,292,345,377	
S06.9XAS	Unspecified intracranial injury with loss of consciousness status unknown, sequela	See above	71,292,345,377	
T43.651A	Poisoning by methamphetamines accidental (unintentional), initial encounter	Poisoning codes are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.651D	Poisoning by methamphetamines accidental (unintentional), subsequent encounter	Poisoning codes are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.651S	Poisoning by methamphetamines accidental (unintentional), sequela	Poisoning codes are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.652A	Poisoning by methamphetamines intentional self-harm, initial encounter	Poisoning codes even when intentional self-harm are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.652D	Poisoning by methamphetamines intentional self-harm, subsequent encounter	Poisoning codes even when intentional self-harm are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.652S	Poisoning by methamphetamines intentional self-harm, sequela	Poisoning codes even when intentional self-harm are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.653A	Poisoning by methamphetamines, assault, initial encounter	Poisoning codes are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.653D	Poisoning by methamphetamines, assault, subsequent encounter	Poisoning codes are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.653S	Poisoning by methamphetamines, assault, sequela	Poisoning codes are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.654A	Poisoning by methamphetamines, undetermined, initial encounter	Poisoning codes are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
T43.654D	Poisoning by methamphetamines, undetermined, subsequent encounter	Poisoning codes are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.654S	Poisoning by methamphetamines, undetermined, sequela	Poisoning codes are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.655A	Adverse effect of methamphetamines, initial encounter	Adverse effects of illicit drugs are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.655D	Adverse effect of methamphetamines, subsequent encounter	Adverse effects of illicit drugs are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.655S	Adverse effect of methamphetamines, sequela	Adverse effects of illicit drugs are on line 102	102 POISONING BY INGESTION, INJECTION, MEDICINAL AND NON-MEDICINAL AGENTS	
T43.656A	Underdosing of methamphetamines, initial encounter	Other underdosing codes are DWF	DIAGNOSTIC WORKUP FILE (DWF)	
T43.656D	Underdosing of methamphetamines, subsequent encounter	Other underdosing codes are DWF	DIAGNOSTIC WORKUP FILE (DWF)	
T43.656S	Underdosing of methamphetamines, sequela	Other underdosing codes are DWF	DIAGNOSTIC WORKUP FILE (DWF)	
V20.01XA	Electric (assisted) bicycle driver injured in collision with pedestrian or animal in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.01XD	Electric (assisted) bicycle driver injured in collision with pedestrian or animal in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.01XS	Electric (assisted) bicycle driver injured in collision with pedestrian or animal in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.09XA	Other motorcycle driver injured in collision with pedestrian or animal in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.09XD	Other motorcycle driver injured in collision with pedestrian or animal in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V20.09XS	Other motorcycle driver injured in collision with pedestrian or animal in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.11XA	Electric (assisted) bicycle passenger injured in collision with pedestrian or animal in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.11XD	Electric (assisted) bicycle passenger injured in collision with pedestrian or animal in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.11XS	Electric (assisted) bicycle passenger injured in collision with pedestrian or animal in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.19XA	Other motorcycle passenger injured in collision with pedestrian or animal in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.19XD	Other motorcycle passenger injured in collision with pedestrian or animal in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.19XS	Other motorcycle passenger injured in collision with pedestrian or animal in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.21XA	Unspecified electric (assisted) bicycle rider injured in collision with pedestrian or animal in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.21XD	Unspecified electric (assisted) bicycle rider injured in collision with pedestrian or animal in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.21XS	Unspecified electric (assisted) bicycle rider injured in collision with pedestrian or animal in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.29XA	Unspecified rider of other motorcycle injured in collision with pedestrian or animal in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V20.29XD	Unspecified rider of other motorcycle injured in collision with pedestrian or animal in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.29XS	Unspecified rider of other motorcycle injured in collision with pedestrian or animal in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.31XA	Person boarding or alighting an electric (assisted) bicycle injured in collision with pedestrian or animal, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.31XD	Person boarding or alighting an electric (assisted) bicycle injured in collision with pedestrian or animal, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.31XS	Person boarding or alighting an electric (assisted) bicycle injured in collision with pedestrian or animal, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.39XA	Person boarding or alighting other motorcycle injured in collision with pedestrian or animal, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.39XD	Person boarding or alighting other motorcycle injured in collision with pedestrian or animal, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.39XS	Person boarding or alighting other motorcycle injured in collision with pedestrian or animal, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.41XA	Electric (assisted) bicycle driver injured in collision with pedestrian or animal in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.41XD	Electric (assisted) bicycle driver injured in collision with pedestrian or animal in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.41XS	Electric (assisted) bicycle driver injured in collision with pedestrian or animal in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.49XA	Other motorcycle driver injured in collision with pedestrian or animal in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V20.49XD	Other motorcycle driver injured in collision with pedestrian or animal in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.49XS	Other motorcycle driver injured in collision with pedestrian or animal in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.51XA	Electric (assisted) bicycle passenger injured in collision with pedestrian or animal in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.51XD	Electric (assisted) bicycle passenger injured in collision with pedestrian or animal in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.51XS	Electric (assisted) bicycle passenger injured in collision with pedestrian or animal in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.59XA	Other motorcycle passenger injured in collision with pedestrian or animal in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.59XD	Other motorcycle passenger injured in collision with pedestrian or animal in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.59XS	Other motorcycle passenger injured in collision with pedestrian or animal in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.91XA	Unspecified electric (assisted) bicycle rider injured in collision with pedestrian or animal in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.91XD	Unspecified electric (assisted) bicycle rider injured in collision with pedestrian or animal in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.91XS	Unspecified electric (assisted) bicycle rider injured in collision with pedestrian or animal in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.99XA	Unspecified rider of other motorcycle injured in collision with pedestrian or animal in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V20.99XD	Unspecified rider of other motorcycle injured in collision with pedestrian or animal in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V20.99XS	Unspecified rider of other motorcycle injured in collision with pedestrian or animal in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.01XA	Electric (assisted) bicycle driver injured in collision with pedal cycle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.01XD	Electric (assisted) bicycle driver injured in collision with pedal cycle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.01XS	Electric (assisted) bicycle driver injured in collision with pedal cycle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.09XA	Other motorcycle driver injured in collision with pedal cycle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.09XD	Other motorcycle driver injured in collision with pedal cycle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.09XS	Other motorcycle driver injured in collision with pedal cycle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.11XA	Electric (assisted) bicycle passenger injured in collision with pedal cycle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.11XD	Electric (assisted) bicycle passenger injured in collision with pedal cycle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.11XS	Electric (assisted) bicycle passenger injured in collision with pedal cycle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.19XA	Other motorcycle passenger injured in collision with pedal cycle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V21.19XD	Other motorcycle passenger injured in collision with pedal cycle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.19XS	Other motorcycle passenger injured in collision with pedal cycle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.21XA	Unspecified electric (assisted) bicycle rider injured in collision with pedal cycle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.21XD	Unspecified electric (assisted) bicycle rider injured in collision with pedal cycle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.21XS	Unspecified electric (assisted) bicycle rider injured in collision with pedal cycle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.29XA	Unspecified rider of other motorcycle injured in collision with pedal cycle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.29XD	Unspecified rider of other motorcycle injured in collision with pedal cycle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.29XS	Unspecified rider of other motorcycle injured in collision with pedal cycle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.31XA	Person boarding or alighting an electric (assisted) bicycle injured in collision with pedal cycle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.31XD	Person boarding or alighting an electric (assisted) bicycle injured in collision with pedal cycle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.31XS	Person boarding or alighting an electric (assisted) bicycle injured in collision with pedal cycle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.39XA	Person boarding or alighting other motorcycle injured in collision with pedal cycle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V21.39XD	Person boarding or alighting other motorcycle injured in collision with pedal cycle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.39XS	Person boarding or alighting other motorcycle injured in collision with pedal cycle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.41XA	Electric (assisted) bicycle driver injured in collision with pedal cycle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.41XD	Electric (assisted) bicycle driver injured in collision with pedal cycle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.41XS	Electric (assisted) bicycle driver injured in collision with pedal cycle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.49XA	Other motorcycle driver injured in collision with pedal cycle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.49XD	Other motorcycle driver injured in collision with pedal cycle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.49XS	Other motorcycle driver injured in collision with pedal cycle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.51XA	Electric (assisted) bicycle passenger injured in collision with pedal cycle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.51XD	Electric (assisted) bicycle passenger injured in collision with pedal cycle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.51XS	Electric (assisted) bicycle passenger injured in collision with pedal cycle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.59XA	Other motorcycle passenger injured in collision with pedal cycle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.59XD	Other motorcycle passenger injured in collision with pedal cycle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V21.59XS	Other motorcycle passenger injured in collision with pedal cycle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.91XA	Unspecified electric (assisted) bicycle rider injured in collision with pedal cycle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.91XD	Unspecified electric (assisted) bicycle rider injured in collision with pedal cycle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.91XS	Unspecified electric (assisted) bicycle rider injured in collision with pedal cycle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.99XA	Unspecified rider of other motorcycle injured in collision with pedal cycle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.99XD	Unspecified rider of other motorcycle injured in collision with pedal cycle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V21.99XS	Unspecified rider of other motorcycle injured in collision with pedal cycle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.01XA	Electric (assisted) bicycle driver injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.01XD	Electric (assisted) bicycle driver injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.01XS	Electric (assisted) bicycle driver injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.09XA	Other motorcycle driver injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V22.09XD	Other motorcycle driver injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.09XS	Other motorcycle driver injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.11XA	Electric (assisted) bicycle passenger injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.11XD	Electric (assisted) bicycle passenger injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.11XS	Electric (assisted) bicycle passenger injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.19XA	Other motorcycle passenger injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.19XD	Other motorcycle passenger injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.19XS	Other motorcycle passenger injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.21XA	Unspecified electric (assisted) bicycle rider injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V22.21XD	Unspecified electric (assisted) bicycle rider injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.21XS	Unspecified electric (assisted) bicycle rider injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.29XA	Unspecified rider of other motorcycle injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.29XD	Unspecified rider of other motorcycle injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.29XS	Unspecified rider of other motorcycle injured in collision with two- or three-wheeled motor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.31XA	Person boarding or alighting an electric (assisted) bicycle injured in collision with two- or three-wheeled motor vehicle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.31XD	Person boarding or alighting an electric (assisted) bicycle injured in collision with two- or three-wheeled motor vehicle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.31XS	Person boarding or alighting an electric (assisted) bicycle injured in collision with two- or three-wheeled motor vehicle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.39XA	Person boarding or alighting other motorcycle injured in collision with two- or three-wheeled motor vehicle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V22.39XD	Person boarding or alighting other motorcycle injured in collision with two- or three-wheeled motor vehicle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.39XS	Person boarding or alighting other motorcycle injured in collision with two- or three-wheeled motor vehicle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.41XA	Electric (assisted) bicycle driver injured in collision with two- or three-wheeled motor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.41XD	Electric (assisted) bicycle driver injured in collision with two- or three-wheeled motor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.41XS	Electric (assisted) bicycle driver injured in collision with two- or three-wheeled motor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.49XA	Other motorcycle driver injured in collision with two- or three-wheeled motor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.49XD	Other motorcycle driver injured in collision with two- or three-wheeled motor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.49XS	Other motorcycle driver injured in collision with two- or three-wheeled motor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.51XA	Electric (assisted) bicycle passenger injured in collision with two- or three-wheeled motor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.51XD	Electric (assisted) bicycle passenger injured in collision with two- or three-wheeled motor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V22.51XS	Electric (assisted) bicycle passenger injured in collision with two- or three-wheeled motor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.59XA	Other motorcycle passenger injured in collision with two- or three-wheeled motor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.59XD	Other motorcycle passenger injured in collision with two- or three-wheeled motor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.59XS	Other motorcycle passenger injured in collision with two- or three-wheeled motor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.91XA	Unspecified electric (assisted) bicycle rider injured in collision with two- or three-wheeled motor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.91XD	Unspecified electric (assisted) bicycle rider injured in collision with two- or three-wheeled motor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.91XS	Unspecified electric (assisted) bicycle rider injured in collision with two- or three-wheeled motor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.99XA	Unspecified rider of other motorcycle injured in collision with two- or three-wheeled motor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.99XD	Unspecified rider of other motorcycle injured in collision with two- or three-wheeled motor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V22.99XS	Unspecified rider of other motorcycle injured in collision with two- or three-wheeled motor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V23.01XA	Electric (assisted) bicycle driver injured in collision with car, pick-up truck or van in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.01XD	Electric (assisted) bicycle driver injured in collision with car, pick-up truck or van in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.01XS	Electric (assisted) bicycle driver injured in collision with car, pick-up truck or van in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.09XA	Other motorcycle driver injured in collision with car, pick-up truck or van in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.09XD	Other motorcycle driver injured in collision with car, pick-up truck or van in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.09XS	Other motorcycle driver injured in collision with car, pick-up truck or van in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.11XA	Electric (assisted) bicycle passenger injured in collision with car, pick-up truck or van in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.11XD	Electric (assisted) bicycle passenger injured in collision with car, pick-up truck or van in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.11XS	Electric (assisted) bicycle passenger injured in collision with car, pick-up truck or van in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.19XA	Other motorcycle passenger injured in collision with car, pick-up truck or van in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.19XD	Other motorcycle passenger injured in collision with car, pick-up truck or van in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V23.19XS	Other motorcycle passenger injured in collision with car, pick-up truck or van in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.21XA	Unspecified electric (assisted) bicycle rider injured in collision with car, pick-up truck or van in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.21XD	Unspecified electric (assisted) bicycle rider injured in collision with car, pick-up truck or van in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.21XS	Unspecified electric (assisted) bicycle rider injured in collision with car, pick-up truck or van in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.29XA	Unspecified rider of other motorcycle injured in collision with car, pick-up truck or van in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.29XD	Unspecified rider of other motorcycle injured in collision with car, pick-up truck or van in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.29XS	Unspecified rider of other motorcycle injured in collision with car, pick-up truck or van in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.31XA	Person boarding or alighting an electric (assisted) bicycle injured in collision with car, pick-up truck or van, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.31XD	Person boarding or alighting an electric (assisted) bicycle injured in collision with car, pick-up truck or van, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.31XS	Person boarding or alighting an electric (assisted) bicycle injured in collision with car, pick-up truck or van, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.39XA	Person boarding or alighting other motorcycle injured in collision with car, pick-up truck or van, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V23.39XD	Person boarding or alighting other motorcycle injured in collision with car, pick-up truck or van, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.39XS	Person boarding or alighting other motorcycle injured in collision with car, pick-up truck or van, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.41XA	Electric (assisted) bicycle driver injured in collision with car, pick-up truck or van in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.41XD	Electric (assisted) bicycle driver injured in collision with car, pick-up truck or van in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.41XS	Electric (assisted) bicycle driver injured in collision with car, pick-up truck or van in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.49XA	Other motorcycle driver injured in collision with car, pick-up truck or van in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.49XD	Other motorcycle driver injured in collision with car, pick-up truck or van in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.49XS	Other motorcycle driver injured in collision with car, pick-up truck or van in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.51XA	Electric (assisted) bicycle passenger injured in collision with car, pick-up truck or van in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.51XD	Electric (assisted) bicycle passenger injured in collision with car, pick-up truck or van in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.51XS	Electric (assisted) bicycle passenger injured in collision with car, pick-up truck or van in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.59XA	Other motorcycle passenger injured in collision with car, pick-up truck or van in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V23.59XD	Other motorcycle passenger injured in collision with car, pick-up truck or van in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.59XS	Other motorcycle passenger injured in collision with car, pick-up truck or van in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.91XA	Unspecified electric (assisted) bicycle rider injured in collision with car, pick-up truck or van in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.91XD	Unspecified electric (assisted) bicycle rider injured in collision with car, pick-up truck or van in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.91XS	Unspecified electric (assisted) bicycle rider injured in collision with car, pick-up truck or van in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.99XA	Unspecified rider of other motorcycle injured in collision with car, pick-up truck or van in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.99XD	Unspecified rider of other motorcycle injured in collision with car, pick-up truck or van in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V23.99XS	Unspecified rider of other motorcycle injured in collision with car, pick-up truck or van in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.01XA	Electric (assisted) bicycle driver injured in collision with heavy transport vehicle or bus in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.01XD	Electric (assisted) bicycle driver injured in collision with heavy transport vehicle or bus in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.01XS	Electric (assisted) bicycle driver injured in collision with heavy transport vehicle or bus in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V24.09XA	Other motorcycle driver injured in collision with heavy transport vehicle or bus in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.09XD	Other motorcycle driver injured in collision with heavy transport vehicle or bus in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.09XS	Other motorcycle driver injured in collision with heavy transport vehicle or bus in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.11XA	Electric (assisted) bicycle passenger injured in collision with heavy transport vehicle or bus in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.11XD	Electric (assisted) bicycle passenger injured in collision with heavy transport vehicle or bus in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.11XS	Electric (assisted) bicycle passenger injured in collision with heavy transport vehicle or bus in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.19XA	Other motorcycle passenger injured in collision with heavy transport vehicle or bus in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.19XD	Other motorcycle passenger injured in collision with heavy transport vehicle or bus in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.19XS	Other motorcycle passenger injured in collision with heavy transport vehicle or bus in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.21XA	Unspecified electric (assisted) bicycle rider injured in collision with heavy transport vehicle or bus in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V24.21XD	Unspecified electric (assisted) bicycle rider injured in collision with heavy transport vehicle or bus in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.21XS	Unspecified electric (assisted) bicycle rider injured in collision with heavy transport vehicle or bus in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.29XA	Unspecified rider of other motorcycle injured in collision with heavy transport vehicle or bus in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.29XD	Unspecified rider of other motorcycle injured in collision with heavy transport vehicle or bus in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.29XS	Unspecified rider of other motorcycle injured in collision with heavy transport vehicle or bus in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.31XA	Person boarding or alighting an electric (assisted) bicycle injured in collision with heavy transport vehicle or bus, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.31XD	Person boarding or alighting an electric (assisted) bicycle injured in collision with heavy transport vehicle or bus, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.31XS	Person boarding or alighting an electric (assisted) bicycle injured in collision with heavy transport vehicle or bus, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.39XA	Person boarding or alighting other motorcycle injured in collision with heavy transport vehicle or bus, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.39XD	Person boarding or alighting other motorcycle injured in collision with heavy transport vehicle or bus, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V24.39XS	Person boarding or alighting other motorcycle injured in collision with heavy transport vehicle or bus, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.41XA	Electric (assisted) bicycle driver injured in collision with heavy transport vehicle or bus in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.41XD	Electric (assisted) bicycle driver injured in collision with heavy transport vehicle or bus in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.41XS	Electric (assisted) bicycle driver injured in collision with heavy transport vehicle or bus in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.49XA	Other motorcycle driver injured in collision with heavy transport vehicle or bus in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.49XD	Other motorcycle driver injured in collision with heavy transport vehicle or bus in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.49XS	Other motorcycle driver injured in collision with heavy transport vehicle or bus in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.51XA	Electric (assisted) bicycle passenger injured in collision with heavy transport vehicle or bus in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.51XD	Electric (assisted) bicycle passenger injured in collision with heavy transport vehicle or bus in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.51XS	Electric (assisted) bicycle passenger injured in collision with heavy transport vehicle or bus in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.59XA	Other motorcycle passenger injured in collision with heavy transport vehicle or bus in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V24.59XD	Other motorcycle passenger injured in collision with heavy transport vehicle or bus in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.59XS	Other motorcycle passenger injured in collision with heavy transport vehicle or bus in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.91XA	Unspecified electric (assisted) bicycle rider injured in collision with heavy transport vehicle or bus in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.91XD	Unspecified electric (assisted) bicycle rider injured in collision with heavy transport vehicle or bus in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.91XS	Unspecified electric (assisted) bicycle rider injured in collision with heavy transport vehicle or bus in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.99XA	Unspecified rider of other motorcycle injured in collision with heavy transport vehicle or bus in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.99XD	Unspecified rider of other motorcycle injured in collision with heavy transport vehicle or bus in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V24.99XS	Unspecified rider of other motorcycle injured in collision with heavy transport vehicle or bus in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.01XA	Electric (assisted) bicycle driver injured in collision with railway train or railway vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.01XD	Electric (assisted) bicycle driver injured in collision with railway train or railway vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V25.01XS	Electric (assisted) bicycle driver injured in collision with railway train or railway vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.09XA	Other motorcycle driver injured in collision with railway train or railway vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.09XD	Other motorcycle driver injured in collision with railway train or railway vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.09XS	Other motorcycle driver injured in collision with railway train or railway vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.11XA	Electric (assisted) bicycle passenger injured in collision with railway train or railway vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.11XD	Electric (assisted) bicycle passenger injured in collision with railway train or railway vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.11XS	Electric (assisted) bicycle passenger injured in collision with railway train or railway vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.19XA	Other motorcycle passenger injured in collision with railway train or railway vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.19XD	Other motorcycle passenger injured in collision with railway train or railway vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.19XS	Other motorcycle passenger injured in collision with railway train or railway vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V25.21XA	Unspecified electric (assisted) bicycle rider injured in collision with railway train or railway vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.21XD	Unspecified electric (assisted) bicycle rider injured in collision with railway train or railway vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.21XS	Unspecified electric (assisted) bicycle rider injured in collision with railway train or railway vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.29XA	Unspecified rider of other motorcycle injured in collision with railway train or railway vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.29XD	Unspecified rider of other motorcycle injured in collision with railway train or railway vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.29XS	Unspecified rider of other motorcycle injured in collision with railway train or railway vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.31XA	Person boarding or alighting an electric (assisted) bicycle injured in collision with railway train or railway vehicle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.31XD	Person boarding or alighting an electric (assisted) bicycle injured in collision with railway train or railway vehicle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.31XS	Person boarding or alighting an electric (assisted) bicycle injured in collision with railway train or railway vehicle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.39XA	Person boarding or alighting other motorcycle injured in collision with railway train or railway vehicle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V25.39XD	Person boarding or alighting other motorcycle injured in collision with railway train or railway vehicle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.39XS	Person boarding or alighting other motorcycle injured in collision with railway train or railway vehicle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.41XA	Electric (assisted) bicycle driver injured in collision with railway train or railway vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.41XD	Electric (assisted) bicycle driver injured in collision with railway train or railway vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.41XS	Electric (assisted) bicycle driver injured in collision with railway train or railway vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.49XA	Other motorcycle driver injured in collision with railway train or railway vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.49XD	Other motorcycle driver injured in collision with railway train or railway vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.49XS	Other motorcycle driver injured in collision with railway train or railway vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.51XA	Electric (assisted) bicycle passenger injured in collision with railway train or railway vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.51XD	Electric (assisted) bicycle passenger injured in collision with railway train or railway vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V25.51XS	Electric (assisted) bicycle passenger injured in collision with railway train or railway vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.59XA	Other motorcycle passenger injured in collision with railway train or railway vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.59XD	Other motorcycle passenger injured in collision with railway train or railway vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.59XS	Other motorcycle passenger injured in collision with railway train or railway vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.91XA	Unspecified electric (assisted) bicycle rider injured in collision with railway train or railway vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.91XD	Unspecified electric (assisted) bicycle rider injured in collision with railway train or railway vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.91XS	Unspecified electric (assisted) bicycle rider injured in collision with railway train or railway vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.99XA	Unspecified rider of other motorcycle injured in collision with railway train or railway vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.99XD	Unspecified rider of other motorcycle injured in collision with railway train or railway vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V25.99XS	Unspecified rider of other motorcycle injured in collision with railway train or railway vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V26.01XA	Electric (assisted) bicycle driver injured in collision with other nonmotor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.01XD	Electric (assisted) bicycle driver injured in collision with other nonmotor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.01XS	Electric (assisted) bicycle driver injured in collision with other nonmotor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.09XA	Other motorcycle driver injured in collision with other nonmotor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.09XD	Other motorcycle driver injured in collision with other nonmotor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.09XS	Other motorcycle driver injured in collision with other nonmotor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.11XA	Electric (assisted) bicycle passenger injured in collision with other nonmotor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.11XD	Electric (assisted) bicycle passenger injured in collision with other nonmotor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.11XS	Electric (assisted) bicycle passenger injured in collision with other nonmotor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.19XA	Other motorcycle passenger injured in collision with other nonmotor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.19XD	Other motorcycle passenger injured in collision with other nonmotor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V26.19XS	Other motorcycle passenger injured in collision with other nonmotor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.21XA	Unspecified electric (assisted) bicycle rider injured in collision with other nonmotor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.21XD	Unspecified electric (assisted) bicycle rider injured in collision with other nonmotor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.21XS	Unspecified electric (assisted) bicycle rider injured in collision with other nonmotor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.29XA	Unspecified rider of other motorcycle injured in collision with other nonmotor vehicle in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.29XD	Unspecified rider of other motorcycle injured in collision with other nonmotor vehicle in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.29XS	Unspecified rider of other motorcycle injured in collision with other nonmotor vehicle in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.31XA	Person boarding or alighting an electric (assisted) bicycle injured in collision with other nonmotor vehicle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.31XD	Person boarding or alighting an electric (assisted) bicycle injured in collision with other nonmotor vehicle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.31XS	Person boarding or alighting an electric (assisted) bicycle injured in collision with other nonmotor vehicle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.39XA	Person boarding or alighting other motorcycle injured in collision with other nonmotor vehicle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V26.39XD	Person boarding or alighting other motorcycle injured in collision with other nonmotor vehicle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.39XS	Person boarding or alighting other motorcycle injured in collision with other nonmotor vehicle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.41XA	Electric (assisted) bicycle driver injured in collision with other nonmotor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.41XD	Electric (assisted) bicycle driver injured in collision with other nonmotor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.41XS	Electric (assisted) bicycle driver injured in collision with other nonmotor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.49XA	Other motorcycle driver injured in collision with other nonmotor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.49XD	Other motorcycle driver injured in collision with other nonmotor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.49XS	Other motorcycle driver injured in collision with other nonmotor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.51XA	Electric (assisted) bicycle passenger injured in collision with other nonmotor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.51XD	Electric (assisted) bicycle passenger injured in collision with other nonmotor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.51XS	Electric (assisted) bicycle passenger injured in collision with other nonmotor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.59XA	Other motorcycle passenger injured in collision with other nonmotor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V26.59XD	Other motorcycle passenger injured in collision with other nonmotor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.59XS	Other motorcycle passenger injured in collision with other nonmotor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.91XA	Unspecified electric (assisted) bicycle rider injured in collision with other nonmotor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.91XD	Unspecified electric (assisted) bicycle rider injured in collision with other nonmotor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.91XS	Unspecified electric (assisted) bicycle rider injured in collision with other nonmotor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.99XA	Unspecified rider of other motorcycle injured in collision with other nonmotor vehicle in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.99XD	Unspecified rider of other motorcycle injured in collision with other nonmotor vehicle in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V26.99XS	Unspecified rider of other motorcycle injured in collision with other nonmotor vehicle in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.01XA	Electric (assisted) bicycle driver injured in collision with fixed or stationary object in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.01XD	Electric (assisted) bicycle driver injured in collision with fixed or stationary object in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.01XS	Electric (assisted) bicycle driver injured in collision with fixed or stationary object in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V27.09XA	Other motorcycle driver injured in collision with fixed or stationary object in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.09XD	Other motorcycle driver injured in collision with fixed or stationary object in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.09XS	Other motorcycle driver injured in collision with fixed or stationary object in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.11XA	Electric (assisted) bicycle passenger injured in collision with fixed or stationary object in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.11XD	Electric (assisted) bicycle passenger injured in collision with fixed or stationary object in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.11XS	Electric (assisted) bicycle passenger injured in collision with fixed or stationary object in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.19XA	Other motorcycle passenger injured in collision with fixed or stationary object in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.19XD	Other motorcycle passenger injured in collision with fixed or stationary object in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.19XS	Other motorcycle passenger injured in collision with fixed or stationary object in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.21XA	Unspecified electric (assisted) bicycle rider injured in collision with fixed or stationary object in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.21XD	Unspecified electric (assisted) bicycle rider injured in collision with fixed or stationary object in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V27.21XS	Unspecified electric (assisted) bicycle rider injured in collision with fixed or stationary object in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.29XA	Unspecified rider of other motorcycle injured in collision with fixed or stationary object in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.29XD	Unspecified rider of other motorcycle injured in collision with fixed or stationary object in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.29XS	Unspecified rider of other motorcycle injured in collision with fixed or stationary object in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.31XA	Person boarding or alighting an electric (assisted) bicycle injured in collision with fixed or stationary object, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.31XD	Person boarding or alighting an electric (assisted) bicycle injured in collision with fixed or stationary object, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.31XS	Person boarding or alighting an electric (assisted) bicycle injured in collision with fixed or stationary object, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.39XA	Person boarding or alighting other motorcycle injured in collision with fixed or stationary object, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.39XD	Person boarding or alighting other motorcycle injured in collision with fixed or stationary object, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.39XS	Person boarding or alighting other motorcycle injured in collision with fixed or stationary object, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.41XA	Electric (assisted) bicycle driver injured in collision with fixed or stationary object in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V27.41XD	Electric (assisted) bicycle driver injured in collision with fixed or stationary object in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.41XS	Electric (assisted) bicycle driver injured in collision with fixed or stationary object in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.49XA	Other motorcycle driver injured in collision with fixed or stationary object in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.49XD	Other motorcycle driver injured in collision with fixed or stationary object in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.49XS	Other motorcycle driver injured in collision with fixed or stationary object in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.51XA	Electric (assisted) bicycle passenger injured in collision with fixed or stationary object in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.51XD	Electric (assisted) bicycle passenger injured in collision with fixed or stationary object in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.51XS	Electric (assisted) bicycle passenger injured in collision with fixed or stationary object in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.59XA	Other motorcycle passenger injured in collision with fixed or stationary object in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.59XD	Other motorcycle passenger injured in collision with fixed or stationary object in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.59XS	Other motorcycle passenger injured in collision with fixed or stationary object in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.91XA	Unspecified electric (assisted) bicycle rider injured in collision with fixed or stationary object in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V27.91XD	Unspecified electric (assisted) bicycle rider injured in collision with fixed or stationary object in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.91XS	Unspecified electric (assisted) bicycle rider injured in collision with fixed or stationary object in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.99XA	Unspecified rider of other motorcycle injured in collision with fixed or stationary object in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.99XD	Unspecified rider of other motorcycle injured in collision with fixed or stationary object in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V27.99XS	Unspecified rider of other motorcycle injured in collision with fixed or stationary object in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.01XA	Electric (assisted) bicycle driver injured in noncollision transport accident in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.01XD	Electric (assisted) bicycle driver injured in noncollision transport accident in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.01XS	Electric (assisted) bicycle driver injured in noncollision transport accident in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.09XA	Other motorcycle driver injured in noncollision transport accident in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.09XD	Other motorcycle driver injured in noncollision transport accident in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.09XS	Other motorcycle driver injured in noncollision transport accident in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V28.11XA	Electric (assisted) bicycle passenger injured in noncollision transport accident in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.11XD	Electric (assisted) bicycle passenger injured in noncollision transport accident in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.11XS	Electric (assisted) bicycle passenger injured in noncollision transport accident in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.19XA	Other motorcycle passenger injured in noncollision transport accident in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.19XD	Other motorcycle passenger injured in noncollision transport accident in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.19XS	Other motorcycle passenger injured in noncollision transport accident in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.21XA	Unspecified electric (assisted) bicycle rider injured in noncollision transport accident in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.21XD	Unspecified electric (assisted) bicycle rider injured in noncollision transport accident in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.21XS	Unspecified electric (assisted) bicycle rider injured in noncollision transport accident in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.29XA	Unspecified rider of other motorcycle injured in noncollision transport accident in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.29XD	Unspecified rider of other motorcycle injured in noncollision transport accident in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V28.29XS	Unspecified rider of other motorcycle injured in noncollision transport accident in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.31XA	Person boarding or alighting an electric (assisted) bicycle injured in noncollision transport accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.31XD	Person boarding or alighting an electric (assisted) bicycle injured in noncollision transport accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.31XS	Person boarding or alighting an electric (assisted) bicycle injured in noncollision transport accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.39XA	Person boarding or alighting other motorcycle injured in noncollision transport accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.39XD	Person boarding or alighting other motorcycle injured in noncollision transport accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.39XS	Person boarding or alighting other motorcycle injured in noncollision transport accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.41XA	Electric (assisted) bicycle driver injured in noncollision transport accident in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.41XD	Electric (assisted) bicycle driver injured in noncollision transport accident in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.41XS	Electric (assisted) bicycle driver injured in noncollision transport accident in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.49XA	Other motorcycle driver injured in noncollision transport accident in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.49XD	Other motorcycle driver injured in noncollision transport accident in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.49XS	Other motorcycle driver injured in noncollision transport accident in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V28.51XA	Electric (assisted) bicycle passenger injured in noncollision transport accident in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.51XD	Electric (assisted) bicycle passenger injured in noncollision transport accident in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.51XS	Electric (assisted) bicycle passenger injured in noncollision transport accident in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.59XA	Other motorcycle passenger injured in noncollision transport accident in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.59XD	Other motorcycle passenger injured in noncollision transport accident in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.59XS	Other motorcycle passenger injured in noncollision transport accident in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.91XA	Unspecified electric (assisted) bicycle rider injured in noncollision transport accident in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.91XD	Unspecified electric (assisted) bicycle rider injured in noncollision transport accident in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.91XS	Unspecified electric (assisted) bicycle rider injured in noncollision transport accident in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.99XA	Unspecified rider of other motorcycle injured in noncollision transport accident in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.99XD	Unspecified rider of other motorcycle injured in noncollision transport accident in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V28.99XS	Unspecified rider of other motorcycle injured in noncollision transport accident in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V29.001A	Electric (assisted) bicycle driver injured in collision with unspecified motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.001D	Electric (assisted) bicycle driver injured in collision with unspecified motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.001S	Electric (assisted) bicycle driver injured in collision with unspecified motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.008A	Other motorcycle driver injured in collision with unspecified motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.008D	Other motorcycle driver injured in collision with unspecified motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.008S	Other motorcycle driver injured in collision with unspecified motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.091A	Electric (assisted) bicycle driver injured in collision with other motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.091D	Electric (assisted) bicycle driver injured in collision with other motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.091S	Electric (assisted) bicycle driver injured in collision with other motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.098A	Other motorcycle driver injured in collision with other motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.098D	Other motorcycle driver injured in collision with other motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V29.098S	Other motorcycle driver injured in collision with other motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.101A	Electric (assisted) bicycle passenger injured in collision with unspecified motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.101D	Electric (assisted) bicycle passenger injured in collision with unspecified motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.101S	Electric (assisted) bicycle passenger injured in collision with unspecified motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.108A	Other motorcycle passenger injured in collision with unspecified motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.108D	Other motorcycle passenger injured in collision with unspecified motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.108S	Other motorcycle passenger injured in collision with unspecified motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.191A	Electric (assisted) bicycle passenger injured in collision with other motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.191D	Electric (assisted) bicycle passenger injured in collision with other motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.191S	Electric (assisted) bicycle passenger injured in collision with other motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.198A	Other motorcycle passenger injured in collision with other motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V29.198D	Other motorcycle passenger injured in collision with other motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.198S	Other motorcycle passenger injured in collision with other motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.201A	Unspecified electric (assisted) bicycle rider injured in collision with unspecified motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.201D	Unspecified electric (assisted) bicycle rider injured in collision with unspecified motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.201S	Unspecified electric (assisted) bicycle rider injured in collision with unspecified motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.208A	Unspecified rider of other motorcycle injured in collision with unspecified motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.208D	Unspecified rider of other motorcycle injured in collision with unspecified motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.208S	Unspecified rider of other motorcycle injured in collision with unspecified motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.291A	Unspecified electric (assisted) bicycle rider injured in collision with other motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.291D	Unspecified electric (assisted) bicycle rider injured in collision with other motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V29.291S	Unspecified electric (assisted) bicycle rider injured in collision with other motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.298A	Unspecified rider of other motorcycle injured in collision with other motor vehicles in nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.298D	Unspecified rider of other motorcycle injured in collision with other motor vehicles in nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.298S	Unspecified rider of other motorcycle injured in collision with other motor vehicles in nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.31XA	Electric (assisted) bicycle (driver) (passenger) injured in unspecified nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.31XD	Electric (assisted) bicycle (driver) (passenger) injured in unspecified nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.31XS	Electric (assisted) bicycle (driver) (passenger) injured in unspecified nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.39XA	Other motorcycle (driver) (passenger) injured in unspecified nontraffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.39XD	Other motorcycle (driver) (passenger) injured in unspecified nontraffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.39XS	Other motorcycle (driver) (passenger) injured in unspecified nontraffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.401A	Electric (assisted) bicycle driver injured in collision with unspecified motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.401D	Electric (assisted) bicycle driver injured in collision with unspecified motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V29.401S	Electric (assisted) bicycle driver injured in collision with unspecified motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.408A	Other motorcycle driver injured in collision with unspecified motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.408D	Other motorcycle driver injured in collision with unspecified motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.408S	Other motorcycle driver injured in collision with unspecified motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.491A	Electric (assisted) bicycle driver injured in collision with other motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.491D	Electric (assisted) bicycle driver injured in collision with other motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.491S	Electric (assisted) bicycle driver injured in collision with other motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.498A	Other motorcycle driver injured in collision with other motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.498D	Other motorcycle driver injured in collision with other motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.498S	Other motorcycle driver injured in collision with other motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.501A	Electric (assisted) bicycle passenger injured in collision with unspecified motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.501D	Electric (assisted) bicycle passenger injured in collision with unspecified motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V29.501S	Electric (assisted) bicycle passenger injured in collision with unspecified motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.508A	Other motorcycle passenger injured in collision with unspecified motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.508D	Other motorcycle passenger injured in collision with unspecified motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.508S	Other motorcycle passenger injured in collision with unspecified motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.591A	Electric (assisted) bicycle passenger injured in collision with other motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.591D	Electric (assisted) bicycle passenger injured in collision with other motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.591S	Electric (assisted) bicycle passenger injured in collision with other motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.598A	Other motorcycle passenger injured in collision with other motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.598D	Other motorcycle passenger injured in collision with other motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.598S	Other motorcycle passenger injured in collision with other motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.601A	Unspecified electric (assisted) bicycle rider injured in collision with unspecified motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V29.601D	Unspecified electric (assisted) bicycle rider injured in collision with unspecified motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.601S	Unspecified electric (assisted) bicycle rider injured in collision with unspecified motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.608A	Unspecified rider of other motorcycle injured in collision with unspecified motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.608D	Unspecified rider of other motorcycle injured in collision with unspecified motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.608S	Unspecified rider of other motorcycle injured in collision with unspecified motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.691A	Unspecified electric (assisted) bicycle rider injured in collision with other motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.691D	Unspecified electric (assisted) bicycle rider injured in collision with other motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.691S	Unspecified electric (assisted) bicycle rider injured in collision with other motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.698A	Unspecified rider of other motorcycle injured in collision with other motor vehicles in traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.698D	Unspecified rider of other motorcycle injured in collision with other motor vehicles in traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V29.698S	Unspecified rider of other motorcycle injured in collision with other motor vehicles in traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.811A	Electric (assisted) bicycle rider (driver) (passenger) injured in transport accident with military vehicle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.811D	Electric (assisted) bicycle rider (driver) (passenger) injured in transport accident with military vehicle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.811S	Electric (assisted) bicycle rider (driver) (passenger) injured in transport accident with military vehicle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.818A	Rider (driver) (passenger) of other motorcycle injured in transport accident with military vehicle, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.818D	Rider (driver) (passenger) of other motorcycle injured in transport accident with military vehicle, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.818S	Rider (driver) (passenger) of other motorcycle injured in transport accident with military vehicle, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.881A	Electric (assisted) bicycle rider (driver) (passenger) injured in other specified transport accidents, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.881D	Electric (assisted) bicycle rider (driver) (passenger) injured in other specified transport accidents, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.881S	Electric (assisted) bicycle rider (driver) (passenger) injured in other specified transport accidents, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.888A	Rider (driver) (passenger) of other motorcycle injured in other specified transport accidents, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
V29.888D	Rider (driver) (passenger) of other motorcycle injured in other specified transport accidents, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.888S	Rider (driver) (passenger) of other motorcycle injured in other specified transport accidents, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.91XA	Electric (assisted) bicycle rider (driver) (passenger) injured in unspecified traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.91XD	Electric (assisted) bicycle rider (driver) (passenger) injured in unspecified traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.91XS	Electric (assisted) bicycle rider (driver) (passenger) injured in unspecified traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.99XA	Rider (driver) (passenger) of other motorcycle injured in unspecified traffic accident, initial encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.99XD	Rider (driver) (passenger) of other motorcycle injured in unspecified traffic accident, subsequent encounter	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
V29.99XS	Rider (driver) (passenger) of other motorcycle injured in unspecified traffic accident, sequela	"V" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
W23.2XXA	Caught, crushed, jammed or pinched between a moving and stationary object, initial encounter	"W" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
W23.2XXD	Caught, crushed, jammed or pinched between a moving and stationary object, subsequent encounter	"W" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
W23.2XXS	Caught, crushed, jammed or pinched between a moving and stationary object, sequela	"W" codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z03.83	Encounter for observation for suspected conditions related to home physiologic monitoring device ruled out	Many "observation codes" are DWF to allow ER visits, etc.	DIAGNOSTIC WORKUP FILE (DWF)	
Z28.310^	Unvaccinated for COVID-19		INFORMATIONAL DIAGNOSES	Already placed
Z28.311^	Partially vaccinated for COVID-19		INFORMATIONAL DIAGNOSES	Already placed

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
Z28.39^	Other underimmunization status		INFORMATIONAL DIAGNOSES	Already placed
Z59.82	Transportation insecurity	Similar codes are INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z59.86	Financial insecurity	Similar codes are INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z59.87	Material hardship	Similar codes are INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z71.87	Encounter for pediatric-to-adult transition counseling		DIAGNOSTIC WORKUP FILE (DWF)	Discussed and approved by BHAP
Z71.88	Encounter for counseling for socioeconomic factors		DIAGNOSTIC WORKUP FILE (DWF)	Discussed and approved by BHAP
Z72.823	Risk of suffocation (smothering) under another while sleeping		INFORMATIONAL DIAGNOSES	
Z79.60	Long term (current) use of unspecified immunomodulators and immunosuppressants	Similar codes are Diagnostic as use may require lab monitoring	DIAGNOSTIC WORKUP FILE (DWF)	
Z79.61	Long term (current) use of immunomodulator		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.620	Long term (current) use of immunosuppressive biologic		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.621	Long term (current) use of calcineurin inhibitor		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.622	Long term (current) use of Janus kinase inhibitor		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.623	Long term (current) use of mammalian target of rapamycin (mTOR) inhibitor		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.624	Long term (current) use of inhibitors of nucleotide synthesis		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.630	Long term (current) use of alkylating agent		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.631	Long term (current) use of antimetabolite agent		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.632	Long term (current) use of antitumor antibiotic		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.633	Long term (current) use of mitotic inhibitor		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.634	Long term (current) use of topoisomerase inhibitor		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.64	Long term (current) use of myelosuppressive agent		DIAGNOSTIC WORKUP FILE (DWF)	
Z79.69	Long term (current) use of other immunomodulators and immunosuppressants		DIAGNOSTIC WORKUP FILE (DWF)	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
Z79.85	Long-term (current) use of injectable non-insulin antidiabetic drugs		DIAGNOSTIC WORKUP FILE (DWF)	
Z87.61	Personal history of (corrected) necrotizing enterocolitis of newborn	Simlar codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	If results in short bowel syndrome, can use that diagnosis for further treatment
Z87.68	Personal history of other (corrected) conditions arising in the perinatal period	Simlar codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z87.731	Personal history of (corrected) tracheoesophageal fistula or atresia	Simlar codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z87.732	Personal history of (corrected) persistent cloaca or cloacal malformations	Simlar codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z87.760	Personal history of (corrected) congenital diaphragmatic hernia or other congenital diaphragm malformations	Simlar codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z87.761	Personal history of (corrected) gastroschisis	Simlar codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z87.762	Personal history of (corrected) prune belly malformation	Simlar codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z87.763	Personal history of other (corrected) congenital abdominal wall malformations	Simlar codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z87.768	Personal history of other specified (corrected) congenital malformations of integument, limbs and musculoskeletal system	Simlar codes are generally INFORMATIONAL	INFORMATIONAL DIAGNOSES	
Z91.110	Patient's noncompliance with dietary regimen due to financial hardship	Parent code Z91.11 (Patient's noncompliance with dietary regimen) was on INFORMATIONAL DIAGNOSES	INFORMATIONAL DIAGNOSES	
Z91.118	Patient's noncompliance with dietary regimen for other reason	See Z91.110	INFORMATIONAL DIAGNOSES	
Z91.119	Patient's noncompliance with dietary regimen due to unspecified reason	See Z91.110	INFORMATIONAL DIAGNOSES	
Z91.190	Patient's noncompliance with other medical treatment and regimen due to financial hardship	Parent code Z91.19 (Patient's noncompliance with other medical treatment and regimen) was on INFORMATIONAL DIAGNOSES	INFORMATIONAL DIAGNOSES	
Z91.198	Patient's noncompliance with other medical treatment and regimen for other reason	See Z91.190	INFORMATIONAL DIAGNOSES	

ICD10 Code	Code Description	Similar Codes	Recommended Placement	Comments
Z91.199	Patient's noncompliance with other medical treatment and regimen due to unspecified reason	See Z91.190	INFORMATIONAL DIAGNOSES	
Z91.A10	Caregiver's noncompliance with patient's dietary regimen due to financial hardship		INFORMATIONAL DIAGNOSES	
Z91.A18	Caregiver's noncompliance with patient's dietary regimen for other reason		INFORMATIONAL DIAGNOSES	
Z91.A20	Caregiver's intentional underdosing of patient's medication regimen due to financial hardship		INFORMATIONAL DIAGNOSES	
Z91.A28	Caregiver's intentional underdosing of medication regimen for other reason		INFORMATIONAL DIAGNOSES	
Z91.A3	Caregiver's unintentional underdosing of patient's medication regimen		INFORMATIONAL DIAGNOSES	
Z91.A4	Caregiver's other noncompliance with patient's medication regimen		INFORMATIONAL DIAGNOSES	
Z91.A5	Caregiver's noncompliance with patient's renal dialysis		INFORMATIONAL DIAGNOSES	
Z91.A9	Caregiver's noncompliance with patient's other medical treatment and regimen		INFORMATIONAL DIAGNOSES	

2023 ICD-10-CM Code Review Issues

1) Postural orthostatic tachycardia syndrome (POTS)

Plain Language: An abnormal increase in heart rate that occurs after sitting up or standing. Some typical symptoms include dizziness and fainting.

Recommendation: Add to uncovered line 535 HYPOTENSION as well as covered lines to allow supportive care, including medication OR only add to line 535 HYPOTENSION as treatment is mostly self-care.

a. Code: **G90.A** Postural orthostatic tachycardia syndrome [POTS]
b. Definition: POTS is an abnormal increase in heart rate that occurs after sitting up or standing. Symptoms can include dizziness and fainting. Treatment is generally lifestyle changes such as increasing fluid intake, rising slowly from laying or sitting, and including more salt in the diet. Medications such as beta blockers, midodrine, fludrocortisone, and SSRIs may be used.
c. Similar codes, such ag ICD-10-CM G90.01 (Carotid sinus syncope) are on the dysfunction lines and on line 535 HYPOTENSION
d. HERC staff recommendation
    i. Place G90.A (Postural orthostatic tachycardia syndrome [POTS]) on the dysfunction lines and line 535 HYPOTENSION
    ii. Alternative: place on just line 535, but this would not allow medications to be prescribed for this condition

2) Fatigue syndromes
a. Codes
    i. **G93.31** Postviral fatigue syndrome
    ii. **G93.32** Myalgic encephalomyelitis/chronic fatigue syndrome
    iii. **G93.39** Other post infection and related fatigue syndromes
b. Definition: Chronic fatigue syndrome and postviral fatigue syndrome are conditions characterized by profound fatigue, sleep abnormalities, pain, and other symptoms that are made worse by exertion. The cause of this condition is unknown, but may include environmental or genetic factors. The main symptom is fatigue for over six months. The fatigue often worsens with activity, but doesn't improve with rest. There is no cure or approved treatment for this condition.
c. Similar codes:
    i. Parent code G93.2 (Postviral fatigue syndrome) is on the DIAGNOSTIC WORKUP FILE (DWF)
    ii. R53.82 (Chronic fatigue, unspecified) is on line 531 FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, AND RELATED DISORDERS
    iii. U09.9 (Post COVID condition, unspecified) is on line 399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS. This code is used for long COVID
d. HERC staff recommendation:

i. Place the G93.3X codes on line 531 FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, AND RELATED DISORDERS

3) Refractory angina

Plain Language: Long-lasting chest pain or pressure (>3 months), a symptom of heart disease not controllable by the best available medical treatment which includes bypass surgery.

Recommendation: Add to covered line 189 CHRONIC ISCHEMIC HEART DISEASE to allow for medications, repeat bypass grafting (taking a blood vessel from another body part, attaching it to the artery that supplies blood to the heart above and below the narrowed area that is blocked) and rehabilitation.

a. Codes
   i. **I20.2** Refractory angina pectoris
   ii. **I25.112** Atherosclerotic heart disease of native coronary artery with refractory angina pectoris
   iii. **I25.702, I25.712, I25.722, I25.732, I25.792** Atherosclerosis of various types of coronary artery bypass graft(s), with refractory angina pectoris
   iv. **I25.752** Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris
   v. **I25.762** Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris
b. Definition: Refractory angina (RA) is conventionally defined as a chronic condition (≥3 months in duration) characterized by angina in the setting of coronary artery disease (CAD), which cannot be controlled by a combination of optimal medical therapy, angioplasty or bypass surgery, and where reversible myocardial ischemia has been clinically established to be the cause of the symptoms
c. Treatment includes beta blockers, calcium channel antagonists, vasodilators, PCI, re-doing cardiac bypass grafting, and cardiac rehabilitation. Several investigational procedures are being studied for this condition including external enhanced counterpulsation, extracorporeal shockwave myocardial revascularization therapy, spinal cord stimulators.
d. HERC staff recommendation:
   i. Place this code series on line 189 CHRONIC ISCHEMIC HEART DISEASE
      1. Contains most other angina diagnosis codes

4) Antineutrophilic cytoplasmic antibody vasculitis

Plain Language: This is a blood test that looks for specific antibodies in blood. Autoantibodies are proteins made by the immune system that mistakenly targets normal tissues. If the antibodies are found vasculitis (swelling of blood vessels) could develop.

Recommendation: Add to covered lines 99 END STAGE RENAL DISEASE,129 GRANULOMATOSIS WITH POLYANGIITIS, and 219 PULMONARY FIBROSIS to allow for treatment of kidney, heart and lung diseases.

a. Code: **I77.81** Antineutrophilic cytoplasmic antibody [ANCA] vasculitis
b. Definition: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of three main diseases, which are granulomatosis with polyangiitis (GPA; formerly known as Wegener granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome), and microscopic polyangiitis (MPA). Other ANCA-associated diseases are drug-induced vasculitis and renal limited vasculitis.
c. Similar codes
    i. Wegener granulomatosis is coded with M31.3X, which is on lines 99,129,219
    ii. Churg-Strauss syndrome is coded with M30.1, which is on lines 99,129,219
d. HERC staff recommendation
    i. Place I77.81 on lines 99 END STAGE RENAL DISEASE,129 GRANULOMATOSIS WITH POLYANGIITIS, and 219 PULMONARY FIBROSIS

5) Transfusion-associated dyspnea (TAD)

Plain Language: An acute breathing problem that develops within 24 hours after getting a blood transfusion but less severe than an allergic reaction.

Recommendation: Add to covered line 285 COMPLICATIONS OF A PROCEDURE ALWAYS REQUIRING TREATMENT for treatment of this condition.

a. Code: **J95.87** Transfusion-associated dyspnea (TAD)
b. Definition: The National Healthcare Safety Network hemovigilance protocol defines transfusion associated dyspnea (TAD) as acute respiratory distress occurring without 24 hours of cessation of transfusion but does not meet the definition of allergic reaction, transfusion associated circulatory overload (TACO) and transfusion related acute lung injury (TRALI)
c. Very little literature found regarding treatment of this condition
d. Similar codes
    i. Transfusion associated circulatory overload (TACO) is coded with E87.71 which is on line 221 DISORDERS OF FLUID, ELECTROLYTE, AND ACID-BASE BALANCE
    ii. Transfusion related acute lung injury (TRALI) is coded with J95.84 which is on 285 COMPLICATIONS OF A PROCEDURE ALWAYS REQUIRING TREATMENT
e. HERC staff recommendation
    i. Place J95.87 on line 285 COMPLICATIONS OF A PROCEDURE ALWAYS REQUIRING TREATMENT

Endometriosis of the intestine

Plain Language: Endometriosis is an ongoing, painful condition in which tissue like the kind that lines the uterus (the endometrium) grows outside of the uterus. When this condition affects the bowels, it appears in two forms: Superficial (on the surface of your bowel) Deep (passes through your bowel wall).

Recommendation: Add codes for superficial and unspecified diagnosis to covered line 395 ENDOMETRIOSIS AND ADENOMYOSIS. Add deep bowel diagnosis codes to covered line 41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION

a. Codes:
    i. **N80.50-NN80.569** Superficial, deep and unspecified endometriosis of various parts of the bowel
b. Definition: Endometriosis is a common benign gynecological disease defined by the presence of endometrium glands outside the uterine cavity. Bowel endometriosis typically presents as a single nodule, with a diameter larger than 1 cm, commonly infiltrating the muscularis of the bowel and the surrounding structures. Bowel involvement accounts for 5% to 12% of the women presenting with the disease, with the rectum and sigmoid involved in up to 90% of all intestinal lesions. Symptoms of bowel endometriosis can be non-specific consisting of dysmenorrhea and dyspareunia. More specific bowel-related symptoms such as diarrhea, constipation, dyschezia and rarely bowel obstruction depend on disease localization, size of nodule and depth of involvement of the bowel wall. Treatment can be medical (oral contraceptives, Lupron, etc.). Surgical treatment of superficial lesions can be done as with other pelvic endometriosis (e.g. laparoscopic excision or ablation). If the endometriosis is deep, the bowel may need to be shaved or resected.
c. Similar codes
    i. Current endometriosis codes are all on line 395 ENDOMETRIOSIS AND ADENOMYOSIS. This line contains laparoscopy codes but no CPT codes for intestinal resection
    ii. Bowel resection CPT codes are on line 13 lines, including lines 29 REGIONAL ENTERITIS, IDIOPATHIC PROCTOCOLITIS, ULCERATION OF INTESTINE, 41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION, 100 CONGENITAL ANOMALIES OF DIGESTIVE SYSTEM AND ABDOMINAL WALL EXCLUDING NECROSIS; CHRONIC INTESTINAL PSEUDO-OBSTRUCTION, various bowel cancer lines and line 638 BENIGN NEOPLASMS OF DIGESTIVE SYSTEM
d. HERC staff recommendation:
    i. Place superficial and unspecified bowel endometriosis diagnoses on line 395 ENDOMETRIOSIS AND ADENOMYOSIS.
    ii. Place deep bowel endometriosis diagnoses on line 395 and on line 41 INTUSSCEPTION, VOLVULUS, INTESTINAL OBSTRUCTION, HAZARDOUS FOREIGN BODY IN GI TRACT WITH RISK OF PERFORATION OR OBSTRUCTION
        1. Line 41 will have all bowel resection codes and would be appropriate if the endometriosis results in bowel obstruction

6) Endometriosis of the bladder and ureters

Plain Language: This is a rare form of deep infiltrating endometriosis (DIE) in which growth of endometriosis (tissue resembling the endometrium) occurs in the bladder, ureters and kidneys.

Recommendation: Add codes for superficial and unspecified bladder/ureter endometriosis diagnoses on covered line 395 ENDOMETRIOSIS AND ADENOMYOSIS. Add deep bladder/ureter endometriosis diagnoses on covered lines 395 and 327 FUNCTIONAL AND MECHANICAL DISORDERS OF THE GENITOURINARY SYSTEM INCLUDING BLADDER OUTLET OBSTRUCTION.

a. Codes: **N80.A0-N80.A69** Superficial, deep and unspecified endometriosis of the bladder and ureters
b. Description: deep endometriosis of the bladder can result in acute urethral syndrome with frequency, tenesmus, burning sensation, pain during micturition, dysuria, hematuria, and suprapubic discomfort and pain. Treatment can be medical (OCPs, GnRH agonists, etc.). Surgical treatment includes partial cystectomy and transurethral resection of lesions
c. Similar codes
    i. Current endometriosis codes are all on line 395 ENDOMETRIOSIS AND ADENOMYOSIS. This line contains laparoscopy codes but no CPT codes for intestinal resection
    ii. Cystoscopy codes with resection of lesions appear on lines 86 CONGENITAL ANOMALIES OF GENITOURINARY SYSTEM, 214 CANCER OF KIDNEY AND OTHER URINARY ORGANS, 271 CANCER OF BLADDER AND URETER and 327 FUNCTIONAL AND MECHANICAL DISORDERS OF THE GENITOURINARY SYSTEM INCLUDING BLADDER OUTLET OBSTRUCTION
    iii. Partial cystoscopy codes appear on lines 86, 214, and 271
d. HERC staff recommendation:
    i. Place superficial and unspecified bladder/ureter endometriosis diagnoses on line 395 ENDOMETRIOSIS AND ADENOMYOSIS.
    ii. Place deep bladder/ureter endometriosis diagnoses on line 395 and on line 327 FUNCTIONAL AND MECHANICAL DISORDERS OF THE GENITOURINARY SYSTEM INCLUDING BLADDER OUTLET OBSTRUCTION
        1. Line 327 has the majority of treatment codes needed for cystectomy and urethroplasty

7) Endometriosis of the lung and thoracic cavity

Plain Language: A rare condition that happens when endometriosis patches grow on or around the lungs. This can cause shortness of breath, chest pain, cough, and in some cases, a collapsed lung.

Recommendation: Add codes to covered lines 372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS and 395 ENDOMETRIOSIS AND ADENOMYOSIS.

a. Codes: **N80.B1-N80.B6** Endometriosis of the pleura, lung, diaphragm, mediastinal and cardiothoracic space
b. Definition: Thoracic Endometriosis Syndrome (TES) is an extremely rare condition that involves around the lungs such as pleura, pulmonary parenchyma, diaphragm, air ways and pericardium. Symptoms can include pneumothorax, hemothorax, hemoptysis, lung nodules as well middle mediastinal involvements such as pericardial effusion, pericardial nodules, and hemopericardium. Medical treatment would include OCPs and GnRH agonists as with other types of endometriosis. If the pulmonary disease is recurrent or progressive, thoracotomy, excision of lesions or pleurodesis may be necessary.
c. Similar codes
    i. Current endometriosis codes are all on line 395 ENDOMETRIOSIS AND ADENOMYOSIS. This line contains laparoscopy codes but no CPT codes for intestinal resection
    ii. Thoracotomy and resection of thoracic lesion CPT codes appear on several lines, including line 372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS
d. HERC staff recommendation:
    i. Place N80.B1-N80.B6 on lines 372 BENIGN NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS and 395 ENDOMETRIOSIS AND ADENOMYOSIS.

8) Isthmocele

Plain Language: A uterine isthmocele is a defect on the inside wall of the womb at the site of a C-section scar.

Recommendation: Add codes to covered line 423 MENSTRUAL BLEEDING DISORDERS

a. Code: **N85.A** Isthmocele
b. Definition: A cesarean scar defect, which represents a myometrial discontinuity with the base communicating to the uterine cavity. The majority are asymptomatic. Symptomatic isthmoceles present with postmenstrual bleeding, secondary infertility, and/or pelvic pain. Symptomatic isthmocele or asymptomatic isthmocele in patients desiring future pregnancy are treated with surgery to close the defect, which can be done hysteroscopically, laparoscopically or transvaginally. In symptomatic patients not desiring fertility, hysterectomy can be a treatment option.
c. CPT 58520 (Hysterorrhaphy, repair of ruptured uterus (nonobstetrical)) is on line 79 INJURY TO INTERNAL ORGANS
d. CPT codes for hysterectomy appear on multiple lines, including 423 MENSTRUAL BLEEDING DISORDERS. Line 423 also contains CPT codes for hysteroscopy

e. HERC staff recommendation
    i. Place N85.A (Isthmocele) on line 423 MENSTRUAL BLEEDING DISORDERS
    ii. Add CPT 58520 (Hysterorrhaphy, repair of ruptured uterus (nonobstetrical)) to line 423

9) Phakomatoses/tumor syndromes
    a. Codes:
        i. **Q85.81** PTEN tumor syndrome
        ii. **Q85.82** Other Cowden syndrome
        iii. **Q85.83** Von Hippel-Lindau syndrome
        iv. **Q85.89** Other phakomatoses, not elsewhere classified
    b. Similar code: Parent code Q85.8 (Other phakomatoses, not elsewhere classified) was on line 125 BENIGN NEOPLASM OF THE BRAIN AND SPINAL CORD. One specified sub-diagnosis of this code was Von Hippel-Lindau syndrome. Other subdiagnoses include Peutz-Jeghers Syndrome and Sturge-Weber syndrome
    c. Definitions
        i. The PTEN hamartoma tumor syndrome (PHTS) is a spectrum of disorders caused by mutations of the PTEN tumor suppressor gene. These disorders are characterized by multiple hamartomas that can affect various areas of the body. People with PTEN mutations have an elevated risk of multiple cancers (see Cowden Syndrome below). 80% of patients with Cowden syndrome have a PTEN mutation.
            1. Per **NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 2.2022**, PTEN elevates breast cancer risk with a lifetime risk of 40-60%. Patients with PTEN mutation/Cowden syndrome should have breast cancer screening with annual mammograms and breast MRIs starting at age 35. Risk reducing mastectomy should be considered. Colon cancer screening should start at age 35 and occur at a minimum of every 5 years
        ii. Cowden syndrome is a genetic disorder characterized by multiple noncancerous, tumor-like growths called hamartomas and an increased risk of developing certain cancers. Cowden syndrome is associated with an increased risk of developing cancers of the breast, thyroid, endometrium, kidney, colorectal cancer and melanoma. See above for NCCN guidelines regarding screening and treatment recommendations
        iii. Von Hippel-Lindau syndrome is a rare, genetic disorder that causes tumors and cysts to grow in certain parts of the body, including the brain, spinal cord, eyes, inner ear, adrenal glands, pancreas, kidney, and reproductive tract. The tumors are usually benign, but some may be malignant. Patients with von Hippel-Lindau syndrome have an increased risk of certain types of cancer, especially kidney cancer and pancreatic cancer. It is caused by a mutation in the VHL gene.
        iv. Phakomatoses, also known as neurocutaneous syndromes, are a broad group of congenital disorders that are characterized by hamartomatous lesions of the skin and the central and peripheral nervous systems.

d. Additional Prioritized List information
    i. PTEN and Cowden Syndrome are mentioned in Diagnostic Guideline D25, HEREDITARY CANCER GENETIC TESTING:
        1. PTEN (Cowden syndrome) services (CPT 81321-81323) should be provided as defined by the NCCN Clinical Practice Guidelines in Oncology (Genetic/Familial High-Risk Assessment: Ovarian and Pancreatic. V1.2022 (8/11/21) or Genetic/Familial High-Risk Assessment: Colorectal V1.2021 (5/11/21) www.nccn.org).
    ii. Other syndromes with elevated risk of breast cancer, such as BRCA, are included on line 191 CANCER OF BREAST; AT HIGH RISK OF BREAST CANCER
    iii. Z15.01 (Genetic susceptibility to malignant neoplasm of breast) is on line 191. Z15.04 (Genetic susceptibility to malignant neoplasm of endometrium) and Z15.09 (Genetic susceptibility to other malignant neoplasm) are on INFORMATIONAL DIAGNOSES
e. HERC staff recommendations
    i. Place Q85.81 and Q85.82 on line 191 CANCER OF BREAST; AT HIGH RISK OF BREAST CANCER
        1. Allows prophylactic mastectomy
    ii. Place Q85.83 and Q85.89 on line 125 BENIGN NEOPLASM OF THE BRAIN AND SPINAL CORD
        1. Previous subdiagnoses of the parent code Q85.8 which was on line 125
    iii. As a 2024 Biennial Review item, consider creating a new line for conditions which place a person at high risk of cancers
        1. This line will take the high risk for breast cancer diagnoses/treatments, and add additional treatments such as prophylactic colectomy, and have a guideline allowing more frequent or more intensive screening

2024 Biennial Review
Temporamandibular Joint Syndrome

Plain Language Summary:
Background: Surgical and medical treatment for disorders of the jaw muscles, temporomandibular joints (TMJ) and the nerves associated with chronic face pain.

Should OHP cover this treatment? Staff recommends not to cover this treatment because the evidence of effectiveness of treatment is extremely limited.

Question: Should any treatment for temporal mandibular joint (TMJ) syndrome be moved into the funded region of the Prioritized List?

Question source: HERC leadership/below the line review

Issue: Surgical and medical treatments for TMJ are on two separate lines below the funding line. As part of the below the line review, HERC staff were asked to look at whether any therapy for TMJ has evidence of effectiveness.

Temporomandibular disorders (TMDs) are a group of more than 30 conditions that cause pain and dysfunction in the jaw joint and muscles that control jaw movement. Symptoms include pain in the jaw joint or face, jaw stiffness, or limited movement or locking of the jaw. Treatment includes eating soft foots, taking NSAIDs or other over the counter pain medications, stopping chewing gum or jaw clenching, physical therapy, relaxation techniques, opioids, intraoral devices, and surgery.

Previous HSC/HERC review: no mention of TMJ were found in the meeting minutes from 1991 onward. January 2000: code D7871 (Reduction of dislocation and management of other temporomandibular joint dysfunctions, non-arthroscopic lysis and lavage) will become part of the exclude list (never covered).

November 2014:

1) Remove 20605 (Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (eg, temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); without ultrasound guidance) from lines 51 DEEP ABSCESSES, INCLUDING APPENDICITIS AND PERIORBITAL ABSCESS, 422 DISORDERS OF SHOULDER, INCLUDING SPRAINS/STRAINS GRADE 3 THROUGH 6, 430 ACUTE PERIPHERAL MOTOR AND DIGITAL NERVE INJURY, 544 LESION OF PLANTAR NERVE; PLANTAR FASCIAL FIBROMATOSIS, 601 GANGLION, 612 DISORDERS OF SOFT TISSUE
2) Place 20606 (Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (eg, temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); with ultrasound guidance, with permanent recording and reporting) on lines 50, 157, 290, 306, 468, 511, 533, 597
3) Place D9130 (temporomandibular joint dysfunction – non-invasive physical therapies) on line 547 TMJ DISORDER

November 2020:

1) Add D0320 (Temporomandibular joint arthrogram, including injection) to line 643 TMJ DISORDERS and remove from DIAGNOSTIC PROCEDURES file
2) Add D0321 (Other temporomandibular joint radiographic images, by report) to line 643 TMJ DISORDERS and remove from DIAGNOSTIC PROCEDURES file

2024 Biennial Review
Temporamandibular Joint Syndrome

Current Prioritized List status
Line 550 TMJ DISORDER Treatment: TMJ SPLINTS (includes office visits and other outpatient care)
Line 643 TMJ DISORDER Treatment: TMJ SURGERY

Evidence

1) **CADTH 2018,** systematic review of reviews of interventions for temporomandibular joint disorder
    a. N=22 systematic reviews
        i. Interventions covered by the included SRs included psychological interventions, orthodontics, surgical interventions, laser therapy, and occlusal appliances
        ii. Comparators included were no treatment or placebo/sham treatment
        iii. Overall, the quality of the included studies was low. Based on the AMSTAR 2 assessment, confidence in the SRs was rated high for two included SRs, moderate in one SR, low in three SRs, and critically low in the remaining 16 SRs
    b. Overall, low-quality evidence showed potentially favorable results for long-term cognitive behavior therapy, low level laser therapy, acupuncture, manual therapy, cyclobenzaprine hydrochloride, Botulinum toxin, Ping-On ointment, inferior or double spaces injections of hyaluronate or prednisolone, open surgery, and arthroscopy. Mixed or neutral results were found regarding stabilization splints and oral pharmacological treatments. Potentially unfavorable results were found for hypnosis and intra-articular injections of corticosteroids. No evidence was found for orthodontic interventions
        i. Psychological interventions: Two SRs examined psychological interventions for TMD. We have low confidence in the results of one SR and critically low confidence in the results from the other SR. They included a total of 18 primary studies. Generally, the evidence regarding various psychological treatments for TMD was of low quality and at unclear or high risk of bias. Additionally, most of the results from MAs were either inconclusive or insignificant.
        ii. Acupuncture or laser therapy: Three SRs examined acupuncture or laser therapy for TMD, and we have critically low confidence in the results from all three SRs. The SRs included a total of 73 primary studies. Overall, much of the evidence regarding acupuncture and laser therapies for the treatment of TMD had unclear or high risk for bias and there was substantial heterogeneity. Interventions that may be associated with improvements in pain are low level laser therapy (LLLT) (versus placebo) and acupuncture (versus sham acupuncture). LLLT may also be associated with improvements in mouth opening (versus placebo)
        iii. Physical therapy: Two SRs examined the effects of manual therapy for TMD, and we have critically low confidence in the results from both SRs. These SRs reported on 57 primary studies and examined a variety of manual therapies such as jaw or neck exercises. Overall, much of the evidence regarding manual and physical therapies for the treatment of TMD was of moderate quality. Interventions that may be associated with improvements in pain are manual therapy targeted to the orofacial region (versus other controls; in patient with myogenous TMD) and manual therapy plus jaw exercises (versus other control;

in patients with arthrogenous TMD). Musculoskeletal manual approaches (versus active control) may be associated with unfavorable pain results.

iv. Splint therapy: Three SRs examined splint therapy for TMD treatment, and we had critically low confidence in the results from all three SRs. These SRs reported on 89 primary studies. Stabilization splints (versus non-occluding appliances), splints (hard, soft, or unspecified; versus other control) and hard stabilization appliances (versus non-occluding appliances) may be associated with improvements in pain scores. None of the comparisons yielded statistically significantly unfavorable results with respect to pain scores. Splints (hard, soft, or unspecified) (versus other control) may be associated with improvements in mouth opening; however, one SR found that stabilization splints (versus other control) had unfavorable results

v. Orthodontic interventions: One SR was identified on the use of orthodontics for treating TMD; however, no primary studies were identified in the SR and therefore no results could be reported. We have moderate confidence in the results of this SR, as there were no critical flaws

vi. Injections: Six SRs investigated the effects of injecting various pharmacological agents for TMD symptoms. We have low confidence in the results from one SR, and critically low confidence in the results from the other five SRs. The risk of bias relating to the evidence regarding pharmacological injections was mixed, though most of the statistically significantly favorable results had low, medium, and moderate risk of bias. Injectable pharmacological interventions that may be associated with improvements in pain were cyclobenzaprine hydrochloride (versus placebo), botulinum toxin (versus placebo), inferior space injection or double spaces injection of hyaluronate or prednisolone (versus the same drug administered as a superior space injection), and pingon (versus placebo). None of the comparisons yielded statistically significantly unfavorable results with respect to pain. Inferior space injection or double spaces injection of hyaluronate or prednisolone (versus the same drug administered as a superior space injection) may also be associated with improvements in mouth opening and corticosteroid intra-articular injection after arthrocentesis (versus saline or Ringer's lactate intra-articular injection with arthrocentesis) may be associated with unfavorable mouth opening results.

c. Conclusions: Due to the low quality of included literature, the limited evidence regarding TMJ clicking and adverse events, and the heterogeneity of SRs included in this report, firm conclusions regarding the optimal interventions for TMD cannot be made

2) **CADTH 2020:** rapid review of botulinum toxin for temporomandibular disorders
   a. N=5 studies
      i. Four systematic reviews were included including three systematic reviews without meta-analysis and one systematic review with a network meta-analysis. One open-label, parallel group RCT was included
      ii. These reports included comparisons of botulinum toxin to occlusive splints, physiotherapy (fascial manipulation, dry needling), pharmacotherapy, placebo, acupuncture, psychological approaches, complementary therapies, saline injections, lidocaine and laser
      iii. None of the included systematic reviews expressed confidence in the efficacy of botulinum toxin for treating TMD. There were some primary studies that

reported improvements in pain scores relative to saline injections. However, this result was not reproduced in several primary studies, and the clinical significance of observed changes is uncertain.

3) **Riley 2020**, Health technology assessment of oral splints for patients with temporomandibular disorders or bruxism
    a. N=52 trials
        i. The evidence identified was of very low quality with unclear reporting
    b. there was no evidence that splints reduced pain [standardized mean difference (at up to 3 months) –0.18, 95% confidence interval –0.42 to 0.06; substantial heterogeneity] when compared with no splints or a minimal intervention. There was no evidence that other outcomes, including temporomandibular joint noises, decreased mouth-opening, and quality of life, improved when using splints
    c. Conclusions: The very low-quality evidence identified did not demonstrate that splints reduced pain in temporomandibular disorders as a group of conditions
4) **Rigon 2011**, Cochrane review of arthroscopy for TMJ
    a. N=7 RCTs (n = 349)
    b. All studies were either at high or unclear risk of bias. The outcome pain was evaluated after 6 months in two studies. No statistically significant differences were found between the arthroscopy versus nonsurgical groups (standardized mean difference (SMD) = 0.004; 95% confidence interval (CI) -0.46 to 0.55, P = 0.81). Two studies, analyzed pain 12 months after surgery (arthroscopy and arthrocentesis) in 81 patients. No statistically significant differences were found (mean difference (MD) = 0.10; 95% CI -1.46 to 1.66, P = 0.90).
    c. Authors' conclusions Both arthroscopy and nonsurgical treatments reduced pain after 6 months. When compared with arthroscopy, open surgery was more effective at reducing pain after 12 months. Nevertheless, there were no differences in mandibular functionality or in other outcomes in clinical evaluations.

<u>Other payer policies</u>

1) Aetna 2022
    a. Note: many plans do not cover TMD or TMJ dysfunction
    b. Medically necessary comprehensive non-surgical management of TMJ/TMD includes *all* of the following, unless contraindicated:
        i. Reversible Intra-Oral Appliances
            1. (i.e., removable occlusal orthopedic appliances-orthotics, stabilization appliances, occlusal splints, bite appliances/planes/splints, mandibular occlusal repositioning appliances [MORAs])
            2. Reversible intra-oral appliances may be considered medically necessary in selected cases only when there is evidence of clinically significant masticatory impairment with documented pain and/or loss of function. Prolonged (greater than 6 months) application of TMD/J intra-oral appliances is not considered medically necessary unless, upon individual case review, documentation is provided that supports prolonged intra-oral appliance use.
        ii. Aetna considers physical therapy to be a medically necessary conservative method of TMD/TMJ treatment

iii. Aetna considers non-opiate analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) medically necessary for mild-to-moderate inflammatory conditions and pain. Low-dosage tricyclic antidepressants (e.g., amitriptyline) are considered medically necessary for treatment of chronic pain, sleep disturbance and nocturnal bruxism. Adjuvant pharmacologic therapies, including anticonvulsants, membrane stabilizers, and sympatholytic agents, are considered medically necessary for unremitting TMJ pain. Opiate analgesics, corticosteroids, anxiolytics, and muscle relaxants are considered medically necessary in refractory pain.

iv. Aetna considers relaxation therapy, electromyographic biofeedback and cognitive behavioral therapy medically necessary for treatment of TMJ/TMD.

v. Aetna considers acupuncture and trigger point injections medically necessary for persons with temporomandibular pain. For acute pain, generally 2 visits per week for 2 weeks are considered medically necessary. Additional treatment is considered medically necessary when pain persists and further improvement is expected.

c. Surgical Procedures
   i. Medically necessary surgical procedures for TMJ/TMD include therapeutic arthroscopy, arthrocentesis, condylotomy/eminectomy, modified condylotomy, arthroplasty, and joint reconstruction using autogenous or alloplastic materials. In general, the least invasive appropriate surgical treatments should be attempted prior to progression to more complicated surgeries

2) Regence BCBS 2021

a. Coverage does not include treatment of temporomandibular joint disorder or developmental maxillofacial conditions that result in overbite, crossbite, malocclusion or similar developmental irregularities of the teeth.

3) **MODA 2022**, TMJ non-surgical treatment

a. Treatment of temporomandibular joint (TMJ) dysfunction may be a limited or excluded benefit under some Moda Health medical plans
b. Treatment of TMJ will be covered to plan limitations when 1 or more of the following criteria are met:
   i. Non-surgical treatment with a custom intra-oral prosthetic devices/splints will be covered with ALL of the following:
      1. At least 2 or more of the following symptoms are present:
         a. Extra-articular pain related to muscles of the head and neck region, or earaches, headaches, masticatory or cervical myalgias
         b. Painful chewing
         c. Restricted range of motion
         d. Popping in the jaw
         e. Diagnosis confirmed by Dental/Periodontal/Maxillofacial Imaging
      2. Failure to respond to total of 6 weeks of conservative treatment with at least 3 or more of the following:
         a. Removal of precipitating activities, analgesics, NSAID's, soft diet and proper chewing techniques
         b. Failure to respond to a course of physical therapy
         c. Use of TENS unit when performed by PT or a dentist

d. Ultrasound
e. Hot/Cold packs
f. Acupuncture
g. Trigger point injections

ii. The following TMJ treatments will NOT be covered. This includes but is not limited to ALL of the following:
    1. Bite (occlusal) adjustment/equilibration
    2. Crowns, bridges, amalgams, etc. to restore tooth alignment or to balance the bite
    3. Orthodontia
    4. Appliances strictly for the treatment of bruxism (grinding of the teeth)
    5. Botox injections
    6. Continuous passive motion (CPM)
    7. Intra-oral appliances for the treatment of headaches or trigeminal neuralgia are considered experimental and investigational, as there is insufficient data on the effectiveness of this therapy
    8. Chiropractic adjustment treatments
    9. Use of TENS units (unless performed by PT or a dentist)
    10. EMG as it is considered investigational since medical necessity has not been established

iii. Orthognathic Surgery – this is typically a plan exclusion.

2024 Biennial Review
Temporamandibular Joint Syndrome

HERC staff summary

The evidence regarding the effectiveness of any treatment for TMJ is extremely limited. Most major insurers note that many of their plans do not cover TMJ treatment.

HERC staff recommendation:

Make no change in the current prioritization of medical and surgical treatment of TMJ on unfunded lines

BHAP 2022
Straightforward Coding Changes

BHAP reviewed the following issues at their July 2022 meeting and recommended these changes go forward for approval by VBBS/HERC.

Issue 1: The CPT codes for drug and alcohol screening (AUDIT/DAST 99408 and 99409) were made Diagnostic in March 2021 to allow use at any type of office visit. However, the similar HCPCS codes were not addressed in that review and remain on lines.

Code	Code Description	Current Placement	Recommended Placement
G0396	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes	600+ lines	DIAGNOSTIC PROCEDURES
G0397	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes	600+ lines	DIAGNOSTIC PROCEDURES
G2011	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes	600+ lines	DIAGNOSTIC PROCEDURES
99408	Alcohol and/or substance (other than tobacco) abuse structured screening (eg, AUDIT, DAST), and brief intervention (SBI) services; 15 to 30 minutes	DIAGNOSTIC PROCEDURES	DIAGNOSTIC PROCEDURES
99409	Alcohol and/or substance (other than tobacco) abuse structured screening (eg, AUDIT, DAST), and brief intervention (SBI) services; greater than 30 minutes	DIAGNOSTIC PROCEDURES	DIAGNOSTIC PROCEDURES

Issue 2: HERC staff have been reviewing CPT and HCPCS codes related to office visits and/or hospital care. Several of these codes appear on behavioral health lines that do not include inpatient care codes. The HERC staff recommendation is to remove from those lines. Several other lines need one or more of these codes.

Code	Code Description	Current Placement	Recommended Change(s)
G0508	Telehealth consultation, critical care, initial, physicians typically spend 60 minutes communicating with the patient and providers via telehealth	500+ lines	Remove from 203 DEPRESSION AND OTHER MOOD DISORDERS, MILD OR MODERATE 438 STEREOTYPED MOVEMENT DISORDER WITH SELF-INJURIOUS BEHAVIOR DUE TO NEURODEVELOPMENTAL DISORDER 450 REACTIVE ATTACHMENT DISORDER OF INFANCY OR EARLY CHILDHOOD

			471 ENCOPRESIS NOT DUE TO A PHYSIOLOGICAL CONDITION 523 SEXUAL DYSFUNCTION
G0509	Telehealth consultation, critical care, subsequent, physicians typically spend 50 minutes communicating with the patient and providers via telehealth	500+ lines	Remove from 203, 438, 450, 471, 523
99225	Subsequent observation care, per day	500+ lines	Remove from 192 AUTISM SPECTRUM DISORDERS 252 PSYCHOLOGICAL FACTORS AGGRAVATING PHYSICAL CONDITION (E.G., ASTHMA, CHRONIC GI CONDITIONS, HYPERTENSION) 575 PERSONALITY DISORDERS EXCLUDING BORDERLINE AND SCHIZOTYPAL Add to 290 ACUTE STRESS DISORDER
99226	Subsequent observation care, per day	500+ lines	Remove from 192, 252, 575 Add to 290

Issue 3: Additional coding changes identified for substance-induced delirium and personality disorders:

CPT code	**Code Description**	**Recommended Line Addition**
90846	Family psychotherapy (without the patient present), 50 minutes	65 SUBSTANCE-INDUCED DELIRIUM; SUBSTANCE INTOXICATION AND WITHDRAWAL
90847	Family psychotherapy (conjoint psychotherapy) (with patient present), 50 minutes	65
90849	Multiple-family group psychotherapy	65
90853	Group psychotherapy (other than of a multiple-family group)	65
90785, 90832-90840	Psychotherapy	575 PERSONALITY DISORDERS EXCLUDING BORDERLINE AND SCHIZOTYPAL

BHAP 2022
Straightforward Coding Changes

Appendix

Consult only lines		
line	Condition	Treatment
193	AUTISM SPECTRUM DISORDERS	MEDICAL THERAPY/BEHAVIORAL MODIFICATION INCLUDING APPLIED BEHAVIOR ANALYSIS
551	SOMATIC SYMPTOMS AND RELATED DISORDERS	CONSULTATION

Behavioral Health Consult Only + ED		
line	Condition	Treatment
437	STEREOTYPED MOVEMENT DISORDER WITH SELF-INJURIOUS BEHAVIOR DUE TO NEURODEVELOPMENTAL DISORDER	CONSULTATION/MEDICATION MANAGEMENT/LIMITED BEHAVIORAL MODIFICATION

Behavioral Health OP only (no ED visits)		
Line	Condition	Treatment
5	TOBACCO DEPENDENCE	MEDICAL THERAPY/BEHAVIORAL COUNSELING
121	ATTENTION DEFICIT/HYPERACTIVITY DISORDERS	MEDICAL/PSYCHOTHERAPY
203	DEPRESSION AND OTHER MOOD DISORDERS, MILD OR MODERATE	MEDICAL/PSYCHOTHERAPY
211	NON-SUBSTANCE-RELATED ADDICTIVE BEHAVIORAL DISORDERS	MEDICAL/PSYCHOTHERAPY
252	PSYCHOLOGICAL FACTORS AGGRAVATING PHYSICAL CONDITION (E.G., ASTHMA, CHRONIC GI CONDITIONS, HYPERTENSION)	MEDICAL/PSYCHOTHERAPY
312	GENDER DYSPHORIA/TRANSEXUALISM	MEDICAL AND SURGICAL TREATMENT/PSYCHOTHERAPY
388	SEPARATION ANXIETY DISORDER	MEDICAL/PSYCHOTHERAPY
414	OVERANXIOUS DISORDER; GENERALIZED ANXIETY DISORDER; ANXIETY DISORDER, UNSPECIFIED	MEDICAL/PSYCHOTHERAPY
421	OPPOSITIONAL DEFIANT DISORDER	MEDICAL/PSYCHOTHERAPY
432	PERSISTENT DEPRESSIVE DISORDER	MEDICAL/PSYCHOTHERAPY
444	ADJUSTMENT DISORDERS	MEDICAL/PSYCHOTHERAPY
446	TOURETTE'S DISORDER AND TIC DISORDERS	MEDICAL/PSYCHOTHERAPY
449	REACTIVE ATTACHMENT DISORDER OF INFANCY OR EARLY CHILDHOOD	MEDICAL/PSYCHOTHERAPY
458	SIMPLE PHOBIAS AND SOCIAL ANXIETY DISORDER	MEDICAL/PSYCHOTHERAPY
462	OBSESSIVE-COMPULSIVE DISORDERS	MEDICAL/PSYCHOTHERAPY
470	ENCOPRESIS NOT DUE TO A PHYSIOLOGICAL CONDITION	MEDICAL/PSYCHOTHERAPY
473	SELECTIVE MUTISM	MEDICAL/PSYCHOTHERAPY
479	CONDUCT DISORDER, AGE 18 OR UNDER	MEDICAL/PSYCHOTHERAPY
494	PARAPHILIAS AND OTHER PSYCHOSEXUAL DISORDERS	MEDICAL/PSYCHOTHERAPY
546	IMPULSE DISORDERS	MEDICAL/PSYCHOTHERAPY
574	PERSONALITY DISORDERS EXCLUDING BORDERLINE AND SCHIZOTYPAL	MEDICAL/PSYCHOTHERAPY

Behavioral Health OP only (no ED visits)		
Line	**Condition**	**Treatment**
631	PICA	MEDICAL/PSYCHOTHERAPY
649	MENTAL DISORDERS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY	EVALUATION

2024 Biennial Review
Conduct Disorder

Question: Should conduct disorder be merged into the line with oppositional defiant disorder to allow this diagnosis to be covered?

Question source: multiple

Issue: Conduct disorder is a serious behavioral and emotional disorder that can occur in children and teens. A child with this disorder may display a pattern of disruptive and violent behavior and have problems following rules. Conduct disorder is typically treated with psychotherapy and parent management training. Co-occurring diagnosis such as anxiety or depression can be treated with medications such as SSRIs.

Conduct disorder is currently on line 479 CONDUCT DISORDER, AGE 18 OR UNDER. This line was a covered line until 2012 when the Oregon Legislature moved the funding line up above this level. Multiple agency partners have requested that the HERC review coverage of conduct disorder, including the Oregon Youth Authority, the mental health clinical advisory group, and child welfare.

The Oregon Youth Authority notes that services for children in custody are provided through general funds. However, lack of coverage of conduct disorder results in disruption of care when the children are release back into the community. Child welfare notes that coverage of conduct disorder may improve a child's ability to stay in their current family situation.

Review of denied claims for children also found that ICD-10-CM F63.81 (Intermittent explosive disorder) which is currently on line 547 IMPULSE DISORDERS had multiple denied claims. OHA mental health staff felt that this was an appropriate diagnosis to have on a covered line.

Current Prioritized List status:
F91.0-F91.2, and F91.8 (Conduct disorder) are on line 479 CONDUCT DISORDER, AGE 18 OR UNDER
F91.3 (Oppositional defiant disorder) is on line 420 OPPOSITIONAL DEFIANT DISORDER
F91.9 (Conduct disorder, unspecified) is on both lines 420 and 479 with a guideline
F63.81 (Intermittent explosive disorder) is on 547 IMPULSE DISORDERS

GUIDELINE NOTE 54, CONDUCT DISORDER

Line 479

Conduct disorder rarely occurs in isolation from other psychiatric diagnosis, the patient should have documented screening for attention deficit/hyperactivity disorder (ADHD); chemical dependency (CD); mood disorders such as anxiety and/or depression; and physical, sexual, and family abuse or other trauma (PTSD).

GUIDELINE NOTE 152, UNSPECIFIED CONDUCT DISORDER

Lines 420,479

ICD-10-CM F91.9 (Conduct disorder, unspecified) is included on Line 420 only for children ages 5 and younger who cannot be diagnosed with a more specific mental health diagnosis. This diagnosis is included on Line 479 for older children and adolescents.

2024 Biennial Review
Conduct Disorder

Evidence

1) **Furlong 2012**, behavioral and cognitive-behavioral group based parenting programs for early onset conduct problems in children aged 3 to 12
    a. N=13 trials (1078 participants); 2 economic evaluations
        i. 10 RCTs and 2 quasi-randomized trials
    b. The results indicate that parent training produced a statistically significant reduction in child conduct problems, whether assessed by parents (standardized mean difference (SMD) -0.53; 95% confidence interval (CI) -0.72 to -0.34) or independently assessed (SMD -0.44; 95% CI -0.77 to - 0.11).
    c. When compared to a waiting list control group, there was a cost of approximately $2500 (GBP 1712; EUR 2217) per family to bring the average child with clinical levels of conduct problems into the non-clinical range.
    d. Conclusions: Behavioral and cognitive-behavioral group-based parenting interventions are effective and cost-effective for improving child conduct problems, parental mental health and parenting skills in the short term. The cost of program delivery was modest when compared with the long-term health, social, educational and legal costs associated with childhood conduct problems. Further research is needed on the long-term assessment of outcomes.
2) **Wolfenden 2010**, Cochrane review of family and parenting interventions in children and adolescents with conduct disorder
    a. N=8 RCTs (749 children)
        i. Intervention: variety of family or parenting interventions
        ii. Control: no intervention, wait list or usual intervention group
    b. At follow up, family and parenting interventions significantly reduced the time spent by juvenile delinquents in institutions (WMD 51.34 days, 95%CI 72.52 to 30.16). There was also a significant reduction in the risk of a juvenile delinquent being re-arrested (RR 0.66, 95%CI 0.44 to 0.98) and in their rate of subsequent arrests at 1-3 years (SMD -0.56, 95% CI -1.100 to - 0.03). For both of these outcomes there was substantial heterogeneity in the results suggesting a need for caution in interpretation. At present there is insufficient evidence that family and parenting interventions reduce the risk of being incarcerated (RR=0.50, 95% CI 0.20 to 1.21). No significant difference was found for psychosocial outcomes such as family functioning, and child/adolescent behavior.
    c. Conclusions: The evidence suggests that family and parenting interventions for juvenile delinquents and their families have beneficial effects on reducing time spent in institutions. This has an obvious benefit to the participant and their family and may result in a cost saving for society. These interventions may also reduce rates of subsequent arrest but at present these results need to be interpreted with caution due to the heterogeneity of the results.

BHAP input:

BHAP members were strongly in favor of coverage for conduct disorder. There was acknowledgement that these diagnoses disproportionately affect black and Hispanic children; however, the panel felt that the importance to cover treatment of these diagnoses overrode any concern for disproportionate use in

certain populations. The requirement to consider other possible diagnoses mitigates the risk of inappropriate diagnosis.

HERC staff summary

Treatment of conduct disorder has been shown to reduce incarceration time and improve parental mental health. Multiple stakeholders have requested that this diagnosis be funded, to allow continuity of treatment after incarceration, improve ability to families to stay together, and reduce costs.

HERC staff/BHAP recommendations:

1) Effective 1/1/23
    a. Add ICD-10-CM F91.0-F91.2, and F91.8 (Conduct disorder) to line 420 OPPOSITIONAL DEFIANT DISORDER
    b. Add ICD-10-CM F63.81 (Intermittent explosive disorder) to line 420 and remove from line 547 IMPULSE DISORDERS
    c. Change the name of line 420 to OPPOSITIONAL DEFIANT DISORDER; CONDUCT DISORDER AGE 18 OR UNDER
    d. Strike through line 479
    e. Modify guideline note 54 as shown below
    f. Delete guideline note 152

~~**Line: 479**~~
~~Condition:CONDUCT DISORDER, AGE 18 OR UNDER (See Guideline Notes 54 and 152)~~
~~Treatment:MEDICAL/PSYCHOTHERAPY~~
~~ICD-10:F91.0-F91.2,F91.8-F91.9~~
~~CPT:90785,90832-90840,90846-90853,90882,90887,98966-98972,99051,99060,99203-99215,99324-99355,99366,99415-99427,99437-99449,99451,99452,99487-99491,99495-99498,99605-99607~~
~~HCPCS:G0068,G0071,G0088-G0090,G0176,G0177,G0248-G0250,G0459,G0463,G0466,G0467,G0469,G0470,G0511,G2012,G2214,G2251,G2252,H0004,H0017-H0019,H0023,H0032-H0034,H0036-H0039,H0045,H2010,H2012,H2014,H2021-H2023,H2027,H2032,H2033,S5151,S9125,S9480,S9484,T1005~~

GUIDELINE NOTE 54, CONDUCT DISORDER

Line 420, ~~479~~

Conduct disorder rarely occurs in isolation from other psychiatric diagnosis, the patient should have documented screening (or documented refusal to be screened) for attention deficit/hyperactivity disorder (ADHD); chemical dependency (CD); mood disorders such as anxiety and/or depression; and physical, sexual, and family abuse or other trauma (PTSD).

ICD-10-CM F91.9 (Conduct disorder, unspecified) is included on Line 420 only for children ages 5 and younger who cannot be diagnosed with a more specific mental health diagnosis.

~~**GUIDELINE NOTE 152, UNSPECIFIED CONDUCT DISORDER**~~

~~*Lines 420,479*~~

~~ICD-10-CM F91.9 (Conduct disorder, unspecified) is included on Line 420 only for children ages 5 and younger who cannot be diagnosed with a more specific mental health diagnosis. This diagnosis is included on Line 479 for older children and adolescents~~.

2) Effective 1/1/24
    a. Delete line 479 CONDUCT DISORDER, AGE 18 OR UNDER

Autoimmune Encephalitis

Plain Language Summary:
Background: Clarify coding related to a type of brain inflammation where the body's immune system attacks healthy cells and tissues in the brain or spinal cord. People with this condition may have various neurologic and/or psychiatric symptoms. Left untreated, the illness can quickly become serious. It may lead to coma or permanent brain injury. In rare cases, it may cause death.

Should OHP cover this treatment? Staff recommends covering this treatment because the evidence shows benefit from the treatments.

Question: Where should autoimmune encephalitis be prioritized and what treatments should be paired?

Question source: EbGS

Issue: EbGS recently reviewed pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS). Autoimmune encephalitis (AE) was initially included as part of this larger review. However, it became clear to EbGS and HERC staff that AE was a distinct and different diagnosis, with established diagnostic criteria and accepted treatment modalities. HERC staff was instructed to ensure that the diagnosis and appropriate treatments were in correct locations on the Prioritized List.

Autoimmune encephalitis refers to a group of conditions that occur when the body's immune system mistakenly attacks healthy brain cells, leading to inflammation of the brain. People with autoimmune encephalitis may have various neurologic and/or psychiatric symptoms. Autoimmune encephalitis may be associated with antibodies to proteins on the surface of nerve cells, or within nerve cells. Some of these proteins are involved in passing signals between nerve cells. In some cases, it occurs in association with cancer (a paraneoplastic syndrome). Left untreated, autoimmune encephalitis can lead to coma or permanent brain injury. In rare cases, it can be fatal.

Per the NIH (https://rarediseases.info.nih.gov/diseases/11979/autoimmune-encephalitis):
Diagnosis of autoimmune encephalitis can be made when all three of the following criteria have been met:
1. Subacute onset (rapid progression of less than 3 months) of working memory deficits (short-term memory loss), altered mental status, or psychiatric symptoms
2. At least one of the following:
    - New focal CNS findings
    - Seizures not explained by a previously known seizure disorder
    - CSF pleocytosis (white blood cell count of more than five cells per mm3)
    - MRI features suggestive of encephalitis
3. Reasonable exclusion of alternative causes

Per expert guidelines, first line treatment of AE is intravenous immunoglobulins (IVIG), steroids and plasmapheresis. Second line treatment is rituximab or cyclophosphamide.

Current Prioritized List status
ICD-10-CM G04.81 (Other encephalitis and encephalomyelitis) is on the dysfunction lines (lines 71, 292, 345, 377) and line 536 VIRAL, SELF-LIMITING ENCEPHALITIS, MYELITIS AND ENCEPHALOMYELITIS.

Note 1: Subdiagnoses of this code include paraneoplastic encephalitis, limbic encephalitis and Bickerstaff encephalitis
Note 2: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is included under ICD-10-CM D89.89 (Other specified disorders involving the immune mechanism, not elsewhere classified)

CPT 90283 (Immune globulin (IgIV), human, for intravenous use) is Ancillary

CPT 36514 (Therapeutic apheresis; for plasma pheresis) is on lines 90,106,124,126,129,131,140,141, 148, 159, 175, 194, 212, 234, 285, 313, 339, 456

Expert guidelines

1) **Abboud 2021**, Best practice recommendations for diagnosis and management of autoimmune encephalitis
    a. First line therapy: high dose corticosteroids (or IVIG or plasmapheresis [PLEX] if steroids are not preferred or contraindicated)
    b. If there is no clinical, radiological or electrophysiological improvement by the end of the initial treatment cycle, add IVIG or PLEX. Consider IVIG first in agitated patients and in those with bleeding disorders. Consider PLEX first in patients with severe hyponatremia, high thromboembolic (or cancer) risk, and if there is associated brain or spinal demyelination.
    c. Consider starting with a combination therapy of steroids/ IVIG or steroids/PLEX from the beginning (as opposed to sequentially) in patients with severe initial presentation (e.g., severe NMDAR-antibody presentation, new onset refractory status epilepticus, severe dysautonomia, etc.).
    d. If there is no clinical or radiological improvement 2–4 weeks after completion of combined acute therapy, consider starting a second-line agent when the clinical suspicion is high and/or a clinically relevant antibody is present.
    e. Consider rituximab in known or highly suspected antibody-mediated autoimmunity (e.g., NMDAR-antibody encephalitis) and consider cyclophosphamide in known or highly suspected cell-mediated autoimmunity (eg, classical paraneoplastic syndrome).
    f. If no clear objective or subjective evidence of improvement with conventional second-line therapies, consider novel approaches such as tocilizumab or bortezomib although there is only minimal evidence to support their use.

HERC staff recommendation:

1) Add ICD-10-CM G04.81 (Other encephalitis and encephalomyelitis) to line 313 DISORDERS INVOLVING THE IMMUNE SYSTEM
    a. Remove G04.81 from line 536 VIRAL, SELF-LIMITING ENCEPHALITIS, MYELITIS AND ENCEPHALOMYELITIS.
    b. Will pair with plasmapheresis (CPT 36514) and will have medications such as IVIG and corticosteroids available as Ancillary
2) Modify the new guideline regarding PANDAS and PANS as shown below

GUIDELINE NOTE XXX PANDAS, PANS AND AUTOIMMUNE ENCEPHALITIS

Line 313

ICD-10-CM G04.81 (Other encephalitis and encephalomyelitis) is only included on this line for autoimmune encephalitis and related non-PANDAS/PANS conditions and is not included in this guideline. Autoimmune encephalitis must meet established diagnostic criteria (for example, the International Encephalitis Consortium 2013 diagnostic criteria).

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is included on this line when coded with ICD-10-CM D89.89 (Other specified disorders involving the immune mechanism, not elsewhere classified). Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) is included on this line when coded with ICD-10-CM D89.9 (Disorder involving the immune mechanism, unspecified).

Up to 3 monthly immunomodulatory courses of intravenous immunoglobulin (IVIG) therapy is included on this line to treat PANDAS and PANS when both of the following are met:

a) A clinically appropriate trial of two or more less-intensive treatments (for example, appropriate limited course of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, selective serotonin reuptake inhibitors (SSRIs), behavioral therapy, short-course antibiotic therapy) was either not effective, not tolerated, or did not result in sustained improvement in symptoms (as measured by a lack of clinically meaningful improvement on a validated instrument directed at the patient's primary symptom complex). These trials may be done concurrently, AND
b) A consultation with and recommendation from a pediatric subspecialist (for example, pediatric neurologist, pediatric psychiatrist, neurodevelopmental pediatrician, pediatric rheumatologist, pediatric allergist/immunologist) as well as the recommendation of the patient's primary care provider (for example, family physician, pediatrician, pediatric nurse practitioner, naturopath). The subspecialist consultation may be a teleconsultation. For adolescents, an adult subspecialist consult may replace a pediatric subspecialist consult.

A reevaluation at 3 months by both the primary care provider and pediatric expert is required for continued therapy of IVIG. This evaluation must include clinical testing with a validated instrument, which must be performed pretreatment and posttreatment to demonstrate clinically meaningful improvement. Long term antibiotic therapy is not included on this line for treatment of PANDAS/PANS. Therapeutic plasma exchange (CPT 36514) does not pair with PANDAS or PANS (ICD-10-CM D89.89 or D89.9).

Modifications to the Severe Inflammatory Skin Disease Guideline

Plain Language Summary:
Background: The staff of the OHA Pharmacy and Therapeutics (P&T) committee requested that language related to drug treatment be removed from the guideline about inflammatory skin diseases. The current language is out of date and the P&T already has guidelines regarding use of these drugs.

Should OHP change this guideline? Staff recommends HERC delete the wording regarding medication use from this guideline.

Question: should the severe inflammatory skin disease guideline be modified to remove mentions of drug tiers?

Question source: Pharmacy and Therapeutics Committee (P&T) staff

Issue: P&T recently reviewed treatments for atopic dermatitis and updated their prior authorization (PA) criteria for targeted immune modulators. Some of the working in current GN21 is out of date and/or does not reflect the current state of the evidence for targeted immune modulators. P&T regularly reviews these medications and new medications are coming to market on a regular basis. P&T staff are requesting that the HERC remove wording regarding these drugs to prevent internal conflicts between the Prioritized List guideline and P&T PA criteria. PA criteria can and do change at more regular intervals than Prioritized Lists can be published.

Specific issues:

1) The current guideline uses the term "biologics" when the correct term currently is "targeted immune modulators (TIMs)."
2) In the guideline, atopic dermatitis has step therapy with oral immunomodulator therapy listed as second line therapy. Based on the P&T review, oral immunomodulator therapy is third line therapy for this condition. From the P&T report: "Current therapies for atopic dermatitis include a variety of pharmaceutical agents and treatment modalities, including orally administered products, topical creams, and subcutaneous injections. Older therapies such as azathioprine and cyclosporine are effective, but carry the risks of significant side effects (e.g., systemic immunosuppression)." P&T requested that failure of these more high risk medications be removed from the requirement of being failed prior to targeted immune modulators.
3) New medications are regularly being released
    a. From P&T staff: "In the past year, 3 new TIMs received FDA-approval for AD [atopic dermatitis] management. A topical JAK inhibitor, ruxolitinib (OPZELURA) was approved in September 2021. A new injectable IL-13 antagonist, tralokinumab (ADBRY), was approved in December 2021. A new oral JAK inhibitor, abrocitinib (CIBINQO) was approved in January 2022. In addition, upadacitinib (RINVOQ), an oral JAK inhibitor originally approved for rheumatoid arthritis (RA), received expanded approval for AD management in January 2022. Additional TIMs currently under investigation for AD include the oral JAK inhibitor baricitinib (OLUMIANT), currently approved for RA treatment, and 2 new injectable IL-13 antagonists, lebrikizumab and nemolizuamb. Lastly, a novel neurokinin-1 receptor antagonist, tradipitant, is being studied for AD. In all the trials for these drugs, patients were either naïve to therapy, or had failed topical

corticosteroids or calcineurin inhibitors (e.g., tacrolimus). Oral immunosuppressants were not included as step therapy."

HERC staff recommendation:

1) Modify GN 21 as shown below

GUIDELINE NOTE 21, SEVERE INFLAMMATORY SKIN DISEASE

Lines 426,482,504,533,542,656

Inflammatory skin conditions included in this guideline are:

A) Psoriasis
B) Atopic dermatitis
C) Lichen planus
D) Darier disease
E) Pityriasis rubra pilaris
F) Discoid lupus
G) Vitiligo

The conditions above are included on Line 426 if severe, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) ≥ 11 or Children's Dermatology Life Quality Index (CDLQI) ≥ 13 (or severe score on other validated tool) AND one or more of the following:

A) At least 10% of body surface area involved
B) Hand, foot, face, or mucous membrane involvement.

Otherwise, these conditions above are included on Lines 482, 504, 533, 542 and 656.

~~For severe psoriasis, first line agents include topical agents, phototherapy and methotrexate. Second line agents include other systemic agents and oral retinoids and should be limited to those who fail, or have contraindications to, or do not have access to first line agents. Biologics are included on this line only for the indication of severe plaque psoriasis; after documented failure of first line agents and failure of (or contraindications to) a second line agent.~~

~~For severe atopic dermatitis/eczema, first line agents include topical moderate- to high- potency corticosteroids and narrowband UVB. Second line agents include topical calcineurin inhibitors (e.g. pimecrolimus, tacrolimus), topical phosphodiesterase (PDE)-4 inhibitors (e.g. crisaborole), and oral immunomodulatory therapy (e.g. cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, or oral corticosteroids). Use of the topical second line agents (e.g. calcineurin inhibitors and phosphodiesterase (PDE)-4 inhibitors) should be limited to those who fail or have contraindications to first line agents. Biologic agents are included on this line for atopic dermatitis only after failure of or contraindications to at least one agent from each of the following three classes: 1) moderate to high potency topical corticosteroids, 2) topical calcineurin inhibitors or topical phosphodiesterase (PDE)-4 inhibitors, and 3) oral immunomodulator therapy.~~

ICD-10-CM Q82.8 (Other specified congenital malformations of skin) is included on Line 426 only for Darier disease.

Microsatellite Instability Analysis for Colon Cancer

Plain Language Summary:
Background: This is a test used to decide colon cancer treatments.

Should OHP cover this test? Staff recommends OHP cover this test because this has become a standard test and is required for doctors to decide a treatment path in many cases.

Question: Should microsatellite instability analysis (MSI) be covered for patients with colon cancer?

Question source: Jeanne Savage, CCO medical director

Issue: Microsatellites, also known as Short Tandem Repeats (STRs) are small (1-6 base pairs) repeating stretches of DNA scattered throughout the entire genome and account for approximately 3 % of the human genome. Due to their repeated structure, microsatellites are prone to high mutation rate. Microsatellite instability (MSI) is a unique molecular alteration and hyper-mutable phenotype, which is the result of a defective DNA mismatch repair (MMR) system. The presence of MSI is found in sporadic colon, gastric, sporadic endometrial and the majority of other cancers. Approximately, 15-20 % of colorectal cancers display MSI. Determination of MSI status in CRC has prognostic and therapeutic implications. Microsatellite instability (MSI) analysis of colorectal cancers is clinically useful to identify patients with hereditary nonpolyposis colorectal cancer (HNPCC) caused by germline mutations of mismatch repair genes. MSI status may also predict cancer response/resistance to certain chemotherapies.

MSI was last reviewed as part of the 2015 coverage guidance on biomarkers for cancer. That coverage guidance concluded: "Evidence from multiple studies supports clinical validity, with added value beyond traditional prognostic factors, for MammaPrint®, Oncotype DX Breast®, KRAS mutation testing for lung cancer, BRAF mutation testing for CRC, KRAS mutation testing for CRC, and MSI for CRC for at least one outcome [risk of recurrence (RR), cancer-specific survival (CSS), or overall survival (OS)]." MSI was given a 1B rating for screening and prognostic value and a IIB rating for predictive value. The final recommendation of the coverage guidance was a weak recommendation against coverage. The CPT code for MSI was added to line 662/GN173 and an entry was included in the new guideline "Biomarkers Tests of Cancer Tissue" which read "Microsatellite instability (MSI) is included on the Services recommended for noncoverage table."

Dr. Savage is requesting a re-review of MSI coverage. Per Dr. Savage: "In order for oncologists to determine appropriate adjuvant treatment (Chemo or Immunotherapy) they need the testing and we require it for some medications."

Of note, MSI testing is included in multiple colon cancer testing panels, usually coded with generic CPT codes such as CPT 88342 (Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure).

Current Prioritized List status
On line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

Microsatellite Instability Analysis for Colon Cancer

CPT 81301 Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (eg, BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed

GUIDELINE NOTE 148, BIOMARKER TESTS OF CANCER TISSUE

Lines 157,184,191,229,262,271,329

The use of tissue of origin testing (e.g. CPT 81504) is included on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS.

For early stage breast cancer, the following breast cancer genome profile tests are included on Line 191 when the listed criteria are met. One test per primary breast cancer is covered when the patient is willing to use the test results in a shared decision-making process regarding adjuvant chemotherapy. Lymph nodes with micrometastases less than 2 mm in size are considered node negative.

- Oncotype DX Breast Recurrence Score (CPT 81519) for breast tumors that are estrogen receptor positive, HER2 negative, and either lymph node negative, or lymph node positive with 1-3 involved nodes.
- EndoPredict (CPT 81522) and Prosigna (CPT 81520 or PLA 0008M) for breast tumors that are estrogen receptor positive, HER2 negative, and lymph node negative.
- MammaPrint (using CPT 81521, 81523 or HCPCS S3854) for breast tumors that are estrogen receptor or progesterone receptor positive, HER2 negative, lymph node negative, and only in those cases categorized as high clinical risk.

For early stage breast cancer that is estrogen receptor positive, HER2 negative, and either lymph node negative or lymph node positive with 1-3 involved nodes, Breast Cancer Index (CPT 81518) is included on Line 191 when the patient is willing to use the test results in a shared decision-making process regarding prolonged adjuvant endocrine therapy.

EndoPredict, Prosigna, and MammaPrint are not included on Line 191 for early stage breast cancer with involved axillary lymph nodes. Oncotype DX Breast Recurrence Score is not included on Line 191 for breast cancer involving four or more axillary lymph nodes or more extensive metastatic disease.

Oncotype DX Breast DCIS Score (CPT 81479) is included on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS.

For melanoma, BRAF gene mutation testing (CPT 81210) is included on Line 229. DecisionDx-Melanoma (CPT 81529) is included on Line 662.

For lung cancer, epidermal growth factor receptor (EGFR) gene mutation testing (CPT 81235) is included on Line 262 only for non-small cell lung cancer. KRAS gene mutation testing (CPT 81275) is not included on this line.

For colorectal cancer, KRAS gene mutation testing (CPT 81275) is included on Line 157. BRAF (CPT 81210) and Oncotype DX are not included on this line. Microsatellite instability (MSI) is included on the Line 662.

For bladder cancer, Urovysion testing is included on Line 662.

For prostate cancer, Oncotype DX Genomic Prostate Score, Prolaris Score Assay (CPT 81541), and Decipher Prostate RP (CPT 81542) are included on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS.

For thyroid cancer, Afirma gene expression classifier (CPT 81546) is included on Line 662.

The development of this guideline note was informed by a HERC coverage guidance on Biomarkers Tests of Cancer Tissue for Prognosis and Potential Response to Treatment; the prostate-related portion of that coverage guidance was superseded by a Coverage Guidance on Gene Expression Profiling for Prostate Cancer. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx

GUIDELINE NOTE 173, INTERVENTIONS THAT ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS FOR CERTAIN CONDITIONS

Line 662

The following Interventions are prioritized on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

Procedure Code	Intervention Description	Rationale	Last Review
81301	Microsatellite instability (MSI) for colorectal cancer	Unproven intervention	August, 2015

Expert recommendations

1) **NCCN Guideline 1.2022** for Colon Cancer treatment
    a. Microsatellite Instability or Mismatch Repair Testing
        i. Universal MMR or MSI testing is recommended in all newly diagnosed patients with colon cancer.
    b. MSI testing is included in the workup algorithms for all colon cancer and is a branchpoint in several chemotherapy algorithms and adjuvant treatment algorithms
    c. Note: MMR and MSI testing use the same CPT code
    d. "The panel recommends universal MMR or MSI testing for all patients with a personal history of colon or rectal cancer to identify individuals with Lynch syndrome, to inform use of immunotherapy in patients with metastatic disease, and to inform decisions for patients with stage II disease."

Other payer policies:

All major insurers are covering MSI testing/CPT 81301

HERC staff summary

Since the 2015 coverage guidance review, MSI testing has become standard of care in colon cancer, and is required to determination of treatment pathway in many NCCN algorithms.

HERC staff wish to discuss whether coverage guidance on Biomarkers Tests of Cancer Tissue for Prognosis and Potential Response to Treatment from 2015 should be updated by EbGS or retired and testing decisions be made following NCCN guidelines.

HERC staff recommendation:

1) Remove CPT 81301 (Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (eg, BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed) from line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS
    a. Advise HSD to add CPT 81302 to the DIAGNOSTIC PROCEDURES file
2) Modify GN 148 as shown below
3) Remove the entry for CPT 81301 from GN 173

GUIDELINE NOTE 148, BIOMARKER TESTS OF CANCER TISSUE

Lines 157,184,191,229,262,271,329

The use of tissue of origin testing (e.g. CPT 81504) is included on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS.

For early stage breast cancer, the following breast cancer genome profile tests are included on Line 191 when the listed criteria are met. One test per primary breast cancer is covered when the patient is willing to use the test results in a shared decision-making process regarding adjuvant chemotherapy. Lymph nodes with micrometastases less than 2 mm in size are considered node negative.

- Oncotype DX Breast Recurrence Score (CPT 81519) for breast tumors that are estrogen receptor positive, HER2 negative, and either lymph node negative, or lymph node positive with 1-3 involved nodes.
- EndoPredict (CPT 81522) and Prosigna (CPT 81520 or PLA 0008M) for breast tumors that are estrogen receptor positive, HER2 negative, and lymph node negative.
- MammaPrint (using CPT 81521, 81523 or HCPCS S3854) for breast tumors that are estrogen receptor or progesterone receptor positive, HER2 negative, lymph node negative, and only in those cases categorized as high clinical risk.

For early stage breast cancer that is estrogen receptor positive, HER2 negative, and either lymph node negative or lymph node positive with 1-3 involved nodes, Breast Cancer Index (CPT 81518) is included on Line 191 when the patient is willing to use the test results in a shared decision-making process regarding prolonged adjuvant endocrine therapy.

EndoPredict, Prosigna, and MammaPrint are not included on Line 191 for early stage breast cancer with involved axillary lymph nodes. Oncotype DX Breast Recurrence Score is not included on Line 191 for breast cancer involving four or more axillary lymph nodes or more extensive metastatic disease.

Oncotype DX Breast DCIS Score (CPT 81479) is included on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS.

For melanoma, BRAF gene mutation testing (CPT 81210) is included on Line 229. DecisionDx-Melanoma (CPT 81529) is included on Line 662.

For lung cancer, epidermal growth factor receptor (EGFR) gene mutation testing (CPT 81235) is included on Line 262 only for non-small cell lung cancer. KRAS gene mutation testing (CPT 81275) is not included on this line.

For colorectal cancer, KRAS gene mutation testing (CPT 81275) is included on Line 157. BRAF (CPT 81210) and Oncotype DX are not included on this line. ~~Microsatellite instability (MSI) is included on the Line 662.~~

For bladder cancer, Urovysion testing is included on Line 662.

For prostate cancer, Oncotype DX Genomic Prostate Score, Prolaris Score Assay (CPT 81541), and Decipher Prostate RP (CPT 81542) are included on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS.

For thyroid cancer, Afirma gene expression classifier (CPT 81546) is included on Line 662.

The development of this guideline note was informed by a HERC coverage guidance on Biomarkers Tests of Cancer Tissue for Prognosis and Potential Response to Treatment; the prostate-related portion of that coverage guidance was superseded by a Coverage Guidance on Gene Expression Profiling for Prostate Cancer. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx

GUIDELINE NOTE 173, INTERVENTIONS THAT ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS FOR CERTAIN CONDITIONS

Line 662

The following Interventions are prioritized on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

Procedure Code	Intervention Description	Rationale	Last Review
~~81301~~	~~Microsatellite instability (MSI) for colorectal cancer~~	~~Unproven intervention~~	~~August, 2015~~

Scoliosis Guideline

Plain Language Summary:
Background: Clarify treatment for adults who have a sideways curvature of the spine; current surgical coverage is only for persons under 20 years of age. A spine surgeon is asking for this to be changed.

Should OHP cover this treatment? Staff recommends covering this treatment because of good evidence of effectiveness of treating adolescent (the phase of life between childhood and adulthood) scoliosis of unknown origin into adulthood; other payers are covering this surgery for adults.

Question: Should the scoliosis guideline be modified to remove age as a criteria for surgical treatment?

Question source: Dr. Joseph Orina, OHSU neurosurgery

Issue: Scoliosis is a sideways curvature of the spine that most often is diagnosed in adolescents. Most cases of scoliosis are mild, but some curves worsen as children grow. Severe scoliosis can be disabling. Scoliosis is treated with back bracing, and when bracing is not effective, spinal fusion surgery.

The current scoliosis guideline restricts scoliosis surgery to age 20 and younger. This guideline was written by the Back Pain Taskforce and adopted in 2015. Dr. Orina is requesting that the age restriction be removed and that surgery coverage be based on clinical criteria.

From Dr. Orina:

> As a spine surgeon, I am a member of the Scoliosis Research Society and multiple national spine organizations. I am also the Head of the Neurosurgery Spine Division at OHSU.
>
> I have never heard of an arbitrary age cutoff for adolescent scoliosis, and certainly not 20 years of age. We make decisions on surgery based on the patient's symptoms, curve magnitude, curve progression, and failure of non-operative management.
>
> Recommendations for treatment focus on the curve magnitude, patient symptoms, and evidence of curve progression not on age. It would make much more clinical sense to draft guidelines based on these criteria as Cigna has done. Aetna's cutoff of 25 years old is also not consistent with any national guidelines.
>
> Criteria I would recommend for surgery:
> - Patients with adolescent idiopathic scoliosis curve greater than 45 degrees
> - Intractable pain and documented failure of non-operative management
> - Patients with adolescent idiopathic scoliosis whose curves progress despite non-operative management.

Current Prioritized List status:
Line 361 SCOLIOSIS Treatment: MEDICAL AND SURGICAL THERAPY

GUIDELINE NOTE 41, SCOLIOSIS

Line 361

Non-surgical treatments of scoliosis (ICD-10-CM M41) are included on Line 361 when

1) the scoliosis is considered clinically significant, defined as curvature greater than or equal to 25 degrees, or
2) there is curvature with a documented rapid progression.

Surgical treatments of scoliosis are included on Line 361

1) only for children and adolescents (age 20 and younger) with
2) a spinal curvature of greater than 45 degrees

Evidence

1) **Hresko 2013**: review of idiopathic scoliosis in adolescents
   a) Operative treatment is indicated when progressive scoliosis exceeds 45 degrees in patients with an immature skeleton or when progression or associated pain occurs after skeletal maturity
   b) Ten years after initial surgery for idiopathic scoliosis, 3 to 10% of patients undergo subsequent surgery
   c) The role of surgery is controversial in patients with a mature skeleton and a curvature greater than 50 degrees but without pain or appreciable progression.

Specialty guidelines

1) **American Association of Neurological Surgeons**
   a) Accessed April 20, 2022: https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Scoliosis
      i) Surgery in children: Most experts would recommend surgery only when the spinal curve is greater than 40 degrees and there are signs of progression.
      ii) In general, surgery in adults may be recommended when the spinal curve is greater than 50 degrees and the patient has nerve damage to their legs and/or is experiencing bowel or bladder symptoms.

Other payer policies:

1) **Aetna 2021**: Aetna considers surgery (e.g., spinal fusion with instrumentation and bone grafting) for the treatment of idiopathic scoliosis medically necessary for *any* of the following conditions:
   a) Idiopathic scoliosis with curve greater than or equal to 40 degrees in an adolescent younger than age 18; *or*
   b) Idiopathic scoliosis with curve greater than or equal to 50 degrees in a young adult age 18 to 25.
2) **Cigna 2022**
   a) Single or multilevel lumbar fusion is considered medically necessary for idiopathic adolescent scoliosis over 40˚

HERC staff summary

Idiopathic adolescent scoliosis may require surgical intervention age ages above 20 if there is a curve greater than or equal to 40 to 50 degrees with pain or other symptoms, based on expert opinion.

HERC staff recommendation

1) Modify GN 41 as shown below

GUIDELINE NOTE 41, SCOLIOSIS

Line 361

Non-surgical treatments of scoliosis (ICD-10-CM M41) are included on Line 361 when

1) the scoliosis is considered clinically significant, defined as curvature greater than or equal to 25 degrees, or
2) there is curvature with a documented rapid progression.

Surgical treatments of adolescent idiopathic scoliosis (ICD-10-CM M41.1 family) are included on Line 361 only for

1) ~~only for children and adolescents (age 20 and younger) with~~
2) patients with documented failure of non-operative management; AND
3) a spinal curvature of greater than 45 degrees

Transluminal Dilation of Aqueous Outflow Canal

Plain Language Summary:
Background: A non-penetrating surgical technique for glaucoma. Last reviewed in 2010, a physician asked for the technique to be re-reviewed considering its improved evidence for treatment of a type of glaucoma called "open-angle" which leads to progressive eye damage and, if untreated, blindness.

Should OHP cover this treatment? Staff recommends covering this treatment because of the evidence of effectiveness and a good safety profile.

Question: Should transluminal dilation of aqueous outflow canal be moved to a covered line?

Question source: Dr. Max Kaiser, medical director, Samaritan Health Plans

Issue: Transluminal dilation of aqueous outflow canal (also known as canaloplasty) is a non-penetrating surgical technique for glaucoma which aims to restore the natural drainage of fluid from the eye. This procedure was last reviewed as a new CPT code in December, 2010. At that time, a NICE 2008 review found insufficient evidence of effectiveness, and the procedure was placed on the Excluded File. It was later moved to line 662/GN173. Dr. Kaiser is requesting re-review of this procedure as it appears to have improved evidence of effectiveness for treatment of open angle glaucoma.

Primary open-angle glaucoma is a chronic condition associated with elevated intraocular pressure. It leads to progressive damage to the optic nerve. Early stages are usually asymptomatic but as the condition progresses it causes visual impairment and, if untreated, blindness. Treatment is usually eye drops containing drugs that either reduce the production of aqueous humor [fluid inside the eye] or increase its drainage. Surgical procedures such as trabeculectomy [creating a new drainage pathway for aqueous fluid], drainage tubes, deep sclerectomy, viscocanalostomy, or laser trabeculoplasty may also be used.

Ab externo canaloplasty is a surgical technique that aims to reduce intraocular pressure by improving drainage of aqueous fluid from the eye. It is done under local or general anesthetic. A superficial hinged flap of sclera is made and a deeper flap excised, exposing the Schlemm's canal. An ultrasound imaging system is used to identify the canal and to visualize the surgical instruments when they are in the canal. A microcatheter with an illuminated tip is introduced into the canal and advanced around its entire circumference. As the catheter tip advances, viscoelastic fluid is injected into the canal to dilate it. When catheterization of the entire canal is complete a suture is tied to the tip of the microcatheter and it is withdrawn, pulling the suture into the canal. The suture is cut, tied in a loop encircling the inner wall of the canal and tightened. This widens the canal.

Current Prioritized List status
The following codes are on line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

CPT **66174** Transluminal dilation of aqueous outflow canal; without retention of device or stent
CPT **66175** Transluminal dilation of aqueous outflow canal; with retention of device or stent

GUIDELINE NOTE 173, INTERVENTIONS THAT ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS FOR CERTAIN CONDITIONS

Line 662

The following Interventions are prioritized on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

Procedure Code	Intervention Description	Rationale	Last Review
66174-66175	Transluminal dilation of aqueous outflow canal	Insufficient evidence of effectiveness	December, 2010

Trabeculectomy (CPT 66170) is on lines 139 GLAUCOMA, OTHER THAN PRIMARY ANGLE-CLOSURE and 336 RUBEOSIS AND OTHER DISORDERS OF THE IRIS. Trabeculectomy with previously scarring (CPT 66172) is only on line 139.

Open angle glaucoma is on line 139 GLAUCOMA, OTHER THAN PRIMARY ANGLE-CLOSURE

Updated evidence review

1) **NICE 2017** Interventional procedure overview of ab externo canaloplasty for primary open-angle glaucoma https://www.nice.org.uk/guidance/ipg591/evidence/overview-final-pdf-4597394077
    a. This IP overview is based on approximately 2,000 patients who had canaloplasty from 1 review, 2 randomized controlled trials, 3 retrospective comparative studies, 1 case series, 1 case report and 1 systematic review and meta-analysis
    b. In a systematic review and meta-analysis of 1,498 eyes, comparing canaloplasty with trabeculectomy, there was no statistically significant difference between groups for complete success rates (maximum postoperative intraocular pressure [IOP] of 18 mmHg without medication) and qualified success rates (maximum IOP of 18 mmHg with or without medication) after the procedure.
    c. In the systematic review and meta-analysis of 1,498 eyes, the mean IOP reduction was 9.94 mmHg (95% confidence interval [CI] 8.42 to 11.45) and was statistically significantly lower in the canaloplasty group (mean difference between groups −3.61, 95% CI −5.53 to −1.69 mmHg) at 1-year follow-up
    d. In the systematic review and meta-analysis of 1,498 eyes, the mean reduction in antiglaucoma medication use was 2.11 (95% CI 1.80 to 2.42) 1 year after canaloplasty, and there was no statistically significant difference in medication reduction between groups (mean difference −0.37, 95% CI −0.83 to 0.08).
    e. Safety
        i. Intraocular pressure (IOP) of more than 30 mmHg after the procedure was reported in 2% to 9% of eyes in a review of 914 eyes treated by canaloplasty alone (n=777 eyes) or by canaloplasty with phacoemulsification (n=137 eyes) at a maximum of 36 months' follow-up.
        ii. Hyphema (greater than 1 mm layered blood) was statistically significantly more frequent in the canaloplasty group than in the trabeculectomy group at 1-year follow-up, in a systematic review and meta-analysis of 1,498 eyes (odds ratio [OR] 9.24, 95% confidence interval [CI] 3.09 to 27.60)
        iii. Hypotony was statistically significantly less frequent after canaloplasty than after trabeculectomy at 1-year follow-up, in the systematic review and meta-

analysis of 1,498 eyes (OR 0.32, 95% CI 0.13 to 0.80). The incidence of hypotony in the canaloplasty group was 9% (94/1091)

2) **Gabai 2019**, safety and efficacy of trabeculectomy vs nonpenetrating surgeries open-angle glaucoma: a meta-analysis
    a. N=5 studies comparing trabeculectomy (TE) with canaloplasty (CP)
        i. 1 RCT and 4 observational studies
    b. IOP-lowering capacity of TE was superior to CP (WMD =2.32 mm Hg, 95% CI: 0.55 to 4.82, I2=0.0%, P=0.610) at 6 months and CP (WMD =2.99 mm Hg, 95% CI: 1.31 to 4.67, I2=66.6%, P=0.018) at 12 months
    c. Hypotony (OR = 2.7, 95% CI: 1.01 to 7.3), choroidals (OR = 19.6, 95% CI: 2.6 to 149.2), and shallow or flat anterior chamber (OR = 4.1, 95% CI: 0.4 to 37.3) were more associated with TE when compared with CP
    d. The meta-analysis of glaucoma medications after TE and NPGSs showed a lower medications' number after TE when compared with CP (WMD = −0.38, 95% CI: −0.66 to−0.11, I2=0.00%, P=0.856)
    e. Four studies comparing TE to CP found that best corrected visual acuity was not significantly different between the groups during follow-up
    f. Conclusions: TE is more effective in reducing IOP. TE presents a higher risk of complications as compared with NPGS, except for hyphema

<u>Other payer policies</u>

1) **NICE 2021**
    a. Current evidence on the safety and efficacy of ab externo canaloplasty for primary open-angle glaucoma is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.
    b. Ab externo canaloplasty for primary open-angle glaucoma should only be done by clinicians with specific training in the procedure.
2) **BCBS 2022**
    a. Canaloplasty may be considered medically necessary as a method to reduce intraocular pressure in patients with chronic primary open-angle glaucoma under the following conditions:
        i. Medical therapy has failed to adequately control intraocular pressure, AND
        ii. The patient is not a candidate for any other intraocular pressure–lowering procedure (e.g., trabeculectomy or glaucoma drainage implant) due to a high risk for complications.
    b. Canaloplasty is considered not medically necessary under all other conditions, including angle-closure glaucoma, due to a lack of peer-reviewed scientific literature demonstrating the efficacy of the procedure.
3) **Aetna 2022**
    a. Aetna considers canaloplasty medically necessary for the treatment of primary open-angle glaucoma (POAG), including normal-tension glaucoma, and for pseudoexfoliation glaucoma.

<u>Expert input</u>

Dr. Aiyin Chen, a glaucoma specialist at Casey Eye Institute, recommended addition of coverage for canaloplasty.

HERC staff summary

Canaloplasty appears to have similar or slightly inferior outcomes to trabeculectomy and appears to have a similar or better safety profile for treatment of open angle glaucoma.

HERC staff recommendation:

1) Add CPT **66174** Transluminal dilation of aqueous outflow canal; without retention of device or stent and CPT **66175** Transluminal dilation of aqueous outflow canal; with retention of device or stent to line 139 GLAUCOMA, OTHER THAN PRIMARY ANGLE-CLOSURE
    a. Remove CPT 66174 and 66175 from line 662
2) Remove the entry from GN173 as shown below

GUIDELINE NOTE 173, INTERVENTIONS THAT ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS FOR CERTAIN CONDITIONS

Line 662

The following Interventions are prioritized on Line 662 CONDITIONS FOR WHICH CERTAIN INTERVENTIONS ARE UNPROVEN, HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS:

Procedure Code	Intervention Description	Rationale	Last Review
~~66174 66175~~	~~Transluminal dilation of aqueous outflow canal~~	~~Insufficient evidence of effectiveness~~	~~December, 2010~~

Section 4.0

Reproductive Health Equity Act Report

HB 3391 Guideline Updates (RHEA Report)

Issue: HERC is required to report to the legislature regarding recommended changes to the Reproductive Health Equity Act (HB 3391) to align with current federal requirements and evidence around coverage of all reproductive and preventive services for women.

Question: Which services remain covered and which services have been updated?

The Reproductive Health Equity Act (HB 3391) requires commercial health benefit plans to cover specific health care services, drugs, devices, products, and procedures related to reproductive health and applies to commercial insurance. In addition, it adds a set of reproductive health benefits for people who could become pregnant and who would be eligible for the Oregon Health Plan if not for their immigration status. Since the passage of this bill, the Legislature has authorized additional benefits for a larger portion of this population. The bill allows exemption for plans sold to religious employers.

Staff was asked to review evidence and federal recommendations for reproductive health services to evaluate whether HERC should recommend any changes to the statute to account for changes in federal law or evidence-based reproductive health services. No major gaps have been identified, but two minor changes would help align coverage with new federal requirements and incorporate updated recommendations about how the listed services should be provided.

Impact:

Staff analysis indicates that the Reproductive Health Equity Act includes the most important services that people with Oregon private health insurance plans, including employee-sponsored coverage, should be able to access without cost sharing regardless of any changes which may occur at the federal level.

While existing law covers the most important services, the statute could be appropriately updated to include new and updated preventive services as recommended by the United States Preventive Services Task Force (USPSTF) or Health Resources and Services Administration (HRSA) since the passage of the bill, or that are not listed in the bill:

Summary of Reproductive and Preventive Services for Women and Adolescents		
Preventive Service	**Recommendation**	**Coverage year***
Screening for diabetes mellitus after pregnancy	HRSA	2016
Screening for gestational diabetes	USPSTF, HRSA	2016
Screening for urinary incontinence	HRSA	2017
Screening for anxiety	HRSA, USPSTF	2019, 2022 (NEW)
Screening for interpersonal and domestic violence	USPSTF, HRSA	2016
Perinatal depression: preventive interventions	USPSTF	2019
Screening for breast cancer	USPSTF, HRSA	2016 (update in progress)
Screening for women with a family history of certain cancers for BRCA1/2 with an appropriate brief risk assessment tool	USPSTF	2018 (updated)
Breast cancer: medication use to reduce risk	USPSTF	2019
Cervical cancer screening	USPSTF, HRSA	2018 (update in progress)
Behavioral counseling for healthy weight gain during pregnancy (USPSTF)		2021 (New)
Breastfeeding services and supplies	HRSA	2022 (expanded)
Contraception	HRSA	2022 (expanded)
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication	USPSTF	2021 (updated)
Screening for Chlamydial Infection (updated 2021)	USPSTF	2021 (updated)
Screening for Gonococcal Infection (USPSTF updated 2021)	USPSTF	2021 (updated)
Screening for Gestational Diabetes (USPSTF updated 2021)	USPSTF	2021 (updated)
STI counseling		2022 (updated)
Well woman preventive visits	HRSA	2022 (updated)

HB 3391 Guideline Updates (RHEA Report)

*coverage year indicates most recent year of coverage unless recommendations cover different groups or areas of listed services

Covered services and guidelines can also be found at: https://www.womenspreventivehealth.org/wp-content/uploads/FINAL_WPSI_WWC_11x17_2022Update.pdf

[IssueDescription]

THIS DOCUMENT AND INFORMATION CONTAINED WITHIN IT IS PRELIMINARY TO ANY FINAL AGENCY ACTION OR RECOMMENDATION. THIS DOCUMENT HAS BEEN CREATED FOR THE PURPOSE OF CONSIDERATION OF POTENTIAL REVIEW BY THE HEALTH EVIDENCE REVIEW COMMISSION (HERC) OR ONE OF ITS SUBCOMMITTEES OR ADVISORY PANELS AND DOES NOT REPRESENT THE OPINION OF THE HERC OR ANY OF ITS SUBCOMMITTEES OR ADVISORY PANELS. THIS DOCUMENT WILL NOT BE PRESENTED TO THE HERC FOR CONSIDERATION IN ITS CURRENT FORM AS THIS DOCUMENT IS EXPECTED TO UNDERGO REVISION ONCE ALL RELEVANT INFORMATION IS GATHERED FROM SUBJECT MATTER EXPERTS, MEMBERS OF THE HERC AND ITS SUBSIDIARY BODIES, AND OTHER STAKEHOLDERS. THE INFORMATION CONTAINED IN THIS DOCUMENT DOES NOT REPRESENT AN OFFICIAL POSITION OF THE OREGON HEALTH AUTHORITY OR HERC AND IS NOT TO BE USED, IN WHOLE OR IN PART, IN ANY CAPACITY IN CONDUCTING BUSINESS RELATED TO THE OREGON HEALTH PLAN EXCEPT FOR THE EXPRESS PURPOSE STATED ABOVE. THIS DOCUMENT MAY BE SUBJECT TO CERTAIN EXEMPTIONS FROM DISCLOSURE UNDER THE OREGON PUBLIC RECORDS LAW AND SHOULD NOT BE DISTRIBUTED TO ANY RECIPIENT OTHER THAN THE ORIGINAL INTENDED RECIPIENTS WITHOUT THE EXPRESS WRITTEN CONSENT OF THE HERC OR ITS DESIGNEE.

Question: RHEA Report 2022

Question source: HERC Staff

Issue: [IssueNotes]

Recommendations: [Recommendation]

Section 5.0

Coverage Guidances

SCOPE STATEMENT FOR HERC COVERAGE GUIDANCE

CONTINUOUS GLUCOSE MONITORING IN DIABETES MELLITUS

Population description	Children, adolescents, and adults, including pregnant people, with diabetes mellitus (DM) on insulin therapy *Population scoping notes: None*
Intervention(s)	Real-time, therapeutic continuous glucose monitoring (CGM) *Intervention exclusions: Retrospective continuous glucose monitoring, glucose monitors which require confirmation of glucose levels prior to treatment change*
Comparator(s)	Self-monitoring of blood glucose (SMBG); routine HbA1c monitoring
Outcome(s) (up to five)	**Critical:** Severe hypoglycemia requiring intervention; change in HbA1c; severe perinatal morbidity (for example, life threatening or disabling neonatal hypoglycemia or shoulder dystocia) **Important:** Quality-of-life; health resource utilization (limited to hospitalizations, ED visits, clinic visits) *Considered but not selected for GRADE Table: Myocardial infarction, cerebrovascular accident, amputations, neuropathy, retinopathy, nephropathy (we chose to generalize these into "severe morbidity" to simplify consideration), time in range, time below range, adherence to CGM, mortality*
Study Design(s)	**Effectiveness:** Randomized controlled trials (RCTs); systematic reviews of RCTS **Harms:** RCTs, cohort studies, case series
Follow-up	12 weeks or greater
Key questions	1. What is the effectiveness of real-time, therapeutic CGM in improving outcomes compared to self-monitoring of blood glucose in people with diabetes who use insulin? 2. Is there evidence of differential comparative effectiveness of CGMs in people with diabetes who use insulin based on: a. Age b. Sex c. Identity-related factors (e.g., race and ethnicity, gender) d. Diabetes type (i.e., Type 1 DM vs. Type 2 DM vs. gestational DM) e. Baseline glycemic control f. CGM adherence g. CGM type (i.e., standard CGM vs. flash glucose monitoring [FGM])

Contextual questions	1. What minimum level of HbA1c change is considered clinically significant? 2. What is the overall impact on healthcare costs associated with CGM vs. FGM vs. SMBG in the United States? 3. How do the costs of monitoring with therapeutic CGM compare to self monitoring with test strips?

CHANGE LOG

Date	Change	Rationale
3/16/2022	Clarified that only severe hypoglycemic events would be considered for an outcome. Added contextual questions about costs of monitoring.	Staff/leadership discussion
3/28/22	Added time below range to considered but not selected outcomes.	Hypoglycemia is a more important and patient-centered outcome
3/28/22	Added study types for harms.	Study designs for harms were missing and we are more inclusive of study designs to capture all harms

Section 6.0

Coverage Guidances

Health Evidence Review Commission (HERC)

Coverage Guidance: High-Frequency Chest Wall Oscillation Devices

DRAFT for HERC meeting 8/11/2022

HERC Coverage Guidance

High-frequency chest wall oscillation devices are recommended for coverage for patients with cystic fibrosis (*weak recommendation*) when there is documentation of frequent exacerbations requiring antibiotics, frequent hospitalization, or rapidly declining lung function measured by spirometry, despite either:

A) having received chest physiotherapy and positive expiratory pressure therapy, OR
B) documentation that such therapies are not tolerated, contraindicated, not effective, or not available (for example, inability of a caregiver to perform chest physiotherapy).

High-frequency chest wall oscillation devices are recommended for coverage for patients with non–cystic fibrosis bronchiectasis *(weak recommendation)* when the 3 criteria below are met:

A) The bronchiectasis is confirmed by computed tomography (CT) scan, AND
B) The patient has experienced either:
    1) Daily productive cough for at least 6 continuous months, OR
    2) Frequent (> 2 times a year) exacerbations requiring antibiotic therapy, *AND*
C) The patient has received mucolytics and less costly airway clearance treatments (for example, chest physiotherapy, positive expiratory pressure therapy, self-management techniques) OR such therapies are not tolerated, contraindicated, not effective, or not available (for example, inability of a caregiver to perform chest physiotherapy).

High-frequency chest wall oscillation devices are recommended for coverage for patients with neuromuscular disease resulting in chronic lung disease (*weak recommendation*) when there is evidence of chronic lung infection, despite either:

A) having received chest physiotherapy and positive expiratory pressure therapy, OR
B) documentation that such therapies are not tolerated, contraindicated, not effective, or not available (for example, inability of a caregiver to perform chest physiotherapy).

High-frequency chest wall oscillation devices are not recommended for coverage for patients with chronic obstructive pulmonary disease *(weak recommendation)*.

Note. Definitions for strength of recommendation are in Appendix A, GRADE Table Element Descriptions. Rationales for each recommendation appear below in the GRADE table.

Oregon Health Authority

Table of Contents

Rationale for development of coverage guidances and multisector intervention reports

Coverage guidances are developed to inform coverage recommendations for public and private health plans in Oregon as plan administrators seek to improve patient experience of care, population health, and the cost-effectiveness of health care. In the era of public and private sector health system transformation, reaching these goals requires a focus on maximizing the benefits and minimizing the harms and costs of health interventions.

The Health Evidence Review Commission (HERC) uses the following principles in selecting topics for its reports to guide public and private payers:

- Represents a significant burden of disease or health problem
- Represents important uncertainty with regard to effectiveness or harms
- Represents important variation or controversy in implementation or practice
- Represents high costs or significant economic impact
- Topic is of high public interest

HERC bases its reports on a review of the best available research applicable to the intervention(s) in question. For coverage guidances, which focus on diagnostic and clinical interventions, evidence is evaluated using an adaptation of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. For more information on coverage guidance methodology, see Appendix A.

Multisector interventions can be effective ways to prevent, treat, or manage disease at a population level. In some cases, HERC has reviewed evidence and identified effective interventions, but has not made formal coverage recommendations when these policies are implemented in settings other than traditional health care delivery systems because effectiveness could depend on the environment in which the intervention is implemented.

GRADE Table

HERC develops recommendations by using the concepts of the GRADE system. GRADE is a transparent and structured process for developing and presenting evidence and for performing the steps involved in developing recommendations. The table below lists the elements that determine the strength of a recommendation. HERC reviews the evidence and assesses each element, which in turn is used to develop the recommendations presented in the coverage guidance box. Estimates of effect are derived from the evidence presented in this document. The level of confidence in the estimate is determined by HERC based on the assessment of two independent reviewers from the Center for Evidence-based Policy.

In some cases, no systematic reviews or meta-analyses encompass the most current literature. In those cases, HERC may describe the additional evidence or alter the assessments of confidence considering all available information. Such assessments are informed by clinical epidemiologists from the Center for Evidence-based Policy. Unless otherwise noted, statements regarding resource allocation, values and preferences, and other considerations are the assessments of HERC, as informed by the evidence reviewed, public testimony, and subcommittee discussion.

Recommendations for coverage are based on the balance of benefit and harms, resource allocation, values and preferences and other considerations. See Appendix A for more details about the factors that constitute the GRADE table.

GRADE Tables

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with cystic fibrosis?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
Hospitalizations *(Critical outcome)*	Compared to chest physiotherapy: No significant difference in mean days of hospitalization (mean difference, -0.20; 95% CI, -2.32 to 1.92; *P* > .05). ●○○○ *(very low confidence, based on 1 RCT, n = 50)*	Coverage of high-frequency chest wall oscillation would add significant cost compared to chest physiotherapy or positive expiratory pressure devices.	Patients may prefer treatment options that can be self-administered, confer greater independence, and ensure reliable and	Some patients may not be able to tolerate chest physiotherapy or positive expiratory pressure devices.
Mortality *(Critical outcome)*	No evidence			

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with cystic fibrosis?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
Pulmonary Exacerbations Requiring Antibiotics *(Important outcome)*	Mixed results Compared to positive expiratory pressure: Significantly more exacerbations requiring antibiotics (median, 2.0; interquartile range, 1.0 to 3.0) than the positive expiratory pressure therapy group (median, 1.14; interquartile range, 0.0 to 2.0; odds ratio, 4.10; 95% CI, 1.42 to 11.84; *P* = .007) No significant difference when limited to IV antibiotics (OR, 2.36; 95% CI, 0.81 to 6.94) ●○○○ *(very low confidence, based on 1 RCT, n = 107)* Compared to chest physiotherapy: No significant difference in time to pulmonary exacerbation requiring antibiotics (*P* > .05). ●○○○ *(very low confidence, based on 1 RCT, n = 115)* Compared to other oral or external oscillatory devices: No significant difference ●○○○ *(very low confidence, based on 1 RCT, n = 16)*	However, in situations in which chest physiotherapy is not consistently available or tolerated and positive expiratory pressure devices are not effective or tolerated, the additional cost of the high-frequency chest wall oscillation device would be offset to the extent that it reduces hospitalizations and exacerbations. Chest physiotherapy must be provided by a trained caregiver for 20 to 40 minutes, one or more times per day; could be provided by a paid or unpaid caregiver.	consistent treatment.	Some patients may not have caregivers who are available or physically able to administer daily chest physiotherapy.
Exercise Capacity *(Important outcome)*	No evidence			

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with cystic fibrosis?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
Breathlessness or Cough *(Important outcome)*	No evidence			

Balance of benefits and harms: Based on very low-confidence evidence, high-frequency chest wall oscillation devices have similar outcomes to chest physiotherapy for reducing hospitalizations. There is mixed evidence compared to positive expiratory pressure, chest physiotherapy, and other oscillating devices for reducing exacerbations in patients with cystic fibrosis. There are few device-related harms found for high-frequency chest wall oscillation devices.
Rationale: High-frequency chest wall oscillation devices are not inferior to other alternatives based on very low certainty evidence, and have a low rate of device-related harms, but much higher cost. However, we recommend coverage because some patients may need other treatment options and due to the small size of the population affected. The recommendation is weak because of the very low quality of the evidence.
Recommendation: High-frequency chest wall oscillation devices are recommended for coverage for patients with cystic fibrosis (*weak recommendation)* when there is documentation of frequent severe exacerbations requiring antibiotics and/or hospitalization, despite either: a) having received chest physiotherapy and positive expiratory pressure therapy, OR b) documentation that chest physical therapy and positive expiratory pressure devices are not tolerated or not available (e.g., inability of a caregiver to perform chest physiotherapy).

Note. GRADE table elements are described in Appendix A. A GRADE Evidence Profile is in Appendix B.
Abbreviations. CI: confidence interval; GRADE: Grading of Recommendations, Assessment, Development, and Evaluation methodology; RCT: randomized controlled trial.

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with non–cystic fibrosis bronchiectasis?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
Hospitalizations *(Critical outcome)*	No evidence	Coverage of high-frequency chest wall oscillation would add significant cost compared to chest physiotherapy or positive expiratory pressure devices. However, in situations in which chest physiotherapy is not consistently available or tolerated and positive expiratory pressure devices are not effective or tolerated, the additional cost of the high-frequency chest wall oscillation device would be offset to the extent that it reduces hospitalizations and exacerbations.	Patients may prefer treatment options that can be self-administered, confer greater independence, and ensure reliable and consistent treatment.	Appointed expert opinion supported coverage of high-frequency chest wall oscillation devices for bronchiectasis, due to the pathophysiologic similarities of this condition to cystic fibrosis bronchiectasis, but only when there is evidence of chronic infection.
Mortality *(Critical outcome)*	No evidence			
Pulmonary Exacerbations Requiring Antibiotics *(Important outcome)*	<u>Respin11 HFCWO device compared to standard pharmacological therapy alone</u>: Significantly fewer exacerbations over 12 months on average for 1 group that used high-frequency chest wall oscillation devices: • Respin11 group (mean, 0.52 exacerbations; SD, 0.14) • Pharmacological therapy with other device-delivered interventions (mean, 0.96 exacerbations; SD, 0.40) • Between-group difference, *P* < .001 <u>SmartVest HFCWO device compared to standard pharmacological therapy alone</u>: The treatment group that used the SmartVest HFCWO device did not have significantly fewer exacerbations when compared to the group that received standard pharmacological therapy • SmartVest group (mean, not reported; SD, not reported) • Pharmacological therapy with other device-delivered interventions (mean, 0.96 exacerbations; SD, 0.40) • Between-group difference, *P* > .05 ●○○○ *(very low confidence, based on 1 RCT, n = 42)*			

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with non–cystic fibrosis bronchiectasis?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
Exercise Capacity *(Important outcome)*	No evidence			
Breathlessness or Cough *(Important outcome)*	Compared to chest physiotherapy: Significant reduction in symptoms as measured by the 12-point Breathlessness Cough Sputum Score scale (mean difference, -5.8; 95% CI, -7.21 to -4.39; N = 20; *P* < .05) ●○○○ *(very low confidence, based on 1 RCT, n = 20)* Respin11 HFCWO device compared to standard pharmacological therapy alone: Significant reduction in symptoms as measured by the 12-point Breathlessness Cough Sputum Score scale: • Respin11 group (mean at 12 months post-baseline, 2.8; SD, not reported) • Pharmacological therapy with other device-delivered interventions group (mean at 12 months post-baseline, 6.1; SD, not reported) • Between-group difference, *P* < .001 ●○○○ *(very low confidence, based on 1 RCT, n = 42)* SmartVest HFCWO device compared to standard pharmacological therapy alone: The treatment group that used the SmartVest high-frequency chest wall oscillation device did not demonstrate a significant reduction in symptoms as measured by the 12-point Breathlessness Cough Sputum Score scale: • SmartVest group (mean at 12 months post-baseline, 4.5; SD, not reported)			

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with non–cystic fibrosis bronchiectasis?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
	• Pharmacological therapy with other device-delivered interventions group (mean at 12 months post-baseline, 6.1; SD, not reported) • Between-group difference, *P* > .05 ●○○○ *(very low confidence, based on 1 RCT, n = 42)*			

Balance of benefits and harms: There is very low confidence evidence that high-frequency chest wall oscillation devices improve key outcomes for patients with non-cystic fibrosis bronchiectasis. However, expert opinion supports use in this population based on data extrapolated from cystic fibrosis, which is a similar condition, but only when there is evidence of chronic airway infection or chronic daily cough. There are few device-related harms to high-frequency chest wall oscillation devices.
Rationale: The evidence is equivocal regarding whether high-frequency chest wall oscillation improves outcomes for patients with non-cystic fibrosis bronchiectasis, but we recommend coverage of these devices based on low risk of harms and the fact that they may result in cost offsets if they prevent hospitalizations. Expert testimony that pathophysiologic reasoning makes extrapolating evidence from the cystic fibrosis population reasonable. The recommendation is weak because of our very low confidence in the available evidence.
Recommendation: High-frequency chest wall oscillation devices are recommended for coverage for patients with non–cystic fibrosis bronchiectasis (*weak recommendation*) when the 3 criteria below are met: A) The bronchiectasis is confirmed by computed tomography (CT) scan, *AND* B) The patient has experienced either: 1. Daily productive cough for at least 6 continuous months, *OR* 2. Frequent (> 2 times a year) exacerbations requiring antibiotic therapy, *AND* C) The patient has received mucolytics and less costly airway clearance treatments (for example, chest physiotherapy, positive expiratory pressure therapy, self-management techniques) OR such therapies are not tolerated, contraindicated, not effective, or not available (for example, inability of a caregiver to perform chest physiotherapy).

Note. GRADE table elements are described in Appendix A. A GRADE Evidence Profile is in Appendix B.
Abbreviations. CI: confidence interval; GRADE: Grading of Recommendations, Assessment, Development, and Evaluation methodology; RCT: randomized controlled trial; SD: standard deviation.

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with chronic obstructive pulmonary disease?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
Hospitalizations *(Critical outcome)*	No evidence	Coverage of high-frequency chest wall oscillation would add significant cost compared to chest physiotherapy or positive expiratory pressure devices. However, in situations in which chest physiotherapy is not consistently available or tolerated and positive expiratory pressure devices are not effective or tolerated, the additional cost of the high-frequency chest wall oscillation device would be offset to the extent that it reduces hospitalizations and exacerbations.	Patients may prefer treatment options that can be self-administered, confer greater independence, and ensure reliable and consistent treatment.	Appointed expert did not recommend high-frequency chest wall oscillation devices for this population.
Mortality *(Critical outcome)*	No evidence			
Pulmonary Exacerbations Requiring Antibiotics *(Important outcome)*	No evidence			
Exercise Capacity *(Important outcome)*	No evidence			
Breathlessness or Cough *(Important outcome)*	Compared to standard pharmacological therapy without oscillatory devices: Significantly greater improvement on the 12-point Breathlessness Cough Sputum Score scale over 4 weeks: • The Vest Airway Clearance System Model 205 group (baseline mean, 6.6; SD, 2.8; post-treatment mean, 5.2; SD, 2.2) • Standard pharmacological therapy group (baseline mean, 4.6; SD, 1.7; post-treatment mean, 5.5; SD, 2.1) • Between-group difference, *P* = .007 ●○○○ *(very low confidence, based on 1 RCT, n = 40)*			

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with chronic obstructive pulmonary disease?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
	Compared to intrapulmonary percussive ventilation: Significantly less improvement on the 12-point Breathlessness Cough Sputum Score scale over 4 weeks: • The Vest Airway Clearance System Model 205 group (baseline mean, 6.6; SD, 2.8; post-treatment mean, 5.2; SD, 2.2) • Intrapulmonary percussive ventilation group (baseline mean, 6.3; SD, 1.4; post-treatment mean, 3.1; SD, 1.7) • Between-group difference, $P < .01$ ●○○○ *(very low confidence, based on 1 RCT, n = 40)*			

Balance of benefits and harms: There is insufficient evidence that high-frequency chest wall oscillation devices improve key outcomes for patients with chronic obstructive pulmonary disease compared to alternatives. Expert opinion does not recommend use in this population. There are few device-related harms to high-frequency chest wall oscillation devices.
Rationale: There is insufficient comparative evidence of benefit for this indication. It is a weak recommendation because of our very low confidence in the evidence.
Recommendation: High-frequency chest wall oscillation devices are not recommended for coverage for children and adults with chronic obstructive pulmonary disease *(weak recommendation).*

Note. GRADE table elements are described in Appendix A. A GRADE Evidence Profile is in Appendix B.
Abbreviations. GRADE: Grading of Recommendations, Assessment, Development, and Evaluation methodology; RCT: randomized controlled trial; SD: standard deviation.

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with pulmonary complications from neuromuscular disease resulting in chronic lung disease?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
Hospitalizations *(Critical outcome)*	Compared to standard chest physiotherapy (pediatric patients with neuromuscular disease): There was a nonsignificant difference in the number of control group participants requiring hospitalizations (2/7) compared to the HFCWO device group (0/7; *P* > .05) ●○○○ *(very low confidence, based on 1 RCT, n = 14)*	Coverage of high-frequency chest wall oscillation would add significant cost compared to chest physiotherapy or positive expiratory pressure devices. However, in situations in which chest physiotherapy is not consistently available or tolerated and positive expiratory pressure devices are not effective or tolerated, the additional cost of the high-frequency chest wall oscillation device would be offset to	Patients may prefer treatment options that can be self-administered, confer greater independence, and ensure reliable and consistent treatment. This group of conditions varies widely in severity and patients may have different preferences based on their condition.	Neuromuscular diseases are a broad range of conditions with very different pulmonary involvement. Many of these conditions have populations that are too small to meaningfully study. Appointed expert recommendation was for use in patients with neuromuscular disease who have evidence of chronic airway infection (defined as persistent culture positivity of organisms known to
Mortality *(Critical outcome)*	No evidence			
Pulmonary Exacerbations Requiring Antibiotics *(Important outcome)*	Compared to standard chest physiotherapy (pediatric patients with neuromuscular disease): There was nonsignificant difference between control group participants requiring antibiotics (3/7) compared to the HFCWO device group (2/7; *P* > .05) ●○○○ *(very low confidence, based on 1 RCT, n = 14)*			
Exercise Capacity *(Important outcome)*	No evidence			

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with pulmonary complications from neuromuscular disease resulting in chronic lung disease?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
Breathlessness or Cough *(Important outcome)*	Compared to no treatment (adult patients with ALS): Significantly greater improvement in breathlessness (high-frequency chest wall oscillation group mean difference, -1.28; untreated group mean difference, 0.84; *P* < .05) Compared to no treatment (adult patients with ALS): No statistically significant differences in day or night cough or dyspnea ●○○○ *(very low confidence, based on 1 RCT, n = 35)*	the extent that it reduces hospitalizations and exacerbations.		cause respiratory infection).

Balance of benefits and harms: There is no evidence that high-frequency chest wall oscillation devices improve key outcomes compared to standard treatments for patients with neuromuscular disease resulting in chronic lung disease. Expert testimony indicates patients with neuromuscular conditions and evidence of chronic airway infection benefit from these devices. There are few device-related harms to high-frequency chest wall oscillation devices.
Rationale: There is insufficient comparative evidence of benefit for this population, but based on expert opinion and the potential to reduce exacerbations/costs, we recommend coverage for patients with neuromuscular disease when there is evidence of chronic airway infection. The disparate types of diseases and small populations within each disease make high-quality studies difficult to conduct and are not anticipated to be forthcoming. The recommendation is weak because of our very low confidence in the available evidence.

Should high-frequency chest wall oscillation devices be recommended for coverage for children and adults with pulmonary complications from neuromuscular disease resulting in chronic lung disease?

Outcomes	Estimate of Effect for Outcome/ *Confidence in Estimate*	Resource Allocation	Values and Preferences	Other Considerations
Recommendation: High-frequency chest wall oscillation devices are recommended for coverage for patients with neuromuscular disease resulting in chronic lung disease (*weak recommendation)* when there is evidence of chronic lung infection, despite either: a) having received chest physiotherapy and positive expiratory pressure therapy, OR b) documentation that such therapies are not tolerated, contraindicated, not effective, or not available (for example, inability of a caregiver to perform chest physiotherapy).				

Note. GRADE table elements are described in Appendix A. A GRADE Evidence Profile is in Appendix B.

Abbreviations. ALS: amyotrophic lateral sclerosis; GRADE: Grading of Recommendations, Assessment, Development, and Evaluation methodology; RCT: randomized controlled trial.

Background

Individuals with impaired airway clearance are unable to effectively clear mucus from their airways.[1] High-frequency chest wall oscillation (HFCWO) devices are designed to help those with impaired airway clearance clear mucus from their airways. Impaired airway clearance can be a characteristic of several respiratory disorders and neuromuscular diseases, including:

- Chronic obstructive pulmonary disorder (COPD)
- Cystic fibrosis
- Bronchiectasis, which is characterized by chronic cough, bronchial wall thickening, permanent expansion of the airway, and overproduction of thick mucus
- Multiple sclerosis
- Muscular dystrophy
- Spinal muscular atrophy
- Amyotrophic lateral sclerosis (ALS)

The Centers for Disease Control and Prevention estimate that 35,000 individuals have been diagnosed with cystic fibrosis in the US, and 16 million US individuals are living with COPD.[2,3] According to a claims-data analysis using information from 2013, aproximately 340,000 to 522,000 adults receive treatment for bronchiectasis in the US, and about half of patients diagnosed with bronichiectasis have comorbid COPD.[4]

Failing to adequately and regularly clear mucus from the airways can result in exacerbations and worsening of chronic lung disease that require antibiotic treatment, hospitalization and other interventions.[5] Therefore, a key element of managing these diseases is to keep airways clear of excess secretions. When patients are unable to mobilize mucus secretions on their own, airway clearance techniques for patients with many respiratory disorders can include:

- Chest physiotherapy
    - Can be administered by respiratory therapists, family members, or other informal caregivers
    - Has been the standard of care for first-line secretion clearance for individuals with excessive or retained mucus.[6]
    - Typically administered by a trained caregiver over 1 to 3 sessions per day, each lasting 20 to 30 minutes, depending on disease severity.[6]
    - May also be known as percussion and postural drainage.
- Breathing techniques
    - Typically taught to patients by pulmonary rehabilitation professionals.
    - Active cycle breathing techniques include breathing control, thoracic expansion exercises, and the forced expiration technique.[6]
    - Autogenic drainage involves breathing techniques in 3 phases (unstick, collect, and evacuate) at different lung volumes.
    - Breathing techniques do not require devices or assistance and can be self-administered.[6]
- Positive expiratory pressure devices
    - Increase resistance, prevent airway closure, and increase collateral ventilation.[6]

    - Some use oscillatory mechanisms to create vibrations when a patient breathes out.[6]
    - Examples include TheraPEP, Resistex PEP mask, Pari RC Cornet Mucus Clearing Device, Flutter, Acapella, Quake, and Aerobika.
    - The therapy from these devices can be self-administered without assistance.[6]
- Intrapulmonary percussive ventilation
    - A pneumatic device that uses high-frequency oscillatory ventilation through a mouthpiece.[6]
    - An example is the Percussionaire Corporation IPV Ventilator.[6]
- High-frequency chest wall oscillation (HFCWO) devices, which are described in the following section of this document.
    - Therapy from these devices can be self-administered.[6]

Indications

Children and adults with cystic fibrosis, bronchiectasis, COPD, or pulmonary complications from neuromuscular disease resulting in chronic lung disease might be prescribed HFCWO devices to assist in the clearance of mucus in airways as part of their treatment plan. HFCWO devices exert external force on the chest wall to assist in mobilizing mucus and use sound waves or pressure from inflation and deflation at variable intensities and frequencies to generate the force. They are much more expensive than the alternative forms of treatment but require less time from caregivers than chest physiotherapy.

Technology Description

We identified 1 nonwearable HFCWO device and 5 wearable HFCWO devices that are currently approved by the US Food and Drug Administration (FDA) and being manufactured for use in children and adults with cystic fibrosis, bronchiectasis, COPD, or pulmonary complications from neuromuscular disease resulting in chronic lung disease. See Table 1 for a description of each device.

Table 1. HFCWO Device Descriptions

Device Name FDA Approval Date	Manufacturer	Features	Indications
Frequencer V2 and V2x[7] January 26, 2011[8]	Dymedso	• Portable • Not wearable • 4 sizes of adaptors for patients of different sizes • Generates low frequency sound waves within the range of 20-65 Hz and offers an adjustable intensity based on the patient's condition	• Cystic fibrosis • Chronic bronchitis • COPD • Bronchiectasis • Ciliary dyskinesia syndromes • Asthma • Muscular dystrophy • Neuromuscular degenerative disorder • Post-operative atelectasis • Thoracic wall defects

Device Name FDA Approval Date	Manufacturer	Features	Indications
SmartVest SQL System[9] December 19, 2013[10]	Electromed	• Portable • Wearable • 8 different sizes • 16 pounds • Quiet (60 decibels) • 91% decompression (greater percent decompression than other vests) • Wireless capabilities that can connect usage to personal reports or to healthcare provider records	• Bronchiectasis • COPD • Cystic fibrosis • Neuromuscular conditions
The Vest Airway Clearance System Model 105[11] February 21, 2003[12]	Hill-Rom	• Portable • Wearable • 4 styles of garment for different body types (full garment, wrap garment, chest garment, C3 garment) • 17 pounds • Multiple programing options, including several languages • Can program a reminder to cough • Vest covers are washable and dryable • Offers at-home training • Wireless capabilities that can connect usage to personal reports or to healthcare provider records	• Bronchiectasis • COPD • Cystic fibrosis • Neuromuscular conditions • Primary ciliary dyskinesia • Post lung transplant • Spinal cord injury

Device Name FDA Approval Date	Manufacturer	Features	Indications
Respin11[13] July 13, 2012[14]	RespInnovation SAS	• Portable • Wearable • Vest plus control unit weight 11 kilograms • Several sizes for different sizes • Can target specific chest areas • Programmable with several protocols • Uses an air pressure piston which inflates and completely empties each cycle enabling the patient to breathe, speak and cough without restriction • Does not provide constant background pressure which manufacturer claims makes the therapy easy to tolerate and puts no pressure onto the patient's physiological state	• Bronchiectasis • COPD • Cystic fibrosis • Neuromuscular conditions • Emphysema
InCourage Vest[15] June 17, 2005[16]	Philips, via RespirTech	• Portable • Wearable • 17.5 pounds • Several sizes for different ages • Uses triangular waveform technology that manufacturer claims delivers a chest physiotherapy-like "thump" to the chest • Offers at-home training	• Bronchiectasis • COPD • Cystic fibrosis • Certain neuromuscular conditions
AffloVest[17] March 27, 2013[12]	International Biophysics Corporation	• Portable • Wearable • Available in 7 sizes • Battery-operated • Has eight mechanical oscillating motors that target all 5 lobes of the lungs, front and back, for fully mobile use • Programmable settings	• Bronchiectasis • COPD • Cystic fibrosis • Neuromuscular diseases

Device Name FDA Approval Date	Manufacturer	Features	Indications
		• Advertised as the lightest vest option (no weight specified)	

Abbreviations. COPD: chronic obstructive pulmonary disorder; FDA: US Food and Drug Administration; HFCWO: high-frequency chest wall oscillation.

Evidence Review

We identified 2 systematic reviews,[6,18] 4 randomized controlled trials (RCTs),[19-21,44] and a single ongoing RCT[22] for the comparative effectiveness of HFCWO devices for children and adults with cystic fibrosis, bronchiectasis, COPD, or pulmonary complications from neuromuscular disease resulting in chronic lung disease. We did not identify any studies of the comparative cost effectiveness of HFCWO devices.

Cystic Fibrosis

We identified a single systematic review that focused on airway clearance techniques in people diagnosed with cystic fibrosis, and included RCTs and quasi-randomized trials of HFCWO devices.[6] The review included external chest oscillating devices as well as oral oscillatory devices.[6] Morrison and colleagues abstracted information related to the scope of this coverage guidance: exercise tolerance and frequency of exacerbations with or without hospitalization.[6] Morrison and colleagues included 39 studies in the qualitative review and 19 studies in meta-analyses; they rated 85% of these studies as having unclear risk of bias.[6] They rated the quality of evidence summarized in the review as very low to low across outcomes.[6] We rated this systematic review as having low risk of bias, and the authors rated component studies as having unclear to high risk of bias.

The studies in this review did not report symptoms of breathlessness or cough, mortality, or exercise capacity for participants using HFCWO devices.

Exacerbations and Hospitalizations

The single RCT (N = 107) that compared HFCWO devices to positive expiratory pressure therapy reported that the average number of exacerbations requiring antibiotics during the 12-month study period was significantly higher in the HFCWO groups (median, 2.0; interquartile range, 1.0 to 3.0) than the positive expiratory pressure therapy group (median, 1.14; interquartile range, 0.0 to 2.0; Odds Ratio [OR] 4.10; 95% CI, 1.42 to 11.84; *P* = .007).[6] However, this result was no longer significant when limited to exacerbations requiring treatment with intravenous antibiotics (OR, 2.36; 95% CI, 0.81 to 6.94, *P* > .05).[6]

Two RCTs compared HFCWO devices to conventional physiotherapy for patients with cystic fibrosis. In 1 RCT (N = 50) of patients with cystic fibrosis admitted to a hospital for an acute exacerbation, there was no significant difference between the study groups for days of hospitalization (mean difference, -0.20; 95% CI, -2.32 to 1.92).[6] The participants in this study were between 16 and 25 years of age, and 64.0% were identified as male.[6] Patients in the conventional physiotherapy group received therapy from a respiratory physiotherapist 3 times per day for approximately 30 minutes each time, along with the use of an inhaler prior to sessions with the physiotherapist.[6] The second RCT (N = 115) reported no

significant between-group difference in time to pulmonary exacerbations requiring antibiotics in children, adolescents, and adults with cystic fibrosis.[6]

Neither of the 2 RCTs that compared HFCWO devices to breathing techniques for cystic fibrosis reported exacerbations or any other outcome scoped for this review.[6]

Only 1 of 6 studies comparing HFCWO devices to other external and oral oscillatory devices assessed exacerbations (N = 16); it reported that there were no significant differences between groups for use of home intravenous therapies.[6]

Bronchiectasis

We identified a single systematic review focused on airway clearance techniques for people diagnosed with bronchiectasis,[18] and a single RCT (Nicollini et al., 2020; N = 60) that was published after the search dates of the systematic review.[19] We rated the systematic review as having a low risk of bias and the RCT as having a moderate risk of bias. The systematic review included 7 RCTs, but only 1 included RCT used HFCWO devices in the intervention group (Nicollini et al., 2013; N = 30).[23] This RCT was rated as having an unclear risk of bias by the authors of the systematic review. Both RCTs focused on adults.[19,23] Neither of these RCTs reported on mortality.

Exacerbations and Hospitalizations

In Nicollini and colleagues' 2020 RCT, both groups that used HFCWO devices had statistically significant improvement in exacerbations during the 12 months of the study compared to the average exacerbations per year prior to baseline.[19] Only the group that used the Respin11 HFCWO device had significantly fewer exacerbations during the 12-month study period, compared to the pharmacological comparison group that only received standard pharmacological care without HFCWO or chest physiotherapy (Respin11: mean, 0.52; standard deviation [SD], 0.14; control: mean, 0.96; SD, 0.40; between-group difference: $P < .001$).[19] The 2 HFCWO devices included in this study are described in Table 1.

Breathlessness or Cough

Nicollini and colleagues' 2013 RCT, identified in the systematic review, reported a statistically significant decrease in breathlessness, cough and sputum on the Breathlessness, Cough, and Sputum Scale (BCSS) in the group treated with HFCWO devices compared to a control group that received chest physiotherapy (mean difference, -5.8; 95% CI, -7.21 to -4.39; N = 20; $P < .05$).[23] This study summed the scores of items across 3 subscales, which makes it challenging to anchor this improvement in patient-response terms; publications that assess the clinical importance of change-scores for this scale rely on reporting the average score across subscales (i.e., mean-scores range from 0 to 4, and sum-scores range from 0 to 12 on this scale). This RCT also reported that use of HFCWO devices was associated with lower scores on a dyspnea scale compared to the group that received chest physiotherapy (mean difference, -1.7; 95% CI, -2.4 to -1; N = 20; $P < .05$). [23]

The additional Nicollini and colleagues' 2020 RCT also reported that the group using the Respin11 HFCWO device demonstrated statistically significant improvement on the BCSS compared to the control group that received pharmacological therapy and standard care without HFCWO (Respin11 mean at 12 months post-baseline, 2.8; SD, not reported; control mean at 12 months post-baseline, 6.1; SD, not reported; $P < .001$).19 The group that used the SmartVest HFCWO device did not demonstrate a

significant improvement on the BCSS compared to the control group (SmartVest mean at 12 months post-baseline, 4.5; SD, not reported; control mean at 12 months post-baseline, 6.1; SD, not reported; $P > .05$).

Exercise Capacity

The Nicollini and colleagues' 2020 RCT used a 6-minute walk test to assess exercise capacity but did not report the results of the walk test.[19]

COPD

We identified a single RCT that reported on the safety and effectiveness of HFCWO devices compared to intrapulmonary percussive ventilation in patients with severe COPD, and rated this RCT as having a moderate risk of bias.[20] The listed authors overlapped with the 2 RCTs reviewed in the bronchiectasis section, and the design of all 3 RCTs was similar.[20] Participants in this study had severe or very severe (but stable) COPD and were followed for 4 weeks after being randomized into 3 groups: 1 group received 2 sessions per day (lasting 15 minutes per session) of intrapulmonary percussive ventilation with a respiratory physiotherapist using a percussive ventilator; 1 group received 2 sessions per day (lasting 20 minutes per session) of HFCWO with a respiratory physiotherapy; and 1 group received standard pharmacological therapy alone that the investigators termed "the best medical therapy."[20] Most participants were 70 years or older and had more than 2 exacerbations and 1 hospitalization per year.[20] This study did not report mortality, hospitalizations, exacerbations, or exercise capacity.[20]

Breathlessness or Cough

The average BCSS score for participants in the control group worsened over time, but average BCSS scores for participants in the intrapulmonary percussive ventilation and HFCWO groups improved; both treatment groups had statistically significantly lower BCSS scores when compared to the standard treatment group (control group baseline mean, 4.6; SD, 1.7; control group post-treatment mean, 5.5; SD, 2.1).[20] Symptoms were nearly halved in the group receiving intrapulmonary percussive ventilation (intrapulmonary percussive ventilation group baseline mean, 6.3; SD, 1.4; intrapulmonary percussive ventilation group post-treatment mean, 3.1; SD, 1.7).[20] The intrapulmonary percussive ventilation group BCSS scores were statistically significantly lower than HFCWO group scores after the 4 weeks of treatment (HFCWO group baseline mean, 6.6; SD, 2.8; HFCWO group post-treatment mean, 5.2; SD, 2.2; between-group difference, $P < .01$).[20] In other words, the participants in the intrapulmonary percussive ventilation group improved more on symptoms of breathlessness or cough on average, compared to participants who received HFCWO device therapy.

Pulmonary Complications from Neuromuscular Disease

We identified 2 RCTs that assessed the safety and effectiveness of HFCWO devices for individuals diagnosed with a neuromuscular disease with pulmonary complications.[21,44] One RCT focused on adults diagnosed with ALS.[21] Participants in this study were followed for 12 weeks after being randomized into groups that received HFCWO therapy (N = 19) or no treatment (N = 16).[21] We rated this RCT as having a high risk of bias. This study did not report mortality, exacerbations, hospitalizations, or exercise capacity.

The second RCT included 14 children various neuromuscular diseases (i.e., Duchenne muscular dystrophy, unown mitochondrial myopathy, congenital muscular dystrophy, mitochondrial thymidine

kinase 2 deficiency, spinal muscular atrophy type 2, muscle-eye-brain disease, and giant axonal neuropathy).[44] None of the participating children had used cough-assistive devices or intrapulmonary percussive ventilation prior to the trial, but 10 relied on nocturnal noninvasive bilevel ventilation and 1 was dependent on a ventilator.[44] Participants were randomized to receive standard chest physiotherapy (N = 7) or to receive HFCWO device therapy (N = 7) for a mean of 5 months; follow-up periods varied nonsignificantly by participant and group assignment.[44] An additional 9 participants in this RCT were diagnosed with cerebral palsey, but did not have neuromuscular disease diagnoses;[44] we report outcomes from this study when the results were reported separately for participants with cerbral palsey and participants with neuromuscular disease (i.e., pulmonary exacerbations and hospitalizations). We rated this study as having a high risk of bias.

Exacerbations and Hospitalizations

The RCT that included children with neuromuscular disease reported hospitalization and pulmonary exacerbations that required antibiotics. There was a nonsignificant difference in the number of control group participants requiring hospitalizations (2/7) compared to the HFCWO device group (0/7; $P > .05$), and nonsignificant difference between control group participants requiring antibiotics (3/7) compared to the HFCWO device group (2/7; $P > .05$).[44]

Breathlessness or Cough

On average, participants in the HFCWO device group had a statistically significantly greater decrease in breathlessness (HFCWO group mean difference, -1.28; group receiving no care mean difference, 0.84; $P < .05$) in the RCT that included adults with ALS, but no statistically significant differences in day or night cough or dyspnea.[21] Among the 21 participants with impaired lung capacity (forced vital capacity of 40% to 70%) in this RCT, this pattern of improvement in breathlessness for participants using HFCWO devices was further accentuated (HFCWO group mean difference, -1.71; untreated group mean difference, 1.51; $P < .05$).[21]

Harms of HFCWO Devices

We reviewed the RCTs described above for information about device-related harms and adverse events. We also searched the FDA's manufacturer and user facility device experience database (MAUDE) for reports of adverse events for each of the HFCWO devices listed in the technology description.

A single RCT comparing HFCWO devices to positive expiratory pressure therapy for patients with cystic fibrosis reported adverse events.[24] This RCT was included in the systematic review described in the cystic fibrosis section, and used the inCourage System from RespirTech for the HFCWO device.[6,24] The authors for this RCT reported that the number of adverse events was not statistically different between the 2 groups (HFCWO, 200 events; positive expiratory pressure, 163 events; $P > .05$).[23] However, the HFCWO device group had significantly more lower airway adverse events (mean, 2.46; SD, not reported) compared to the positive expiratory pressure group (mean, 1.72; SD not reported; $P = .023$).[24] Lower airway events included increased cough, chest infection, hemoptysis, decreased lung function and chest pain.[24]

Reports identified in the MAUDE database are listed in Table 2, by device.

Table 2. Adverse Events Reported in MAUDE by HFCWO Device

Device Name FDA Approval Date	Manufacturer	Adverse Event(s)
Frequencer V2 and V2x[7] January 26, 2011[8]	Dymedso	• No records
SmartVest SQL System[9] December 19, 2013[10]	Electromed	• No records
The Vest Airway Clearance System Model 105[11] February 21, 2003[12]	Hill-Rom	• No records
Respin11[13] July 13, 2012[14]	RespInnovation SAS	• No records
InCourage Vest[15] June 17, 2005[16]	Philips, via RespirTech	• 8 reports identified classified under injury event type ○ Rib bone fractures in 3 different patients ○ 1 vertebral fracture ○ 1 electromagnetic interference problem with a pacemaker ○ 1 hematoma ○ 1 pneumothorax ○ 1 pressure problem with co-occurring mastitis
AffloVest[17] March 27, 2013[12]	International Biophysics Corporation	• 1 report identified • Fractured ribs

Abbreviations. FDA: US Food and Drug Administration; HFCWO: high-frequency chest wall oscillation; MAUDE: manufacturer and user facility device experience database.

Comparative Cost Effectiveness of HFCWO Devices

We did not identify any comparative cost-effectiveness studies of HFCWO devices.

Ongoing Studies for HFCWO Devices

We identified a single ongoing comparative study for HFCWO devices in the Clinical Trials Registry. This pilot study will evaluate the use of the Vest system for treatment of bronchiectasis patients in the home setting.[25] This study is a nonblinded, multi-site, randomized controlled trial that anticipates enrolling 70 participants, and will compare the Vest HFCWO therapy to oscillating positive expiratory pressure (OPEP) therapy for adults aged 18 years and older diagnosed with bronchiectasis.[25] Assessed outcomes will include pulmonary exacerbations and quality of life.[25] The anticipated study completion date was November 2020.[25]

Evidence Summary

For patients with cystic fibrosis, we have very low confidence that HCWFO device therapy is equivalent to conventional chest physiotherapy for reducing hospitalizations. There is mixed evidence for

prevention of exacerbations requiring antibiotics compared to positive expiratory pressure, conventional chest physiotherapy, and other oscillating devices. There is no evidence regarding other outcomes.

For patients with bronchiectasis, we have very low confidence that HFCWO device therapy reduces hospitalizations from exacerbations and improves symptoms of breathlessness and cough compared to pharmacological therapy with other device-delivered interventions (e.g., positive expiratory pressure mask), and compared to pharmacological therapy without other devices. There is no evidence regarding other outcomes.

For patients with COPD, we have very low confidence that HFCWO device therapy is associated with less improvement in breathlessness and cough compared to intrapulmonary percussive ventilation. There is no evidence regarding other outcomes.

For patients with pulmonary complications from neuromuscular disease, we have very low confidence that HFCWO device therapy improves symptoms of breathlessness compared to no treatment or to standard chest physiotherapy. One study only included patients with ALS receiving HFCWO devices compared to no treatment, and the study that included children with neuromuscular disease likely had too few participants to identify whether there was a benefit to using HFCWO devices compared to standard chest physiotherapy. We have very low confidence that HFCWO device therapy does not improve day or night cough, or dyspnea compared to receiving no treatment for patients with ALS. There is no evidence regarding other outcomes for other neuromuscular diseases resulting in chronic lung disease.

We identified few reports of adverse events or device-related harms of HFCWO devices in the reviewed studies and the FDA's database for adverse event reporting for devices.

Policy Landscape

Payer Coverage Policies

We identified HFCWO device coverage policies for Washington State's Medicaid program, a local coverage determination from Medicare, and 4 private payers. Medicare's local coverage determination and all 4 private payer policies require documentation that standard treatments, such as chest physiotherapy, have failed or are not tolerated before covering HFCWO devices; these policies cover HFCWO devices for patients with cystic fibrosis and bronchiectasis, but coverage for neuromuscular diseases with pulmonary complications varies. None of these policies cover HFCWO devices for patients with COPD except when there is comorbid bronchiectasis.

Medicaid

The Washington Health Care Authority's (HCA) policy for respiratory care considers chest physiotherapy to be the standard of care for secretion clearance, but states that there are situations in which conventional chest physiotherapy is unavailable, ineffective, or not tolerated.[26] The HCA covers HFCWO air-pulse generator systems when medically necessary for a person with a diagnosis characterized by excessive mucus production and difficulty clearing secretions.[26] Other airway-clearance devices covered by the HCA include mechanical percussors, oscillatory positive expiratory pressure devices, positive expiratory pressure devices, and cough stimulating devices, including alternating positive and negative

airway pressure devices, and replacement batteries.[26] Prior authorization is required, and the policy also states that the rental of a HFCWO device and generator includes all repairs and replacements, and that the manufacturer will replace the vest according to changes in user's size during the rental and purchase period.[26] The HFCWO device is considered to be purchased after 12 months of rental, and there is a limit of 1 HFCWO device per client, per lifetime.[24] The fee schedule, which was last updated in October 2020, lists the maximum allowable monthly rental fee for a HFCWO device (HCPCS E0483) as $1,224.07, and the maximum allowable fee for replacement parts (HCPCS A7025) as $465.90.[27]

Medicare

The local coverage determination for HFCWO devices (L33785) for Medicare, last updated in 2020, provides the following criteria for medical necessity[28]:

- There is a diagnosis of cystic fibrosis; or
- There is a diagnosis of bronchiectasis that has been confirmed by a high resolution, spiral, or standard CT scan and which is characterized by daily productive cough for at least 6 continuous months and frequent exacerbations requiring antibiotic therapy (2 or more times per year); chronic bronchitis and COPD in the absence of a confirmed diagnosis of bronchiectasis do not meet this criterion; or
- The beneficiary has one of the following neuromuscular disease diagnoses: post-polio; acid maltase deficiency; anterior horn cell diseases; multiple sclerosis; quadriplegia; hereditary muscular dystrophy; myotonic disorders; other myopathies; or paralysis of the diaphragm; and
- There must be well-documented failure of standard treatments to adequately mobilize retained secretions.
- It is not reasonable and necessary for a beneficiary to use both a HFCWO device and a mechanical in-exsufflation device.
- Replacement supplies, HCPCS A7025 and A7026, used with beneficiary owned equipment, are covered if the beneficiary meets the criteria listed above for the base device, HCPCS E0483. If these criteria are not met, the claim will be denied as not reasonable and necessary.

Private Payers

Aetna updated its policy for HFCWO devices in March 2021 and anticipates re-review in January 2022. This policy provides the following criteria for medical necessity[29]:

- Patient has a well-documented failure of standard treatments to adequately mobilize retained secretions; and
- Patient has been diagnosed with bronchiectasis confirmed by CT scan, characterized by daily productive cough for at least 6 continuous months or by frequent (i.e., more than 2 times per year) exacerbations requiring antibiotic therapy; or
- Patient has been diagnosed with cystic fibrosis or immotile cilia syndrome; or
- Patient has been diagnosed with 1 of the following neuromuscular diseases: acid maltase deficiency; anterior horn cell diseases, including amyotrophic lateral sclerosis; hereditary muscular dystrophy; multiple sclerosis; myotonic disorders; other myopathies; paralysis of the diaphragm; post-polio; or quadriplegia regardless of underlying etiology.
- Lung transplant recipients, within the first 6 months post-operatively, who are unable to tolerate standard chest physiotherapy.

- Aetna considers continuous high-frequency chest wall oscillation therapy for the treatment of bronchitis, and secretion-induced atelectasis to be experimental and investigational because there is insufficient evidence of effectiveness.
- Aetna considers high-frequency chest compression systems experimental and investigational for other indications in members who do not meet medical necessity criteria above (e.g., alpha 1antitrypsin deficiency, cerebral palsy, childhood atelectasis, chronic inflammatory demyelinating polyneuropathy, coma, Cri-du-Chat syndrome, individuals with acute pneumonic respiratory failure receiving mechanical ventilation, interstitial lung disease, kyphosis, leukodystrophy, protein alveolar proteinosis, scoliosis, stiff-person (stiff-man) syndrome, and Zellweger syndrome; not an all-inclusive list) because their effectiveness for these indications has not been established.

Cigna updated its policy for HFCWO devices in March 2021 and anticipates reviewing this policy in September 2021. This policy provides the following criteria for medical necessity[30]:

- Patient has been diagnosed with cystic fibrosis and there is a failure, intolerance, or contraindication to home chest physiotherapy, or it cannot be provided; or
- Patient has been diagnosed with bronchiectasis confirmed by high-resolution computed tomography; has daily productive cough for at least 6 months or requires antibiotic treatment of exacerbations 2 or more times per year; and failure of standard treatments (e.g., pharmacotherapy, postural drainage, chest percussion, vibration) to mobilize secretions; or
- Patient has been diagnosed with neuromuscular disease; that disease is characterized by excessive mucus production, infection and difficulty clearing secretions; and there is a failure, intolerance, or contraindication to standard treatment (e.g., pharmacotherapy, postural drainage, daily chest percussion) and standard airway clearance device (e.g., mechanical percussors, positive expiratory pressure device).

Moda updated its policy for HFCWO devices in March 2021, and considers airway oscillating devices, mechanical percussors, positive expiration masks to be medically necessary to assist in mobilizing respiratory tract secretions for patients with cystic fibrosis, chronic bronchitis, bronchiectasis, immotile cilia syndrome, or asthma. Their policy requires prior authorization and provides the following criteria for medical necessity[31]:

- Face-to-face visit with provider within 6 months prior to the request;
- Documentation of failure of standard treatments to adequately mobilize retained secretions;
- Cannot request both HFCWO and mechanical in-exsufflation device; and
- One or more of the following conditions are met:
    - A high resolution, spiral, or standard CT scan documentation of bronchiectasis that is characterized by 1 or more of the following: at least 6 months of daily productive cough, or frequent exacerbations requiring antibiotic therapy (i.e., more than 2 times per year);
    - The patient does not have chronic bronchitis and COPD in the absence of confirmed diagnosis of bronchiectasis
    - Cystic fibrosis or immotile cilia syndrome
    - The patient has one of the following neuromuscular diseases: acid maltase deficiency; anterior horn cell diseases, including amyotrophic lateral sclerosis; hereditary muscular dystrophy; multiple sclerosis; myotonic disorders; other myopathies; paralysis of the

diaphragm; post-polio; quadriplegia regardless of etiology; lung transplant recipients who are unable to tolerate standard chest physiotherapy, and who have submitted a request within the first 6 months post-operatively.

- Indications for which HFCWO is considered investigational include alpha 1-antitrypsin deficiency, childhood atelectasis, cerebral palsy, coma, kyphosis, leukodystrophy, scoliosis, and stiff-person syndrome.

Moda's policy specifically names the following devices but notes that the list is not all-inclusive: Frequencer, SmartVest, MedPulse Respiratory Vest System, The Vest Airway Clearance System, ABI Vest, Respin11 Bronchial Clearance System, and InCourage Vest/System.[31]

Regence BlueCross BlueShield updated their policy for oscillatory devices in July 2020 and anticipates starting a new review for their policy in June 2021. This policy required prior authorization and provides the following criteria for medical necessity for use of HFCWO devices[32]:

- Among patients with cystic fibrosis: demonstrated need for airway clearance and documentation that standard chest physiotherapy has failed, is not tolerated, or cannot be performed. Failure is defined as continued frequent severe exacerbations of respiratory distress.
- Among patients with chronic diffuse bronchiectasis: demonstrated need for airway clearance; documentation that standard chest physiotherapy has failed, is not tolerated, or cannot be performed; and high resolution or spiral chest tomography scan to document bronchiectasis, plus either daily productive cough for at least 6 continuous months, or exacerbations requiring antibiotic therapy 3 or more times per year.
- Among patients with COPD or conditions associated with other neuromuscular disorders, HFCWO devices are considered investigational.

Evidence-based Guidelines and Recommendations

National Institute for Health Care and Excellence (NICE)

The NICE guidelines published in 2017 for the diagnosis, treatment, and management of cystic fibrosis explicitly state that HFCWO devices should not be offered as an airway clearance technique for people with cystic fibrosis except in exceptional clinical circumstances.[33] There is a special cystic fibrosis team that decides when circumstances are exceptional; otherwise, the guidance states that based on published evidence, HFCWO is not as effective as other airway clearance techniques.[33]

We did not identify any NICE guidelines for the diagnosis, treatment, and management of bronchiectasis, COPD, or neuromuscular diseases that explicitly included HFCWO devices in the recommendations sections.

European Respiratory Society

The European Respiratory Society published guidelines in 2017 for the management of adult bronchiectasis from determinations made by a task force comprised of respiratory medicine, microbiology, physiotherapy, thoracic surgery, primary care, and patient advocates.[34] Systematic reviews of published evidence were conducted, reviewed, and debated by this task force during 4 in-person meetings that took place over 21 months, with additional communication by email and teleconference when drafting the final recommendations.[34] Any task force members with conflicts of interest were forced to abstain from all voting activities during the process of developing

recommendations.[34] The guideline recommends that patients with bronchiectasis be taught to use an airway clearance technique 1 to 2 times daily by a trained physiotherapist, as a weak recommendation based on low quality of evidence.[34] HFCWO therapy was one of multiple airway clearance techniques that the task force considered while making this recommendation, but there was no statement of which airway clearance technique might be superior to others.[34] There was a strong recommendation for use of pulmonary rehabilitation in patients with impaired exercise capacity.[34]

European Neuromuscular Centre (ENMC)

ENMC convened a meeting in March 2017 with 21 internationally recognized experts in airway clearance techniques for patients with neuromuscular disorders.[35] Several of the participating experts had received funding, honoraria, or expenses for travel paid for by manufacturers of devices that assist in airway clearance.[35] HFCWO devices were addressed in the review that the experts published after the meeting in the section related to peripheral airway clearance techniques, which also included discussion of intrapulmonary percussive ventilation, manual chest compression, and chest wall strapping.[35] Other sections of the review included information about manually assisted cough, assisted inspiration and expiration, mechanical insufflation-exsufflation.[35] The authors concluded that peripheral airway clearance techniques such as HFCWO therapy may be effective, and should be considered for use in management of chronic lung disease associated with neuromuscular disorders alongside manually assisted cough or other equipment to clear secretions from airways.[35] The authors noted that HFCWO devices are expensive in comparison to other available devices and techniques.[35]

American College of Chest Physicians

The American College of Chest Physicians published an expert panel report in 2018 on treating cough due to non–cystic fibrosis bronchiectasis and cystic fibrosis bronchiectasis with nonpharmacological airway clearance after conducting a systematic review of published evidence.[36] The authors were unable to make recommendations due to insufficient evidence, but provided the following consensus-based suggestions[36]:

- For children and adults with productive cough due to bronchiectasis related to any cause, we suggest that they be taught airway clearance techniques by professionals with advanced training in airway clearance techniques.
- For children and adults with productive cough due to bronchiectasis related to any cause, we suggest that the frequency of airway clearance should be determined by disease severity and amount of secretions.
- For children and adults with productive cough due to bronchiectasis related to any cause, we suggest that airway clearance techniques are individualized as there are many different techniques.

American Association for Respiratory Care (AARC)

AARC published clinical practice guidelines about the effectiveness of nonpharmacologic airway clearance therapies in hospitalized patients with impaired secretion clearance, based on a systematic review of published studies.[37] The guidelines provided focused recommendations for adult and pediatric patients without cystic fibrosis; adult and pediatric patients with neuromuscular disease, respiratory muscle weakness, or impaired cough; and postoperative adult and pediatric patients.[37] These guidelines note that HFCWO was not recommended for adult and pediatric patients with neuromuscular disease,

respiratory muscle weakness, or impaired cough, due to insufficient evidence.[37] Airway clearance techniques were not recommended for routine treatment of COPD or post-operative care.[37] The authors propose the following process questions when considering the use of airway clearance techniques in these populations[37]:

- Does the patient have difficulty clearing airway secretions? Are retained secretions affecting gas exchange or lung mechanics? Focus on patient's level of difficulty for mobilizing and expectorating secretions.
- Which therapy is likely to provide the greatest benefit with the least harm?
- What is the cost of the therapy in terms of the device cost and clinician time to apply or supervise the therapy? The authors note that this is especially relevant for devices or therapies to be used at home.
- What factors are important to the patient about performing airway clearance therapy? This is an important consideration, given the lack of high-quality evidence that any one technique is more effective than other techniques.

Recommendations and Guidelines from Professional Societies

American Thoracic Society

The American Thoracic Society published a clinical practice guideline in 2011 for the diagnosis and management of stable COPD in partnership with the American College of Physician, American College of Chest Physicians, and European Respiratory Society.[38] This guideline did not consider oscillation devices as part of standard management of COPD.[38]

Recommendations from Advocacy Organizations

American Lung Association

The American Lung Association does not list HFCWO devices as part of the management and treatment of cystic fibrosis, bronchiectasis, or COPD.[39-41]

Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation promotes the use of clinical practice guidelines from a systematic review of the evidence that the foundation commissioned in 2009 to compare airway clearance techniques and devices.[42] The review concluded that airway clearance should be part of managing cystic fibrosis to maintain lung function and improve quality of life, and assessed that this could provide a moderate net benefit based on fair quality body of evidence.[43] No airway clearance technique or device was found to be superior to others, and the authors recommended that airway clearance technique be individualized to the patient in consideration of age, preference, and history of adverse events.[43]

References

1. Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. *Ann Med.* 2006;38(2):116-125. doi: 10.1080/07853890600585795.
2. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease (COPD). 2021; https://www.cdc.gov/copd/index.html. Accessed May 3, 2021.
3. Centers for Disease Control and Prevention. Cystic fibrosis. 2021; https://www.cdc.gov/genomics/disease/cystic_fibrosis.htm. Accessed May 3, 2021.
4. Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. *Chron Respir Dis.* 2017;14(4):377-384. doi: 10.1177/1479972317709649.
5. Konstan M, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. *Pediatr Pulmonol.* 1997;24(2):137-142.
6. Morrison L, Milroy S. Oscillating devices for airway clearance in people with cystic fibrosis. *The Cochrane database of systematic reviews.* 2020;4:CD006842. doi: https://dx.doi.org/10.1002/14651858.CD006842.pub5.
7. Dymedso. Frequencer. 2021; https://dymedso.com/frequencer/. Accessed April 21, 2021.
8. US Food and Drug Administration. Dymedso Frequencer V2 and Frequencer V2x airway clearance device. 2011; https://www.accessdata.fda.gov/cdrh_docs/pdf10/K103176.pdf. Accessed April 22, 2021.
9. Electromed Inc. The smart shoice for HFCWO therapy. 2021; https://smartvest.com/smart-choice-for-hfcwo-therapy/?gclid=EAIaIQobChMIz92Cqb-K7gIV2zizAB01yAGgEAAYASAAEgJoaPD_BwE. Accessed April 21, 2021.
10. US Food and Drug Administration. Special 510(k) summary. 2013; https://www.accessdata.fda.gov/cdrh_docs/pdf13/K132794.pdf. Accessed April 22, 2021.
11. Hill-Rom Inc. The Vest airway clearance system, model 105. 2021. Accessed April 21, 2021.
12. US Food and Drug Administration. 510(k) summary of safety and effetiveness. 2013; https://www.accessdata.fda.gov/cdrh_docs/pdf12/K122480.pdf. Accessed April 22, 2021.
13. respInnovation. RespIn 11 bronical clearance system. 2021; http://respin11.com/index.php/respin/respin-11. Accessed April 21, 2021.
14. US Food and Drug Administration. Premarket notification 510(k). 2012; https://www.accessdata.fda.gov/cdrh_docs/pdf12/K121170.pdf. Accessed April 22, 2021.
15. Philips, RespirTech. InCourage system airway clearance device. 2021; https://www.usa.philips.com/healthcare/product/HC500055/incourage-system-airway-clearance-device. Accessed April 22, 2021.
16. US Food and Drug Administration. 510(k) summary of safety and effectiveness. 2005; https://www.accessdata.fda.gov/cdrh_docs/pdf5/K051383.pdf. Accessed April 22, 2021.
17. International Biophysics Corportation. AffloVest mobile mechanial HFCWO vest therapy. 2020; https://www.afflovest.com/. Accessed Aprik 22, 2021.
18. Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. *Cochrane Database Syst Revs.* 2015(11):CD008351. doi: 10.1002/14651858.CD008351.pub3.
19. Nicolini A, Grecchi B, Banfi P. Effectiveness of two high frequency chest wall oscillation techniques in patients with bronchiectasis: a randomized controlled preliminary study. *Panminerva Med.* 2020. doi: 10.23736/S0031-0808.20.03735-0.
20. Nicolini A, Grecchi B, Ferrari-Bravo M, Barlascini C. Safety and effectiveness of the high-frequency chest wall oscillation vs intrapulmonary percussive ventilation in patients with severe COPD. *International journal of chronic obstructive pulmonary disease.* 2018;13:617-625. doi: 10.2147/COPD.S145440.

21. Lange DJ, Lechtzin N, Davey C, et al. High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial. *Neurology.* 2006;67(6):991-997.
22. Clinical Trials Registry. Clinical effectiveness of high frequency chest wall oscillation (HFCWO) in a bronchiectasis population. 2021; https://clinicaltrials.gov/ct2/show/NCT04271969. Accessed April 23, 2021.
23. Nicolini A, Cardini F, Landucci N, Lanata S, Ferrari-Bravo M, Barlascini C. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. *BMC Pulm Med.* 2013;13:21. doi: 10.1186/1471-2466-13-21.
24. McIlwaine MP, Alarie N, Davidson GF, et al. Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. *Thorax.* 2013;68(8):746-751. doi: 10.1136/thoraxjnl-2012-202915.
25. Clinical Trials Registry. A pilot study to evaluate the use of the Vest system for treatment of bronchiectasis patients in the home setting. 2020; https://clinicaltrials.gov/ct2/show/NCT04017312. Accessed April 23, 2021.
26. Washington Apple Health (Medicaid). Respiratory care billing guide. 2019; https://www.hca.wa.gov/assets/billers-and-providers/Respiratory-care-bi-20190101.pdf.
27. Washington Health Care Authority. Provider billing guides and fee schedules. 2021; https://www.hca.wa.gov/billers-providers-partners/prior-authorization-claims-and-billing/provider-billing-guides-and-fee-schedules. Accessed April 30, 2021.
28. Centers for Medicare & Medicaid Services. Local coverage determination: high frequency chest wall oscillation devices (L33785). 2020; https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33785. Accessed Arpil 22, 2021.
29. Aetna. Chest physiotheray and airway clearance devices. 2021; http://www.aetna.com/cpb/medical/data/1_99/0067.html. Accessed April 22, 2021.
30. Cigna. Airway clearance devices in the ambulatory setting. 2021; https://chk.static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_Future/mm_0069_coveragepositioncriteria_airway_clearance_devices.pdf. Accessed April 22, 2021.
31. Moda. High frequency chest wall oscillation devices (HFCWO). 2021; https://www.modahealth.com/pdfs/med_criteria/HighFrequencyChestWallOscillationDevices.pdf. Accessed April 22, 2021.
32. Regence BlueCross BlueShield. Oscillatory devices for the treatment of cystic fibrosis and other respiratory conditions. 2020; http://blue.regence.com/trgmedpol/dme/dme45.pdf. Accessed April 22, 2021.
33. National Institute for Health and Care Excellence. Cystic fibrosis: diagnosis and management NG78. 2017; https://www.nice.org.uk/guidance/ng78/chapter/Recommendations#pulmonary-monitoring-assessment-and-management. Accessed April 30, 2021.
34. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. *Eur Respir J.* 2017;50(3). doi: 10.1183/13993003.00629-2017.
35. Chatwin M, Toussaint M, Goncalves MR, et al. Airway clearance techniques in neuromuscular disorders: a state of the art review. *Respir Med.* 2018;136:98-110. doi: 10.1016/j.rmed.2018.01.012.
36. Hill AT, Barker AF, Bolser DC, et al. Treating cough due to non-CF and CF bronchiectasis with nonpharmacological airway clearance: CHEST expert panel report. *Chest.* 2018;153(4):986-993. doi: 10.1016/j.chest.2018.01.014.
37. Strickland SL, Rubin BK, Drescher GS, et al. AARC clinical practice guideline: effectiveness of nonpharmacologic airway clearance therapies in hospitalized patients. *Respir Care.* 2013;58(12):2187-2193. doi: 10.4187/respcare.02925.

38. Qaseem A, Wilt T, Weinberger S, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Ann Intern Med.* 2011;155:179-191. doi: 10.7326/0003-4819-155-3-201108020-00008.
39. American Lung Association. Treating COPD. 2021; https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treating. Accessed April 30, 2021.
40. American Lung Association. Treating and managing bronchiectasis. 2021; https://www.lung.org/lung-health-diseases/lung-disease-lookup/bronchiectasis/treating-and-managing. Accessed April 30, 2021.
41. American Lung Association. Treating and managing cystic fibrosis. 2021; https://www.lung.org/lung-health-diseases/lung-disease-lookup/cystic-fibrosis/treating-and-managing. Accessed April 30, 2021.
42. O'Conner M, O'Sullivan B, Cystic Fibrosis Foundation. Cystic fibrosis airway clearance therapies clinical care guidelines. 2019; https://www.cff.org/Care/Clinical-Care-Guidelines/Respiratory-Clinical-Care-Guidelines/CF-Airway-Clearance-Therapies-Clinical-Care-Guidelines/. Accessed April 19, 2021.
43. Flume PA, Robinson KA, O'Sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522-537.
44. Yuan N, Kane P, Shelton K, Matel J, Becker BC, Moss RB. Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial. *J Child Neurol*. 2010;25(7):815-821. doi: https://dx.doi.org/10.1177/0883073809350223.

Suggested citation: Godlewski B, Durbin S, King VJ, & Smits A, Walker E, Gingerich J. *Coverage guidance: high-frequency chest wall oscillation devices*. Portland, OR: Center for Evidence-based Policy, Oregon Health & Science University; 2022.

Appendix A. GRADE Table Element Descriptions

Element	Description
Balance of benefits and harms	The larger the difference between the desirable and undesirable effects, the higher the likelihood that a strong recommendation is warranted. An estimate that is not statistically significant or has a confidence interval crossing a predetermined clinical decision threshold will be downgraded.
Quality of evidence	The higher the quality of evidence, the higher the likelihood that a strong recommendation is warranted
Resource allocation	The higher the costs of an intervention—that is, the greater the resources consumed in the absence of likely cost offsets—the lower the likelihood that a strong recommendation is warranted
Values and preferences	The more values and preferences vary, or the greater the uncertainty in values and preferences, the higher the likelihood that a weak recommendation is warranted
Other considerations	Other considerations include issues about the implementation and operationalization of the technology or intervention in health systems and practices within Oregon.

Strong recommendation

In Favor: The subcommittee concludes that the desirable effects of adherence to a recommendation outweigh the undesirable effects, considering the balance of benefits and harms, resource allocation, values and preferences and other factors.

Against: The subcommittee concludes that the undesirable effects of adherence to a recommendation outweigh the desirable effects, considering the balance of benefits and harms, resource allocation, values and preferences and other factors.

Weak recommendation

In Favor: The subcommittee concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, considering the balance of benefits and harms, resource allocation, values and preferences and other factors., but further research or additional information could lead to a different conclusion.

Against: The subcommittee concludes that the undesirable effects of adherence to a recommendation probably outweigh the desirable effects, considering the balance of benefits and harms, cost and resource allocation, and values and preferences, but further research or additional information could lead to a different conclusion.

Confidence in estimate rating across studies for the intervention/outcome

Assessment of confidence in estimate includes factors such as risk of bias, precision, directness, consistency and publication bias.

High: The subcommittee is very confident that the true effect lies close to that of the estimate of the effect. Typical sets of studies are RCTs with few or no limitations and the estimate of effect is likely stable.

Moderate: The subcommittee is moderately confident in the estimate of effect: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Typical sets of studies are RCTs with some limitations or well-performed nonrandomized studies with additional strengths that guard against potential bias and have large estimates of effects.

Low: The subcommittee's confidence in the estimate of effect is limited: The true effect may be substantially different from the estimate of the effect. Typical sets of studies are RCTs with serious limitations or nonrandomized studies without special strengths.

Very low: The subcommittee has very little confidence in the estimate of effect: The true effect is likely to be substantially different from the estimate of effect. Typical sets of studies are nonrandomized studies with serious limitations or inconsistent results across studies.

Appendix B. GRADE Evidence Profile

Certainty Assessment (Confidence in Estimate of Effect) for Cystic Fibrosis							
No. of Studies	**Study Design(s)**	**Risk of Bias**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other Factors**	**Certainty**
Hospitalizations							
1	RCT	Serious	Not serious	Serious	Serious	Small samples, short follow-up	Very low ●○○○
Mortality							
0							
Pulmonary Exacerbations Requiring Antibiotics							
3	RCTs	Serious	Not serious	Serious	Serious	Small samples, short follow-up	Very low ●○○○
Exercise Capacity							
0							
Breathlessness or Cough							
0							

Abbreviation. RCT: randomized controlled trial.

Certainty Assessment (Confidence in Estimate of Effect) for Bronchiectasis							
No. of Studies	**Study Design(s)**	**Risk of Bias**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other Factors**	**Certainty**
Hospitalizations							
0							
Mortality							
0							
Pulmonary Exacerbations Requiring Antibiotics							
1	RCT	Serious	Unable to rate (single study)	Not serious	Serious		Very low ●○○○
Exercise Capacity							
0							
Breathlessness or Cough							
1	RCT	Serious	Unable to rate (single study)	Not serious	Serious		Very low ●○○○

Abbreviation. RCT: randomized controlled trial.

Certainty Assessment (Confidence in Estimate of Effect) for COPD							
No. of Studies	**Study Design(s)**	**Risk of Bias**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other Factors**	**Certainty**
Hospitalizations							
0							
Mortality							
0							
Pulmonary Exacerbations Requiring Antibiotics							
0							
Exercise Capacity							
0							
Breathlessness or Cough							
1	RCT	Moderate	Unable to rate (single study)	Serious	Serious	Short intervention period and follow-up	Very low ●○○○

Abbreviation. RCT: randomized controlled trial.

Certainty Assessment (Confidence in Estimate of Effect) for Pulmonary Complications from Neuromuscular Disease Resulting in Chronic Lung Disease							
No. of Studies	**Study Design(s)**	**Risk of Bias**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other Factors**	**Certainty**
Hospitalizations							
0							
Mortality							
0							
Pulmonary Exacerbations Requiring Antibiotics							
0							
Exercise Capacity							
0							
Breathlessness or Cough							
1	RCT	Serious	Unable to rate (single study)	Serious	Serious	Small sample, short follow-up	Very low ●○○○

Abbreviation. RCT: randomized controlled trial.

Appendix C. Methods

Scope Statement

Populations

Children and adults with cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disorder, or pulmonary complications from neuromuscular disease resulting in chronic lung disease

Population scoping notes: Patients without any of the above conditions are excluded.

Interventions

High-frequency chest wall oscillation devices approved for use in the US

Intervention exclusions: None

Comparators

Home physiotherapy, mechanical percussors, positive expiratory pressure masks, airway clearance devices (e.g., oscillating devices, intrapulmonary percussive ventilation), or other types of high-frequency chest wall oscillation devices not approved for use in the US

Outcomes

Critical: Hospitalizations, mortality

Important: Frequency of pulmonary exacerbations requiring antibiotics, changes in exercise capacity, symptoms of breathlessness or cough

Considered but not selected for GRADE Table: Sputum volume or weight, forced expiratory volume, forced vital capacity, total lung capacity

Key Questions

KQ1: What is the comparative effectiveness of high-frequency chest wall oscillation devices?

KQ2: Does the comparative effectiveness of high-frequency chest wall oscillation devices vary by:

a. Disease type

b. Patient characteristics

c. Device characteristics

KQ3: What are the harms of high-frequency chest wall oscillation devices?

KQ4: What is the comparative cost effectiveness of high-frequency chest wall oscillation devices?

Contextual Questions

CQ1: What resources are required to use the interventions and comparators?

Search Strategy

A full search of the core sources was conducted to identify systematic reviews, meta-analyses, and technology assessments that meet the criteria for the scope described above. Searches of core sources were limited to citations published after 2015.

The following core sources were searched:

Agency for Healthcare Research and Quality (AHRQ)
Canadian Agency for Drugs and Technologies in Health (CADTH)
Cochrane Library (Wiley Online Library)
Institute for Clinical and Economic Review (ICER)
Medicaid Evidence-based Decisions Project (MED)
National Institute for Health and Care Excellence (NICE)
Tufts Cost-effectiveness Analysis Registry
Veterans Administration Evidence-based Synthesis Program (ESP)
Washington State Health Technology Assessment Program

An Ovid MEDLINE® search was also conducted to identify systematic reviews, meta-analyses, and technology assessments, using the search terms *chest wall oscillation, high frequency chest wall oscillation, high frequency Chest wall compression, Frequencer, SmartVest, MedPulse Respiratory Vest, Vest Airway Clearance System, ABI Vest, Respin11, bronchial clearance, InCourage Vest,* and *Afflovest*. The search was limited to publications in English published since 2015. In addition, a MEDLINE® search was conducted for randomized controlled trials published after the search dates of the identified systematic reviews for cystic fibrosis and bronchiectasis. An additional search for randomized controlled trials published since 2006 was conducted for chronic obstructive pulmonary disorder and neuromuscular diseases with pulmonary complications leading to chronic lung disease, because no systematic reviews were identified for these populations. The searches were limited to publications in English.

Searches for clinical practice guidelines were limited to those published since 2015. A search for relevant clinical practice guidelines was also conducted using MEDLINE® and the following sources:

Australian Government National Health and Medical Research Council (NHMRC)
Canadian Agency for Drugs and Technologies in Health (CADTH)
Centers for Disease Control and Prevention (CDC), Community Preventive Services
National Institute for Health and Care Excellence (NICE)
Scottish Intercollegiate Guidelines Network (SIGN)
United States Preventive Services Task Force (USPSTF)
Veterans Administration/Department of Defense (VA/DoD) Clinical Practice Guidelines

Inclusion/Exclusion Criteria

Studies were excluded if they were not published in English, did not address the scope statement, or were study designs other than systematic reviews, meta-analyses, technology assessments, randomized controlled trials, or clinical practice guidelines.

Appendix D. Applicable Codes

HCPCS	
A7025	High frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each
A7026	High frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each
E0467	Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions
E0480	Percussor, electric or pneumatic, home model
E0481	Intrapulmonary percussive ventilation system and related accessories
E0482	Cough stimulating device, alternating positive and negative airway pressure
E0483	High frequency chest wall oscillation system, includes all accessories and supplies, each
E0484	Oscillatory positive expiratory pressure device, non-electric, any type, each
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk
E0657	Segmental pneumatic appliance for use with pneumatic compressor, chest
CPT	
94669	Mechanical chest wall oscillation to facilitate lung function, per session
ICD-10-CM	
B91	Sequelae of poliomyelitis
D81.810	Biotinidase deficiency
D84.1	Defects in the complement system
E84	Cystic fibrosis
G12	Spinal muscular atrophy and related syndromes
G14	Post-polio syndrome
G35	Multiple sclerosis
G71.0-G71.1	Primary disorders of muscles
G72	Other and unspecified myopathies
G73.7	Myopathy in diseases classified elsewhere
G82.5	Quadriplegia
G95	Syringomyelia and syringobulbia
J44	Chronic obstructive pulmonary disease
J47	Bronchiectasis
J98.6	Disorders of diaphragm
M33	Dermatopolymyositis
M34.82	Systemic sclerosis with myopathy
M35.03	Sicca syndrome with myopathy
Q33.4	Congenital bronchiectasis

Note. Inclusion on this list does not guarantee coverage.

Coverage Guidance – High-Frequency Chest Wall Oscillation Devices

Question: How should the Coverage Guidance *High-Frequency Chest Wall Oscillation Devices* be applied to the Prioritized List?

Question source: EbGS

Issue: EbGS re-assessed and modified a coverage guidance regarding High-Frequency Chest Wall Oscillation Devices at their June 2, 2022 meeting. The "blue box" wording was modified at that meeting. Base don previous discussion at VBBS and HERC, the December 2021 "blue box" wording was modified to remove coverage for non-cystic fibrosis bronchiectasis based on the low level of supporting evidence. Based on expert comment and testimony, EbGS has proposed re-adding coverage for non-cystic fibrosis bronchiectasis in certain clinical situations.

HERC Coverage Guidance

High-frequency chest wall oscillation devices are recommended for coverage for patients with cystic fibrosis (*weak recommendation)* when there is documentation of frequent exacerbations requiring antibiotics, frequent hospitalization, or rapidly declining lung function measured by spirometry, despite either:

A) having received chest physiotherapy and positive expiratory pressure therapy, OR
B) documentation that chest physiotherapy and positive expiratory pressure devices are not tolerated or not available (e.g., inability of a caregiver to perform chest physiotherapy).

High-frequency chest wall oscillation devices are recommended for coverage for patients with non–cystic fibrosis bronchiectasis (weak recommendation) when the 4 criteria below are met:

A) The bronchiectasis is confirmed by computed tomography (CT) scan, *AND*
B) The patient has experienced either:
    1) Daily productive cough for at least 6 continuous months, *OR*
    2) Frequent (> 2 times a year) exacerbations requiring antibiotic therapy, *AND*
C) The patient has received chest physiotherapy and positive expiratory pressure therapy OR such therapies are not tolerated, contraindicated, not effective, or not available (for example, inability of a caregiver to perform chest physiotherapy).

High-frequency chest wall oscillation devices are recommended for coverage for patients with neuromuscular disease resulting in chronic lung disease (*weak recommendation)* when there is evidence of chronic lung infection, despite either:

A) having received chest physiotherapy and positive expiratory pressure therapy, OR
B) documentation that chest physiotherapy and positive expiratory pressure devices are not tolerated, contraindicated, or not available (e.g., inability of a caregiver to perform chest physiotherapy).

High-frequency chest wall oscillation devices are not recommended for coverage for patients with chronic obstructive pulmonary disease *(weak recommendation)*.

Current Prioritized List status

HCPCS		**Placement**
A7025	High frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each	Never reviewed
A7026	High frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each	Never reviewed
E0483	High frequency chest wall oscillation system, includes all accessories and supplies, each	Never reviewed
CPT		**Placement**
94669	Mechanical chest wall oscillation to facilitate lung function, per session	502 CONDITIONS FOR WHICH INTERVENTIONS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS

ICD-10-CM		**Current Placement**
E84	Cystic fibrosis	20 CYSTIC FIBROSIS
J44	Chronic obstructive pulmonary disease	283 CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CHRONIC RESPIRATORY FAILURE
J47	Bronchiectasis	58 BRONCHIECTASIS
Q33.4	Congenital bronchiectasis	197 CONGENITAL LUNG ANOMALIES
various	Various neuromuscular conditions causing breathing issues	71 NEUROLOGICAL DYSFUNCTION IN BREATHING, EATING, SWALLOWING, BOWEL, OR BLADDER CONTROL CAUSED BY CHRONIC CONDITIONS; ATTENTION TO OSTOMIES

HERC staff recommendations:

1) Delete CPT 94669 (Mechanical chest wall oscillation to facilitate lung function, per session) from line 502 CONDITIONS FOR WHICH INTERVENTIONS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS and the associated entry in GN172 as shown below

GUIDELINE NOTE 172, INTERVENTIONS WITH MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS FOR CERTAIN CONDITIONS

Line 502

The following interventions are prioritized on Line 502 CONDITIONS FOR WHICH INTERVENTIONS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS:

Procedure Code	Intervention Description	Rationale	Last Review
~~94669~~	~~Mechanical chest wall oscillation~~	~~More costly than equally effective therapies~~	~~October, 2016~~

2) Add CPT 94669 to lines 20 CYSTIC FIBROSIS, 71 NEUROLOGICAL DYSFUNCTION IN BREATHING, EATING, SWALLOWING, BOWEL, OR BLADDER CONTROL CAUSED BY CHRONIC CONDITIONS; ATTENTION TO OSTOMIES, and 197 CONGENITAL LUNG ANOMALIES
3) Add HCPCS A7025 (High frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each), A7026(High frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each), and E0483 (High frequency chest wall oscillation system, includes all accessories and supplies, each) to lines 20 CYSTIC FIBROSIS, 71 NEUROLOGICAL DYSFUNCTION IN BREATHING, EATING, SWALLOWING, BOWEL, OR BLADDER CONTROL CAUSED BY CHRONIC CONDITIONS; ATTENTION TO OSTOMIES and 197 CONGENITAL LUNG ANOMALIES
4) Add a new guideline to lines 20, 71, and 197 as shown below

GUIDELINE NOTE XXX HIGH-FREQUENCY CHEST WALL OSCILLATION DEVICES

Lines 20, 71, 197

High-frequency chest wall oscillation devices are included on these lines ONLY when:

A) The patient has cystic fibrosis, AND
   1) There is documentation of frequent exacerbations requiring antibiotics, frequent hospitalization, OR rapidly declining lung function measured by spirometry, despite either:
      a) receiving chest physiotherapy and positive expiratory pressure therapy, OR
      b) documentation that chest physiotherapy and positive expiratory pressure devices are not tolerated or not available (e.g., inability of a caregiver to perform chest physiotherapy); OR

B) The patient has non-cystic fibrosis bronchiectasis AND the four criteria below are all met:
   1) The bronchiectasis is confirmed by computed tomography (CT) scan, AND
   2) There is evidence of chronic lung infection, AND
   3) The patient has experienced either:
      a) daily productive cough for at least 6 continuous months, OR
      b) frequent (> 2 times a year) exacerbations requiring antibiotic therapy, AND
   4) The patient has received chest physiotherapy and positive expiratory pressure therapy OR chest physiotherapy and positive expiratory pressure devices are not tolerated, contraindicated, or not available (e.g., inability of a caregiver to perform chest physiotherapy); OR

C) The patient has neuromuscular disease resulting in chronic lung disease when there is evidence of chronic lung infection, despite either:
    1) receiving chest physiotherapy and positive expiratory pressure therapy, OR
    2) documentation that chest physiotherapy and positive expiratory pressure devices are not tolerated, contraindicated, or not available (e.g., inability of a caregiver to perform chest physiotherapy).

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

Table of Contents

Discussion Table

IDs/#s	Summary of Issue	Subcommittee Response
A3, A4, A6, B2–B8, C3–C6, C8	Evidence not included in this review shows effectiveness of HFCWO for COPD, bronchiectasis, neuromuscular disease, and cystic fibrosis.	Most of the data submitted from commenters were not published in peer-reviewed journals (e.g., posters and conference abstracts) or used noncomparative before-after designs. Others did not appropriately include the relevant populations or appropriate outcomes to address the Key Questions. One study did meet inclusion criteria and has since been added to the coverage guidance, but it did not change conclusions.
B1, B2, B9, C3	The state of the evidence for HFCWO therapy is sparse given the rare diseases it treats, lack of consensus on study endpoints, and inability to use blinding. Lower-quality evidence obtained from real-world data (claims databases) shows this therapy is effective and cost-effective. This lower-quality evidence should be considered, and coverage should be recommended for other conditions.	Although observational before-and-after studies (like those submitted by commenters), do appear to show benefit, the study designs do not permit us to determine whether the effect was caused by HFCWO devices; these study designs cannot control for confounding factors. More robust study designs exist, such as the randomized trial, or if that is not feasible, a matched-cohort or interrupted-time-series study. Though a randomized trial would be very challenging for the heterogenous population with neuromuscular disease, it would be feasible for COPD and bronchiectasis, as they are relatively common conditions. Initially, evidence related to non-CF bronchiectasis and neuromuscular conditions supported non-coverage. However, we have revised our recommendation to allow limited coverage based on the potential benefit and expert recommendation to extrapolate evidence from CF to other non-CF bronchiectasis and on pathophysiological reasoning. For neuromuscular conditions, the variety of disease manifestations makes

IDs/#s	Summary of Issue	Subcommittee Response
		the development of a strong evidence base for each condition unlikely. Thus, we have based our recommendation on expert input and the potential to reduce costs associated with hospitalization and chronic airway infection.
A9, C2, D1, D4	Patients prefer the convenience and independence afforded by HFCWO. The availability of HFCWO devices respects patient preferences and offers several practical advantages. Some patients with varying conditions cannot use chest physiotherapy for practical reasons or because of contraindications related to their conditions.	We note patient preferences for convenience and independence in our GRADE tables and the Values and Preferences section in the report. Patient values and preferences are an important part of the rationale for coverage of HFCWO for patients with cystic fibrosis, for which evidence indicates HFCWO is comparably safe and effective to chest physiotherapy.
A5, C3, C7	Medicare, most state Medicaid programs, and most commercial payers provide coverage for cystic fibrosis, neuromuscular disease, and bronchiectasis. HERC should recommend coverage for patients with these conditions for whom other therapies are ineffective or contraindicated.	The report describes coverage for Medicare, Washington's Medicaid program, and selected payers active in Oregon (e.g., Aetna, Moda, Cigna, and BlueCross BlueShield of Oregon). These payers do cover HFCWO device therapy for cystic fibrosis and bronchiectasis, as well as for certain neuromuscular disorders. However, the subcommittee views other payer policies as contextual information rather than evidence of effectiveness. Step therapy is an appropriate utilization management tool for facilitating limited access to higher-cost services. However, even second-line covered services need to have sufficient evidence of effectiveness for improving critical or important outcomes.
D1–D5	Description of personal experience with a child with Rett's Syndrome and knowledge of other families whose children use the devices and are part of the Children's In-Home Intensive Waiver program.	Personal experiences, including reports of variation in provider and health plan decisions and processes, provide important context for the subcommittee's decisions. HERC's coverage decisions are made at the population level based on available evidence, informed by testimony and expert opinion. These decisions are intended primarily for health plans, including the Oregon Health Plan. The Children's In-Home Intensive Waiver program is not a health plan, and recommendations for that program are outside the scope of this report and outside the purview of the HERC.

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

Commenters

Identification	Stakeholder
A	David Chandler, Senior Director of Payer Relations at American Association for Homecare *[Submitted July 2, 2021]*
B	Gary Hansen, Director of Scientific Affairs at RespirTech *[Submitted June 29, 2021]*
C	Kari Roehrich, Executive Director Managed Care Market Access at Hillrom Respiratory Health *[Submitted July 1, 2021]*
D	Joey Razzano, Oregon Representative for the International Rett Syndrome Foundation, NW Rett Syndrome Association Board member, and mother to child with Rett Syndrome *[Submitted July 5, 2021]*

Public Comments

ID/#	Comment	Disposition
A1	Dear Committee Members, The American Association for Homecare ("AAHomecare") includes a cross section of durable medical equipment ("DME") suppliers, manufacturers, and other stakeholders that furnish DME to acute patients and chronically ill individuals. AAHomecare's members are proud to be part of the continuum of care that assures that individuals receive cost-effective medical equipment and supplies, and related services, in their homes. AAHomecare supports high frequency chest wall oscillation (HFCWO) coverage for patients with airway clearance needs and appreciates the opportunity to comment on the Evidence-based Guidance Subcommittee coverage recommendations for HFCWO. HFCWO is an airway clearance therapy that healthcare professionals have long-used to treat patients with impaired mucociliary clearance and mucus hypersecretion – specifically for the clinical management of cystic fibrosis, neuromuscular disease (NMD), bronchiectasis, and chronic obstructive pulmonary disease (COPD). Due to the lack of coverage criteria and fee schedule for HFCWO in Oregon Medicaid's Durable Medical Equipment (DME), Prosthetics, Orthotics and Supplies	*Thank you for your comments. We have written specific responses to individual sections of your letter in the rows that follow.*

ID/#	Comment	Disposition
	Administrative Rulebook and corresponding fee schedule, there may be access issues for patients with airway clearance concerns. AAHomecare strongly supports the subcommittee's guidance to recommend HFCWO coverage for patients with cystic fibrosis (CF) and urges the committee to consider HFCWO coverage for patients with NMD, bronchiectasis and COPD for the following reasons:	
A2	1) HFCWO therapy is an established technology that has served chronic respiratory patients for decades and is considered the standard of care for cystic fibrosis patients with an estimated 76% of the US CF population using the therapy for airway clearance, according to the 2019 CF Foundation Patient Registry Annual Data Report.	*Our background section acknowledges HFCWO device therapy is a commonly used treatment option for cystic fibrosis.*
A3	2) Respiratory complications are the leading cause of morbidity and mortality for patients with NMD, and HFCWO has been shown to reduce these complications. Some NMD patients are not able to tolerate manual CPT or be put in all of the required positions to receive the treatment.	*Our review found insufficient evidence that HFCWO device therapy reduces exacerbations and hospitalizations for conditions other than cystic fibrosis.*
A4	3) For patients with non-cystic fibrosis bronchiectasis, HFCWO therapy reduces the frequency of acute exacerbations, hospitalizations, antibiotic use and costs.	*For bronchiectasis, our review found very-low-confidence evidence that HFCWO device therapy improves key outcomes.*
A5	4) Medicare, most state Medicaid programs, and nearly all commercial payers, provide HFCWO coverage for CF, NMD and bronchiectasis patients.	*Our policy is to report coverage for Medicare, Washington's Medicaid program, and selected payers active in Oregon (e.g., Aetna, Moda, Cigna, and BlueCross BlueShield of Oregon). These payers do cover HFCWO device therapy for cystic fibrosis and bronchiectasis as well as for certain neuromuscular disorders.*
A6	5) For COPD, airway clearance devices reduce exacerbations and hospitalizations. According to a recent meta-analysis across 18 studies of airway clearance devices, future exacerbations were reduced by 50%. In addition, analysis of real-world data	*We identified the meta-analysis that you refer to (Daynes et al., 2021). The single included study of HFCWO devices that reported exacerbations for patients with COPD in this*

ID/#	Comment	Disposition
	from the Optum claims database found that respiratory-related hospitalizations were reduced by 17% with the application of vest therapy. All-cause hospitalizations were reduced by 40%, ER visits by 27%, and office visits by 12% during the same time in a 2017 study using the Truven MarketScan database.	*meta-analysis was included and summarized in the coverage guidance. The other 17 studies included in this meta-analysis did not report exacerbations for patients with COPD in studies testing the effectiveness of HFCWO devices.* *The 2 other studies that you refer to (Berry et al., 2019; McEvoy et al., 2020) do not meet the study design requirement of the scope of this coverage guidance, as they were retrospective registry studies which additional devices and a broader set of disease entities than was included in this review. The analysis of claims from the Optum database was published as a poster (McEvoy et al., 2020), and is ineligible for inclusion.*
A7	6) Coverage criteria can ensure appropriate utilization by requiring patients to either try and fail other airway clearance therapies or have the therapy be contra-indicated by the patient's prescriber.	*Step therapy is an appropriate coverage tool for enabling access to higher-cost services. However, even second-line covered services need to have sufficient evidence of effectiveness for improving critical or important outcomes.*
A8	7) It is in the best interest of the patient to give physicians access to all therapies and devices to address specific patient needs.	*Thank you for your comment.*
A9	8) Coverage for HFCWO would respect patient preference, increase adherence to therapy, and provide assurance of reliable and consistent treatment, which would ultimately offset costs through reduced exacerbations and hospitalizations. 9) HFCWO offers practical advantages over other airway clearance approaches. For example, unlike chest physical therapy (e.g. chest physiotherapy, which is when a respiratory therapist claps on the chest to loosen mucus from the lungs), HFCWO	*Our review did not look at evidence regarding adherence to therapy and found insufficient evidence that HFCWO device therapy reduces exacerbations and hospitalizations for conditions other than cystic fibrosis. We have noted patient preference for convenience and efficiency in our GRADE table.*

ID/#	Comment	Disposition
	devices make it easier and more efficient to perform chest physical therapy at home without the need for care delivery by a respiratory therapist or caregiver.	*The Values and Preferences section of the coverage guidance details how the lack of trained or willing caregivers can be a barrier to care, as well as how the use of HFCWO device therapy provides independence from caregivers.*
A10	HFCWO reduces respiratory complications for patients with CF, NMD, bronchiectasis and COPD. AAHomecare believes every effort should be made to facilitate access to effective therapies that can improve patient outcomes, reduce hospitalizations, and reduce further burdens to the healthcare system. For these reasons, AAHomecare encourages the committee to provide HFCWO coverage for CF, NMD, bronchiectasis and COPD patient populations. AAHomecare appreciates the opportunity to provide these comments.	*Thank you for your comments.*
B1	To Whom It May Concern: We reviewed the draft guidance for coverage of high-frequency chest wall oscillation (HFCWO) and are pleased with the recommendation for coverage of cystic fibrosis (CF). Thank you for this change and for hearing my testimony at the HERC meeting on June 3. We ask that you reconsider the recommendation for denial of coverage to patients with bronchiectasis (BE), neuromuscular conditions, and COPD in light of real-world evidence that was possibly not considered in the analysis presented. We would first like to comment on the state of evidence for HFCWO therapy. Despite being used for over 20 years, there is a paucity of comparative evidence for any airway clearance technique and a particular paucity of randomized control trials (RCT). There are good reasons for this.	*Thank you for your comments. We have written responses to specific individual sections of your letter in the rows that follow.*

ID/#	Comment	Disposition
	1. HFCWO often treats rare diseases which makes it difficult to recruit cohorts of adequate size. There is little agreement on study endpoints. Prior studies did not identify or control for machine power settings or adherence. 2. Airway clearance studies cannot be blinded, making it impossible to do a double-blind study. HFCWO patients tend to be considerably sicker because of current prescribing habits, making post hoc comparisons between different types of devices difficult to interpret. 3. Lastly, there seems to be little interest among independent researchers on this topic, perhaps because the therapy has been around for so long. These difficulties should be considered when setting expectations for the evidence.	
B2	Here we provide additional evidence about the impact of HFCWO for bronchiectasis, neuromuscular disorders, and COPD that may have been overlooked in the systematic review. This evidence is derived from several objective sources (principally healthcare claims databases) and is complemented by patient-reported outcomes collected in a clinical registry of users of the Philips InCourage System. Collectively, real-world data supports the effectiveness of HFCWO for outcomes such as hospitalization, quality of life, and antibiotic use. We respectfully ask that this evidence be taken into account as you work to finalize the guidance. In 2016, your group expressed enthusiasm about our HFCWO outcomes in bronchiectasis patients and recommended that we publish the results - advice that we followed. We and others have made efforts to address evidence gaps by reporting patient outcomes as well as leveraging external databases of cleared healthcare claims. Collectively, these complementary sources have been published and/or presented at national and international conferences. Based on the data overview provided at the recent HERC meeting, much of this evidence was not considered or shared with the members of the committee.	*Although observational before-and-after studies, such as the real-world studies you refer to, do appear to show benefit, this study design does not permit causal inference, and cannot control for confounding factors. More robust study designs exist, such as the randomized trial or, if that is not feasible, a matched-cohort or interrupted-time-series study.*

ID/#	Comment	Disposition
B3	The RespirTech bronchiectasis registry has been a source of outcomes for our product, the methodology and results appearing in a recent peer-reviewed publication.[4] The results show a reduction in hospitalizations for bronchiectasis patients after the initiation of HFCWO (Figure 1).[4] The authors took specific measures to reduce the risk of bias: (1) registry findings were validated against objective patient chart data, (2) all data were housed and managed by an independent actuarial firm, and (3) all statistics were conducted by a 3d-party biostatistician. While pre-post studies are subject to regression to the mean, these concerns are mitigated by the large sample and the persistent character of the improvement. The data show the response to HFCWO is sustained for up to two years; regression to the mean, if present, would become evident by this point.	*See response to B2 regarding study designs.* *Fundamentally, a before-and-after study may have other limitations in addition to regression toward the mean. In the example of a registry, confounders can include, but are not limited to, the patient characteristics and family context of individuals who have access to HFCWO device therapy, and changes in clinical care aside from the HFCWO device therapy.*
B4	With a larger data set of over 12,000 patients, we extended the results to two years of follow-up, revealing a 72% reduction in hospitalization rate in the two years after initiating vest therapy (Figure 2).[5] Regarding potential cost savings, this works out to be a bit less than one-half of an avoided hospitalization per patient per year. The avoided cost of an expensive inpatient admission compares favorably with the purchase price of the device.	*See response to B2 regarding study designs.*
B5	Real-world evidence from two separate databases of cleared healthcare claims also demonstrates reductions in hospitalization in bronchiectasis patients following initiation of vest therapy. As an example, Weycker showed all-cause hospitalizations were reduced by 33% (n=865 patients).[6] A new study by Basavaraj presented at the 2021 ATS meeting reports that hospitalizations reduced by 73% in year one and by 64% in year two.[7]	*See response to B2 regarding study designs.*
B6	Claims data support the benefits of HFCWO therapy for neuromuscular patients. Analysis of claims data showed a 25% reduction in respiratory-related hospitalizations.[8] In addition, a peer-reviewed publication found a corresponding 20% reduction in inpatient admissions and a 44% reduction in inpatient days.[9]	*Although Lechtzin et al., 2016 is a peer-reviewed publication, the study design was before-after, and the McEvoy et al., 2020 reference cited in this row was presented at a conference and not published in a peer-*

ID/#	Comment	Disposition
		reviewed journal. See response to B2 regarding study design.
B7	Concerning COPD, we bring to your attention a new systematic review and meta-analysis which found that the use of airway clearance devices can improve exacerbation frequency.[10] 18 randomized controlled trials of airway clearance devices for patients with stable COPD were evaluated and reported that using devices to support everyday management reduced future exacerbations by 50%.	*The single included study of HFCWO devices that reported exacerbations for patients with COPD in this meta-analysis was included and summarized in the coverage guidance. The other 17 studies included in this meta-analysis did not report exacerbations for patients with COPD in studies testing the effectiveness of HFCWO devices.*
B8	In terms of hospitalization outcomes from patients with COPD (n=219) within our registry, we found a 54.4% reduction in annualized hospitalization rate for respiratory causes.[11] In addition, a study of Optum claims data found that respiratory-related hospitalization was reduced by 17% in the year after receiving vest therapy.[12] Similarly, a 2017 study using MarketScan data showed that all-cause hospitalization was reduced by 40%.[6]	*All 3 references cited in this row were presented as conference submissions and not published in peer-reviewed journals.*
B9	In summary, this beneficial therapy should be available in the toolkit for physicians in the treatment of patients with bronchiectasis, COPD, and neuromuscular disorders. The difficulties of designing and performing true comparative studies in this area are considerable and the likelihood of new large-scale RCTs being conducted for these disease states is low. However, recent real-world evidence directly addresses critical outcomes identified by this committee. The outcomes for HFCWO have been demonstrated using multiple independent sources. The convergent findings from these studies, specifically as it relates to reducing hospitalizations and improving patient quality of life, should be considered so that this life-altering treatment is available to those who need it.	*Thank you for your comments.* *We reviewed the references that you provided and considered each for inclusion in the coverage guidance. Two references were excluded for not meeting the scope of the coverage guidance (Mikesell et al., 2017; Rubin, 2007). Six references were excluded because they were conference presentations (Barto et al., 2019a; Barto et al., 2019b; Weycker et al., 2017; Basavaraj et al., 2021; McEvoy et al., 2020a; McEvoy et al., 2020b). Three references were excluded due to ineligible study designs (noncomparative observational: Basavaraj et al., 2020; Barto et al., 2020; observational before-after: Lechtzin et al., 2016).*

ID/#	Comment	Disposition
		Your work to address the evidence gaps is helpful and may motivate others to perform more rigorous research on these conditions. However, the subcommittee uses only peer-reviewed studies and generally requires between-group comparison for evidence of treatment effectiveness.
C1	Dear EbGS Committee Members, Hillrom appreciates the opportunity to provide comment on the coverage recommendation for high frequency chest wall oscillation (HFCWO). HFCWO therapy is an established technology that has served chronic respiratory patients for over 30 years. Hillrom strongly supports the EbGS Committee's guidance to recommend HFCWO coverage for patients with cystic fibrosis (CF). Hillrom also requests the committee consider HCFWO coverage for patients with neuromuscular disease (NMD) and bronchiectasis.	*Thank you for your comments. We have written responses to specific individual sections of your comment in the rows that follow.*
C2	HFCWO coverage for patients with CF has expanded across the payer continuum such that at least 45 of the Medicaid fee-for-service plans cover HFCWO for CF beneficiaries. HFCWO is considered standard of care for CF as evidenced by the CF foundation's estimate that 76% of the US CF population uses HFCWO for airway clearance.[1] This is largely attributable to assurance or reliable and consistent treatment, adherence to therapy, and patient preference. Accordingly, providing HFCWO coverage for the CF population would ultimately offset costs through reduced exacerbations and hospitalizations.	*We recognize that HFCWO device therapy is a commonly used treatment option for cystic fibrosis. Though the available evidence shows no difference in hospitalizations compared to chest physiotherapy, we are recommending coverage because of patient preferences and because chest physiotherapy may not be available or feasible for all patients.*
C3	Hillrom strongly encourages the committee also consider coverage for patients with NMD. Respiratory complications are the leading cause of morbidity and mortality for patients with NMD and HFCWO has been shown to reduce these complications. The rationale for the recommendation for coverage for patients with NMD starts that there is no evidence that HFCWO devices improve key outcomes compared to	*No economic studies met our inclusion criteria for this coverage guidance.* *See response to comment A5 regarding other payer coverage.*

ID/#	Comment	Disposition
	standard treatments. Hillrom asserts that sufficient comparative clinical evidence is available that supports the HFCWO therapy on improved key outcomes over standard treatments. Multiple economic outcome studies from highly reputable sources support HFCWO as a cost-saving strategy. Further, including HFCWO coverage for patients with NMD is consistent with Medicare, many Medicaid departments, and an increasing number of commercial payers.	
C4	The Yuan and Landon clinical studies compared the efficacy of HFCWO to chest physiotherapy (CPT). Both studies demonstrated significantly decreased rates of hospitalization for intravenous antibiotics and superior oxygenation for patients using HFCWO as well as superior adherence to the therapy. The investigator-initiated Fitzgerald study demonstrated a 32% reduction in hospitalizations (P<.01) in neurologically impaired children with respiratory symptoms. These studies provide sufficient comparative evidence of the superior benefits of HFCWO over standard treatment for this population.	*The Yuan et al., 2010 reference has been added to the coverage guidance since the submission of this comment. The Landon et al., 2022 reference was excluded because it was a conference abstract. The Fitzgerald et al., 2014 reference reported a before-after study. Although observational before-and-after studies, such as the real-world studies you refer to, do appear to show benefit, this study design does not permit causal inference, and more robust study designs exist, such as the randomized trial or, if that is not feasible, a matched-cohort study.*
C5	In addition, multiple economic outcomes data studies confirm the positive impact of HFCWO therapy on healthcare costs for neuromuscular disorders, which supports the efficacy of HFCWO when compared to standard treatment. Most notable is the 2019 research article published by the National Institute for Health Care Excellence (NICE) which analysed the cost-effectiveness of HFCWO compared to CPT in patients with complex neurological disorders, including neuromuscular disease and cerebral palsy.[5] This analysis revealed that per 1000 patients, the Vest System results in 2,422 less hospitalizations, and 49,868 less bed days compared to CPT, resulting in $8 M in cost savings over a five-year time frame.[5]	*This reference was excluded because the cost effectiveness estimates produced for the health system in the UK are not directly related to cost effectiveness estimates for the health system in the US (Javanbakht et al., 2019). Additionally, this study included information from a before-after study and from the Yuan et al., 2010 study that we have incorporated into the coverage guidance.*

ID/#	Comment	Disposition
C6	Another important economic data study, 2020 Pandya,[6] analysed the claimed of 1008 patients from the Optum healthcare claims repository. The study demonstrated a reduction of respiratory-related hospitalizations by 24.7% ($p<0.005$) in patients receiving HFCWO therapy. Similarly, Lechtzin demonstrated a 41.7% decrease in inpatients costs post intitation of HFCWO.[7] These studies are based on thousands of patient records and clearly show the benefit of HFCWO compared to standard treatment.	*The Pandya et al., 2020 reference was a conference presentation of a before-after study; the other 2 references also utilized a before-after design.*
C7	Additionally, Medicare, most Medicaid departments, and nearly all commercial payers include HFCWO coverage for NMD patients. As of October 1, 2008, all CMS jurisdictions revised the HFCWO Local Coverage Determination to include NMD while over 40 Medicaid departments cover NMD disease state. Consistent with the criteria considerations included in the guidance, payer coverage policies ensure appropriate utilization by requiring patients must either try and fail other airway clearance therapies or have the therapy by contra-indicated by the patient's prescriber.	*See response to comment A5 regarding other payer coverage.*
C8	Hillrom also strongly encourages the committee to approve coverage for patients with non-cystic fibrosis bronchiectasis. In a comparative study, bronchiectasis patients on HFCWO demonstrated superior improvement in dyspnea, pulmonary function tests, and quality of life compared to patients on PEP or CPT.[8] Additional analyses suggest that HFCWO therapy reduces the frequency of acute exacerbations, hospitalizations, antibiotic use and costs in patients with bronchiectasis.[9,10,11,12,13]	*The first reference (Nicolini et al., 2013) is already included in the coverage guidance. The Weycker et al., 2017 and Basavaraj et al., 2021 references are conference abstracts. The remaining 3 references (Barto et al., 2020; Seivert et al., 2018; Sievert et al., 2017) references report studies with noncomparative observational designs. The remaining references are addressed in the previous rows.*
D1	I personally know hundreds of families in the Northwest that have benefited from the use of the HFCWO device aka "The Shaker Vest" when experiencing respiratory distress. The scope of the current coverage guidance is limited to CF and bronchiecstasis. While it refers to other neuromuscular disease resulting in chronic lung disease, Rett Syndrome does not really fall into any of those categories.	*Thank you for your comments and for sharing the story of a patient's care. While individual stories provide context for the Subcommittee's decisions, the Subcommittee makes coverage decisions on a population-level basis and*

ID/#	Comment	Disposition
	Rett Syndrome is like having a child with autism, cerebral palsy, Parkinson's epilepsy and an anxiety disorder all in one. Our daughter also experiences osteoporosis, scoliosis and uses a wheelchair. She is at constant risk for aspiration which can lead to pneumonia literally in a matter of hours. The majority (>80%) of people with Rett Syndrome experience a neurological scoliosis which can require titanium rods to assist with opening the chest cavity. Otherwise, the lung is crushed and tends to fester a chronic infection in one lobe that quickly turns acute. When O2 sats drop, the shaker vest is the first step to increase O2 saturation. In the year before her spinal surgery, [Redacted name] was hospitalized 6 times for pneumonia and this was always the protocol. O2 sats drop, use shaker vest, then on to cough assist, bi-pap, cpap and then trach in that order. If a family has a shaker vest at home, this can often be avoided and it also helps with home care after a hospital stay. During each of these stays the therapists made sure we had this device at home despite having both primary and secondary insurance denying it. We appealed the denial over the course of a year, eventually losing all appeals because this committee has determined that CPT is cost effective and only bronchiecstasis and CF are coverable conditions. We were also at Randall Children's Hospital. My personal experience is that these devices get covered if you go to OHSU but not if you go to Randall. Why the inconsistency? As a parent, the unequal coverage and prescription among hospital systems suggests to me there are magic buzzwords being used that I am not privy to. As a family we were repeatedly assured that we had to go through the appeal and denial process – but that we would be denied eventually due to the current HERC guidance – and that Hill-Rom would gift it to us after that process. That is how I learned that Oregon is the ONLY state that doesn't cover these devices. What is it that 49 other states saw that Oregon does not? At the end of the long and complicated process of applications, appeals and denials, we had to send the device back to the company or pay them	*must base these decisions on evidence and other factors with respect to the population in general.* *Health plans can and sometimes do make individual coverage exceptions for patient circumstances. Appeal and hearing processes are required by law, but outside the Subcommittee's purview.* *The draft coverage guidance recommends coverage for certain patients with cystic fibrosis.* *HERC's coverage decisions are intended primarily for health plans, including the Oregon Health Plan. The Children's In-Home Intensive Waiver program is a separate program, and decisions on which services that program provides are outside the scope of this report.*

ID/#	Comment	Disposition
	$16,000 for the privilege of having it on hand. We made the decision as a family that if her sats drop, we will take her straight to the emergency room because we don't have a shaker vest at home, even though it's the first thing the ER will do after the X-ray confirms diminished breathing in the lower lobes – every single winter….we are just one family on the hundreds of families on the CIIS waivers. Reading this guidance the short version is that: It ONLY covers CF and bronchiectasis and other neuromuscular disease resulting in chronic lung disease. What if you had a MEDICALLY INVOLVED person (as defined by the Children's In Home Intensive Waiver) that resulted in multiple chronic and acute lung and respiratory-related incidents that were not considered 'disease'?	
D2	The current recommendation is "weak" but I find this term vague for a variety of reasons – is it weak because there no empirical evidence or independent analysis on the cost-benefit ratio on the reduction or avoidance of hospitalization? Or is it weak due to the small sample size? IS it weak because the population is limited in scope? Any of those reasons would keep the financial liability limited as well	*According to the subcommittee's methodology (Appendix A), a weak recommendation indicates that "The subcommittee concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, considering the balance of benefits and harms, resource allocation, values and preferences and other factors, but further research or additional information could lead to a different conclusion."* *The factors leading to the recommendation are described in the GRADE table.*
D3	CPT is as cost effective as the shaker vest with similar results and can be done by paid or unpaid caregivers for 20-40 minutes per day multiple times a day – try to do that for even 10 minutes on a girl with a T2-Pelvis titanium rod in her back and see how effective that is! It is exhausting and the CPT provider is in constant fear of injuring the patient.	*We did not identify any cost-effectiveness studies that met our inclusion criteria and also addressed the scope of this coverage guidance with information that is relevant to the US health system.* *See response to comment D1 regarding individual patient circumstances.*

ID/#	Comment	Disposition
	There is not enough evidence because the sample size is too small - but it always will be due to the population making it too small to fall under normal distribution confidence intervals – chicken and egg.	*Evidence is often insufficient, especially for rare conditions, which is why the subcommittee considers public comments and expert testimony, among other factors.*
D4	Evidence showing cost effectiveness has been presented as reduction or avoidance of hospital visits– this committee has disregarded such evidence because it was produced from the manufacturer. Has any analysis been done on any of the population covered by the CIIS waiver? This is the target population that would benefit from this device (even after they turn 18), allowing them to be treated in their home, saving the state money. You could extrapolate what 6 hospitalizations in one year cost the Oregon Health Plan even as secondary provider to determine the cost effectiveness of the shaker vest. I am not including the multiple times that we provided acute care at home during the same time period although there are many. While it would be a sound decision to expand the coverage guidance to people who meet the "medically involved" definition, it would also be financially prudent to cover the shaker vest if the initial expenditure of approximately $16k is less than the cost of even one nights hospitalization which is what the unintended consequence of the current guidance has been. Thank you for your consideration.	*The subcommittee bases decisions regarding effectiveness on peer-reviewed evidence. The Subcommittee does not disregard evidence produced from the manufacturer merely because it was produced by the manufacturer. Registry information from the manufacturers was excluded from the coverage guidance because the way that the information was gathered (a before-after study design) cannot account for competing hypotheses for why individuals using HFCWO device therapy improved or stabilized in terms of symptoms or health care utilization.* *Thank you for your comments.*

References Provided by Commenters

ID	References
A	Excluded from the coverage guidance Berry JG, Goodman DM, Coller RJ, et al. Association of home respiratory equipment and supply use with health care resource utilization in children. *J Pediat*. 2019;207:169-175.e162. doi: 10.1016/j.jpeds.2018.11.046. Daynes E, Jones AW, Greening NJ, Singh SJ. The use of airway clearance devices in the management of chronic obstructive pulmonary disease. A systematic review and meta-analysis of randomized controlled trials. *Ann Am Thorac Soc*. 2021;18(2):308-320. doi: 10.1513/AnnalsATS.202005-482OC McEvoy C, Pandya P, Weycker D, Hanson GL. Outcomes with high-frequency chest wall oscillation among patients with COPD using a large claims database. Presented at: CHEST 2020 Annual Meeting; October 18-21, 2020; Online. P1468.
B	Excluded from the coverage guidance Barto TL, Maselli DJ, Daignault S, et al. Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasis. *Ther Adv Respir Dis*. 2020;14:1753466620932508. (letter reference #4) Barto T, Maselli DJ, Daignault S, Hansen G. Outcomes of high frequency chest wall oscillation (HFCWO) in COPD patients without bronchiectasis. Presented at: CHEST 2019 Annual Meeting; October 19-23, 2019; New Orleans, LA. E1080. (letter reference #11) Barto T, Maselli DJ, Daignault S, Porter J, Kraemer C, Hansen G. Two years of high frequency chest wall oscillation (HFCWO) outcomes in a large registry of non-CF bronchiectasis patients. Presented at: American Thoracic Society Conference; May 21, 2019. (letter reference #5) Basavaraj A, Choate R, Addrizzo-Harris D, et al. Airway clearance techniques in bronchiectasis: analysis from the United States bronchiectasis and non-TB mycobacteria research registry. *CHEST*. 2020;158(4):1376-1384. (letter reference #3) Basavaraj A, Shah D, DeKoven M, et al. A pre-post analysis assessing the 3-year long-term impact of high frequency chest wall oscillation therapy on clinical outcomes, healthcare cost and utilization in adult patients with non-cystic fibrosis bronchiectasis in the US. ATS 2021 Abstract. 2021:A3944. (letter reference #7) Daynes E, Jones AW, Greening NJ, Singh SJ. The use of airway clearance devices in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. *Ann Am Thorac Soc*. 2021;18(2):308-320. doi:10.1513/AnnalsATS.202005-482OC (letter reference #10) Lechtzin N, Wolfe LF, Frick KD. The impact of high-frequency chest wall oscillation on healthcare use in patients with neuromuscular diseases. *Ann Am Thorac Soc.* 2016;13(6):904-909. (letter reference #9) McEvoy C, Pandya P, Weycker D, Hansen G. A Retrospective Real-World Cohort Study Demonstrating the Impact of HFCWO Therapy on Patients with Neuromuscular Disorders. Presented at: CHEST 2020 Annual Meeting; October 18-21, 2020; Online.P1943. (letter reference #8) McEvoy C, Pandya P, Weycker D, Hansen G. Outcomes with high-frequency chest wall oscillation among patients with COPD using a large claims database. Presented at: CHEST 2020 Annual Meeting; October 18-21, 2020; Online. P1468. (letter reference #12) Mikesell CL, Kempainen RR, Laguna TA, et al. Objective measurement of adherence to out-patient airway clearance therapy by high-frequency chest wall compression in cystic fibrosis. *Respir Care*. 2017;62(7):920-927. doi: 10.4187/respcare.05349 (letter reference #2)

ID	References
	Rubin BK. Designing clinical trials to evaluate mucus clearance therapy. *Respir Care*. 2007;52(10):1348-1358; discussion 1358-1361. (letter reference #1) Weycker D, Hansen GL, Seifer FD. Outcomes with high-frequency chest wall oscillation among patients with non-CF bronchiectasis or COPD. Presented at: American Thoracic Society Conference; May 21, 2017. P1122. (letter reference #6)
C	<u>Newly included in the coverage guidance</u> Yuan YN, Kane P, Shelton K, Matel J, Becker BC, Moss RB. Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial, *J. Child Neurol*. 2010;25(7):815–821. (letter reference #2) <u>Already included in coverage guidance</u> Nicolini A, Cardini F, Landucci N, Lanata S, Ferrari-Bravo M, Barlascini C. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. *BMC Pulm Med*. 2013;13:21. doi: 10.1186/1471-2466-13-21. (letter reference #8) <u>Excluded from the coverage guidance</u> Barto TL, Maselli DJ, Daignault S, et al. Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasis. *Ther Adv Respir Dis*. 2020;14:1753466620932508. (letter reference #9) Basavaraj A, Shah D, DeKoven M, et al. A pre-post analysis assessing the 3-year long-term impact of high frequency chest wall oscillation therapy on clinical outcomes, healthcare cost and utilization in adult patients with non-cystic fibrosis bronchiectasis in the US. ATS 2021 Abstract. 2021:A3944. (letter reference #13) CF Foundation Patient Registry Annual Data Report, 2019. (letter reference #1) Fitzgerald K, Dugre J, Pagala S, et al. High-frequency chest wall compression therapy in neurologically impaired children. *Respir Care.* 2014;59(1):107-112. doi: 10.4187/respcare.02446. (letter reference #4) Javanbakht M, Mashayekhi A, Montazeri M, Hemami MR, Branagan-Harris M. The Vest high frequency chest wall oscillation system compared with chest wall physical therapy for managing airway clearance in patients with complex neurological disorders: a UK-based cost-effectiveness analysis. *Open Pharmacoeconomics Health Econ J.* 2019;7:1-8. doi: 10.2174/1874129001907010001. (letter reference #5) Landon C, Goldie W and Evans JR. Airway clearance therapy utilizing high frequency chest wall oscillation (HFCWO) for medically fragile children [Abstract/Poster]. *J Am Med Dir Assoc.* 2002; 3(2):A17. (letter reference #3) Lechtzin N, Wolfe LF, Frick KD. The impact of high-frequency chest wall oscillation on healthcare use in patients with neuromuscular diseases. *Ann Am Thorac Soc.* 2016;13(6):904-909. (letter reference #7) Pandya P, McEvoy C. A retrospective real-world cohort study demonstrating the impact of HFCWO therapy on healthcare costs in patients with neuromuscular disorders. *CHEST.* 2020;156(4Suppl):A2292. doi: 10.1016/j.chest.2020.08.1943

ID	References
	Sievert C, Beaner C. Incidence of bronchiectasis-related exacerbation rates after high frequency chest wall oscillation (HFCWO) treatment — a longitudinal outcome-based study. *Respir Ther*. 2018;13(2):30-33. (letter reference #10) Sievert C, Beaner C. Cost-effective analysis of using high frequency chest wall oscillation (HFCWO) in patients with non-cystic fibrosis bronchiectasis. *Respir Ther*. 2017;12(1):45-49. (letter reference #11) Weycker D, Hansen GL, Seifer FD. Outcomes with high-frequency chest wall oscillation among patients with non-CF bronchiectasis or COPD. Presented at: American Thoracic Society Conference; May 21, 2017. P1122. (letter reference #12) Winfield NR, Barker NJ, Turner ER, Quin GL. Non-pharmaceutical management of respiratory morbidity in children with severe global developmental delay. *Cochrane Database Syst Rev.* 2014;2014(10):CD010382. doi: 10.1002/14651858.CD010382.pub2. (no letter reference number provided)
D	None provided

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

Table of Contents

Discussion Table

IDs/#s	Summary of Issue	Subcommittee Response
A2, C1–C2, C9	Chest physiotherapy and airway clearance devices are not effective for patients with intellectual or developmental disabilities who cannot actively engage with such therapies effectively.	The revised coverage guidance recommendation includes a recommendation for coverage of high-frequency chest wall oscillation (HFCWO) devices for patients for whom chest physiotherapy and positive expiratory pressure device therapy are not tolerated, contraindicated, or not available (e.g., inability of a caregiver to perform).
A3	Some bronchiectasis patients do not have a cough and thus the coverage guidance should remove the daily productive cough as a requirement for HFCWO device therapy	The inclusion of daily productive cough was added as a requirement for HFCWO therapy for patients with non-cystic fibrosis (non-CF) bronchiectasis based on information extrapolated from studies of the cystic fibrosis (CF) population, and as recommended by our appointed ad hoc expert. *For EbGS discussion.*
C3–C4	This coverage guidance should include a list of covered conditions and include Rett Syndrome in that list.	This subcommittee declined to produce a list of covered conditions given the heterogeneity of neuromuscular disorders for whom HFCWO therapy may be effective. Instead, detailed coverage indications ensure that a patient with a very rare disorder may still be eligible for HFCWO therapy provided they meet the criteria.

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

Commenters

Identification	Stakeholder
A	Jenna Kelly, parent/caregiver of a child with non-CF bronchiectasis *[Submitted September 24, 2021]*
B	Sharon Skidmore, PT, DPT Physical Therapy for Kids, LLC *[Submitted September 28, 2021]*
C	Joey Razzano, parent/advocate/caregiver of person experiencing Rett Syndrome, International Rett Syndrome Foundation, NW Rett Syndrome Association *[Submitted October 14, 2021]*

Public Comments

ID/#	Comment	Disposition
A1	Please make the vests affordable for families. My child has non-CF-bronchiectasis. It took me years to pay his off and it was a significant struggle for my family.	*Thank you for your comments. We have written specific responses to individual sections of your letter in the rows that follow.*
A2	He also is Autistic and blowing in the little devices was not feasible. He was too young and not able to use them effectively. Once he started using the vest he improved so incredibly much.	*The revised draft coverage guidance includes a pathway to coverage for HFCWO device therapy if other treatments are not tolerated, available or contraindicated.*
A3	Also, I don't like the cough requirement. My son never coughed. He just had a ton of mucus and couldn't/would not expel it on his own, so he would get infections constantly.	*Based on expert testimony, HFCWO device therapy is most effective among patients with non-CF bronchiectasis who have a daily productive cough.*
A4	By expanding the coverage of devices It will also make it easier to get them serviced and sized.	*Thank you for your comment.*
B1	I agree with coverage as the use of High Frequency Chest Wall Oscillation Devices has shown to be very effective and reduces hospitalization when used correctly and consistently which ultimately leads to better patient care and reduced overall cost.	*Thank you for your comment.*

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

ID/#	Comment	Disposition
C1	I am just a mom and Rett rep who has personally seen ICU's fill every winter with Rett patients in respiratory distress. When determining criteria for when a HFCWO device should be covered, there are a few observations I've made specific to Rett Syndrome - that is the presence of both scoliosis and hypotonia, often including the use of a wheelchair. Rett patients cannot speak and have no functional hand use to indicate difficulty breathing. Most are at risk of constant aspiration as well. The "cycle" is this: a Rett patient aspirates or is exposed to a virus, develops pneumonia, end up in the emergency room at their O2 sats drop and they will be hospitalized. Respiratory therapy is ordered and the HFCWO device is used, often in conjunction with a cough-assist device.	*Thank you for your comments. We have written specific responses to individual sections of your letter in the rows that follow.*
C2	If scoliosis is present, the kiddo will get well enough to recover at home but a dimness or small amount of infection tends to remain in the lower lobe of one or both lungs. Kiddos with low-tone, scoliosis and a wheelchair can never really expand their chest cavity so the HFCWO provides an effective home therapy that can be done safely and in the home to provide lung clearance. It is not typically prescribed before hospitalization but the pulmonologist will often send the device home as part of routine care following an emergency room visit or hospitalization.	*This level of clinical specificity is not included in the studies identified for this review.*
C3	I would suggest Rett Syndrome or similarly complex syndromes be added to the list defined on page 18 in the background section.	*The subcommittee elected to produce detailed coverage criteria instead of producing a list of covered conditions in order that persons with very rare disorders can obtain access to HFCWO therapy provided they meet the criteria.*
C4	I also suggest that this group look at other states' recommendations for coverage in neuromuscular conditions for more definitive criteria.	*Our policy is to report coverage for Medicare, Washington's Medicaid program, and selected payers active in Oregon (e.g., Aetna, BlueCross BlueShield of Oregon, Cigna, and Moda).*

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

ID/#	Comment	Disposition
C5	I also think there should be a return on investment study performed on the neuromuscular population that evaluates the cost of the device versus the expense of a single night in an ICU and I know you will find it is comparatively cheap insurance for this specific population.	*We searched for comparative cost effectiveness studies for this coverage guidance and did not identify any that met our inclusion criteria.* *The subcommittee relies on existing, peer-reviewed published research to make coverage recommendations. It is outside of this group's scope to independently conduct economic studies.*
C6	I also think th4ere's typo on page 24 where it should read CONGENITAL muscular dystrophy under pulmonary complications.	*Thank you for drawing our attention to this typographical error. We have corrected this in the current draft.*
C7	I also wonder if the lungs themselves are considered part of the airway since the wording of the recommendation specifically says "chronic airway infection" - and what defines chronic? My daughter was hospitalized 6 times in one year with pneumonia but we have been able to avoid hospitalization multiple times since then.	*The subcommittee decided against defining "chronic," leaving ability for the exercise of clinical judgment.*
C8	The word CONTRAINDICATED is included in the neuromuscular bronchiecstatis guidance but not the CF guidance. I wonder why they are different.	*We agree and we have updated the wording in both sections.*
C9	The inability of the caregiver to provide chest physiotherapy is an important factor and I am glad to see it included in the criteria for recommendation	*Thank you for your comments.*

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

Table of Contents

Discussion Table

IDs/#s	Summary of Issue Raised by Commenters	Subcommittee Response
A3, A4	Bronchiectasis is a rare disease, resulting in low impact of adding coverage.	Bronchiectasis is not a rare disease, although it is a heterogenous condition. Data for Oregon Health Plan (OHP) claims from 2018-2020 showed claims for nearly 1,500 members which included a diagnosis of bronchiectasis. This number is likely an underestimate to the true bronchiectasis population in Oregon.
A1, A4-A9, B1, C2	The nature of the very low quality evidence for bronchiectasis stems from lack of consensus on study endpoints and other factors, as well as lack of interest among independent researchers, making it difficult to conduct novel research for this population. This lower-quality evidence should be included in this review.	Although observational noncomparative studies (like those submitted by commenters), do appear to show benefit, the study designs do not permit us to determine whether the effect was caused by HFCWO devices; these study designs cannot control for confounding factors and more robust study designs exist. Further, the size of the bronchiectasis population is large enough to feasibly conduct studies.
A2, A10, A11, B8, C3	There is an equity consideration in noncoverage of HFCWO devices, as patients may be located in more rural or economically disadvantaged areas, are from developing countries, have comorbidities, and/or have language or cultural barriers to care.	The subcommittee acknowledges that patients in these groups/areas may have more limited access to care options. These contextual factors will inform subcommittee deliberation. *For EbGS discussion.*

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

IDs/#s	Summary of Issue Raised by Commenters	Subcommittee Response
B2, C1	Expert opinion supports the use of HFCWO in selected patients with bronchiectasis	*For EbGS consideration:* Previous expert opinion-generated "blue box" language is shown below and can be included again if EbGS considers the expert recommendations to be strong enough to justify inclusion. High-frequency chest wall oscillation devices are recommended for coverage for patients with non–cystic fibrosis bronchiectasis (*weak recommendation*) when the 4 criteria below are met: A. The bronchiectasis is confirmed by computed tomography (CT) scan, *AND* B. There is evidence of chronic lung infection, *AND* C. The patient has experienced either: 1. Daily productive cough for at least 6 continuous months, *OR* 2. Frequent (> 2 times a year) exacerbations requiring antibiotic therapy, *AND* D. The patient has received chest physiotherapy and positive expiratory pressure therapy OR chest physiotherapy and positive expiratory pressure devices are not tolerated, contraindicated, or not available (e.g., inability of a caregiver to perform chest physiotherapy).

Commenters

Identification	Stakeholder
A	Gary Hansen, PhD, Director of Scientific Affairs, RespirTech [April 29, 2022]
B	Alan Barker, MD, Professor of Medicine, Pulmonary and Critical Care, Oregon Health & Science University [May 4, 2022]
C	Aaron Trimble, MD, Assistant Professor of Medicine, Pulmonary and Critical Care, Oregon Health & Science University [May 10, 2022]

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

Public Comments

ID/#	Comment	Disposition
A1	We reviewed the revised draft guidance for coverage of high-frequency chest wall oscillation (HFCWO) and are pleased with the recommendation for coverage of cystic fibrosis (CF) and neuromuscular disorders. However, we strongly urge the EbGS and HERC committee to reconsider the recommendation for denial of coverage to the vulnerable and at-risk Oregonian patients with bronchiectasis (BE). Despite the lack of high-quality evidence, HFCWO has become well-established as an important means of airway clearance therapy for this population.	*Thank you for your comments. We have written responses to specific individual sections of your letter in the rows that follow.*
A2	Vest therapy has been clinically shown to be just as effective as other methods of airway clearance and does not depend on the user's skill or effort.[1] This makes the device an important alternative for persons in disadvantaged socio-economic circumstances, or for persons who have not been successful with other methods.	*The publication referenced here presents narrative summaries of published studies but does not include meta-analyses or present any original research findings.*

<table>
<tr><th>ID/#</th><th>Comment</th><th>Disposition</th></tr>
<tr><td>A3</td><td>Accordingly, allow me to address several points raised in the most recent meeting.
There seemed to be some uncertainty about the number of BE patients in the state who are potential users of HFCWO, and a few members suspected that the number was large. We have found it to be otherwise. A recent study reports the prevalence of diagnosed BE in the general population; this may be extrapolated to the Oregonian under-65 population as follows:

<table>
<tr><th>Age Range</th><th>Oregon Population[2]</th><th>BE Prevalence Cases/100,000[3]</th><th>Estimated BE Cases</th></tr>
<tr><td>35 to 44 years</td><td>568,712</td><td>18</td><td>102</td></tr>
<tr><td>45 to 54 years</td><td>510,127</td><td>43</td><td>219</td></tr>
<tr><td>55 to 64 years</td><td>538,950</td><td>122</td><td>658</td></tr>
<tr><td>Total</td><td>1,617,789</td><td>183</td><td>979</td></tr>
</table>

The roughly one-thousand BE cases in Oregon can be further reduced because not all cases require airway clearance and most patients below age 65 have coverage other than Medicaid.[4] A few members suggested that studies for BE are easier to conduct than for CF or neuromuscular conditions. As noted in previous meetings, conducting a randomized controlled trial (RCT) for BE has proven challenging and is unlikely to occur despite considerable and well-intentioned efforts. We provided considerable rationale in prior communications to this committee (Submissions dated 12/1/2020 and 6/25/2021). There are good reasons for this.[5]</td><td>The Weycker et al., 2017 publication cited here used health-care claims data from 2009 to 2013 to estimate the prevalence and incidence of bronchiectasis in adults enrolled in multiple private health plans. Between 2018-2020, claims were submitted for nearly 1,500 OHP members showing a diagnosis of bronchiectasis, and this number is likely an underestimate of the true size of this population in Oregon.

Furthermore, the Weycker et al., 2017 publication estimates that there has been an annual growth rate of 8% per year since 2001 of patients with newly diagnosed bronchiectasis, and further suggests that cases that were identified represented only a small part of the true population with bronchiectasis. This suggests that even their proposed method of estimating prevalence and incidence may provide underestimates.

Responses to prior comments can be viewed here and here.</td></tr>
<tr><td>A4</td><td>First, HFCWO often treats rare diseases which makes it difficult to recruit cohorts of adequate size.</td><td>We understand that cystic fibrosis and many of the neuromuscular diseases in scope for this topic are rare, but chronic obstructive pulmonary disorder and non–cystic fibrosis bronchiectasis are not rare diseases. See response A3 regarding the population estimate for bronchiectasis in Oregon.</td></tr>
</table>

ID/#	Comment	Disposition
A5	Second, there is little agreement on study endpoints, and many older studies rely on problematical proxy measures such as sputum volume or changes in forced expiratory volume (FEV1).	*Outcomes such as sputum volume or changes in volume were not selected as critical or important outcomes for this report.*
A6	Third, past studies did not identify or control for machine power settings or adherence.[6]	*Our review did not look at evidence regarding adherence to therapy and found insufficient evidence that HFCWO device therapy reduces exacerbations and hospitalizations for conditions other than cystic fibrosis.*
A7	Fourth, airway clearance studies cannot be blinded, making it impossible to do a truly double-blind study.	*The subcommittee does not require studies to have a double-blind design for inclusion in coverage guidance reports.*
A8	Lastly, there has been little interest among independent researchers on this topic, perhaps because the therapy has been around for so long. We ask that you take these well-known difficulties into account.	*Thank you for your comment. The EbGS does take these contextual factors into account in its decision-making.*
A9	The Barto et al (2020) peer-reviewed publication[7] was unfortunately not among those included in the overall evidence evaluation by all members of the committee, yet it is among the most substantial pieces of contemporary evidence that supports the use of vest therapy in the BE patient population. This peer-reviewed outcomes publication has already been cited by several key thought leaders in the field of bronchiectasis as a positive contribution to the BE airway clearance literature – so we were naturally disappointed that the broader committee elected to not consider this data in their assessment.	*The Barto et al., 2020 publication did not meet inclusion criteria for this coverage guidance because it used noncomparative observational data from a registry using patient-reported outcomes that they were asked to retrospectively recall.*
A10	From a health equity perspective, the collective needs of these patients need to be considered. Patients with pulmonary diseases requiring airway clearance are likely to be located in areas where access to health care services may be limited. This situation is clear from the following map, which shows the high prevalence of COPD in rural and/or economically disadvantaged areas in Oregon.[8]	*Though we acknowledge that access to treatments may be more difficult to obtain in rural areas, any available treatment must still be evidence-based and be sufficiently effective at improving critical or important outcomes. Our review found insufficient evidence that HFCWO devices improve key outcomes for patients with chronic obstructive pulmonary disease compared to*

ID/#	Comment	Disposition
	[Image of CDC model of COPD prevalence by census tract, 2018, retrieved from: https://www.cdc.gov/copd/data.html]	*alternatives. Expert opinion does not recommend use in this population.*
A11	Dr. Trimble stated, and medical literature concurs, that patients respond differently to different forms of airway clearance and a personalized approach to airway clearance is key to positive patient outcomes.[9] For various reasons, patients frequently fail their initial attempts at an airway clearance modality; this may be due to motivational issues, lack of social support, physical limitations, or improper use of devices. There is a high treatment burden for traditional chest physiotherapy and the number of personnel with appropriate training is limited. In addition, there is a tremendous amount of variability in the delivery of many of the manual airway clearance techniques that are offset/addressed by the standardization offered by HFCWO. Therefore, Medicare and most insurance payors in the US include HFCWO as an option for BE patients and specifically took into account a 'tried and failed criterion'. We respectfully request that the draft coverage be amended to include coverage for BE on a tried-and-failed basis. This would minimize confusion among patients and health care providers in Oregon and better align with Medicare, other state Medicaid programs, and most private insurance payors. By doing so, it would help Oregonians avoid having to pursue an arduous and time-consuming appeals process and would likely proactively reduce healthcare resource utilization from a population health perspective. We hope these comments are constructive to the committee as they make their final recommendations for coverage criteria to the HERC committee. Thank you for considering our request to include BE for the aforementioned reasons. Please let us know if we can answer any questions, and do not hesitate to contact me directly.	*The Sontag et al., 2010 publication referenced here reports on lessons learned after a randomized trial of airway clearance techniques for patients with cystic fibrosis. This draft of the coverage guidance has a weak recommendation for covering HFCWO devices for patients with cystic fibrosis who have frequent exacerbations and for whom chest physiotherapy and positive expiratory pressure are not available, effective, or tolerated.* *The coverage criteria from Medicare, Aetna, Cigna, Moda, Regence BlueCross BlueShield, and the Washington Medicaid program are summarized in the coverage guidance.* *Thank you for your detailed comments and your interest in ensuring that Oregon Medicaid members have access to the best available treatment options.*

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

ID/#	Comment	Disposition
B1	I would like to address and encourage consideration of coverage for HFCWO devices for (non-CF) bronchiectasis. The draft document on HFCWO is well studied and researched. Part of the problem acquiring evidence for HFCWO is the lack of endpoints for studies in bronchiectasis. Mortality over a few months is not an appropriate endpoint. Bronchiectasis patients have permanent structural airway damage that does not show improvement in pulmonary function after antibiotics or other therapies. In uncontrolled studies exacerbations are reduced and quality of life improved after airway clearance therapies (ACT). I would suggest several considerations for provision of HFCWO devices based on authoritative opinion:	*Thank you for your comments. We have written responses to specific individual sections of your letter in the rows that follow.*
B2	Bronchiectasis is the prototypical condition for which ACT including HFCWO is therapeutic. The pathophysiology includes airway inflammation and infection leading to exceptional and tenacious mucus for which enhancing secretion removal is salutary (1).	*The publication referenced here is for a nearly 200-page issue of the publication* Clinics in Chest Medicine*. This issue presented articles that summarize the current state of research related to bronchiectasis and future directions in research.*
B3	International Guidelines for the diagnosis of bronchiectasis and for exacerbations can be utilized for clinical consideration and management as well as research studies (2,3).	*The Aliberti et al., 2022 publication summarized consensus recommendations for establishing criteria and definitions for radiological and clinical diagnosis of bronchiectasis to improve patient recruitment for future clinical trials of treatments for bronchiectasis. Similarly, the Hill et al., 2017 publication summarized a consensus definition for pulmonary exacerbations in adults with bronchiectasis.*
B4	Airway Clearance Therapies (ACT) are a well accepted part of the management of bronchiectasis, promoted strongly by Guidelines from Great Britain, Europe, Spain, Australia, and New Zealand. There are no US Guidelines, but the Bronchiectasis Research Registry (of which I am a board member and includes experts throughout the US) actively promotes ACT and further study of ACT.	*For bronchiectasis, our review included evidence-based guidelines and recommendations from the European Respiratory Society and the American College of Chest Physicians.*

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

ID/#	Comment	Disposition
B5	In US bronchiectasis centers, HFCWO is the 2nd most utilized ACT modality. Chest physical therapy (CPT) is rarely practiced (4). The Guidelines from abroad do not focus on HFCWO because they have a long tradition of encouraging traditional CPT (patient positioning and chest percussion) through specialized physiatry services. CPT is labor intensive and the positioning can be uncomfortable for some patients. HFCWO mimics percussion in a more gentle and concerted fashion. Some types of HFCWO (battery generated) allow movement away from a fixed source and patients do not need a companion or professional assistant (Respiratory or Physical Therapist).	*The Basavaraj et al., 2020 publication cited here was not eligible for inclusion in the coverage guidance due to the study's noncomparative observational retrospective design. Additionally, very few of the participants in this study (N = 51) used HFCWO devices and only two-thirds of those participants were included in the follow-up (N = 34).* *The Values and Preferences section of the coverage guidance details how the lack of trained or willing caregivers can be a barrier to care, as well as how the use of HFCWO device therapy provides independence from caregivers.*
B6	HFCWO is approved for cystic fibrosis (CF). The airway condition in CF IS bronchiectasis. CF is now an adult disease and has many similarities to (non-CF) bronchiectasis	*Our review found insufficient evidence that HFCWO device therapy reduces exacerbations and hospitalizations for conditions other than cystic fibrosis.*
B7	The FDA now promotes patient centered outcomes in diseases. There are well-studied and established HRQL instruments in bronchiectasis including SGRQ, QOL-B, LQ, and CAT. They have been used and can be followed during management including ACT in bronchiectasis (5).	*The De la Rosa Carrillo et al., 2020 publication cited here did not meet inclusion criteria for the coverage guidance due to its noncomparative observational design. The primary purpose of the publication was to validate the COPD assessment tool (CAT) for use in patients with bronchiectasis, and this publication may be helpful for researchers planning clinical trials.*

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

ID/#	Comment	Disposition
B8	Most importantly each patient adapts, finds efficacy, and tolerates various forms of ACT. Although many can utilize directed coughing, or positive expiratory pressure (PEP) devices, elderly patients (average age bronchiectasis patients-63) with substantial co-morbidities may not tolerate or even perform directed coughing or PEP. HFCWO may be more effective, comfortable, and tolerable. Use of HFCWO fits into the principle of personal and collaborative management and furthering education that include regular exercise, pulmonary rehabilitation, maintaining a healthy diet, and on-going learning that are key to chronic disease management including bronchiectasis (6).	*Thank you for providing important context for the subcommittee's deliberation.*
C1	I am a clinician with experience and expertise in the area of Cystic Fibrosis (CF) as well as non-CF bronchiectasis. I am concerned that Health Evidence Review Commission is proposing a guideline for patients with non-CF bronchiectasis involving High Frequency Chest Wall Oscillating Vests (HFCWO vests) for airway clearance therapy (ACT) which burdens patients with an appeals process to secure coverage for this therapy. While data supporting the use of ACT techniques and devices is better in CF than in non-CF bronchiectasis, even in CF, the data supporting its use is weak and of low quality. However, the use of ACT remains central to the treatment of both CF and non-CF bronchiectasis, and effective adherence to ACT is widely considered to be among the most important factors in patient outcomes, including exacerbation/hospitalization frequency and even mortality.	*Thank you for providing your expertise for this coverage guidance report. The health equity concerns you outline will be important considerations for subcommittee discussion.*
C2	The reasons for the low quality and quantity of data for ACT likely stem, at least in part, from need for personalization of ACT technique to the individual patient, as different methods of ACT may have variable efficacy for each patient. HFCWO vests are important tools as they do not require the use of a caregiver (manual chest PT requires 40-60 minutes a day of high-intensity manual therapy from a caregiver) and produce more force transmitted through the airway than active-ACT devices such as positive expiratory pressure devices and autogenic drainage.	*The Values and Preferences section of the coverage guidance details how the lack of trained or willing caregivers can be a barrier to care, as well as how the use of HFCWO device therapy provides independence from caregivers.*

HERC Coverage Guidance: High-Frequency Chest Wall Oscillation Devices
Disposition of Public Comments

ID/#	Comment	Disposition
C3	I am particularly concerned that the current planned recommendation of the HERC places the burden of appeal on the individual patient, which will lead to disparities of care. The most common cause of clinically significant bronchiectasis is prior severe infection with organisms such as TB, which disproportionally affects vulnerable individuals, such as those with low socioeconomic status and/or those who have immigrated from developing countries. These individuals are more likely to have language and cultural barriers making it unacceptably difficult to obtain an exception to allow coverage for HFCWO devices. These individuals are also more likely to need access to effective independent ACT therapy options.	*The health equity concerns you outline will be important considerations for subcommittee discussion.*
C4	I urge the HERC to recommend that individuals with non-CF bronchiectasis with clinically active/severe disease (as defined by the HERC; i.e. frequent exacerbations, declining lung function, etc.) be allowed access to HFCWO devices. Note, the vast minority of individuals with the diagnosis of bronchiectasis have clinically active/severe disease. The diagnosis is frequently given to individuals based on imaging, but these clinical criteria are rarely met.	*Thank you for providing important context for the subcommittee's deliberation.*

References Provided by Commenters

ID	References
A	1. Belli S, Prince I, Savio G, et al. Airway clearance techniques: the right choice for the right patient. *Front Med (Lausanne).* 2021;8:544826. 2. 2019 US Census Annual Estimate. https://www.census.gov/data/tables/time-series/demo/popest/2010s-state-detail.html 3. Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. *Chron Respir Dis.* 2017;14:377-384. 4. Oregon Health Insurance Survey Early Release Results. 2019; https://www.oregon.gov/oha/ERD/Pages/2019-Oregon-Health-Insurance-Survey.aspx. 5. Rubin BK. Designing clinical trials to evaluate mucus clearance therapy. *Respir Care.* 2007;52(10):1348-1358; discussion 1358-1361. 6. Mikesell CL, Kempainen RR, Laguna TA, et al. Objective measurement of adherence to out-patient airway clearance therapy by high-frequency chest wall compression in cystic fibrosis. *Respir Care.* 2017. 7. Barto TL, Maselli DJ, Daignault S, et al. Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasis. *Ther Adv Respir Dis.* 2020;14:1753466620932508. 8. CDC 2019 COPD Data. https://www.cdc.gov/copd/data.html. 9. Sontag MK, Quittner AL, Modi AC, et al. Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis. *Pediatr Pulmonol.* 2010;45(3):291-300.
B	1. Chalmers J, ed. Bronchiectasis. *Clin Chest Med.* 2022, March issue 2. Aliberti S, Goeminne PC, O'Donnell AE, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. *Lancet Respir Med*, March, 2022. 3. Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. *Eur Respir J.* 2017;49. 4. Basavaraj A, Choate R, Addrizzo-Harris D, et al. Airway clearance techniques in bronchiectasis: analysis from the United States Bronchiectasis and Non-TB Mycobacteria Research Registry. *CHEST.* 2020;158:1376 5. De la Rosa Carrillo D, Olveira C, García-Clemente M, et al. COPD assessment test in bronchiectasis: minimum clinically important difference and psychometric validation: a prospective study. *CHEST.* 2020;157:824. 6. British Thoracic Society. Bronchiectasis self-management plan. https://www.brit-thoracic.org.uk/quality-improvement/quality-standards/bronchiectasis/ .